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Abstract	  Investigating	  the	  immune	  mechanisms	  that	  predispose	  the	  development	  of	  TB	  disease	  is	  essential	  to	  expand	  our	  understanding	  of	  immune	  protection	  from	  TB.	  	  We	  hypothesized	  younger	  children	  would	  have	  a	  distinctly	  different	  immune	  response	  to	  mycobacteria	  than	  older	  children	  predisposing	  them	  to	  severe	  TB	  disease.	  We	  compared	  mycobacterial	  immune	  responses	  in	  healthy,	  BCG	  vaccinated	  children	  of	  increasing	  ages,	  focusing	  on	  CD4,	  γδ	  and	  regulatory	  T	  cells	  and	  their	  related	  cytokines.	  	  Additionally	  we	  compared	  these	  responses	  in	  4	  groups	  of	  children;	  healthy	  controls,	  latent	  TB	  infection	  (LTBI),	  pulmonary	  TB	  (PTB)	  and	  extra-­‐pulmonary	  TB	  (EPTB)	  both	  at	  diagnosis	  and	  after	  6	  months	  TB	  treatment.	  	  Our	  data	  demonstrates	  that	  healthy	  children	  of	  all	  ages	  have	  robust	  and	  comparable	  antigen	  specific	  effector	  and	  central	  memory	  immune	  responses	  to	  BCG.	  However,	  distinct	  differences	  between	  children	  <1yr	  of	  age	  and	  older	  children	  identified	  on	  analysis	  of	  secreted	  cytokine	  data	  supports	  further	  studies	  into	  potential	  age-­‐related	  differences	  in	  the	  innate	  immune	  response	  to	  BCG.	  	  In	  addition	  we	  demonstrate	  a	  waning	  of	  proliferative	  T	  cell	  responses	  to	  BCG	  with	  increasing	  age	  which	  raises	  the	  question	  of	  benefit	  of	  re-­‐vaccination	  with	  BCG	  in	  high	  endemic	  areas	  to	  protect	  children	  2yrs	  and	  over	  from	  disseminated	  TB.	  	  	  All	  children	  with	  TB	  disease	  had	  suppressed	  mycobacterial	  immune	  responses	  at	  the	  time	  of	  disease.	  However	  these	  recovered	  and	  were	  of	  greater	  magnitude	  after	  6	  months	  than	  those	  of	  healthy	  controls,	  suggesting	  a	  boosting	  effect	  on	  the	  central	  memory	  compartment	  of	  the	  immune	  response.	  	  We	  report	  for	  the	  first	  time	  in	  children	  that	  regulatory	  T	  cells	  are	  increased	  in	  children	  with	  both	  TB	  infection	  and	  disease.	  	  Although	  at	  baseline	  our	  assays	  could	  not	  distinguish	  children	  with	  PTB	  from	  those	  with	  EPTB,	  after	  6	  months	  those	  with	  EPTB	  have	  lower	  effector	  and	  central	  memory	  responses,	  in	  association	  with	  differences	  in	  their	  secreted	  cytokine	  responses.	  	  This	  warrants	  further	  exploration	  to	  determine	  whether	  it	  is	  a	  function	  of	  timing,	  bacterial	  load	  or	  mycobacterial	  clearance,	  but	  may	  be	  primary	  evidence	  of	  an	  underlying	  susceptibility	  linked	  to	  immune	  profiles.	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1. Background	  
	  
1.1. Tuberculosis	  Tuberculosis	  (TB)	  remains	  a	  major	  cause	  of	  morbidity	  and	  mortality	  globally	  accounting	  for	  an	  estimated	  7	  million	  deaths	  and	  9.4	  million	  new	  TB	  cases	  in	  2009	  (WHO	  2010	  report).	  	  The	  aim	  of	  the	  UN’s	  Millennium	  Development	  Goal	  (MDG)	  6	  is	  to	  halt	  and	  begin	  reversal	  of	  national,	  regional,	  and	  global	  tuberculosis	  incidence	  by	  2015.	  	  The	  Stop	  TB	  Partnership	  aims	  to	  halve	  global	  tuberculosis	  prevalence	  and	  associated	  mortality	  by	  2015	  compared	  with	  1990,	  and	  to	  eliminate	  tuberculosis	  (less	  than	  one	  case	  per	  million	  population)	  by	  20501.	  	  Poor	  case	  ascertainment	  and	  limited	  surveillance	  data	  hampers	  the	  efforts	  to	  accurately	  quantify	  the	  disease	  burden	  associated	  with	  childhood	  TB2.	  	  No	  formal	  figures	  are	  currently	  available	  from	  the	  World	  Health	  Organization	  (WHO).	  	  Recently	  all	  National	  TB	  control	  Programmes	  (NTPs)	  were	  requested	  to	  report	  future	  TB	  cases	  in	  3	  age	  categories;	  less	  than	  5	  years,	  5–14	  years	  and	  adult	  cases	  (≥15	  years).	  	  Hopefully	  more	  accurate	  figures	  will	  become	  available	  in	  the	  near	  future,	  but	  this	  will	  be	  greatly	  dependent	  on	  improved	  access	  to	  care	  and	  more	  reliable	  diagnosis	  of	  TB	  in	  children.	  The	  only	  published	  estimates	  of	  the	  global	  pediatric	  TB	  disease	  burden	  are	  outdated	  and	  likely	  represent	  an	  underestimate	  of	  the	  current	  situation.	  	  Of	  the	  estimated	  8.3	  million	  new	  cases	  of	  TB	  diagnosed	  in	  2000,	  84,019	  (11%)	  were	  children	  less	  than	  15	  years	  of	  age.	  In	  a	  prospective	  community-­‐based	  survey	  performed	  in	  an	  area	  of	  South	  Africa	  little	  affected	  by	  the	  HIV-­‐epidemic,	  children	  <13	  years	  of	  age	  contributed	  13.7%	  of	  the	  total	  disease	  burden	  with	  a	  calculated	  TB	  incidence	  of	  408/100,000/year;	  the	  reported	  adult	  TB	  incidence	  in	  this	  community	  during	  the	  same	  time	  period	  was	  840/100,000/year2.	  	  It	  is	  estimated	  that	  with	  accurate	  diagnosis	  and	  good	  reporting	  systems	  children	  <15	  years	  are	  likely	  to	  contribute	  10–20%	  of	  the	  disease	  burden	  in	  TB	  endemic	  areas,	  with	  an	  TB	  incidence	  estimated	  at	  roughly	  50%	  of	  that	  recorded	  in	  adults.	  World	  Health	  Organization	  (WHO)	  figures	  suggests	  that	  the	  global	  tuberculosis	  (TB)	  incidence	  has	  stabilized	  since	  2004,	  with	  many	  regions	  on	  track	  to	  meet	  Millennium	  Developmental	  Goal	  targets	  set	  for	  2015.	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Control	  of	  the	  tuberculosis	  epidemic	  depends	  on	  the	  prevention,	  rapid	  detection,	  and	  cure	  of	  infectious	  cases,	  but	  a	  major	  stumbling	  block	  in	  achieving	  this	  is	  the	  identification	  of	  a	  correlate	  of	  immune	  protection.	   	   .	  	  
1.2. Tuberculosis	  in	  Children	  –the	  Differences	  Historical	  data	  show	  that	  following	  prolonged	  household	  contact	  with	  a	  sputum	  smear-­‐positive	  source	  case,	  60–80%	  of	  children	  became	  infected	  and	  when	  the	  source	  case	  was	  smear-­‐negative,	  30–40%	  of	  children	  became	  infected.	  	  Most	  children	  (80%)	  who	  became	  infected	  before	  2	  years	  of	  age	  were	  infected	  by	  a	  household	  source	  case3.	  Following	  infection,	  children	  have	  a	  higher	  risk	  not	  only	  of	  progression	  to	  disease,	  but	  also	  of	  extrapulmonary	  dissemination	  and	  death4	  and	  this	  risk	  changes	  with	  age	  (Figure	  1).	  	  Infants	  have	  a	  particularly	  high	  morbidity	  and	  mortality	  from	  tuberculosis.	  	  Although	  many	  factors	  including	  host	  genetics,	  microbial	  virulence,	  and	  underlying	  conditions	  that	  impair	  immune	  competence	  (eg,	  malnutrition	  and	  HIV	  infection)	  determine	  the	  outcome	  of	  infection,	  it	  is	  likely	  that	  the	  high	  rate	  of	  progressive	  tuberculosis	  seen	  in	  young	  children	  is	  largely	  a	  reflection	  of	  the	  immaturity	  of	  the	  immune	  response5.	  
	  
Figure	  1	  -­‐	  The	  pathway	  from	  TB	  exposure	  to	  disease	  
In	  adults,	  following	  primary	  pulmonary	  infection,	  90%	  contain	  the	  mycobacteria	  within	  a	  
granuloma,	  as	  described	  by	  latent	  TB	  infection	  (LTBI).	  	  10%	  of	  these	  will	  develop	  late	  
reactivation	  of	  disease	  in	  their	  lifetime.	  	  Primary	  progression	  of	  disease	  is	  less	  common	  in	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adults,	  but	  in	  children,	  and	  in	  particular	  infants	  under	  1	  year,	  almost	  50%	  will	  develop	  
primary	  progressive	  pulmonary	  disease	  and	  20%	  of	  those	  will	  develop	  a	  disseminated	  form	  
of	  disease	  such	  as	  TB	  meningitis	  or	  miliary	  TB.	  	  This	  risk	  decreases	  with	  age,	  as	  shown	  in	  
the	  table	  Adapted	  from6.	  	  
1.3. BCG-­‐	  the	  only	  current	  vaccine	  for	  protection	  from	  TB	  BCG	  vaccine	  was	  developed	  by	  Calmette	  and	  Guérin	  in	  France	  by	  the	  attenuation	  of	  virulent	  Mycobacterium	  bovis	  through	  230	  passages.	  It	  was	  first	  administered	  as	  an	  oral	  vaccine	  to	  a	  newborn	  in	  1921	  and	  was	  recommended	  for	  global	  use	  by	  the	  League	  of	  Nations	  in	  1928.	  	  BCG	  was	  introduced	  into	  the	  Expanded	  Program	  of	  Immunization	  (EPI)	  in	  19747.	  	  Since	  then	  an	  estimated	  4	  billion	  children	  have	  been	  vaccinated	  with	  BCG,	  with	  acceptable	  safety	  and	  at	  low	  cost.	  	  Many	  different	  BCG	  vaccines	  are	  available	  worldwide.	  	  Although	  all	  currently	  used	  vaccines	  were	  derived	  from	  the	  original	  M.	  bovis	  strain,	  they	  differ	  in	  their	  characteristics	  when	  grown	  in	  culture	  and	  in	  their	  ability	  to	  induce	  an	  immune	  response	  to	  tuberculin.	  These	  variations	  may	  be	  caused	  by	  genetic	  changes	  that	  occurred	  in	  the	  bacterial	  strains	  during	  the	  passage	  of	  time	  and	  by	  differences	  in	  production	  techniques.	  
Although	  early	  studies	  reported	  that	  children	  were	  protected	  against	  TB,	  subsequent	  studies	  including	  a	  number	  of	  meta-­‐analyses	  have	  shown	  that	  the	  efficacy	  of	  BCG	  in	  imparting	  protection	  against	  TB	  has	  varied	  from	  0	  to	  80%8-­‐10.	  Trials	  conducted	  in	  the	  1940s	  and	  1950s	  in	  some	  European	  countries	  demonstrated	  the	  vaccine	  to	  be	  highly	  effective	  (70–80%).	  	  In	  young	  children,	  the	  estimated	  protective	  efficacy	  rates	  of	  the	  vaccine	  have	  ranged	  from	  52%	  to	  100%	  for	  prevention	  of	  tuberculous	  meningitis	  and	  miliary	  TB	  and	  from	  2%	  to	  80%	  for	  prevention	  of	  pulmonary	  TB9.	  The	  results	  of	  one	  meta-­‐analysis	  indicated	  an	  86%	  protective	  effect	  of	  BCG	  against	  meningeal	  and	  miliary	  TB	  in	  children	  in	  clinical	  trials	  (95%	  confidence	  interval	  [CI]=65%–95%)	  and	  a	  75%	  protective	  effect	  in	  case-­‐control	  studies	  (95%	  CI=61%–84%)9.	  	  The	  variability	  in	  the	  rates	  of	  protective	  efficacy	  of	  BCG	  against	  pulmonary	  TB	  differed	  significantly	  enough	  to	  preclude	  the	  estimation	  of	  a	  summary	  protective	  efficacy	  rate.	  	  However,	  studies	  in	  India	  have	  shown	  no	  protection	  and	  even	  suggested	  that	  in	  some	  cases,	  vaccinated	  individuals	  were	  more	  likely	  to	  develop	  tuberculosis	  compared	  to	  the	  placebo	  group11	  .	  Surprisingly,	  no	  clinical	  trial	  was	  conducted	  in	  Africa	  before	  integrating	  BCG	  into	  mass	  vaccination	  programmes.	  	  
In	  addition	  to	  controversies	  concerning	  the	  protective	  efficacy	  of	  BCG,	  very	  little	  is	  known	  about	  the	  mechanisms	  of	  immune	  protection	  imparted	  by	  BCG	  and	  like	  most	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vaccines	  currently	  in	  use,	  BCG	  was	  developed	  empirically	  without	  a	  clear	  understanding	  of	  how	  it	  induces	  protection	  immunity.	  	  Although	  the	  mechanism	  of	  protection	  from	  most	  other	  vaccines	  is	  now	  understood	  however,	  we	  still	  don’t	  have	  a	  clear	  understanding	  of	  how	  or	  why	  BCG	  is	  protective	  against	  some	  forms	  of	  TB	  in	  some	  populations.	  Understanding	  how	  BCG	  confers	  protection	  is	  central	  to	  the	  development	  of	  new	  vaccines	  that	  aim	  at	  either	  boosting/augmenting	  the	  efficacy	  of	  BCG	  or	  replacing	  it12.	  	  	  
BCG	  induces	  CD4+	  T	  cells	  that	  produce	  IFNγ,	  which	  in	  turn	  activates	  macrophages	  to	  kill	  Mtb	  and	  most	  studies	  have	  concentrated	  their	  efforts	  on	  measuring	  IFNγ	  responses	  as	  a	  surrogate	  of	  a	  protective	  response.	  	  Only	  a	  few	  have	  looked	  at	  the	  persistence	  of	  an	  IFNγ	  immune	  response	  to	  TB,	  demonstrating	  a	  waning	  in	  magnitude,	  but	  ongoing	  production	  in	  response	  to	  whole	  blood	  stimulation	  with	  mycobacterial	  antigens	  up	  to	  15	  years	  later13,14.	  	  However,	  recent	  studies	  report	  a	  lack	  of	  correlation	  between	  immune	  protection	  imparted	  by	  BCG	  and	  IFNγ	  produced	  by	  CD4+	  T	  cells15,16.	  	  IFNγ	  appears	  to	  be	  necessary	  but	  not	  sufficient	  to	  protect	  against	  Mtb.	  	  The	  role	  of	  other	  immune	  cells	  and	  cytokines	  including	  polyfunctional	  T	  cells,	  are	  being	  explored	  with	  varying	  results.	  	  A	  number	  of	  groups	  have	  explored	  cytokine	  production	  in	  infants	  following	  BCG	  vaccination	  using	  multiplex	  cytokine	  platforms	  and	  identified	  different	  cytokine	  signatures	  in	  different	  countries	  and	  settings14,17,18	  which	  can	  be	  attributed	  to	  a	  combination	  of	  genetic	  differences,	  environmental	  variation	  and	  perinatal	  influences.	  	  The	  results	  are	  difficult	  to	  interpret	  and	  it	  is	  unclear	  whether	  the	  differences	  seen	  in	  these	  cytokine	  signatures	  indicate	  variability	  in	  protective	  efficacy	  from	  BCG	  or	  not.	  	  Recent	  results	  from	  a	  large	  cohort	  of	  BCG-­‐vaccinated	  South	  African	  infants	  have	  shown	  that	  the	  frequency	  of	  multi-­‐functional	  T	  cells	  making	  IFNγ,	  TNFα	  and	  IL-­‐2,	  10	  weeks	  post-­‐vaccination	  was	  not	  associated	  with	  protection	  in	  this	  population16.	  	  Other	  members	  of	  the	  immune	  response	  to	  Mtb	  currently	  being	  investigated	  as	  part	  of	  both	  BCG	  and	  novel	  vaccine	  candidate	  studies	  include	  CD8+	  T	  cells,	  γδ	  T	  cells,	  IL17,	  IL22,	  polyfunctional	  CD4	  T	  cells	  and	  regulatory	  T	  cells19,20	  and	  I	  describe	  what	  is	  currently	  understood	  about	  their	  role	  in	  protection	  from	  TB	  in	  the	  following	  pages.	  	  	  
1.4. A	  brief	  overview	  of	  pathogenesis	  of	  TB	  A	  child	  in	  close	  contact	  with	  an	  infectious	  index	  case	  may	  inhale	  Mtb	  aerosolised	  in	  infected	  droplets.	  	  Should	  the	  bacilli	  be	  successful	  in	  traversing	  the	  physical	  and	  anatomical	  barriers	  encountered,	  Mtb	  bacilli	  are	  inhaled	  into	  the	  terminal	  alveoli.	  	  Once	  in	  the	  terminal	  alveoli,	  Mtb	  is	  readily	  phagocytosed	  by	  resident	  alveolar	  macrophages	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and	  dendritic	  cells.	  	  This	  process	  of	  internalisation	  results	  in	  activation	  of	  antimicrobial	  mechanisms,	  which	  serve	  to	  limit	  the	  growth	  of	  Mtb	  and	  recruit	  additional	  immune	  cells.	  	  Bacilli	  are	  processed	  and	  presented	  on	  the	  cell	  surface	  by	  antigen	  presenting	  cells	  that	  migrate	  to	  regional	  lymph	  nodes	  and	  present	  the	  Mtb	  antigens	  to	  T	  cells.	  	  Secretion	  of	  cytokines,	  such	  as	  IL-­‐12,	  causes	  CD4+T	  cells	  to	  proliferate	  and	  secrete	  cytokines	  including	  IFNγ,	  which	  further	  activates	  macrophages	  to	  become	  microbicidal.	  	  These	  specific	  T	  cells,	  stimulated	  in	  the	  draining	  lymph	  nodes,	  induce	  bacterial	  containment	  in	  small	  granulomatous	  lesions	  of	  the	  lung.	  	  The	  fate	  of	  Mtb	  within	  the	  macrophage	  leads	  to	  four	  possible	  outcomes;	  Mtb	  infection	  can	  either	  cause	  primary	  TB	  disease,	  become	  dormant	  in	  a	  granuloma	  (“latent	  TB”,	  LTBI),	  be	  eliminated	  or	  reactivate	  later	  to	  cause	  disease.	  	  Factors	  assigned	  to	  innate	  as	  well	  as	  acquired	  immune	  responses	  will	  determine	  the	  outcome,	  as	  well	  as	  the	  mycobacteria	  themselves.	  	  A	  dynamic	  balance	  between	  bacterial	  persistence	  and	  host	  defence	  develops	  and	  in	  children,	  this	  balance	  tips	  in	  the	  favour	  of	  the	  mycobacteria	  more	  frequently	  than	  in	  adults.	  	  A	  summary	  of	  the	  key	  components	  of	  innate	  and	  adaptive	  immune	  mechanisms	  in	  the	  response	  to	  Mycobacterium	  tuberculosis	  (Mtb)	  is	  illustrated	  in	  Figure	  2.	  21	  
	  
Figure	  2	  -­‐	  This	  figure	  illustrates	  the	  key	  components	  of	  innate	  and	  adaptive	  immune	  
mechanisms	  in	  the	  response	  to	  Mycobacterium	  tuberculosis	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Innate	  defense	  molecules	  in	  the	  airways	  facilitate	  the	  phagocytosis	  of	  Mtb	  by	  macrophages	  
and	  dendritic	  cells	  (antigen	  presenting	  cells,	  APCs)	  and	  Toll-­‐like	  receptor	  (TLR)	  signaling.	  
Mtb	  is	  processed	  within	  the	  APC	  and	  presented	  to	  CD4	  cells	  in	  regional	  lymph	  nodes	  on	  
major	  histocompatability	  complex	  (MHC)	  class	  II	  molecules.	  IL-­‐12	  is	  secreted	  by	  APCs,	  
which	  causes	  CD4	  cells	  to	  proliferate	  and	  produce	  IFNγ.	  IFNγ,	  produced	  by	  CD4	  cells,	  CD8	  
cells,	  NK	  cells	  and	  γδ	  cells	  activates	  the	  APC	  to	  become	  microbicidal.	  Other	  molecules	  such	  
as	  perforins	  and	  granzymes,	  produced	  by	  CD8	  cells,	  NK	  cells	  and	  γδ	  cells,	  also	  facilitate	  
destruction	  of	  Mtb	  bacilli.	  T	  regulatory	  (Treg)	  cells,	  Th17	  cells	  and	  B	  cells	  act	  to	  modulate	  
the	  immune	  response	  to	  Mtb.	  	  (Illustration	  ©	  Hugh	  Gifford	  2010).	  
1.5. Immunological	  differences	  in	  the	  paediatric	  response	  to	  
tuberculosis	  Although	  it	  is	  assumed	  that	  differences	  in	  the	  immune	  response	  between	  adults	  and	  children	  are	  responsible	  for	  the	  differences	  in	  susceptibility	  to	  infection	  and	  development	  of	  severe	  disease,	  only	  a	  limited	  number	  of	  studies	  have	  assessed	  the	  impact	  of	  age	  on	  crucial	  aspects	  of	  the	  immune	  response.	  	  Some	  differences	  have	  been	  identified,	  but	  these	  do	  not	  account	  fully	  for	  the	  differences	  in	  disease	  progression.	  Antigen	  presenting	  cells,	  such	  as	  macrophages	  and	  dendritic	  cells	  (DCs)	  play	  a	  vital	  role	  in	  the	  initial	  response	  to	  mycobacteria.	  	  Following	  engulfment	  of	  Mtb,	  these	  phagocytic	  cells	  undergo	  activation	  and	  maturation	  with	  the	  resulting	  synthesis	  of	  inflammatory	  cytokines	  and	  chemokines	  that	  elicit	  a	  specific	  immune	  response,	  in	  particular	  IL1,	  IL12	  and	  TNFα.	  	  Multiple	  cell	  types,	  in	  particular	  CD4+	  and	  gammadelta	  (γδ)	  T	  cells	  are	  recruited	  to	  the	  disease	  site.	  	  Mature	  DCs	  then	  migrate	  to	  the	  lymph	  node	  where	  they	  present	  MHC-­‐peptide	  complexes	  to	  T	  cells	  and	  through	  co-­‐stimulatory	  molecules	  and	  cytokines,	  including	  IL12p70,	  trigger	  the	  expansion	  and	  differentiation	  of	  naïve	  T	  cells.	  	  Young	  children	  demonstrate	  deficient	  macrophage	  phagocytosis	  and	  recruitment	  during	  early	  childhood	  with	  consequences	  for	  the	  initiation	  of	  an	  antigen-­‐specific	  response.	  	  In	  addition,	  infants	  have	  fewer	  circulating	  DCs	  than	  adults	  and	  their	  functional	  capacity	  is	  reduced.	  	  In	  particular,	  the	  ability	  of	  DCs	  to	  present	  antigen	  to	  naïve	  T	  cells	  appears	  to	  be	  reduced	  until	  the	  second	  year	  of	  life22,23	  and	  the	  production	  of	  IL12p70	  is	  impaired	  compared	  to	  adult	  levels	  until	  12	  years	  of	  age24.	  	  Together,	  these	  may	  contribute	  to	  susceptibility	  to	  infection	  and	  disease	  in	  younger	  children.	  	  Other	  aspects	  of	  the	  initial	  innate	  response	  to	  mycobacteria	  are	  altered	  in	  neonates	  and	  early	  infancy,	  such	  as	  collectin	  levels25	  and	  the	  complement	  pathway26,	  however	  how	  these	  differences	  relate	  to	  susceptibility	  is	  not	  yet	  clear	  and	  further	  studies	  are	  warranted.	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T	  cell	  immunity	  is	  well	  recognized	  as	  essential	  for	  protection	  against	  TB	  infection	  and	  disease	  and	  CD4+	  T	  cell	  depletion,	  such	  as	  seen	  in	  HIV,	  is	  a	  contributing	  factor	  to	  TB	  susceptibility.	  	  However,	  non-­‐HIV	  infected	  children	  are	  nevertheless	  more	  susceptible	  to	  TB	  disease	  despite	  having	  higher	  numbers	  of	  CD4+	  lymphocytes	  than	  adults27-­‐29.	  	  Immune	  reconstitution	  with	  anti-­‐retrovirals	  leads	  to	  normalization	  of	  CD4+	  numbers,	  but	  despite	  this,	  higher	  susceptibility	  to	  TB	  remains	  a	  key	  feature	  in	  HIV29.	  	  Restoration	  of	  CD4+	  numbers	  is	  not	  associated	  with	  significant	  increases	  in	  production	  of	  IFNγ	  in	  response	  to	  mycobacteria,	  as	  shown	  previously	  by	  Kampmann	  et	  al30.	  	  Mtb-­‐specific	  CD4+	  T	  cells	  primarily	  produce	  Th1	  cytokines,	  which	  include	  IFNγ,	  IL-­‐2	  and	  TNFα.	  	  Studies	  of	  human	  immune	  deficiencies	  associated	  with	  disseminated	  mycobacterial	  disease	  reveal	  that	  IFNγ	  is	  critical	  for	  optimal	  activation	  of	  macrophages	  and	  hence	  for	  protection	  against	  TB31.	  	  A	  hallmark	  of	  the	  clinical	  presentation	  in	  patients	  with	  complete	  IFNγR	  deficiency	  is	  impaired	  granuloma	  formation,	  highlighting	  the	  importance	  of	  IFNγ	  for	  containment	  of	  mycobacteria	  within	  granulomata.	  	  Healthy	  adults	  with	  LTBI	  demonstrate	  strong	  Mtb-­‐specific	  IFNγ	  responses	  in	  comparison	  to	  adults	  with	  active	  TB,	  but	  children	  have	  poorer	  responses,	  particularly	  when	  suffering	  from	  disseminated	  disease,	  suggesting	  that	  immaturity	  of	  the	  IFNγ	  response	  may	  contribute	  to	  the	  age-­‐related	  impairment	  of	  mycobacterial	  immunity30,32,33.	  Neonatal	  CD4+	  T	  cells	  exhibit	  reduced	  capacity	  to	  express	  Th1-­‐effector	  function,	  partly	  attributed	  to	  hypermethylation	  of	  the	  proximal	  promoter	  of	  the	  IFNγ	  gene34.	  	  This	  results	  in	  a	  highly	  restricted	  pattern	  of	  IFNγ	  response	  to	  a	  variety	  of	  stimuli.	  	  	  Although	  CD4+	  T	  cells	  and	  IFNγ	  are	  important	  components	  of	  an	  effective	  anti-­‐	  mycobacterial	  immune	  response,	  they	  do	  not	  fully	  explain	  observed	  differences	  in	  host	  susceptibility	  to	  TB.	  	  γδ	  T	  cells	  are	  a	  further	  source	  of	  IFNγ	  and	  granulysins	  as	  part	  of	  the	  immune	  response	  to	  TB35.	  
1.6. Gammadelta	  T	  cells	  T	  cells	  develop	  normally	  from	  pluripotent	  precursor	  cells	  in	  the	  thymus.	  	  A	  complex	  series	  of	  signaling	  events	  direct	  developing	  thymocytes	  to	  become	  either	  αβ	  or	  γδ	  T	  cells.	  	  In	  the	  case	  of	  αβ	  T	  cells,	  positive	  selection	  defines	  lineage,	  marked	  by	  expression	  of	  CD4	  or	  CD8,	  depending	  on	  whether	  MHC	  Class	  I	  or	  II	  molecules	  are	  recognized	  by	  the	  αβ	  T	  cell	  receptor	  (TCR).	  	  Cells	  recognizing	  MHC	  class	  I	  downregulate	  expression	  of	  CD4,	  become	  single	  positive	  for	  CD8,	  and	  evolve	  as	  cytolytic	  effectors.	  	  Those	  cells	  recognizing	  MHC	  class	  II	  will	  downregulate	  expression	  of	  CD8,	  become	  single	  positive	  for	  CD4,	  and	  adopt	  cytokine-­‐secreting	  helper	  functions36.	  	  Additional	  signals,	  received	  either	  during	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development	  or	  upon	  activation,	  push	  αβ	  T	  cells	  down	  other	  paths	  including	  Th1,	  Th2,	  Th17,	  and	  regulatory	  lineages,	  each	  with	  distinct	  functions.	  	  	  	  The	  γδ	  T	  cell	  population	  was	  first	  described	  in	  1986	  with	  reports	  of	  a	  new	  heterodimeric	  T	  cell	  receptor	  that	  was	  associated	  with	  CD337.	  	  Human	  γδ	  T	  cells	  can	  be	  subdivided	  into	  two	  main	  populations	  based	  upon	  δ	  chain	  expression.	  	  γδ	  T	  cells	  expressing	  the	  Vδ1	  chain	  are	  most	  often	  found	  in	  mucosal	  tissues,	  where	  they	  are	  thought	  to	  be	  involved	  in	  maintaining	  epithelial	  tissue	  integrity	  in	  the	  face	  of	  damage,	  infection,	  or	  transformation38.	  	  A	  second	  population	  of	  γδ	  T	  cells	  expresses	  the	  Vδ2	  chain	  and	  makes	  up	  about	  1%–10%	  of	  circulating	  lymphocytes	  in	  healthy	  human	  adults[26].	  	  The	  Vδ2	  chain	  pairs	  almost	  exclusively	  with	  Vγ2	  (called	  Vγ9	  interchangeably).	  The	  Vγ9Vδ2	  pairing	  is	  only	  present	  in	  humans	  and	  nonhuman	  primates39.	  γδ	  T	  cells	  are	  often	  termed	  innate-­‐like	  lymphocytes,	  due	  to	  their	  rapid,	  antigen-­‐triggered	  responses,	  and	  lack	  of	  classical	  MHC	  restriction.	  	  Although	  they	  do	  not	  require	  conventional	  antigen	  presentation	  in	  the	  context	  of	  MHC40,	  they	  possess	  a	  TCR	  composed	  of	  rearranging	  germline	  elements41,	  require	  antigen	  presentation42,	  and	  undergo	  peripheral	  selection43	  and	  could	  also	  be	  classified	  as	  components	  of	  adaptive	  immunity.	  	  The	  γ	  and	  δ	  TCR	  chains	  share	  an	  immunoglobulin-­‐like	  structure	  similar	  to	  the	  αβ	  T	  cell	  receptor;	  chain	  expression	  is	  determined	  by	  randomly	  rearranging	  V,	  (D)	  and	  J	  segments.	  However,	  in	  the	  case	  of	  γ	  and	  δ	  chains,	  the	  germline	  repertoire	  is	  restricted	  severely,	  due	  to	  a	  limited	  number	  of	  rearranging	  elements44.	  	  They	  undergo	  extrathymic	  positive	  selection	  in	  a	  non-­‐MHC	  restricted	  manner.	  	  Human	  γδ	  T	  cells	  rarely	  recognize	  peptides	  processed	  from	  complex	  protein	  antigens	  by	  professional	  APC	  but	  rather	  see	  unconventional	  antigens	  such	  as	  phosphorylated	  microbial	  metabolites	  and	  lipid	  antigens40.	  	  They	  are	  stimulated	  in	  vitro	  by	  killed	  microorganisms	  such	  as	  Mtb	  and	  plasmodium	  falciparum45	  and	  characterization	  of	  these	  ligands	  identified	  the	  critical	  role	  of	  non-­‐protein	  phosphate	  residues	  or	  phosphoantigens.	  	  These	  antigens	  include	  isopentenyl	  pyrophosphate	  (IPP)	  and	  (E)-­‐4-­‐hydroxy-­‐3-­‐methyl-­‐but-­‐2-­‐enyl	  pyrophosphate	  (HMB-­‐PP),	  which	  specifically	  activate	  the	  Vγ9Vδ2	  γδ	  T	  cell	  subset46.	  	  Vγ9Vδ2	  T	  cells	  use	  their	  T	  cell	  Receptor	  (TCR)	  as	  a	  pattern	  recognition	  receptor	  to	  sense	  the	  presence	  of	  bacteria	  via	  these	  phosphoantigens	  to	  respond	  more	  rapidly	  than	  through	  the	  MHC	  with	  the	  production	  of	  pro-­‐inflammatory	  cytokines	  or	  in	  a	  directly	  cytotoxic	  manner.	  	  The	  combination	  of	  gene	  rearrangement	  constraints	  and	  phosphoantigen-­‐driven	  selection	  may	  allow	  for	  the	  production	  of	  a	  large	  pool	  of	  γδ	  T	  cells	  that	  is	  able	  to	  rapidly	  respond	  to	  microbial	  phosphoantigens.	  
	   27	  
Functionally,	  γδ	  T	  cells	  demonstrate	  cytotoxic	  responses	  against	  cells	  infected	  with	  a	  variety	  of	  viruses,	  bacteria,	  or	  protozoa	  and	  they	  also	  recognize	  and	  kill	  many	  human	  tumors46.	  	  Cytotoxicity	  is	  mediated	  in	  much	  the	  same	  manner	  as	  for	  αβ	  T	  cells,	  namely,	  through	  perforin/granzyme	  and	  Fas/FasL	  pathways	  or	  the	  production	  of	  TNFα47.	  Human	  patients	  with	  infections	  such	  as	  tuberculosis	  or	  malaria,	  often	  have	  large	  expansions	  of	  the	  peripheral	  γδ	  T	  cell	  subset,	  sometimes	  comprising	  up	  to	  80%	  of	  all	  T	  cells48.	  	  Human	  Immunodeficiency	  Virus	  type	  1	  (HIV-­‐1)	  infection	  results	  in	  rapid	  and	  specific	  depletion	  of	  the	  peripheral	  Vδ2	  T	  cell	  population	  with	  consequences	  for	  the	  host’s	  ability	  to	  resist	  intercurrent	  infections49.	  	  Interestingly,	  γδ	  T	  cell	  levels	  and	  activity	  are	  high	  among	  patients	  who	  have	  natural	  control	  of	  HIV	  without	  the	  use	  of	  antiretroviral	  therapy50.	  	  	  Although	  it	  was	  originally	  believed	  that	  γδ	  T	  cells	  did	  not	  develop	  memory,	  the	  expression	  of	  CD45RA	  and	  CD27	  antigens	  that	  define	  four	  subsets	  of	  human	  Vγ9Vd2	  T	  cells	  with	  distinctive	  compartmentalization	  routes	  and	  functions	  has	  recently	  been	  described51.	  	  In	  peripheral	  blood,	  cells	  with	  the	  memory	  CD45RA–CD27+	  phenotype	  represent	  the	  most	  abundant	  Vγ9Vδ2	  subset.	  	  At	  inflammatory	  sites	  two	  Vγ9Vδ2	  subsets	  are	  detected-­‐	  an	  effector	  CD45RA–CD27–	  subset	  and	  a	  second	  subset	  with	  an	  unusual	  CD45RA+CD27–	  phenotype,	  which	  resembles	  a	  subset	  of	  terminally	  differentiated	  CD8	  memory	  T	  cells,	  suggesting	  an	  antigen	  induced	  differentiation.	  	  On	  further	  investigation,	  CD45RA+CD27–	  cells	  taken	  from	  inflammatory	  sites	  failed	  to	  proliferate	  and	  produced	  low	  amounts	  of	  IFNγ	  on	  IPP	  stimulation	  in	  vitro,	  but	  had	  increased	  levels	  of	  intracellular	  perforin	  and	  granulysin.	  	  It	  is	  possible	  that	  upon	  in	  vitro	  culture	  with	  antigen,	  Vγ9Vδ2	  T	  lymphocytes	  differentiate	  through	  the	  following	  lineage	  pattern:	  CD45RA+CD27+	  →	  CD45RA–CD27+	  →	  CD45RA–CD27–51.	  	  From	  a	  functional	  point	  of	  view,	  the	  CD45RA–CD27+	  central	  memory	  subset	  may	  represent	  a	  previously	  antigen-­‐primed	  Vγ9Vδ2	  population	  trafficking	  to	  the	  lymph	  nodes	  and	  upon	  encounter	  with	  antigen,	  generates	  a	  new	  wave	  of	  effector	  cells	  which	  further	  differentiate	  to	  cytotoxic	  terminally	  differentiated	  CD45RA+CD27–	  cells.	  Cord	  blood	  contains	  very	  low	  levels	  of	  the	  Vγ9Vδ2	  subset	  and	  this	  increases	  with	  age,	  so	  that	  by	  2	  years	  of	  age,	  children	  have	  adult	  levels.	  However,	  they	  are	  nearly	  all	  naïve	  at	  birth,	  with	  30%	  expressing	  a	  memory	  phenotype	  by	  1	  yr	  of	  age,	  increasing	  to	  60%	  (adult	  levels)	  by	  18	  years	  of	  age52.	  	  Neonatal	  γδ	  T	  cells	  are	  also	  weakly	  cytolytic	  with	  low	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adhesion	  molecule	  expression	  suggesting	  they	  are	  less	  able	  to	  mount	  an	  adequate	  immune	  response	  to	  Mtb53.	  
1.7. Gammadelta	  T	  cells	  and	  Tuberculosis.	  As	  mentioned,	  γδ	  T	  cells	  appear	  to	  play	  a	  role	  in	  the	  immune	  response	  to	  M.	  tuberculosis.	  Initial	  studies	  demonstrated	  that	  M.	  tuberculosis	  selectively	  expands	  human	  γδ	  T	  cells	  from	  healthy	  donors	  in	  vitro,	  with	  the	  majority	  of	  responding	  γδ	  T	  cells	  expressing	  Vγ9Vδ2	  chains54.	  	  Most	  studies	  in	  humans	  have	  shown	  that	  both	  the	  relative	  percentage	  and	  absolute	  numbers	  of	  peripheral	  blood	  γδ	  T	  cells	  are	  not	  changed	  during	  TB48,55,56.	  	  However,	  most	  of	  the	  cited	  studies	  involved	  adult	  patients.	  	  In	  children	  it	  was	  found	  that	  Vγ9Vδ2	  T	  cells	  from	  tuberculin	  (PPD)-­‐positive	  children,	  either	  healthy	  or	  affected	  by	  different	  clinical	  forms	  of	  TB,	  strongly	  proliferate	  to	  different	  phosphoantigens	  in	  vitro,	  while	  Vγ9Vδ2	  T	  cells	  from	  healthy	  PPD-­‐negative	  subjects	  proliferate	  very	  poorly57.	  	  This	  indicates	  that	  Vγ9Vδ2	  T	  cells	  require	  in	  vivo	  priming	  to	  be	  able	  to	  expand	  in	  vitro	  upon	  subsequent	  antigen	  stimulation.	  This	  is	  supported	  by	  the	  following	  observations:	  1)	  Vγ9Vδ2	  T	  cell	  proliferation	  is	  increased	  by	  BCG	  vaccination58;	  and	  2)	  Vγ9Vδ2	  T	  cell	  proliferation	  strongly	  decreases	  after	  chemoprophylaxis	  or	  chemotherapy,	  which	  is	  perhaps	  attributable	  to	  the	  reduction	  in	  bacterial	  load57,59.	  	  However,	  despite	  a	  very	  high	  proliferative	  capacity,	  the	  percentages	  of	  Vγ9Vδ2	  T	  cells	  containing	  IFNγ	  and	  granulysin	  were	  significantly	  reduced,	  when	  compared	  with	  those	  of	  healthy	  tuberculin-­‐positive	  children35.	  	  Similar	  findings	  have	  been	  reported	  for	  adult	  TB	  patients56,60.	  	  Gioia	  et	  al	  also	  found	  that	  a	  population	  of	  effector	  type	  CD27–	  Vγ9Vδ2	  T	  cells	  was	  strongly	  reduced	  in	  TB	  patients,	  while	  a	  population	  of	  central	  memory-­‐type	  CD27+	  Vγ9Vδ2	  was	  consistently	  increased60.	  	  Yokoburi	  et	  al	  identified	  that	  although	  central	  memory	  low	  IFNγ	  producing	  Vγ9Vδ2	  T	  cells	  were	  present	  in	  peripheral	  blood,	  effector	  type	  Vγ9Vδ2	  T	  cells	  were	  found	  in	  pleural	  effusions	  –	  i.e.	  at	  the	  site	  of	  infection61.	  	  Human	  in	  vitro	  work	  investigating	  this	  further	  identified	  that	  MTB-­‐infected	  DC’s	  induced	  proliferative,	  but	  not	  cytokine	  producing	  or	  cytolytic	  responses	  of	  Vγ9Vδ2	  T	  cells,	  and	  this	  was	  associated	  with	  the	  expansion	  of	  phenotypically	  immature,	  central	  memory-­‐type	  Vγ9Vδ2	  T	  cells	  and	  reduction	  of	  the	  pool	  of	  effector	  and	  terminally	  differentiated	  Vγ9Vδ2	  T	  cells.	  	  This	  effect	  was	  demonstrated	  in	  vivo	  also	  in	  adult	  patients	  with	  active	  TB62.	  	  However,	  Spencer	  et	  al,	  using	  a	  functional	  mycobacterial	  growth	  assay,	  demonstrated	  that	  mycobacterial	  antigen	  specific	  γδ	  T	  cells,	  but	  not	  phosphoantigen	  stimulated	  γδ	  T	  cells,	  could	  inhibit	  mycobacterial	  growth63.	  	  	  More	  recent	  work	  in	  mice	  has	  suggested	  that	  γδ	  T	  cells	  are	  a	  significant	  source	  of	  IL17,	  a	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cytokine	  believed	  to	  be	  of	  importance	  in	  mycobacterial	  infection.	  	  Peng	  et	  al	  demonstrated	  that	  in	  adult	  patients	  with	  active	  TB,	  γδ	  T	  cells	  producing	  IL17	  were	  increased	  compared	  to	  healthy	  controls64.	  	  There	  have	  been	  few	  other	  studies	  to	  date.	  
1.8. IL17	  IL17	  is	  a	  pro-­‐inflammatory	  cytokine	  that	  appears	  unique	  amongst	  cytokines	  with	  no	  clear	  resemblance	  to	  any	  known	  protein	  or	  structural	  domain	  and	  it	  has	  its	  own	  distinct	  receptor	  and	  signaling	  pathway.	  	  	  There	  are	  at	  least	  6	  members	  of	  the	  IL17	  family	  –	  IL17	  A-­‐F	  -­‐	  which	  are	  all	  expressed	  as	  dimers.	  	  Both	  IL-­‐17A	  and	  IL-­‐17F	  have	  pro-­‐inflammatory	  properties	  and	  act	  on	  a	  broad	  range	  of	  cell	  types	  to	  induce	  the	  expression	  of	  cytokines	  (IL-­‐6,	  IL-­‐8,	  GM-­‐CSF,	  G-­‐CSF),	  chemokines	  (CXCL1,	  CXCL10)	  and	  metalloproteinases65.	  IL-­‐17A	  and	  IL-­‐17F	  are	  also	  key	  cytokines	  for	  the	  recruitment,	  activation	  and	  migration	  of	  neutrophils66,67.	  IL17	  also	  stimulates	  the	  production	  of	  the	  costimulatory	  molecule	  intercellular	  adhesion	  molecule	  (ICAM)	  promoting	  further	  T	  cell	  responses68.	  	  Hence,	  IL17	  promotes	  both	  an	  innate	  immune	  response	  (via	  neutrophil	  recruitment	  and	  expansion	  of	  myeloid	  line)	  and	  an	  adaptive	  immune	  response	  (through	  ICAM	  induction).	  	  The	  functional	  analysis	  of	  IL-­‐17	  has	  suggested	  an	  important	  and	  unique	  role	  for	  this	  cytokine	  in	  host	  protection	  against	  specific	  pathogens.	  The	  production	  of	  IL-­‐17	  and	  the	  recruitment	  of	  neutrophils	  seem	  important	  in	  host	  protection	  against	  Gram-­‐negative	  bacteria	  and	  fungal	  infections	  and	  IL17	  is	  preferentially	  produced	  in	  infections	  with	  
Klebsiella	  pneumonia,	  Bacteroides	  fragilis,	  Borrelia	  burgdorferi,	  Mycobacterium	  
tuberculosis67.	  	  Overproduction	  of	  IL17	  is	  associated	  with	  chronic	  inflammatory	  and	  autoimmune	  diseases,	  such	  as	  Rheumatoid	  Arthritis	  and	  Multiple	  Sclerosis69.	  	  	  	  
IL-­‐17	  is	  produced	  by	  activated	  memory	  T	  cells,	  but	  categorization	  into	  Th1/Th2	  has	  proven	  difficult,	  indeed	  both	  IFNγ	  and	  IL4,	  the	  key	  cytokines	  produced	  by	  Th1/Th2	  respectively,	  inhibit	  the	  production	  of	  IL17.	  	  Thus	  it	  was	  proposed	  that	  IL17	  producing	  T	  cells	  represented	  a	  new	  lineage	  or	  Th17	  cells.	  	  	  
Activation	  of	  T	  cells	  in	  the	  presence	  of	  IL23,	  a	  member	  of	  the	  IL12	  family,	  leads	  to	  the	  expansion	  of	  IL-­‐17	  producing	  T	  cells70.	  	  However,	  IL23	  is	  not	  the	  differentiation	  factor,	  but	  probably	  acts	  on	  already	  differentiated	  T	  cells	  to	  stabilize	  the	  Th17	  phenotype.	  	  Th17	  cells	  specifically	  express	  and	  require	  the	  presence	  of	  the	  transcription	  factor	  RORγt	  and	  the	  complete	  complex	  signaling	  pathway	  has	  not	  yet	  been	  described71.	  	  IL6	  and	  TGFβ 	  together	  lead	  to	  the	  differentiation	  of	  IL17	  producing	  T	  cells,	  most	  likely	  through	  activation	  of	  STAT1	  and	  STAT3.	  	  Interestingly,	  TGFβ 	  alone	  leads	  to	  the	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activation	  of	  FoxP3	  and	  regulatory	  T	  cells,	  and	  there	  appears	  to	  be	  a	  reciprocal	  relationship	  between	  Foxp3+	  regulatory	  T	  cells	  and	  Th17	  cells	  in	  which	  IL-­‐6	  plays	  a	  pivotal	  role	  in	  dictating	  whether	  the	  immune	  response	  is	  dominated	  by	  pro-­‐inflammatory	  Th17	  cells	  or	  protective	  regulatory	  T	  cells72.	  	  IL21,	  a	  cytokine	  highly	  expressed	  by	  IL17	  producing	  T	  cells,	  can	  also	  lead	  to	  the	  differentiation	  of	  naïve	  T	  cells	  in	  the	  presence	  of	  TGFβ	  in	  the	  absence	  of	  IL6.	  	  Furthermore,	  IL-­‐21	  is	  induced	  not	  only	  by	  IL-­‐6	  plus	  TGF-­‐β	  but	  also	  by	  IL-­‐6	  alone73.	  	  This	  suggests	  that	  IL-­‐21	  can	  be	  produced	  in	  vivo	  under	  inflammatory	  conditions	  and	  must	  develop	  a	  positive	  feedback	  loop	  to	  further	  amplify	  the	  Th17	  response.	  	  IL-­‐1β	  and	  IL-­‐6,	  in	  the	  absence	  of	  TFGβ,	  can	  also	  lead	  to	  the	  differentiation	  of	  IL17	  producing	  RORγT	  expressing	  T	  cells	  –	  in	  fact	  IL-­‐1β	  alone	  induces	  the	  expression	  of	  RORγT	  and	  production	  of	  both	  IFNγ	  and	  IL-­‐17,	  the	  addition	  of	  IL-­‐6	  promoted	  the	  differentiation	  of	  IL-­‐17	  production	  alone74.	  More	  recently,	  T	  cells	  producing	  both	  IFNγ	  and	  IL17	  have	  been	  described	  in	  a	  number	  of	  circumstances,	  including	  Mtb	  infection,	  and	  whether	  these	  cells	  are	  Th1	  or	  Th17	  polarised	  is	  undetermined75.	  	  The	  extent	  to	  which	  IL17	  producing	  T	  cells	  represent	  terminally	  differentiated	  cells	  or	  whether	  they	  retain	  plasticity	  and	  can	  develop	  into	  another	  lineage	  such	  as	  IFNγ	  secreting	  Th1	  cells	  is	  under	  investigation	  and	  may	  play	  an	  important	  role	  in	  an	  effective	  immune	  response	  to	  Mtb76.	  	  	  IL17	  is	  produced	  by	  both	  αβ	  and	  γδ	  T	  cells.	  	  Work	  looking	  at	  the	  cytokines	  required	  for	  differentiation	  of	  Vγ9Vδ2	  T	  cells	  (those	  which	  respond	  to	  Mtb,	  see	  above)	  has	  demonstrated	  that	  IL-­‐6,	  IL-­‐1b,	  and	  TGF-­‐β	  are	  required	  to	  generate	  IL17	  producing	  γδ	  T	  cells	  (T	  γδ	  17	  cells)	  in	  neonates,	  whereas	  IFNγ/IL17	  co-­‐producing	  γδ	  T	  cells	  (T	  γδ	  1/17	  cells)	  additionally	  required	  IL-­‐23.	  In	  adults,	  memory	  T	  γδ	  1/17	  and	  T	  γδ	  17	  cells	  required	  IL-­‐23,	  IL-­‐1b,	  and	  TGF-­‐b,	  but	  not	  IL-­‐677.	  	  The	  plasticity	  and	  different	  responses	  of	  naïve	  and	  memory	  IL17	  producing	  T	  cells	  may	  explain	  some	  of	  the	  age-­‐related	  differences	  in	  the	  immune	  response	  to	  TB.	  
1.9. IL17	  and	  TB	  in	  Mice	  Murine	  researchers	  investigating	  various	  components	  of	  the	  immune	  response	  to	  mycobacteria	  examined	  members	  of	  the	  IL12	  family,	  as	  IL12	  is	  known	  to	  play	  an	  important	  role	  in	  immune	  responses	  to	  mycobacteria.	  IL23,	  a	  cytokine	  produced	  by	  macrophages	  and	  dendritic	  cells,	  is	  composed	  of	  an	  IL-­‐23-­‐specific	  p19	  subunit	  and	  a	  p40	  subunit	  common	  to	  IL-­‐12	  and	  IL-­‐23.	  	  The	  IL-­‐23R	  also	  consists	  of	  two	  components,	  a	  unique	  IL-­‐23R	  subunit	  (IL-­‐23R)	  and	  a	  subunit	  shared	  by	  IL-­‐12	  and	  IL-­‐23	  receptors	  (IL-­‐
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12R1).	  	  Given	  the	  close	  relationship	  between	  IL23	  and	  Il12,	  IL23	  was	  further	  investigated.	  	  Mice	  lacking	  both	  IL-­‐12	  and	  IL-­‐23	  (IL-­‐12/23p40-­‐deficient	  mice)	  had	  a	  higher	  bacterial	  burden	  in	  BCG-­‐	  or	  Mtb-­‐	  infected	  organs	  than	  mice	  deficient	  in	  IL-­‐12	  alone	  (IL-­‐12p35-­‐deficient	  mice)78	  .	  	  However,	  IL-­‐23p19-­‐deficient	  mice	  did	  not	  demonstrate	  the	  same	  susceptibility	  to	  infection79.	  	  IL23	  plays	  a	  primary	  role	  in	  mice	  of	  inducing	  the	  expression	  of	  IL17	  producing	  T	  cells	  and	  the	  role	  of	  IL17	  in	  murine	  mycobacterial	  infections	  was	  further	  studied.	  	  	  The	  role	  of	  IL17	  producing	  T	  cells	  was	  first	  examined	  in	  mycobacteria	  infected	  IFNγ	  deficient	  mice	  who	  were	  noted	  to	  have	  enhanced	  numbers	  of	  neutrophils	  in	  granulomatous	  lesions,	  but	  poor	  control	  of	  bacterial	  growth	  and	  decreased	  tissue	  integrity.	  	  This	  was	  associated	  with	  an	  increase	  in	  IL17	  producing	  T	  cells.	  	  The	  addition	  of	  exogenous	  IFNγ	  led	  to	  a	  decrease	  in	  IL23	  and	  a	  subsequent	  decrease	  in	  IL17	  producing	  T	  cells.	  	  This	  led	  to	  questions	  about	  the	  role	  of	  a	  balance	  between	  IFNγ	  and	  IL17	  producing	  T	  cells	  in	  limiting	  immune	  mediated	  pathology	  in	  tuberculosis80.	  	  Further	  work	  identified	  that	  γδ	  T	  cells	  were	  producing	  much	  of	  the	  IL17	  in	  mice	  infected	  with	  mycobacteria	  and	  suggested	  an	  important	  role	  of	  IL17	  in	  the	  innate	  immune	  response	  to	  mycobacteria.	  	  IL17	  knockout	  mice	  were	  developed	  and	  these	  produced	  less	  IFNγ	  and	  had	  impaired	  granuloma	  formation	  following	  infection	  with	  mycobacteria.	  IL23	  is	  known	  to	  act	  on	  memory	  or	  activated	  T	  cells	  and	  investigations	  into	  its	  role	  in	  vaccine	  responses	  has	  demonstrated	  that	  it	  is	  essential	  for	  response	  to	  a	  mycobacterial	  DNA	  vaccine,	  for	  the	  generation	  of	  IFNγ	  producing	  T	  cells	  and	  that	  IL17	  producing	  T	  cells	  played	  an	  important	  role	  in	  both	  the	  initial	  and	  a	  recall	  response81.	  	  This	  has	  led	  to	  the	  development	  of	  a	  hypothetical	  dual	  role	  for	  IL17	  in	  murine	  mycobacterial	  infections:	  firstly	  as	  an	  innate	  immune	  response,	  produced	  by	  γδ	  T	  cells	  to	  recruit	  neutrophils	  to	  the	  site	  of	  infection	  and	  initiate	  a	  more	  specific	  T	  cell	  response;	  secondly	  for	  previously	  antigen	  specific	  primed	  memory	  IL17	  T	  cells	  to	  produce	  chemokines	  that	  accelerate	  the	  response	  of	  memory	  IFNγ	  producing	  T	  cells82.	  	  Khader	  et	  al	  also	  hypothesized	  that	  the	  stability	  of	  the	  granuloma	  and	  the	  development	  of	  progressive/disseminated	  disease	  was	  likely	  to	  rest	  on	  the	  balance	  between	  antigen	  specific	  memory	  IL17	  and	  IFNγ	  producing	  T	  cells.	  
1.10. IL17	  and	  TB	  in	  humans	  Fewer	  studies	  investigation	  the	  role	  of	  IL17	  producing	  T	  cells	  in	  humans	  have	  been	  done.	  	  	  A	  similar	  cross-­‐regulatory	  role	  between	  IL12	  and	  IL23	  on	  IL17	  production	  exists	  (IL23	  promotes	  IL17	  production,	  while	  IL12	  inhibits	  it)83.	  	  In	  adults	  with	  pulmonary	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tuberculosis,	  levels	  of	  mycobacteria	  specific	  IL17	  producing	  T	  cells	  were	  reduced	  in	  peripheral	  blood	  compared	  to	  healthy	  controls84.	  	  Interestingly,	  these	  IL17	  producing	  T	  cells	  display	  a	  ‘central	  memory’	  phenotype	  (CCR7+	  CD45RA-­‐)	  distinct	  from	  the	  Th1	  population’s	  ‘effector	  memory’	  phenotype,	  indicating	  that	  mycobacteria-­‐specific	  IL17	  producing	  T	  cells	  may	  provide	  long-­‐lasting	  immunity	  while	  Th1	  cells	  more	  rapidly	  target	  the	  site	  of	  infection	  but	  may	  not	  expand	  or	  survive	  long-­‐term.	  	  mRNA	  for	  IL17	  and	  IL23	  was	  measured	  in	  the	  lungs	  and	  peripheral	  blood	  of	  TB	  patients	  and	  controls	  and	  no	  difference	  was	  noted	  in	  IL17mRNA	  between	  patients	  and	  controls.	  	  However,	  IL23	  mRNA	  was	  increased	  in	  the	  lungs	  but	  not	  the	  blood	  of	  TB	  patients	  compared	  to	  controls85.	  	  One	  group	  has	  identified	  an	  increased	  number	  of	  IL17	  producing	  γδ	  T	  cells	  in	  peripheral	  blood	  of	  patients	  with	  TB	  versus	  healthy	  controls	  and	  this	  was	  associated	  with	  a	  decrease	  in	  IFNγ	  producing	  γδ	  T	  cells	  in	  the	  same	  patients.	  	  The	  number	  of	  IL17	  producing	  CD4+	  T	  cells	  was	  unchanged	  in	  the	  two	  groups64.	  Modified	  vaccinia	  Ankara-­‐expressing	  Ag85A	  (MVA85A),	  a	  recombinant	  strain	  of	  modified	  vaccinia	  Ankara-­‐expressing	  Ag85A	  from	  Mtb	  is	  one	  of	  a	  number	  of	  TB	  candidate	  vaccines	  undergoing	  clinical	  trials	  currently.	  A	  novel	  population	  of	  polyfunctional	  CD41	  T	  cells	  that	  co-­‐	  expressed	  all	  four	  of	  IFNγ,	  IL2,	  TNFα	  and	  IL17	  was	  induced	  in	  adolescents,	  but	  not	  young	  children,	  vaccinated	  with	  MVA85A.	  	  The	  significance	  of	  these	  polyfunctional	  T	  cells	  is	  not	  yet	  known86.	  	  The	  phenotype	  of	  the	  majority	  of	  T	  cells	  induced	  was	  effector	  memory	  cells	  (CCR7+CD45RA-­‐).	  	  Further	  work	  looking	  at	  the	  responses	  to	  MVA85A	  in	  adults	  identified	  that	  prior	  exposure	  to	  mycobacterial	  antigens	  led	  to	  decreased	  numbers	  of	  IL17	  producing	  T	  cells	  and	  increased	  numbers	  of	  regulatory	  T	  cells87.	  	  The	  impact	  of	  this	  on	  vaccine	  efficacy	  is	  not	  known.	  	  This	  effect	  was	  also	  seen	  in	  a	  study	  looking	  at	  timing	  of	  BCG	  vaccination	  in	  infants	  –	  those	  vaccinated	  at	  birth	  had	  greater	  IL17	  responses	  at	  12	  weeks	  post	  vaccination	  than	  those	  vaccinated	  at	  12	  weeks	  of	  age	  –	  this	  was	  hypothesized	  to	  be	  related	  to	  exposure	  to	  non-­‐tuberculous	  mycobacteria	  in	  the	  interim18.	  	  These	  few	  studies	  indicate	  that	  IL17	  has	  a	  role	  to	  play	  in	  the	  human	  immune	  response	  to	  tuberculosis	  and	  regulation	  of	  IL-­‐17	  may	  be	  critical	  to	  promote	  appropriate,	  but	  not	  excessive,	  lung	  inflammation	  in	  TB.	  	  This	  regulation	  may	  be	  distorted	  in	  children	  who	  have	  greater	  numbers	  of	  naïve	  and	  γδ	  T	  cells	  and	  altered	  IL12	  and	  IFNγ	  responses	  leading	  to	  disseminated	  TB	  disease.	  
1.11. IL22	  and	  Tuberculosis	  IL22	  is	  produced	  in	  addition	  to	  IL17A	  and	  IL17	  F	  by	  IL17	  producing	  T	  cells.	  	  IL-­‐22	  is	  a	  member	  of	  the	  IL10	  family	  and	  modulates	  tissue	  responses	  during	  inflammation.	  Through	  activation	  of	  Stat3-­‐signaling	  cascades,	  the	  cytokine	  induces	  proliferative	  and	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anti-­‐apoptotic	  pathways,	  as	  well	  as	  anti-­‐microbial	  molecules,	  that	  help	  prevent	  tissue	  damage	  and	  aid	  in	  its	  repair.	  	  IL22	  is	  expressed	  by	  both	  the	  adaptive	  arm	  of	  the	  immune	  system,	  such	  as	  CD4	  T	  cell	  subsets,	  as	  well	  as	  by	  innate	  lymphocytes,	  including	  NK	  cells88,89.	  	  IL22	  has	  dual	  functions	  –	  when	  secreted	  alongside	  IFNγ,	  TNFα	  and	  IL2,	  it	  enhances	  the	  pro-­‐inflammatory	  immune	  reaction,	  but	  unlike	  IL17,	  when	  produced	  alone,	  IL22	  has	  protective	  and	  regenerative	  functions90,91.	  	  More	  recently,	  due	  to	  its	  relationships	  with	  IL17	  producing	  T	  cells,	  its	  role	  in	  the	  immune	  response	  to	  mycobacteria	  has	  been	  investigated.	  	  In	  non-­‐human	  primates	  with	  severe	  TB	  disease,	  unbalanced	  upregulation	  of	  immune	  gene	  networks,	  including	  overexpression	  of	  IL22,	  was	  demonstrated	  by	  Yao	  et	  al92.	  	  In	  human	  work,	  Scriba	  et	  al	  described	  a	  distinct	  subset	  of	  IL22	  producing	  T	  cells	  in	  the	  lungs	  of	  patients	  with	  TB	  disease	  and	  IL22	  was	  found	  to	  be	  more	  abundant	  in	  both	  blood	  and	  at	  the	  disease	  site	  of	  patients	  with	  pericardial	  TB	  disease84,93.	  	  To	  date,	  its	  role	  in	  BCG	  vaccine	  responses	  or	  TB	  disease	  in	  children	  has	  not	  been	  explored.	  
1.12. Regulatory	  T	  cells	  Regulatory	  T	  cells	  with	  the	  CD4+CD25+FOXP3+	  phenotype	  (Tregs)	  represent	  5	  to	  10%	  of	  circulating	  CD4+	  T	  cells	  but	  in	  humans	  only	  the	  subset	  expressing	  higher	  levels	  of	  CD25	  (a	  chain	  of	  IL-­‐2R)	  exhibit	  a	  strong	  suppressive	  capacity94.	  	  Tregs	  are	  a	  key	  component	  of	  peripheral	  tolerance	  suppressing	  auto-­‐reactive	  T	  cells	  and	  preventing	  autoimmune	  diseases.	  	  Human	  FOXP3+	  regulatory	  T	  cells	  exist	  in	  two	  forms	  –	  either	  thymically	  derived	  or	  peripherally	  induced.	  	  No	  cell	  surface	  markers	  have	  been	  identified	  to	  distinguish	  between	  the	  two	  types	  and	  it	  is	  unclear	  if	  there	  are	  any	  functional	  differences.	  	  Antigen-­‐specific	  peripherally	  induced	  regulatory	  T	  cells	  have	  been	  demonstrated	  to	  be	  actively	  suppressive	  using	  the	  same	  mechanisms	  as	  thymically	  derived	  regulatory	  T	  cells,	  i.e.	  via	  direct	  cell	  to	  cell	  contact,	  IL10	  and	  TGFβ	  production	  and	  ATP	  consumption95.	  	  The	  main	  difference	  is	  that	  peripherally	  induced	  regulatory	  T	  cells	  have	  a	  shorter	  life	  span	  than	  those	  derived	  from	  the	  thymus96.	  	  	  There	  is	  strong	  evidence	  that	  Tregs	  are	  involved	  in	  the	  immune	  response	  against	  Mtb,	  although	  whether	  this	  is	  protective	  or	  pathogenic	  remains	  a	  topic	  of	  debate.	  	  Adults	  with	  TB	  infection	  and	  disease	  have	  increased	  levels	  of	  Tregs	  in	  comparison	  to	  healthy	  controls	  and	  particularly	  in	  those	  patients	  with	  extra-­‐pulmonary	  TB	  disease97-­‐99.	  	  Raised	  levels	  of	  Tregs	  persist	  even	  in	  patients	  with	  ‘cured’	  extrapulmonary	  TB100,101.	  	  Additionally,	  Tregs	  have	  been	  shown	  to	  suppress	  IFNγ	  production	  in	  patients	  with	  TB	  disease98,102.	  	  Semple	  et	  al	  recently	  reported	  a	  greater	  increase	  in	  Tregs	  in	  patients	  with	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active	  TB	  disease	  compared	  to	  LTBI,	  particularly	  in	  bronchoalveolar	  lavage	  (BAL)	  samples;	  that	  Tregs	  mediated	  suppression	  of	  T	  helper	  cell	  proliferation	  in	  a	  dose	  dependent	  manner	  and	  finally	  that	  mycobacterial	  growth	  restriction	  in	  infected	  alveolar	  macrophages	  was	  affected	  by	  the	  addition	  of	  Tregs103.	  	  	  FOXP3	  expression	  correlates	  well	  with	  regulatory	  activity;	  it	  is	  expressed	  in	  CD4+CD25+	  Tregs	  and	  is	  considered	  a	  key	  player	  for	  their	  development	  and	  function.	  	  FoxP3	  represses	  IL-­‐2,	  IL-­‐4	  and	  IFNγ	  gene	  expression	  and	  interacts	  with	  nuclear	  transcription	  factors	  of	  activated	  T	  cells	  (nuclear	  factor-­‐kB,	  nuclear	  factor	  of	  activated	  cells),	  resulting	  in	  poor	  cytokine	  production	  and	  impaired	  proliferation104.	  However,	  the	  FoxP3	  marker	  is	  also	  present	  in	  activated	  T	  cells	  in	  the	  presence	  of	  IL2105.	  	  Recently,	  CD39	  was	  found	  to	  be	  expressed	  on	  a	  subpopulation	  of	  Treg	  cells.	  	  CD39	  is	  an	  ectonucleotidase	  that	  cleaves	  ATP	  in	  a	  rate-­‐limiting	  step	  to	  form	  AMP,	  which	  can	  then	  be	  cleaved	  by	  CD73	  to	  form	  adenosine.	  Extracellular	  ATP	  has	  multiple	  proinflammatory	  effects,	  and	  its	  removal	  may	  therefore	  have	  a	  net	  anti-­‐inflammatory	  influence106.	  	  CD4+CD25hiCD39+FoxP3+	  cells	  are	  found	  to	  suppress	  IL17	  production107	  and	  they	  are	  increased	  in	  TB	  patients	  after	  antigen-­‐specific	  stimulation	  both	  in	  the	  presence	  or	  absence	  of	  IL-­‐2.	  	  Depletion	  of	  CD4+CD25hiCD39+FoxP3+	  led	  to	  increased	  antigen	  specific	  IFNγ	  responses108.	  	  	  	  	  The	  role	  of	  regulatory	  T	  cells	  as	  part	  of	  an	  effective	  vaccine	  response	  has	  been	  investigated	  in	  a	  couple	  of	  animal	  and	  human	  models.	  	  In	  a	  murine	  model,	  Quinn	  et	  al	  found	  that	  despite	  the	  inactivation	  of	  regulatory	  T	  cells	  leading	  to	  increased	  numbers	  of	  antigen	  specific	  IFNγ+	  CD4	  T	  cells,	  this	  was	  not	  associated	  with	  increased	  protection	  from	  virulent	  Mtb	  infection109.	  	  DeCassan	  et	  al	  described	  both	  the	  induction	  of	  regulatory	  T	  cells	  in	  response	  to	  the	  vaccine	  candidate	  MVA85A,	  and	  an	  association	  with	  higher	  levels	  of	  CD4+CD39+FOXP3+	  T	  cells	  in	  those	  with	  pre-­‐existing	  immune	  responses	  to	  mycobacterial	  antigens87.	  Neither	  the	  role	  of	  regulatory	  T	  cells	  nor	  the	  relationship	  with	  IL17	  producing	  T	  cells	  has	  been	  investigated	  in	  children	  with	  tuberculosis	  to	  date.	  	  
1.13. Other	  cytokines	  related	  to	  the	  TH17	  pathway	  IL1β	  plays	  an	  important	  role	  in	  host	  protection	  against	  infection	  but	  can	  also	  promote	  tissue	  damage	  in	  chronic	  inflammatory	  diseases.	  	  IL1β	  and	  its	  antagonist	  IL1Ra	  (IL1	  receptor	  agonist)	  are	  both	  strongly	  induced	  by	  Mtb	  in	  humans.	  	  Genetic	  polymorphisms	  of	  the	  IL1	  locus	  are	  recognized	  to	  influence	  cytokine	  expression	  and	  disease	  expression	  in	  human	  TB110.	  	  In	  murine	  and	  human	  studies,	  IL-­‐1β	  synergizes	  with	  IL23	  to	  induce	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IL17	  production	  from	  CD4	  and	  γδ	  T	  cells	  in	  the	  presence	  or	  absence	  of	  TCR	  engagement74,111.	  	  Naive	  γδ	  T	  cells	  present	  in	  neonates	  are	  polarized	  to	  an	  IL17	  producing	  γδ	  T	  cell	  phenotype	  by	  antigen	  activation	  in	  the	  presence	  of	  IL-­‐6,	  IL-­‐1β,	  and	  TGF-­‐β.	  	  However,	  in	  adults,	  IL-­‐23,	  in	  addition	  to	  IL1β	  and	  TGFβ,	  but	  not	  IL6	  is	  required	  for	  expansion	  of	  IL17	  producing	  γδT	  cells77.	  	  Following	  recent	  large	  biomarker	  studies	  suggesting	  the	  importance	  of	  type	  I	  IFN	  signaling	  in	  TB	  disease,	  the	  role	  of	  IL1β	  is	  being	  further	  explored	  as	  the	  IL1	  family	  commonly	  counter	  the	  IFN	  pathways	  in	  immune	  control112-­‐114.	  	  A	  recent	  study	  has	  shown	  that	  a	  M.	  tuberculosis	  Zn2+	  metalloprotease,	  Rv0198c	  (zmp1),	  required	  for	  full	  virulence	  of	  the	  pathogen	  in	  mice,	  suppresses	  IL1β	  processing	  by	  inhibiting	  inflammasome	  activation	  in	  murine	  macrophages115.	  This	  observation	  has	  led	  to	  the	  hypothesis	  that	  mycobacteria	  regulate	  IL-­‐1b	  maturation	  as	  part	  of	  their	  survival	  strategy	  in	  macrophages116.	  	  Kumar	  et	  al	  found	  no	  significant	  differences	  in	  IL1β	  secretion	  following	  PPD	  or	  Mtb	  CFP	  stimulation	  of	  PBMC’s	  for	  24hrs	  between	  healthy	  controls	  and	  children	  with	  TB	  disease117.	  	  In	  a	  further	  publication	  by	  the	  same	  group,	  no	  differences	  in	  IL1β	  levels	  in	  unstimulated	  plasma	  were	  identified	  between	  healthy	  TB	  uninfected	  children	  and	  those	  with	  pulmonary	  or	  extrapulmonary	  TB117.	  	  Interleukin4	  (IL4)	  is	  a	  cytokine	  that	  induces	  differentiation	  of	  naive	  helper	  T	  cells	  (Th0	  cells)	  to	  Th2	  cells.	  	  It	  has	  many	  biological	  roles,	  including	  the	  stimulation	  of	  activated	  B-­‐cell	  and	  T-­‐cell	  proliferation,	  and	  the	  differentiation	  B	  cells	  into	  Plasma	  Cells.	  	  It	  is	  a	  key	  regulator	  in	  humoral	  and	  adaptive	  immunity.	  	  IL4	  decreases	  the	  production	  of	  Th1	  cells,	  macrophages,	  IFNγ	  and	  IL12.	  	  Persistently	  increased	  levels	  in	  patients	  exposed	  to	  TB	  were	  associated	  with	  subsequent	  development	  of	  active	  TB	  disease118,119.	  	  Studies	  measuring	  secreted	  cytokines	  in	  patients	  with	  TB	  compared	  to	  healthy	  controls	  have	  not	  identified	  any	  differences	  in	  levels	  of	  IL4117,120,121	  .	  IL-­‐6	  is	  a	  pleiotropic	  cytokine	  with	  a	  wide	  range	  of	  biological	  activities	  in	  immune	  regulation,	  hematopoiesis,	  inflammation	  and	  oncogenesis122.	  	  It	  has	  been	  identified	  as	  a	  possible	  biomarker	  for	  TB113.	  	  IL6	  and	  TGFβ	  drive	  the	  production	  of	  IL17	  and	  IL10	  by	  T	  cells123	  and	  IL6	  receptor	  expression	  in	  patients	  with	  TB	  correlates	  with	  a	  reduced	  IL17	  T	  cell	  response124	  .	  IL10	  is	  made	  by	  T	  cells,	  B	  cells,	  neutrophils,	  macrophages	  and	  dendritic	  cells	  and	  inhibits	  the	  ability	  of	  macrophages	  and	  dendritic	  cells	  from	  activating	  Th1	  T	  cells	  via	  blockage	  of	  pro-­‐inflammatory	  cytokines	  such	  as	  TNFα	  and	  IL12.	  	  It	  can	  also	  directly	  inhibit	  phagocytosis	  and	  the	  production	  of	  reactive	  oxygen	  products.	  	  Regulatory	  T	  cells	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serve	  as	  a	  major	  source	  of	  immunoregulatory	  IL10125.	  	  IL10	  is	  increased	  in	  the	  lungs	  and	  blood	  of	  patients	  with	  TB	  disease	  and	  neutralization	  of	  IL10	  enhances	  and	  sustains	  Th1	  and	  IL17	  responses	  to	  Mtb126.	  	  Kumar	  et	  al	  showed	  no	  significant	  differences	  in	  IL10	  production	  after	  24	  hour	  stimulation	  of	  PBMC’s	  in	  children	  with	  TB	  compared	  to	  healthy	  controls	  or	  in	  ex	  vivo	  plasma	  samples	  from	  the	  same	  groups	  of	  children117,121.	  IL21	  is	  both	  produced	  in	  addition	  to	  IL17A	  and	  IL17	  F	  by	  IL17	  producing	  T	  cells.	  	  IL21	  is	  important	  for	  driving	  IL17	  production.	  	  It	  is	  a	  cytokine	  with	  immunoregulatory	  activity	  and	  may	  promote	  the	  transition	  between	  innate	  and	  adaptive	  immunity.	  	  It	  is	  also	  produced	  by	  follicular	  helper	  T	  cells	  and	  induces	  the	  production	  of	  IgG	  in	  B	  cells	  and	  may	  regulate	  proliferation	  of	  mature	  B	  and	  T	  cells	  in	  response	  to	  IL15127,128.	  	  Expression	  of	  IL21	  in	  unstimulated,	  but	  not	  PPD	  stimulated	  samples	  of	  PBMCs	  from	  children	  with	  TB	  was	  suppressed	  compared	  to	  healthy	  control	  responses,	  however	  in	  ex-­‐vivo	  plasma	  samples,	  the	  levels	  were	  increased117,121.	  	  IL23	  is	  a	  member	  of	  the	  IL12	  family,	  sharing	  the	  p40	  subunit	  coupled	  to	  a	  second	  subunit	  p19.	  	  Similarly	  to	  IL12,	  deficiencies	  in	  the	  p19	  subunit	  enhance	  susceptibility	  to	  mycobacterial	  disease129.	  	  IL23	  in	  humans	  is	  important	  to	  maintain	  IL17	  responses,	  but	  unlike	  mice	  it	  is	  not	  essential	  for	  their	  induction.	  	  Increased	  IL23	  expression	  in	  the	  lungs	  of	  patients	  with	  TB	  supports	  a	  role	  for	  this	  cytokine	  in	  TB	  immunity85.	  	  IL23	  production	  was	  suppressed	  in	  PPD	  stimulated	  PBMC’s	  from	  children	  with	  TB	  compared	  to	  healthy	  controls	  in	  a	  small	  study	  by	  Kumar	  et	  al117.	  	  	  	  IL31	  is	  a	  member	  of	  the	  IL6	  family	  produced	  by	  Th2	  T	  cells.	  	  It	  may	  have	  a	  role	  in	  allergic	  and	  autoimmune	  skin,	  lung	  and	  bowel	  conditions	  alongside	  IL17130.	  	  	  IL33	  is	  a	  member	  of	  the	  IL1	  family	  and	  promotes	  protection	  against	  helminth	  infections	  via	  Th2	  responses	  –	  it	  is	  also	  involved	  in	  the	  pathogenesis	  of	  asthma	  and	  other	  inflammatory	  lung	  conditions131.	  	  IL33	  can	  suppress	  IL17	  and	  IFNγ	  responses	  in	  mice,	  but	  the	  role	  of	  IL33	  in	  human	  TB	  has	  not	  been	  examined	  to	  date132.	  
IFNγ	  is	  one	  of	  the	  key	  cytokines	  involved	  in	  protection	  from	  TB	  and	  its	  role	  in	  mycobacterial	  immune	  responses	  is	  described	  in	  detail	  above.	  	  	  Soluble	  CD40	  ligand	  (sCD40L)	  interacts	  with	  CD40	  on	  endothelial	  and	  smooth	  muscle	  cells	  to	  trigger	  the	  release	  of	  inflammatory	  mediators.	  CD40	  is	  a	  cell	  surface	  receptor	  that	  belongs	  to	  the	  TNF	  receptor	  superfamily133.	  	  Baseline	  levels	  of	  sCD40L	  in	  one	  TB	  biomarker	  study	  were	  useful	  for	  distinguishing	  between	  TB	  disease	  and	  latent	  TB	  infection134.	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TNFα	  is	  a	  cytokine	  involved	  in	  systemic	  inflammation	  and	  plays	  an	  essential	  role	  in	  the	  immune	  response	  to	  TB135.	  	  In	  children	  with	  TB	  disease,	  secreted	  levels	  of	  TNFα	  were	  suppressed	  compared	  to	  those	  in	  healthy	  controls	  following	  stimulation	  with	  CFP,	  but	  not	  PPD;	  there	  were	  no	  differences	  in	  ex-­‐vivo	  plasma	  samples117,121.	  
1.14. Conclusions	  In	  summary,	  the	  characteristics	  of	  a	  protective	  immune	  response	  to	  TB	  remain	  elusive.	  	  Increasing	  our	  comprehension	  of	  the	  mechanisms	  underlying	  ‘protective	  immunity’	  is	  essential	  for	  the	  development	  of	  efficacious	  vaccines,	  better	  diagnostics	  and	  immunotherapy	  for	  TB.	  	  Determining	  the	  mechanism	  of	  ‘TB	  containment’	  through	  the	  study	  of	  different	  manifestations	  of	  tuberculosis	  in	  children	  will	  provide	  information	  that	  will	  hopefully	  contribute	  to	  the	  development	  of	  correlates	  of	  immune	  protection	  to	  TB.	  	  The	  role	  of	  γδ,	  CD4+	  and	  regulatory	  T	  cells	  and	  the	  balance	  of	  the	  cytokines	  they	  produce	  (IFNγ,	  IL17	  and	  IL22)	  is	  key	  to	  our	  understanding.	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2. Hypotheses	  	  
• Containment	  or	  dissemination	  of	  mycobacteria	  is	  determined	  by	  the	  balance	  
of	  Th1/IL17	  responses	  (To	  be	  addressed	  in	  Specific	  Aim	  1)	  
	  
• The	  balance	  of	  Th1/IL17	  responses	  correlates	  functionally	  with	  the	  ability	  to	  
restrict	  mycobacterial	  growth	  in-­‐vitro	  (To	  be	  addressed	  in	  Specific	  Aim	  2)	  
	  
• Differences	  in	  the	  balance	  of	  Th1/IL17	  responses	  may	  explain	  age-­‐related	  
differences	  in	  susceptibility	  to	  disseminated	  disease	  (To	  be	  addressed	  in	  
Specific	  Aim	  3)	  
	  
Figure	  3	  -­‐	  Hypothetical	  role	  for	  IL17	  producing	  T	  cells.	  
This	  figure	  demonstrates	  a	  hypothetical	  role	  for	  IL17	  producing	  T	  cells,	  both	  CD4+	  and	  γδ	  
T	  cells,	  at	  different	  stages	  of	  the	  immune	  response	  to	  mycobacteria,	  in	  particular	  the	  
importance	  of	  a	  balance	  between	  IFNγ	  and	  IL17	  to	  prevent	  the	  dissemination	  of	  TB.	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2.1. Specific	  Aim	  1:	  
To	  characterise	  the	  distribution	  of	  IL-­‐17	  producing	  and	  Th1	  type	  immune	  cells	  in	  
children	  with	  pulmonary	  versus	  disseminated	  manifestations	  of	  TB	  We	  postulate	  that	  high	  levels	  of	  IL17	  are	  associated	  with	  paediatric	  primary	  TB	  disease,	  in	  particular	  with	  disseminated	  disease	  and	  lower	  levels	  with	  more	  adult-­‐type	  contained	  disease.	  	  	  We	  will	  recruit	  30	  HIV-­‐negative	  children	  with	  pulmonary	  TB	  and	  30	  HIV-­‐negative	  children	  with	  disseminated	  TB	  and	  measure	  functional	  and	  phenotypical	  markers,	  secreted	  key	  cytokines	  and	  characteristic	  transcription	  factors	  associated	  with	  T-­‐cell	  lineage	  using	  multi-­‐parameter	  flow	  cytometry,	  multiplex	  cytokine	  assays	  and	  quantitative	  rt-­‐PCR.	  
2.2. Specific	  Aim	  2:	  	  	  
To	  determine	  if	  the	  immune	  profile	  found	  in	  children	  with	  TB	  is	  induced	  by	  the	  
acute	  TB	  infection	  or	  represents	  an	  underlying	  prevailing	  immune	  phenotype,	  
which	  can	  be	  shown	  to	  have	  a	  functional	  correlate	  in-­‐vitro.	  We	  will	  re-­‐investigate	  all	  patients	  six	  months	  post	  completion	  of	  TB	  treatment	  using	  the	  same	  laboratory	  assays.	  In	  addition,	  blood	  will	  be	  analysed	  post	  therapy	  using	  a	  functional	  whole	  blood	  reporter	  assay,	  which	  measures	  mycobacterial	  viability	  in-­‐vitro.	  	  This	  assay	  will	  provide	  a	  read-­‐out	  of	  the	  functional	  relevance	  of	  the	  observed	  T-­‐cell	  and	  cytokine	  profiles	  for	  the	  containment	  of	  mycobacteria	  and	  has	  been	  shown	  to	  correlate	  with	  in-­‐vivo	  studies	  of	  anti-­‐mycobacterial	  immunity.	  	  	  
2.3. Specific	  Aim	  3:	  	  	  
To	  analyse	  the	  potential	  influence	  of	  age	  on	  the	  balance	  between	  T-­‐cell	  lineages	  	  	  We	  suggest	  that	  the	  susceptibility	  to	  develop	  contained	  TB	  disease	  with	  age	  is	  regulated	  by	  a	  shift	  from	  a	  primarily	  IL17	  immune	  phenotype	  in	  very	  young	  children	  towards	  a	  predominantly	  IFNγ	  response	  in	  older	  children	  and	  adults.	  To	  address	  this,	  we	  will	  recruit	  a	  cross-­‐sectional,	  age-­‐reference	  group	  of	  80	  healthy,	  HIV-­‐negative,	  ethnically	  matched	  and	  BCG-­‐vaccinated,	  children	  with	  no	  history	  of	  TB	  contact	  and	  no	  evidence	  of	  TB	  infection	  (interferon-­‐gamma	  release-­‐assay	  negative).	  	  Results	  will	  be	  stratified	  to	  the	  following	  age	  groups:	  <1,	  1-­‐4,	  5-­‐9,	  >10	  (n=20	  in	  each	  group).	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This	  group	  will	  serve	  as	  the	  reference	  standard	  to	  describe	  the	  baseline	  characteristics	  of	  IL17-­‐producing	  T-­‐cell	  populations	  and	  cytokine	  milieu.	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3. Materials	  and	  Methods	  
	  	  In	  this	  chapter	  I	  describe	  how	  we	  addressed	  the	  specific	  aims	  of	  the	  project,	  including	  study	  setting,	  design	  and	  participants,	  and	  the	  laboratory	  assays	  and	  data	  analysis	  techniques	  used.	  	  	  
3.1. Recruitment	  and	  Consent	  
3.1.1. Study	  setting	  The	  majority	  of	  the	  study	  was	  conducted	  at	  the	  Red	  Cross	  War	  Memorial	  Children’s	  Hospital	  (RCH)	  in	  Cape	  Town,	  South	  Africa.	  This	  site	  was	  selected	  because	  of	  the	  high	  incidence	  of	  TB	  in	  this	  region,	  the	  infrastructure	  and	  expertise	  at	  RCH	  and	  the	  accessibility	  of	  the	  laboratory	  facilities	  locally	  at	  RCH	  and	  the	  Institute	  of	  Infectious	  Diseases	  and	  Molecular	  Medicine	  (IIDMM)	  at	  the	  University	  of	  Cape	  Town.	  	  More	  than	  500	  children	  are	  admitted	  to	  RCH	  annually	  for	  suspected	  TB;	  in	  2006,	  there	  were	  372	  TB	  notifications	  at	  RCH.	  	  Over	  the	  last	  5	  years	  the	  research	  team	  at	  RCH	  has	  demonstrated	  the	  capacity	  to	  conduct	  a	  range	  of	  immunological	  and	  microbiological	  diagnostic	  TB	  trials	  at	  the	  site.	  More	  than	  1000	  children	  have	  been	  recruited	  to	  diagnostic	  TB	  research	  studies	  during	  this	  period.	  The	  healthy	  control	  group	  was	  recruited	  primarily	  at	  RCH,	  Cape	  Town.	  	  Additionally	  a	  smaller	  group	  of	  16	  children	  were	  recruited	  at	  St.	  Mary’s	  Hospital,	  London,	  UK	  for	  laboratory	  optimization	  purposes	  –	  the	  data	  from	  these	  children	  is	  not	  included	  in	  the	  main	  analysis	  and	  is	  only	  presented	  in	  Chapter	  4.	  	  
3.1.2. Ethical	  Considerations	  	  Ethical	  approval	  to	  perform	  the	  study	  in	  the	  UK	  was	  obtained	  from	  the	  Central	  London	  Research	  Ethics	  Committee	  2,	  London	  (REC	  reference	  number:	  10/H0713/40).	  Local	  Site	  Specific	  Approval	  was	  obtained	  from	  the	  Research	  and	  Development	  Office,	  St	  Mary’s	  Hospital,	  London	  (R&D	  reference	  number:	  RD10/040).	  	  	  The	  study	  was	  CLRN	  adopted	  (NIHR	  Portfolio	  ID	  8793).	  Ethical	  approval	  to	  perform	  the	  study	  in	  South	  Africa	  was	  obtained	  from	  the	  Health	  Sciences	  Ethics	  Committee	  at	  the	  University	  of	  Cape	  Town	  (HREC:	  062/2011).	  	  Mothers	  were	  reimbursed	  for	  their	  travel	  expenses	  and	  the	  children	  received	  a	  meal	  at	  the	  follow	  up	  appointments	  in	  the	  Clinical	  Research	  Unit	  at	  Red	  Cross	  War	  Memorial	  Children’s	  Hospital,	  but	  no	  financial	  incentive	  was	  given	  for	  participation	  in	  the	  study.	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3.1.3. Study	  Design	  and	  Participants	  The	  study	  was	  a	  cohort	  study	  design	  with	  longitudinal	  follow	  up	  in	  the	  disease	  group.	  	  	  The	  children	  with	  TB	  disease	  were	  recruited	  at	  the	  time	  of	  admission	  for	  investigation	  of	  presumed	  TB	  disease	  to	  the	  inpatient	  wards	  at	  RCH.	  	  The	  study	  nurse,	  in	  collaboration	  with	  the	  medical	  teams	  on	  the	  children’s	  wards,	  identified	  the	  children	  for	  the	  cohort	  and	  explained	  the	  study	  to	  them	  and	  their	  parents.	  	  We	  employed	  a	  local	  Xhosa	  and	  Africaans	  speaking	  nurse	  in	  Cape	  Town	  specifically	  for	  this	  purpose.	  	  All	  participants	  and	  their	  parents	  were	  given	  a	  patient	  information	  leaflet	  in	  the	  appropriate	  language.	  	  All	  children	  being	  investigated	  and	  receiving	  treatment	  for	  TB	  at	  RCH	  had	  blood	  samples	  taken	  as	  part	  of	  their	  routine	  management.	  	  Extra	  blood	  for	  the	  study	  was	  taken	  at	  the	  same	  time,	  provided	  written	  informed	  consent	  was	  first	  obtained.	  	  The	  blood	  was	  taken	  within	  the	  first	  48	  hours	  of	  establishing	  the	  TB	  diagnosis	  and	  starting	  treatment.	  Standard	  management	  of	  children	  with	  TB	  is	  to	  receive	  6	  months	  of	  anti-­‐tuberculosis	  treatment	  and	  to	  be	  followed	  up	  in	  outpatient	  clinic	  until	  the	  end	  of	  therapy.	  	  When	  they	  returned	  for	  their	  final	  visit	  at	  6	  months,	  a	  further	  5mls	  of	  blood	  was	  taken.	  	  There	  were	  no	  extra	  clinic	  visits	  for	  these	  children	  beyond	  routine	  management	  of	  childhood	  TB,	  but	  an	  extra	  episode	  of	  venipuncture	  at	  the	  follow	  up	  time	  point.	  In	  order	  to	  correctly	  classify	  disease	  manifestations	  (lung	  disease	  vs	  disseminated	  disease),	  we	  recorded	  clinical	  details	  including:	  presenting	  symptoms,	  history	  of	  TB	  contact,	  CXR	  and	  any	  other	  radiological	  findings,	  blood	  test	  results,	  microbiology	  results	  and	  clinical	  examination	  findings	  on	  a	  standardized	  case	  record	  form	  (CRF)	  and	  bespoke	  secure	  database.	  	  The	  CRF	  can	  be	  seen	  in	  Appendix	  x.	  	  Further	  details	  of	  the	  classification	  of	  TB	  cases	  are	  described	  in	  Chapter	  5.	  	  	  The	  healthy	  control	  group	  was	  recruited	  at	  RCH,	  Cape	  Town.	  Eligible	  children	  were	  identified	  from	  families	  presenting	  to	  RCH	  for	  either	  elective	  surgery	  (eg.	  adeno-­‐tonsillectomy,	  grommet	  insertion,	  orthopaedic	  surgery,	  dental	  procedures	  etc)	  or	  for	  paediatric	  outpatient	  clinics.	  	  The	  study	  nurse	  approached	  them	  and	  explained	  the	  study	  to	  them	  in	  English,	  Xhosa	  or	  Africaans.	  A	  patient	  information	  sheet	  was	  provided	  along	  with	  adequate	  time	  to	  read	  it	  and	  have	  questions	  answered	  prior	  to	  recruitment.	  	  	  Following	  fully	  informed	  written	  consent,	  5mls	  of	  blood	  was	  taken	  either	  at	  the	  same	  time	  as	  their	  routine	  blood	  sampling	  or	  when	  an	  intravenous	  cannula	  was	  placed	  pre-­‐operatively.	  	  All	  appropriate	  distraction	  techniques	  and	  local	  anaesthetic	  cream	  were	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used.	  There	  were	  no	  extra	  clinic	  visits	  or	  blood	  sampling	  necessary	  for	  this	  control	  group.	  	  A	  brief	  medical	  and	  TB	  contact	  history	  was	  documented	  prior	  to	  recruitment.	  Exclusion	  criteria	  were	  significant	  contact	  with	  TB;	  a	  history	  of	  recurrent	  infections	  or	  hospital	  admissions;	  persistent	  cough	  for	  longer	  than	  4	  weeks;	  intercurrent	  febrile	  illness;	  failure	  to	  thrive.	  	  All	  children	  were	  additionally	  screened	  for	  Mtb	  sensitisation	  with	  an	  in-­‐house	  interferon	  gamma	  release	  assay	  (IGRA)	  and	  the	  parents	  counseled	  about	  the	  implications	  of	  a	  positive	  test	  result	  prior	  to	  taking	  the	  blood.	  	  In	  the	  event	  of	  a	  positive	  test,	  the	  children	  were	  invited	  to	  return	  for	  a	  clinical	  review	  and	  chest	  x-­‐ray	  and	  if	  evidence	  of	  TB	  disease	  was	  excluded,	  children	  under	  5	  were	  treated	  with	  6	  months	  isoniazid	  as	  per	  local	  guidelines.	  	  If	  their	  HIV	  status	  was	  unknown,	  these	  children	  were	  routinely	  tested	  for	  HIV	  as	  part	  of	  their	  medical	  care.	  	  HIV	  infection	  was	  part	  of	  the	  exclusion	  criteria,	  but	  none	  of	  the	  children	  recruited	  were	  found	  to	  be	  HIV	  infected.	  	  
3.1.4. Inclusion	  Criteria	  Study	  group	  	   • Aged	  0-­‐16yrs.	  • Confirmed	  or	  probable	  Tuberculosis	  -­‐	  Smear	  or	  culture	  positive	  tuberculosis	  on	  microbiological	  investigations,	  chest	  x-­‐ray	  changes	  consistent	  with	  a	  diagnosis	  of	  tuberculosis,	  clinical	  history	  of	  TB,	  close	  contact	  with	  TB,	  Interferon	  Gamma	  Release	  Assay	  positive	  
• Parental	  Consent	  +/-­‐	  child	  assent	  obtained	  
• HIV	  negative	  	  Age-­‐matched	  healthy	  control	  group.	  	  
• Healthy	  	  
• Aged	  0-­‐16yrs	  	  
• BCG	  vaccinated	  children	  in	  the	  care	  of	  the	  Paediatric	  team	  having	  blood	  taken	  for	  another	  clinical	  reason.	  	  
• Ethnically	  matched	  to	  the	  TB	  group	  in	  South	  Africa	  -­‐	  Black	  African,	  Black	  British,	  Afro-­‐Caribbean.	  	  
• Parental	  Consent	  +/-­‐	  child	  assent	  obtained	  	  
• Interferon	  Gamma	  Release	  Assay	  negative	  (no	  evidence	  of	  prior	  sensitisation	  to	  Mtb)	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3.1.5. Exclusion	  Criteria	  Study	  Group	   • Known	  immunosuppression	  or	  immunodeficiency,	  including	  HIV	  Age-­‐related	  healthy	  control	  group	  	  
• Non	  Black	  African/Caribbean/British	  ethnicity	  (The	  large	  majority	  of	  children	  with	  Tuberculosis	  in	  the	  UK	  and	  South	  Africa	  are	  of	  Black	  African/Caribbean/British	  ethnicity.	  This	  exclusion	  criteria	  is	  to	  remove	  ethnicity	  as	  a	  potential	  confounding	  factor)	  	  
• Known	  immunosuppression	  or	  immunodeficiency,	  including	  HIV.	  	  	  
• Febrile	  illness.	  	  	  
• Interferon	  Gamma	  release	  Assay	  positive	  
	  	  
3.1.6. Consent	  In	  line	  with	  ethical	  requirements,	  parents	  of	  all	  children	  included	  in	  the	  study	  provided	  written	  informed	  consent	  for	  study	  entry.	  Those	  children	  deemed	  competent	  provided	  informed	  consent.	  The	  opportunity	  to	  provide	  informed	  assent	  was	  given	  to	  children	  deemed	  not	  competent	  to	  give	  consent.	  If	  there	  was	  disagreement	  between	  child	  and	  parent	  about	  inclusion	  in	  the	  study	  they	  were	  no	  longer	  eligible	  for	  study	  entry.	  All	  consent	  forms	  and	  information	  sheets	  were	  designed	  accordingly	  and	  in	  an	  age-­‐appropriate	  form	  and	  can	  be	  seen	  in	  Appendix	  1.	  
3.1.7. Funding	  	  Research	  was	  fully	  funded	  by	  a	  Wellcome	  Trust	  Research	  Training	  Fellowship	  competitively	  awarded	  to	  Dr	  Elizabeth	  Whittaker.	  The	  BCG	  vaccine	  vials	  (SSI)	  were	  generously	  provided	  by	  the	  pharmacy	  at	  St.	  Mary’s	  Hospital	  Paddington.	  	  
3.1.8. Clinical	  Data	  management	  and	  statistics	  	  A	  study-­‐specific	  Filemaker	  Pro	  (Filemaker	  Inc.	  version	  10.0v3)	  relational	  database	  was	  used	  to	  capture	  clinical,	  laboratory	  and	  experimental	  data.	  All	  personal	  information	  was	  excluded	  from	  the	  database,	  which	  was	  password	  protected.	  Statistical	  analysis	  was	  performed	  using	  SPSS	  (version	  21),	  STATA	  (version	  12)	  and	  GraphPad	  Prism	  (version	  5.0a,	  2008).	  Mean	  values	  and	  standard	  deviation	  are	  quoted	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for	  normally	  distributed	  data	  sets	  and	  the	  unpaired	  t	  test	  used.	  Median	  values	  and	  interquartile	  ranges	  are	  quoted	  for	  non-­‐normally	  distributed	  data	  and	  the	  Mann-­‐Whitney	  test	  is	  used.	  	  The	  Chi-­‐squared	  or	  Fisher’s	  exact	  test	  was	  used	  to	  compare	  proportions.	  	  
3.2. Laboratory	  Methodology	  	  Some	  of	  the	  whole	  blood	  protocols	  described	  below	  have	  been	  previously	  developed	  and	  were	  adapted	  for	  use	  in	  this	  study136.	  	  Other	  protocols	  were	  developed	  specifically	  for	  the	  conduct	  of	  this	  research.	  	  
3.2.1. Optimisation	  of	  Whole	  Blood	  Intracellular	  Cytokine	  Detection	  Assay	  	  
3.2.1.1. Aim	  To	  optimize	  the	  concentration	  of	  antigens	  in	  a	  whole	  blood	  assay	  and	  to	  determine	  the	  optimal	  timepoint	  to	  harvest	  cells	  in	  order	  to	  detect	  a	  range	  of	  phenotypical	  markers	  and	  intracellular	  cytokines	  by	  flow	  cytometry	  
3.2.1.2. Specific	  Aims	  1. To	  determine	  the	  optimum	  concentration	  of	  Staphylococcal	  enterotoxin	  B	  (SEB)	  for	  use	  as	  a	  positive	  control	  for	  T	  cells	  in	  a	  whole	  blood	  assay	  2. To	  determine	  the	  optimum	  concentration	  of	  BCG	  to	  stimulate	  whole	  blood	  3. To	  determine	  the	  optimum	  concentration	  of	  Isopentenyl	  pyrophosphate	  (IPP)	  to	  stimulate	  γδ	  T	  cells	  as	  a	  positive	  control	  in	  a	  whole	  blood	  assay	  4. To	  determine	  the	  optimum	  incubation	  time	  to	  detect	  production	  of	  IFNγ	  and	  IL17A	  cytokine	  release	  in	  response	  to	  these	  antigens	  
3.2.1.3. Antigens	  BCG	  SSI	  (Statens	  Serum	  Institut)	  was	  prepared	  directly	  from	  the	  clinical	  vaccine	  vial:	  lyophilized	  vaccine	  was	  reconstituted	  in	  200µl	  RPMI	  (Gibco),	  from	  which	  different	  volumes	  (50,	  25,	  12.5	  µl/500µl	  whole	  blood)	  corresponding	  to	  different	  concentrations	  (2.5	  x	  106,	  1.25	  x	  106,	  6.25	  x	  105	  cfu/ml)	  was	  added	  to	  each	  sample.	  	  Staphylococcal	  enterotoxin	  B	  (SEB,	  Sigma)	  was	  used	  at	  1,	  5	  and	  10µg/ml.	  	  Isopentenyl	  pyrophosphate	  (Sigma)	  was	  used	  at	  a	  25µM	  and	  50	  µM	  solution.	  Whole	  blood	  was	  stimulated	  with	  the	  antigens	  SEB,	  BCG	  and	  IPP	  in	  an	  overnight	  whole	  blood	  assay.	  	  Cells	  were	  harvested	  and	  cryopreserved	  and	  subsequently	  stained	  with	  fluorescent-­‐conjugated	  antibodies	  and	  analysed	  by	  multiparameter	  flow	  cytometry	  to	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assess	  antigen	  specific	  cytokine	  expression	  profile	  of	  a	  variety	  of	  T	  cells	  as	  described	  below.	  Blood	  was	  collected	  in	  preservative	  free	  sodium	  heparin	  tubes	  and	  processed	  within	  4	  hours	  of	  collection.	  	  500µl	  of	  whole	  blood	  was	  incubated	  with	  antigens	  as	  described	  above	  at	  37°C,	  5%	  CO2,	  80%	  humidity.	  	  After	  2	  hours,	  5	  hours	  or	  15	  hours,	  Brefeldin	  A	  (Sigma,	  10µg/ml)	  was	  added,	  to	  capture	  newly	  formed	  intracellular	  cytokines	  in	  the	  Golgi	  apparatus.	  	  The	  tubes	  were	  again	  placed	  in	  the	  incubator	  and	  the	  cells	  harvested	  after	  15	  hours,	  12	  hours	  or	  5	  hours	  respectively:	  EDTA	  (Sigma)	  was	  added	  at	  2mM	  to	  detach	  T	  cells	  from	  the	  tube	  walls,	  followed	  by	  high	  speed	  vortexing	  for	  10	  seconds,	  incubation	  at	  room	  temperature	  for	  15	  minutes	  and	  repeat	  of	  the	  vortexing.	  	  Ten	  times	  the	  volume	  alternative	  lysing	  solution	  (150mM	  NH4Cl,	  10mM	  KHCO3,	  1mM	  Na4EDTA)	  was	  added	  to	  lyse	  red	  cells,	  by	  incubation	  for	  10min	  at	  room	  temperature	  and	  then	  centrifugation	  for	  5	  minutes	  at	  1400rpm.	  	  Supernatant	  was	  discarded	  and	  the	  lysis	  process	  is	  repeated,	  followed	  by	  a	  wash	  with	  PBS.	  	  The	  cells	  were	  then	  incubated	  for	  30mins	  with	  LIVE/DEAD	  fixable	  Aqua	  dead	  cell	  stain	  (Invitrogen).	  	  After	  centrifugation	  at	  1400rpm	  for	  5	  minutes,	  cells	  were	  re-­‐suspended	  and	  fixed	  in	  FACS	  lysing	  solution	  (BD	  biosciences).	  	  Cells	  were	  centrifuged	  at	  1400rpm	  for	  5	  minutes	  and	  re-­‐suspended	  in	  cryo-­‐solution	  (10%DMSO,	  40%	  Foetal	  Calf	  Serum	  and	  RPMI	  (Lonza))	  and	  stored	  at	  -­‐80°C.	  
3.2.2. Optimisation	  of	  Whole	  Blood	  cytokine	  secretion	  assay	  and	  ELISA	  
3.2.2.1. Aim	  To	  optimize	  the	  concentration	  of	  antigens	  in	  a	  whole	  blood	  assay	  and	  to	  determine	  the	  optimal	  timepoint	  to	  harvest	  supernatants	  in	  order	  to	  detect	  a	  range	  of	  cytokines	  by	  ELISA.	  
3.2.2.2. Specific	  Aims	  1. To	  determine	  the	  optimum	  concentration	  of	  Staphylococcal	  enterotoxin	  B	  (SEB)	  for	  use	  as	  a	  positive	  control	  in	  a	  whole	  blood	  assay	  	  2. To	  determine	  the	  optimum	  concentration	  of	  BCG	  to	  stimulate	  whole	  blood	  	  3. To	  determine	  the	  optimum	  timepoint	  to	  detect	  the	  production	  of	  interferon	  gamma	  (IFNγ)	  and	  Interleukin	  17A	  (IL17A)	  cytokine	  release	  in	  response	  to	  these	  antigens	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3.2.2.3. Whole	  blood	  assay	  Similar	  protocols	  have	  been	  described	  elsewhere	  which	  were	  adapted	  for	  use	  in	  this	  study[88].	  	  180µl	  of	  1:10	  diluted	  whole	  blood	  was	  added	  in	  quadruplicate	  to	  round	  bottomed	  96	  well	  tissue	  culture	  plates.	  	  Cells	  were	  stimulated	  with:	  SEB	  (Sigma-­‐Aldrich,	  St	  Louis,	  MO,	  USA)	  at	  a	  final	  concentration	  of	  5µg/ml,	  1µg/	  ml	  and	  0.5µg/ml	  and	  Bacille	  Calmette-­‐Guerin	  (BCG,	  Danish	  Strain	  1331,	  Statens	  Institut	  (SSI),	  Copenhagen,	  Denmark)	  at	  a	  final	  concentration	  of	  5x105,	  2.5x105	  and	  1x	  105	  colony	  forming	  units	  (cfu)/ml.	  	  Cultures	  were	  incubated	  at	  37°C,	  5%	  CO2,	  80%	  humidity.	  	  Supernatants	  were	  harvested	  at	  the	  time	  points	  specified	  below	  and	  stored	  at	  -­‐80°C	  until	  required.	  
3.2.2.4. Interferon	  γ 	  ELISA	  ELISA	  are	  described	  extensively	  in	  the	  literature,	  the	  assay	  used	  here	  is	  similar	  to	  that	  used	  previously	  by	  Black	  et	  al137.	  Ninety-­‐six	  well	  plates	  were	  coated	  with	  mouse	  anti-­‐human	  IFNγ	  capture	  antibody	  (all	  antibodies	  and	  standards	  supplied	  by	  Pharmingen,	  BD,	  Oxford,	  United	  Kingdom)	  and	  incubated	  overnight	  at	  4°C.	  	  Following	  washing	  and	  blocking	  steps,	  samples	  (diluted	  1:4	  and	  1:2,	  harvested	  on	  days	  1	  or	  6)	  and	  recombinant	  human	  IFNγ	  standards	  were	  added	  in	  duplicate	  and	  incubated	  overnight	  at	  4°C.	  	  Bound	  cytokine	  was	  detected	  with	  biotinylated	  mouse	  anti-­‐human	  IFNγ	  antibody	  and	  reacted	  with	  avidin-­‐peroxidase	  conjugate	  (Sigma-­‐Aldrich,	  St	  Louis,	  MO,	  USA).	  	  O-­‐phenylenediamine	  di-­‐hydrochloride	  (OPD)	  enzyme	  substrate	  solution	  (Sigma-­‐Aldrich)	  was	  added	  for	  10	  min	  and	  the	  reaction	  was	  stopped	  with	  2M	  H2SO4	  (Sigma-­‐Aldrich).	  	  The	  absorbance	  was	  read	  at	  490nm	  using	  and	  ELISA	  plate	  reader.	  
3.2.2.5. IL17A	  ELISA	  IL-­‐17A	  ELISA	  was	  carried	  out	  using	  the	  Diaclone	  ELISA	  kit	  from	  Genprobe	  according	  to	  the	  manufacturers	  instructions.	  	  In	  brief,	  samples	  (diluted	  1:2,	  harvested	  on	  days	  1	  and	  6)	  and	  standards	  were	  incubated	  on	  pre-­‐coated	  plates	  for	  2	  hours.	  	  Biotinylated	  antibody	  is	  added	  and	  incubated	  for	  one	  hour.	  	  Streptavidin-­‐HRP	  was	  added	  and	  then	  reacted	  with	  Tetramethylbenzidine	  (TMB)	  substrate	  solution.	  	  The	  reaction	  was	  stopped	  and	  read	  at	  450nm.	  	  	  An	  average	  of	  duplicates	  was	  calculated	  and	  a	  standard	  curve	  plotted	  on	  a	  log/log	  scale	  for	  all	  ELISAs.	  	  Background	  was	  subtracted	  from	  all	  results.	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3.2.3. Six-­‐day	  whole	  blood	  Ki-­‐67	  lymphoproliferation	  assay	  
3.2.3.1. Specific	  Aims:	  1. To	  determine	  the	  percentage	  of	  proliferating	  lymphocytes	  in	  response	  to	  BCG	  stimulation	  in	  healthy	  and	  TB	  infected	  individuals	  2. To	  characterise	  the	  cytokines	  produced	  by	  these	  proliferating	  lymphocytes	  –	  ie	  are	  they	  predominantly	  IFNγ,	  IL17	  or	  IL22	  producing	  T	  cells.	  3. To	  distinguish	  the	  memory	  phenotypes	  of	  the	  proliferating	  and	  cytokine	  producing	  lymphocytes	  stimulated	  by	  BCG.	  
3.2.3.2. Background:	  A	  long-­‐term	  whole	  blood	  lymphoproliferation	  assay	  (LPA)	  assesses	  both	  the	  capacity	  of	  T	  cells	  to	  proliferate	  and	  the	  capacity	  to	  produce	  cytokines.	  	  In	  particular	  this	  may	  lead	  to	  the	  differentiation	  of	  naïve	  and	  memory	  T	  cells	  to	  effector	  or	  terminally	  differentiated	  T	  cells	  and	  allows	  an	  exploration	  of	  the	  memory	  phenotypes	  of	  both	  IFNγ	  and	  IL17	  producing	  T	  cells.	  During	  the	  6	  day	  incubation	  period,	  cells	  divide	  in	  response	  to	  antigens.	  	  This	  longer	  incubation	  time	  may	  increase	  the	  sensitivity	  of	  the	  assay	  as	  cells	  that	  are	  ‘resting’	  or	  require	  more	  than	  a	  short	  period	  of	  stimulation	  to	  divide	  can	  be	  detected.	  This	  long	  term	  LPA	  allows	  for	  measurement	  of	  cytokine	  release	  in	  response	  to	  antigen	  stimulation	  (supernatants	  harvested	  on	  day	  1	  and	  6)	  whilst	  also	  allowing	  measurement	  of	  frequency	  of	  antigen-­‐specific	  and	  non-­‐specific	  cells	  expressing	  the	  cytokines	  of	  most	  interest	  (IFNγ,	  IL17	  and	  IL22)	  after	  re-­‐stimulation	  of	  cells	  by	  multiparameter	  flow	  cytometry.	  Diluted	  whole	  blood	  is	  stimulated	  with	  the	  antigens	  SEB,	  BCG	  and	  IPP	  in	  a	  6-­‐day	  whole	  blood	  assay	  with	  and	  without	  added	  Interleukin	  2	  (IL2).	  	  The	  supernatants	  are	  harvested	  and	  analysed	  by	  ELISA	  or	  multiplex	  techniques	  to	  determine	  the	  levels	  of	  secreted	  cytokines.	  	  Cells	  are	  subsequently	  stained	  with	  fluorescent-­‐conjugated	  antibodies,	  including	  Ki-­‐67,	  and	  analysed	  by	  multiparameter	  flow	  cytometry	  to	  assess	  antigen	  specific	  and	  non-­‐specific	  lymphoproliferation	  potential,	  cytokine	  expression	  profile	  and	  memory	  phenotype	  of	  T	  cells.	  Ki-­‐67	  is	  a	  protein	  that	  is	  expressed	  during	  all	  active	  phases	  of	  the	  cell	  cycle	  (G1,	  S	  G2	  and	  mitosis),	  but	  is	  absent	  in	  resting	  cells	  (G0),	  making	  it	  a	  useful	  maker	  of	  proliferation138.	  	  It	  reflects	  not	  only	  division	  of	  cells	  but	  also	  reflects	  the	  capacity	  of	  cells	  to	  divide.	  	  It	  has	  most	  commonly	  been	  used	  in	  oncology	  as	  a	  prognostic	  indicator	  for	  disease	  free	  survival,	  disease	  recurrence	  and	  progression	  in	  breast	  and	  prostate	  cancer.	  	  More	  
	   49	  
recently	  it	  has	  been	  developed	  as	  a	  novel	  marker	  in	  whole	  blood	  proliferation	  assays139.	  	  This	  assay	  has	  been	  used	  primarily	  for	  identification	  of	  proliferating	  CD4+	  and	  CD8+	  T	  cells	  and	  optimization	  of	  this	  assay	  for	  use	  to	  identify	  proliferating	  γδ	  T	  cells	  was	  developed	  and	  performed	  for	  the	  first	  time	  for	  this	  study.	  	  
3.2.3.3. Method	  Whole	  blood	  was	  diluted	  1:10	  with	  warm	  RPMI	  1640	  tissue	  culture	  medium	  containing	  L-­‐Glutamine.	  	  1225µl	  was	  added	  to	  wells	  in	  a	  24	  well	  flat-­‐bottomed	  tissue	  culture	  plate.	  	  Diluted	  whole	  blood	  was	  incubated	  in	  duplicate	  with	  antigens	  at	  a	  final	  concentration	  of	  1µg/ml	  SEB	  (Sigma-­‐Aldrich),	  5x105cfu/ml	  BCG	  Vaccine	  SSI,	  25mM	  IPP	  (Sigma-­‐Aldrich)	  at	  37°C,	  5%	  CO2,	  80%	  humidity.	  	  After	  24	  hours,	  150	  µl	  supernatant	  was	  removed	  and	  stored	  at	  -­‐80°C.	  	  On	  day	  3,	  50IU/ml	  IL-­‐2	  (Peprotech)	  was	  added	  to	  half	  of	  the	  wells.	  	  On	  day	  6,	  a	  further	  500µl	  of	  supernatant	  was	  removed	  and	  stored	  at	  -­‐80°C.	  	  3µl	  of	  Brefeldin	  A	  (Sigma-­‐Aldrich)	  at	  a	  final	  concentration	  of	  0.5mg/ml	  was	  added	  to	  all	  conditions.	  	  16µl	  of	  phorbol	  myristate	  acetate	  (PMA)	  (Sigma	  Aldrich)	  at	  a	  final	  concentration	  of	  1µg/ml	  and	  160µl	  of	  ionomycin	  (Sigma	  Aldrich)	  at	  a	  final	  concentration	  of	  50µg/ml	  were	  added	  to	  all	  stimulated	  wells.	  	  After	  4	  hours	  of	  incubation	  at	  37°C,	  5%	  CO2	  and	  80%	  humidity,	  80µl	  of	  20mM	  EDTA	  was	  added	  and	  incubated	  for	  15	  minutes	  at	  room	  temperature	  to	  aid	  detachment	  of	  cells	  from	  plastic	  wells.	  	  Cells	  were	  re-­‐suspended	  and	  incubated	  with	  alternative	  lysing	  solution	  for	  10	  minutes	  and	  then	  centrifuged	  for	  10	  minutes	  at	  1400rpm	  for	  5	  minutes.	  	  Supernatant	  was	  discarded	  and	  the	  process	  was	  repeated.	  	  The	  cells	  were	  washed	  with	  PBS	  and	  then	  incubated	  for	  30minutes	  with	  LIVE/DEAD	  fixable	  Aqua	  dead	  cell	  stain	  (Invitrogen).	  	  	  Cells	  were	  washed	  with	  2ml	  PBS.	  	  After	  centrifugation	  at	  1400rpm	  for	  5	  minutes,	  cells	  were	  re-­‐suspended	  and	  fixed	  in	  FACS	  lysing	  solution	  (BD	  biosciences)	  for	  10	  minutes.	  	  Cells	  were	  centrifuged	  at	  1400rpm	  for	  5	  minutes	  and	  re-­‐suspended	  in	  cryo-­‐solution	  (10%	  DMSO,	  40%	  foetal	  calf	  serum,	  50%	  RPMI)	  and	  stored	  at	  -­‐80°C.	  Cell	  staining	  and	  flow	  cytometric	  analysis	  was	  performed	  on	  the	  BD	  Fortessa	  Flow	  Cytometer.	  	  The	  entire	  sample	  was	  acquired,	  which	  was	  a	  minimum	  of	  100,000	  events	  to	  allow	  for	  rare	  event	  analysis.	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3.2.4. Cell	  staining	  for	  Flow	  Cytometric	  Analysis	  Multiparameter	  flow	  cytometry	  was	  used	  to	  assess	  the	  phenotype	  and	  cytokine	  expression	  profile	  of	  antigen-­‐specific	  T	  cells.	  	  All	  reagents	  and	  equipment	  were	  supplied	  by	  BD	  Biosciences,	  San	  Jose,	  Ca,	  USA	  unless	  otherwise	  stated.	  Cryopreserved	  white	  cells	  were	  rapidly	  thawed,	  washed	  and	  pelleted.	  	  Cells	  were	  incubated	  for	  30	  minutes	  at	  4°C	  in	  the	  dark	  with	  a	  combination	  of	  the	  following	  fluorescence-­‐conjugated	  antibodies:	  anti-­‐CD3	  Pacblue,	  anti-­‐CD4	  QDot605	  (Invitrogen),	  anti-­‐gammadelta	  TCR	  PE,	  anti-­‐CD27	  PECy7,	  anti-­‐CD45RA	  QDot655(Invitrogen),	  anti-­‐CD8	  QDot605	  (Invitrogen),	  anti-­‐CD25	  APC,	  anti-­‐CD39	  FITC	  (eBioscience).	  Cells	  were	  then	  washed	  twice,	  pelleted	  and	  re-­‐suspended	  in	  perm/wash	  solution	  to	  permeabilise	  the	  cells	  for	  15	  minutes.	  	  Cells	  were	  incubated	  at	  4°C	  for	  1	  hour	  in	  the	  dark	  with	  a	  combination	  of	  the	  following	  fluorescence-­‐conjugated	  antibodies:	  anti-­‐IFNγ	  Alexafluor	  700,	  anti-­‐IL17A	  Alexafluor	  647,	  anti-­‐Ki67	  FITC,	  anti-­‐IL22	  PerCP-­‐Efluor710	  (eBioscience),	  anti-­‐FOXP3	  PE	  (eBioscience).	  	  Anti-­‐mouse	  Ig,	  κ	  compensation	  beads	  were	  incubated	  with	  the	  above	  antibodies	  at	  4°C	  for	  1	  hour.	  	  The	  ArC™	  Amine	  Reactive	  Compensation	  Bead	  Kit	  was	  used	  with	  the	  live	  dead	  Aqua	  stain	  for	  compensation.	  	  Following	  incubation,	  the	  cells	  and	  beads	  were	  centrifuged	  and	  re-­‐suspended	  in	  50	  µl	  perm/wash	  solution.	  For	  FOXP3	  staining,	  a	  nuclear	  permeabilisation	  buffer	  from	  eBioscience	  was	  used	  in	  place	  of	  the	  perm/wash	  solution	  as	  per	  protocol.	  	  	  All	  available	  sample	  volume	  was	  acquired	  on	  a	  BD	  LSRFortessa	  Flow	  Cytometer	  (model	  649225B7,	  power	  690W,	  manufactured	  Sept	  2010)	  configured	  with	  4	  lasers	  and	  22	  detectors	  using	  FACSDiva	  software	  (BD	  Biosciences,	  San	  Jose,	  CA,	  USA)	  the	  configuration	  is	  shown	  in	  Figure	  4.	  Optimal	  photomultiplier	  tube	  voltages	  were	  established	  for	  this	  study.	  	  BD	  Cytometer	  Setup	  and	  Tracking	  (CS&T)	  Beads	  were	  used	  to	  set	  baseline	  settings	  of	  cytometer	  and	  to	  provide	  target	  values	  for	  reproducible	  application	  settings	  for	  each	  flow	  cytometry	  run.	  The	  CS&T	  beads	  were	  run	  daily	  to	  track	  cytometer	  performance	  and	  ensure	  data	  consistency	  over	  time.	  	  Analysis	  was	  completed	  with	  Flowjo	  (Tree	  Star	  software).	  	  Compensation	  for	  overlap	  of	  fluorescence	  detection	  was	  performed	  using	  compensation	  beads.	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Figure	  4	  Laser	  Configuration	  of	  Fortessa	  Flow	  Cytometer	  at	  IIDMM,	  UCT,	  Cape	  Town.	  
The	  BD	  LSRFortessa™	  cell	  analyser	  is	  a	  high	  end	  analytical	  flow	  cytometer	  with	  four	  lasers,	  
405	  nm	  (violet),	  488nm	  (blue),	  544nm	  (green)	  and	  633	  nm	  (red)	  capable	  of	  detecting	  19	  
fluorochromes.	  
3.2.5. Optimisation	  of	  flow	  cytometry	  method	  	  Some	  of	  the	  populations	  of	  interest	  (especially	  IL17A	  producing	  cells)	  are	  relatively	  rare	  in	  whole	  blood.	  For	  this	  reason	  it	  was	  important	  to	  include	  adequate	  controls	  in	  the	  flow	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cytometry	  panels	  to	  ensure	  that	  the	  cells	  detected	  are	  a	  true	  population140,141.	  	  There	  follows	  a	  discussion	  on	  the	  controls	  that	  have	  been	  incorporated	  into	  the	  flow	  cytometry	  methods	  in	  order	  to	  ensure	  data	  collected	  was	  of	  a	  high	  quality.	  	  
3.2.5.1. Titration	  of	  monoclonal	  antibodies	  Monoclonal	  antibody	  titration	  experiments	  were	  performed	  for	  each	  monoclonal	  antibody	  used.	  	  For	  each	  titration	  experiment,	  the	  monoclonal	  antibody	  of	  interest	  was	  added	  to	  cells	  harvested	  and	  cryopreserved	  from	  500μl	  of	  whole	  blood	  at	  a	  range	  of	  volumes,	  the	  top	  volume	  being	  that	  recommended	  by	  the	  manufacturer,	  subsequent	  volumes	  determined	  by	  serial	  halving	  of	  this	  volume.	  Optimum	  volume	  of	  monoclonal	  antibody	  to	  be	  used	  was	  determined	  as	  the	  volume	  leading	  to	  the	  largest	  value	  for	  the	  ratio	  of	  mean	  fluorescence	  intensity	  (MFI)	  of	  the	  positive	  population	  to	  MFI	  of	  the	  negative	  population140.	  	  
3.2.5.2. Compensation	  controls	  	  Compensation	  beads	  vs.	  stained	  cells:	  In	  order	  to	  accurately	  compensate	  for	  fluorescence	  spillover	  it	  is	  relatively	  common	  practice	  to	  use	  single	  stained	  cells	  as	  compensation	  controls.	  This	  is	  only	  really	  accurate,	  however,	  if	  using	  the	  same	  monoclonal	  antibody/fluorochrome	  combination	  in	  the	  single	  stain	  compensation	  tube	  as	  in	  the	  complete	  panel.	  If	  the	  expression	  of	  the	  marker	  on	  the	  cell	  type	  of	  interest	  is	  not	  clearly	  positive	  or	  negative,	  this	  becomes	  inaccurate.	  In	  this	  instance,	  it	  is	  possible	  to	  use	  the	  same	  fluorochrome	  conjugated	  to	  an	  antibody	  specific	  for	  a	  surface	  antigen	  with	  a	  clear	  positive/negative	  population	  (e.g.	  CD3).	  However	  this	  adds	  an	  element	  of	  inaccuracy	  as	  the	  fluorochrome	  may	  behave	  differently	  when	  bound	  to	  another	  antibody	  or	  if	  the	  manufacturing	  process	  is	  not	  the	  same.	  This	  is	  especially	  true	  for	  tandem	  dyes.	  Compensation	  beads	  provide	  a	  solution	  to	  this	  problem	  as	  they	  are	  designed	  to	  bind	  any	  fluorochrome/antibody	  combination	  with	  a	  distinct	  positive	  and	  negative	  population.	  This	  allows	  use	  of	  the	  same	  monoclonal	  antibodies	  in	  the	  panel,	  irrespective	  of	  the	  pattern	  of	  expression	  on	  cells	  [91,	  92].	  	  Compensation	  beads	  (BD)	  were	  therefore	  used	  as	  compensation	  controls	  for	  flow	  cytometry	  in	  this	  project.	  	  The	  ArC™	  Amine	  Reactive	  Compensation	  Bead	  Kit	  was	  used	  for	  compensation	  of	  the	  LIVE/DEAD	  fixable	  Aqua	  dead	  cell	  stain	  (Invitrogen).	  	   	  
3.2.5.3. Gating	  controls	  	  Fluorescence	  minus	  one	  (FMO)	  vs.	  isotype:	  Gating	  controls	  are	  necessary	  when	  there	  is	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no	  clear	  division	  between	  positive	  and	  negative	  expression	  of	  a	  cell	  surface	  marker.	  For	  isotype	  control	  gating,	  an	  antibody	  that	  is	  not	  specific	  for	  any	  human	  marker,	  labeled	  with	  the	  same	  fluorochrome	  as	  that	  used	  in	  the	  flow	  panel,	  is	  used	  to	  detect	  any	  nonspecific	  binding	  and	  therefore	  a	  true	  boundary	  between	  positive	  and	  negative	  expression.	  Historically	  this	  has	  been	  the	  main	  method	  used	  for	  gating.	  However	  more	  recently	  the	  accuracy	  of	  this	  technique	  has	  been	  called	  into	  question.	  The	  monoclonal	  antibody/fluorochrome	  combination	  used	  in	  the	  isotype	  control	  may	  be	  similar	  to	  the	  antibody	  used	  in	  the	  panel,	  but	  it	  is	  not	  exactly	  the	  same	  and	  therefore	  patterns	  of	  non-­‐specific	  binding	  will	  also	  not	  be	  the	  same.	  In	  addition,	  unless	  the	  experiment	  consists	  of	  a	  separate	  tube	  for	  each	  antibody	  of	  interest,	  in	  which	  only	  the	  relevant	  antibody	  is	  replaced	  by	  the	  corresponding	  isotype	  control,	  the	  effect	  of	  fluorescence	  spillover	  from	  other	  antibodies	  in	  the	  panel	  will	  not	  be	  accounted	  for	  [91].	  FMO	  controls	  are	  considered	  to	  be	  a	  solution	  to	  this	  problem.	  An	  FMO	  control	  consists	  of	  a	  tube	  with	  only	  the	  antibody	  of	  interest	  left	  out.	  This	  is	  used	  to	  gate	  a	  true	  negative	  population	  and	  accounts	  for	  fluorescence	  spillover	  from	  other	  fluorochromes	  in	  the	  panel.	  It	  could	  be	  argued	  that	  this	  does	  not	  detect	  non-­‐specific	  binding,	  however	  it	  is	  thought	  that	  if	  an	  antibody	  has	  been	  titrated	  accurately	  there	  should	  be	  negligible	  background	  staining.	  Moreover,	  spillover	  induced	  background	  is	  a	  more	  prominent	  feature	  of	  multicolour	  flow	  cytometry141.	  	  FMO	  controls	  were	  therefore	  used	  as	  gating	  controls	  in	  this	  project.	  	  
3.2.5.4. Internal	  negative	  control	  	  If	  there	  is	  a	  population	  within	  the	  cell	  type	  of	  interest	  that	  is	  negative	  for	  the	  marker	  of	  interest,	  this	  can	  be	  used	  as	  an	  internal	  negative	  control.	  The	  advantage	  of	  this	  approach	  is	  that	  the	  internal	  negative	  cells	  have	  been	  exposed	  to	  the	  same	  conditions	  as	  the	  cell	  of	  interest	  including	  the	  monoclonal	  antibody	  of	  interest.	  Any	  non-­‐specific	  binding	  of	  the	  antibody	  will	  be	  present	  on	  internal	  negative	  controls	  and	  the	  fluorescence	  spillover	  effects	  will	  also	  be	  equivalent.	  	  An	  internal	  negative	  control	  is	  therefore	  included	  in	  the	  T	  cell	  flow	  cytometry	  panel	  in	  the	  form	  of	  the	  unstimulated	  sample	  from	  which	  we	  expect	  minimal	  production	  of	  cytokine.	  	  	  
3.2.5.5. Live/dead	  discrimination	  Non-­‐specific	  binding	  of	  monoclonal	  antibodies	  to	  dead	  cells	  can	  lead	  to	  significant	  measurement	  errors.	  A	  viability	  dye,	  such	  as	  an	  amine	  reactive	  dye,	  can	  be	  used	  to	  identify	  and	  gate	  out	  dead	  cells.	  These	  dyes	  penetrate	  the	  dead	  cell’s	  damaged	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membrane	  and	  bind	  to	  amine	  groups	  in	  the	  cytoplasm.	  They	  also	  bind	  to	  amine	  groups	  on	  the	  cell	  surface	  but	  at	  a	  much	  lower	  intensity.	  Their	  use	  has	  been	  validated	  for	  cell	  surface	  immunophenotyping142	  and	  they	  are	  therefore	  included	  in	  the	  staining	  methods	  used	  here.	  	  	  
3.2.5.6. Doublet	  discrimination	  	  Cells	  can	  adhere	  to	  each	  other	  to	  form	  clumps	  or	  doublets,	  therefore	  producing	  inaccurate	  results.	  Doublets	  can	  be	  reliably	  gated	  out	  by	  plotting	  forward	  scatter	  (FSC)	  area	  vs.	  FSC	  height,	  as	  the	  readout	  for	  these	  values	  from	  a	  single	  cell	  should	  be	  proportional143.	  A	  doublet	  discrimination	  stage	  is	  therefore	  included	  in	  the	  gating	  strategy	  in	  this	  project.	  
3.2.6. Multi-­‐parameter	  flow	  cytometry	  data	  analysis	  Multi-­‐parameter	  flow	  cytometry	  data	  was	  analysed	  using	  FlowJo	  v	  9.4.11	  (TreeStar,	  Ashland,	  OR).	  In	  order	  to	  minimise	  variability	  in	  analysis,	  gating	  was	  performed	  by	  a	  single	  operator	  using	  a	  pre-­‐determined	  gating	  strategy	  and	  template,	  with	  minor	  adjustments	  made	  to	  account	  for	  individual	  differences	  in	  samples.	  	  Combinations	  of	  antigen-­‐specific	  cytokine-­‐producing	  cells	  were	  determined	  by	  Boolean	  Gating	  in	  FlowJo.	  	  Background	  subtraction	  of	  cytokine-­‐producing	  cells	  for	  the	  short	  term	  assay	  and	  proliferating	  cytokine-­‐producing	  cells	  for	  the	  Ki67	  6	  day	  assay	  was	  performed.	  	  Where	  background	  subtraction	  of	  the	  value	  of	  the	  unstimulated	  samples	  from	  the	  value	  of	  the	  stimulated	  samples	  resulted	  in	  values	  less	  than	  zero,	  negative	  values	  were	  set	  to	  zero.	  To	  eliminate	  the	  systematic	  bias	  inherent	  in	  increasing	  only	  negative	  values,	  all	  measurements	  below	  a	  nominal	  value	  of	  0.01	  (for	  frequencies	  of	  cells	  expressing	  intracellular	  cytokines)	  or	  0.5	  (for	  total	  frequency	  of	  proliferating	  cells)	  were	  also	  set	  to	  zero.	  These	  values	  were	  decided	  based	  on	  the	  distribution	  of	  negative	  values	  and	  positive	  values	  close	  to	  zero.	  	  All	  participants	  responded	  to	  the	  SEB	  positive	  control.	  	  	  
3.2.7. Statistical	  analysis	  of	  multi-­‐parameter	  flow	  cytometry	  data	  SPSS	  (version	  21)	  and	  GraphPad	  Prism	  (version	  5.0a,	  2008)	  were	  used	  for	  statistical	  analysis	  of	  multiparameter	  flow	  cytometry	  data.	  The	  assumption	  of	  normality	  of	  distribution	  of	  data	  was	  assessed	  by	  visual	  inspection	  of	  Normal	  Q-­‐Q	  plots	  and	  Shapiro	  Wilk's	  test	  (p<	  .05	  was	  considered	  significant	  and	  the	  null	  hypothesis	  of	  normality	  was	  rejected).	  Square	  root	  transformation	  was	  applied	  to	  non-­‐normally	  distributed	  data	  (data	  positively	  skewed).	  Where	  transformation	  resulted	  in	  normally	  distributed	  data,	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parametric	  tests	  were	  applied	  to	  transformed	  data,	  otherwise	  non-­‐parametric	  testing	  was	  applied	  to	  untransformed	  data.	  	  
3.3. Multiplex	  ELISA	  Supernatants	  were	  collected	  from	  the	  whole	  blood	  assay	  after	  6	  days	  of	  incubation	  with	  BCG,	  ESAT	  6/CFP10	  peptides	  or	  SEB	  and	  were	  analysed	  by	  multiplex	  ELISA	  to	  determine	  levels	  of	  secreted	  chemokines	  and	  cytokines.	  	  This	  technique	  is	  particularly	  suited	  to	  studies	  involving	  infants	  as	  large	  numbers	  of	  analytes	  can	  be	  measured	  in	  small	  volumes	  of	  blood.	  	  The	  principal	  of	  multiplex	  ELISA	  is	  based	  on	  the	  use	  of	  fluorescent-­‐coded	  beads,	  so-­‐called	  microspheres,	  coated	  with	  antibodies	  to	  measure	  a	  large	  number	  of	  analytes	  simultaneously	  (Figure	  5).	  Two	  lasers	  detect	  the	  individual	  fluorescent	  signal	  from	  each	  microsphere	  along	  with	  the	  tagged	  detection	  antibody.	  	  	  The	  study	  employed	  customized	  15-­‐plex	  plates	  (Bio-­‐plex	  ProTM	  Human	  Th17	  Cytokine	  Panel)	  containing	  the	  following	  cytokines	  and	  chemokines:	  IL-­‐1β,	  IL-­‐4,	  IL-­‐6,	  IL-­‐10,	  IL-­‐17A,	  IL-­‐17F,	  IL-­‐21,	  IL-­‐22,	  IL-­‐23,	  IL-­‐25,	  IL-­‐31,	  IL-­‐33,	  IFNγ,	  sCD40L,	  TNFα.	  	  
	  
Figure	  5	  Bioplex	  Sandwich	  Immunoassay	  
Bio-­‐plex	  Pro	  assays	  are	  immunoassays	  formatted	  on	  magnetic	  beads.	  	  The	  assay	  principle	  
is	  similar	  to	  that	  of	  a	  sandwich	  ELISA.	  	  Capture	  antibodies	  directed	  against	  the	  desired	  
biomarker	  are	  covalently	  coupled	  to	  the	  magnetic	  beads.	  	  Coupled	  beads	  react	  with	  the	  
sample	  containing	  the	  biomarker	  of	  interest.	  	  After	  a	  series	  of	  washes	  to	  remove	  unbound	  
protein,	  a	  biotinylated	  detection	  antibody	  is	  added	  to	  create	  a	  sandwich	  complex.	  	  The	  final	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detection	  complex	  is	  formed	  with	  the	  addition	  of	  a	  streptavidin-­‐phycoerythrin	  conjugate.	  	  
Phycoerythrin	  serves	  as	  a	  fluorescent	  indicator.	  Samples	  were	  run	  in	  singulate	  by	  a	  single	  researcher	  (E.	  Whittaker)	  without	  reference	  to	  the	  patient	  grouping.	  Manufacturers	  instructions	  were	  followed.	  SEB-­‐stimulated	  samples	  were	  not	  run	  as	  a	  positive	  control	  in	  this	  assay	  due	  to	  high	  cost.	  	  IFNγ	  responses	  had	  already	  been	  assessed	  to	  the	  SEB	  positive	  control	  using	  flow	  cytometry	  which	  is	  less	  sensitive.	  	  Vortexed	  and	  diluted	  magnetic	  beads	  coated	  with	  capture	  antibody	  were	  added	  to	  each	  well	  of	  the	  assay	  plate.	  	  The	  wells	  were	  washed	  twice	  with	  Bio-­‐Plex	  wash	  buffer	  and	  undiluted	  samples	  and	  standards	  were	  added	  and	  incubated	  in	  the	  dark	  for	  1	  hour	  at	  room	  temperature	  on	  a	  shaker.	  Following	  washing	  steps,	  biotinylated	  detection	  antibodies	  were	  incubated	  with	  samples	  and	  standards	  for	  30	  minutes	  and	  then	  reacted	  with	  Streptavidin-­‐Phycoerythrin	  for	  a	  further	  30	  minutes.	  	  Beads	  were	  washed	  and	  re-­‐suspended	  in	  sheath	  fluid	  and	  analysed	  immediately	  on	  a	  Bio-­‐Plex	  array	  reader	  (Bio-­‐Rad,	  Hercules,	  CA,	  USA).	  	  The	  standard	  curve	  for	  all	  analytes	  ranged	  from	  3.2	  –	  10,000pg/ml.	  	  All	  analyte	  levels	  in	  the	  quality	  controls	  supplied	  with	  the	  kit	  were	  within	  the	  expected	  ranges.	  	  
3.4. Mycobacterial	  Growth	  Inhibition	  Assay	  The	  mycobactericidal	  assay	  used	  in	  this	  thesis	  utilises	  diluted	  whole	  blood	  and	  reporter-­‐gene	  tagged	  mycobacteria	  (M.	  tuberculosis	  H37Rv).	  The	  reporter-­‐gene	  (lux	  AB)	  is	  carried	  on	  a	  plasmid	  (pSMT1)	  under	  the	  control	  of	  the	  inactivated	  heat-­‐shock	  promoter	  (hsp60)144.	  Metabolic	  activity,	  which	  is	  the	  viability	  marker	  of	  the	  bacteria,	  is	  measured	  by	  recording	  the	  emitting	  bioluminescence	  signal	  as	  relative	  light	  units	  (RLU).	  The	  bioluminescence	  signal	  is	  induced	  by	  adding	  an	  exogenous	  substrate,	  n-­‐decyl-­‐aldehyde.	  Bioluminescence,	  the	  biological	  production	  of	  light,	  is	  ATP-­‐dependent	  and	  only	  viable	  bacteria	  emit	  light.	  It	  is	  a	  marker	  of	  mycobacterial	  viability,	  which	  was	  shown	  to	  correlate	  directly	  and	  consistently	  with	  mycobacterial	  quantification	  by	  counting	  CFU144..	  Figure	  6	  shows	  a	  schematic	  representation	  of	  the	  whole	  blood	  luminescence	  assay.	  In	  this	  thesis,	  we	  used	  the	  reporter-­‐gene	  tagged	  mycobacterial	  assay	  developed	  by	  Kampmann	  et	  al.	  to	  complement	  and	  correlate	  the	  data	  gathered	  by	  ICS	  whole	  blood	  cytokine	  assays	  with	  a	  functional	  read-­‐out145.	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Figure	  6	  Schematic	  representation	  of	  the	  whole	  blood	  luminescence	  assay.	  
3.4.1. Mycobacterial	  growth	  inhibition	  assay	  One	  of	  the	  main	  obstacles	  when	  working	  with	  M.	  tuberculosis	  in	  bactericidal	  assays	  is	  the	  need	  for	  containment	  facilities	  and	  the	  fact	  that	  bacterial	  cultures	  are	  only	  available	  after	  more	  than	  4	  weeks.	  To	  facilitate	  more	  rapid	  read-­‐outs,	  new	  assays	  based	  on	  metabolic	  activity	  have	  been	  developed,	  which	  measure	  metabolic	  activity	  as	  a	  correlate	  of	  mycobacterial	  numbers.	  One	  of	  these	  has	  tagged	  mycobacteria	  with	  a	  reporter	  gene,	  luciferase	  (lux),	  and	  employs	  growth	  restriction	  of	  mycobacteria	  as	  a	  functional	  read-­‐out.	  Kampmann	  et	  al.	  developed	  this	  assay	  for	  use	  with	  whole	  blood	  rather	  than	  peripheral	  blood	  mononuclear	  cells	  (PBMC)145.	  Whole	  blood	  assays	  need	  considerably	  smaller	  volumes	  of	  blood	  compared	  to	  PBMC-­‐based	  assays,	  which	  makes	  them	  more	  suitable	  for	  paediatric	  applications.	  The	  mycobacterial	  species	  used	  in	  this	  study	  was	  the	  virulent	  M.	  tuberculosis	  H37Rv	  lux	  strain,	  provided	  by	  my	  supervisor,	  Prof	  Kampmann,	  Imperial	  College	  London.	  All	  work	  with	  the	  virulent	  strain	  was	  done	  in	  a	  BSL3,	  containment	  facility,	  following	  certified	  BSL3	  training.	  	  
3.4.2. Mycobacterial	  media	  7H9	  broth:	  4.7	  g	  of	  powdered	  7H9	  broth	  (Middlebrook,	  BD,	  Difco)	  was	  dissolved	  in	  900	  ml	  dH20	  (containing	  2	  ml	  glycerol,	  BDH,	  Merck)	  and	  500	  µl	  Tween	  80	  (Sigma).	  The	  broth	  was	  autoclaved	  for	  15	  min	  at	  121°C.	  The	  prepared	  media	  was	  supplemented	  with	  10%	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(20	  ml)	  ADC	  enrichment	  (Middlebrook,	  BD,	  Difco)	  and	  10	  mg	  hygromycin	  B	  (200	  µl	  of	  50	  mg/ml	  stock,	  Boehringer	  Mannheim,	  Roche	  Diagnostics)	  before	  use	  as	  liquid	  growth	  medium	  for	  MTB	  lux	  and	  stored	  at	  4°C.	  7H11	  agar:	  10.5	  g	  of	  powdered	  7H11	  agar	  (Middlebrook,	  BD,	  Difco)	  in	  450	  ml	  dH20	  (containing	  2.5	  ml	  glycerol)	  was	  boiled	  to	  dissolve	  completely.	  The	  agar	  was	  then	  sterilized	  by	  autoclaving	  for	  15	  min	  at	  121°C.	  	  The	  prepared	  media	  was	  supplemented	  with	  10%	  (50	  ml)	  OADC	  enrichment	  (Middlebrook,	  BD,	  Difco),	  10	  mg	  of	  amphotericin	  B	  (50	  mg/ml	  stock)	  and	  25	  mg	  hygromycin	  B	  (500	  µl	  of	  50	  mg/ml	  stock)	  before	  use	  as	  solid	  growth	  medium	  for	  MTB	  lux.	  The	  medium	  was	  then	  poured	  into	  plates	  under	  sterile	  conditions	  and	  left	  to	  set.	  Plates	  were	  stored	  at	  4°C	  until	  use.	  
3.4.3. Preparation	  and	  storage	  of	  mycobacteria	  Recombinant	  mycobacteria	  (MTB	  lux)	  were	  grown	  into	  logarithmic	  phase	  over	  72	  hours	  in	  a	  shaking	  incubator	  at	  37°C	  in	  7H9/ADC/Tween	  80/hygromycin	  medium.	  Logarithmic	  growth	  of	  MTB	  lux	  was	  initially	  detected	  by	  plating	  100	  µl	  aliquots	  of	  serial	  dilutions	  of	  MTB	  lux	  culture	  on	  solid	  media	  and	  counting	  colony-­‐forming	  units	  (CFU)	  after	  4	  weeks	  of	  incubation	  at	  37°C.	  Subsequently,	  mycobacterial	  growth	  was	  determined	  by	  measuring	  relative	  light	  units	  (1	  CFU	  =	  10	  RLU).	  The	  culture	  was	  dispensed	  into	  1	  ml	  vials;	  glycerol	  (Sigma)	  was	  added	  to	  a	  final	  concentration	  of	  25%	  and	  the	  vials	  frozen	  at	  -­‐80°C.	  Each	  vial	  was	  shown	  to	  contain	  1.8	  x	  107	  RLU/ml	  viable	  mycobacteria.	  
3.4.4. Preparation	  of	  mycobacterial	  culture	  for	  inoculation	  into	  whole	  
blood	  Prior	  to	  each	  experiment,	  a	  vial	  of	  stored	  MTB	  lux	  was	  thawed,	  added	  to	  15	  ml	  of	  7H9/ADC/	  Tween	  80/hygromycin	  medium	  in	  a	  sterile	  disposable	  250	  ml	  Erlenmeyer	  flask	  (Corning)	  and	  incubated	  with	  shaking	  at	  120	  rev/min	  in	  a	  37°C	  incubator	  for	  72	  hours.	  The	  mycobacteria	  were	  then	  resuspended	  in	  sterile	  PBS	  to	  a	  concentration	  of	  4-­‐5	  x	  106	  RLU/ml	  prior	  to	  inoculation.	  
3.4.5. Mycobacterial	  growth	  inhibition	  assay	  protocol	  A	  whole	  blood	  luminescence	  assay,	  as	  previously	  described,	  was	  performed.	  5	  ml	  of	  heparinised	  whole	  blood	  was	  diluted	  1	  in	  2	  with	  RPMI	  1640	  medium	  (Sigma).	  900	  µl	  volumes	  of	  blood	  were	  then	  aliquoted	  into	  7	  ml	  screw	  top,	  endotoxin-­‐free	  tubes	  (Sterilin,	  Merck),	  and	  inoculated	  with	  100	  µl	  luciferase-­‐labelled	  M.	  tuberculosis	  H37Rv	  
	   59	  
(MTB	  lux)	  at	  4-­‐5	  x	  106	  RLU/ml	  to	  give	  a	  final	  volume	  of	  1	  ml	  per	  tube.	  Cells	  were	  inoculated	  in	  triplicate	  with	  MTB	  lux	  at	  two	  time	  points:	  0	  and	  96	  hours	  to	  measure	  mycobacterial	  growth.	  	  The	  samples	  were	  then	  incubated	  at	  37°C	  (no	  CO2)	  on	  a	  platform	  shaker	  (Merck,	  Stuart	  Scientific,	  STR6)	  set	  at	  20	  rev/min.	  The	  0	  hour	  time	  point	  samples	  were	  analysed	  immediately	  after	  inoculation,	  on	  the	  day	  of	  blood	  collection.	  To	  harvest,	  10	  ml	  dH2O	  was	  first	  added	  to	  lyse	  the	  red	  blood	  cells.	  The	  samples	  were	  incubated	  for	  10	  minutes	  at	  room	  temperature	  and	  centrifuged	  for	  10	  minutes	  2000	  x	  g	  to	  recover	  the	  MTB	  lux.	  The	  supernatant	  was	  discarded	  and	  the	  pellet	  was	  vortexed	  to	  disperse	  the	  MTB	  lux,	  and	  resuspended	  in	  1	  ml	  of	  sterile	  PBS.	  Samples	  were	  diluted	  10-­‐fold	  in	  duplicate	  (to	  minimise	  any	  reduction	  of	  luminescence	  in	  opaque	  samples	  [quenching])	  prior	  to	  luminescence	  measurement.	  	  Luminescence	  was	  measured	  using	  a	  single	  tube	  luminometer	  (Turner	  Design	  20/20,	  Germany).	  This	  design	  uses	  an	  injectable	  port	  to	  inject	  100	  µl	  of	  the	  substrate,	  1%	  n-­‐decyl	  aldehyde,	  (Sigma)	  in	  ethanol	  into	  each	  luminometer	  tube	  (Sarstedt).	  Measurements	  were	  collected	  over	  20	  seconds	  from	  each	  tube	  and	  reported	  as	  a	  mean.	  Duplicate	  measurements	  were	  reported	  for	  each	  sample	  prepared	  in	  triplicate..	  Growth	  of	  MTB	  lux	  in	  mycobacterial	  culture	  medium	  only	  was	  also	  measured	  after	  96h	  to	  assess	  the	  successful	  growth	  of	  the	  inoculum	  in	  the	  absence	  of	  blood	  and	  its	  cellular	  components.	  Luminescence	  was	  measured	  in	  units	  of	  relative	  light	  units	  and	  results	  were	  expressed	  as	  a	  calculated	  growth	  ratio	  (GR),	  which	  relates	  the	  RLU	  reading	  at	  96	  hours,	  to	  the	  RLU	  reading	  of	  the	  inoculum	  (0	  hours),	  using	  the	  following	  formula:	  	   RLU	  of	  MTB	  lux	  at	  T96	  	   Growth	  ratio	  =	  	  	   RLU	  of	  MTB	  lux	  at	  T0	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4. Results	  of	  Optimisation	  Experiments	  As	  part	  of	  the	  training	  and	  preparation	  for	  this	  project,	  I	  spent	  9	  months	  in	  the	  laboratories	  at	  the	  Department	  of	  Paediatrics,	  Imperial	  College	  London	  training	  in	  the	  laboratory	  methods	  to	  be	  used	  as	  part	  of	  the	  project.	  As	  described	  in	  Chapter	  3,	  there	  were	  a	  number	  of	  assays	  to	  be	  optimized	  for	  the	  project.	  The	  results	  of	  these	  optimization	  experiments	  are	  outlined	  here.	  
4.1. Flow	  Cytometry	  –	  Optimisation	  Experiments	  Before	  meaningful	  flow	  cytometry	  experiments	  can	  be	  conducted,	  a	  range	  of	  optimization	  experiments	  must	  be	  performed	  and	  a	  gating	  strategy	  determined.	  
4.1.1. Monoclonal	  antibody	  titration.	  As	  part	  of	  the	  initial	  optimization	  experiments,	  all	  monoclonal	  fluorescent	  antibodies	  were	  titrated	  to	  determine	  the	  optimal	  volume	  to	  be	  used	  in	  each	  antibody	  panel.	  	  An	  example	  of	  a	  titration	  experiment	  is	  shown	  in	  figure	  7.	  	  Monoclonal	  antibody	  to	  CD4	  conjugated	  to	  QDot605	  was	  added	  in	  increasing	  volumes	  to	  harvested	  SEB	  stimulated	  white	  cells.	  	  Fluorescence	  was	  measured	  after	  gating	  on	  monocytes	  and	  lymphocytes	  by	  forward	  scatter	  (FSC)	  vs.	  side	  scatter	  (SSC).	  	  The	  ratio	  of	  the	  mean	  fluorescence	  intensity	  (MFI)	  of	  the	  positive	  population	  to	  the	  MFI	  of	  the	  negative	  population	  was	  then	  calculated.	  	  The	  lowest	  volume	  of	  antibody	  giving	  the	  highest	  ratio	  is	  seen	  as	  optimal.	  	  In	  the	  case	  of	  CD4	  QDot605	  this	  was	  1μl.	  (Fig.	  7)	  All	  other	  antibodies	  were	  titrated	  according	  to	  the	  same	  principle.	  
	  
Figure	  7	  –	  Example	  of	  titration	  experiment.	  
Example	  of	  titration	  experiment.	  Monoclonal	  antibody	  to	  CD4	  conjugated	  to	  QDot605	  was	  
added	  in	  increasing	  volumes	  to	  whole	  blood.	  Fluorescence	  was	  measured	  after	  gating	  on	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lymphocytes	  by	  forward	  scatter	  (FSC)	  vs.	  side	  scatter	  (SSC).	  a)	  Graph	  showing	  ratio	  of	  
mean	  fluorescence	  intensity	  (MFI)	  of	  the	  positive	  population	  over	  MFI	  of	  the	  negative	  
population	  and	  Stain	  Index	  (SI)	  calculated	  using	  the	  MFI	  and	  5th	  and	  95th	  percentiles;	  b)	  
contour	  plot	  of	  fluorescence	  measured	  for	  each	  volume	  of	  antibody	  added	  (note	  log	  scale)	  
Antibody	   Volume	  
CD3	  Pacblue	   1.5µ l	  
CD4	  Qdot605	   0.5µ l	  
Gammadelta	  TCR	  PE	   5µ l	  
IFNγ 	  Alexafluor	  700	   1µ l	  
IL17a	  APC	   5µl	  
IL22	  PerCP.eFluor710	   1.25µl	  
CD27	  PE.Cy7	   0.5µl	  
CD45RA	  QDot655	   0.125µl	  
Ki67	  FITC	   2.5µl	  
CD8	  QDot605	   0.1µ l	  
CD25	  APC	   2.5µ l	  
CD39	  FITC	   1µ l	  
Foxp3	  PE	   1μl	  
Table	  1	  Optimum	  volume	  for	  all	  antibody-­‐fluorochrome	  combinations	  used	  following	  
titration	  
Short	  term	  intracellular	  
cytokine	  assay	  panel	  
6	  day	  Ki67	  assay	  panel	   Regulatory	  T	  cell	  
panel	  





CD3	  PacBlue	   1.5µl	   CD3	  PacBlue	   1.5µl	  µl	   CD3	  
PacBlue	  
1.5µl	  
CD4	  QDot605	   0.5µl	   CD8	  QDot605	   0.1	  µl	   CD4	  
QDot605	  
0.5µl	  
γδ 	  TCR	  PE	   5	  µl	   γδ 	  TCR	  PE	   5	  µl	   CD25	  APC	   2.5µ l	  
CD45RA	  QDot65	   0.125	  µl	   CD45RA	  QDot65	   0.125	  µl	   CD39	  FITC	   1µ l	  
CD27	  PECy7	   0.5	  µl	   CD27	  PECy7	   0.5	  µl	   Foxp3	  PE	   1μl	  
Ki67	  FITC	   2.5	  µl	   Ki67	  FITC	   2.5	  µl	   	  
IFNγ 	  AF	  700	   1	  µl	   IFNγ 	  AF	  700	   1	  µl	  
IL17	  AF647	   5	  µl	   IL17AF	  647	   5	  µl	  
IL22	  
PerCP.eFluor710	  
1.25	  µl	   IL22	  
PerCP.eFluor710	  
1.25	  µl	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4.1.2. Optimisation	  of	  Photomultiplier	  tubes	  (PMT)	  voltages	  Voltages	  were	  optimised	  so	  that	  populations	  of	  cells	  were	  distinguishable	  and	  obtain	  visibility	  on	  scale	  using	  an	  unstained	  sample	  and	  a	  fully	  stained	  sample.	  	  Voltages	  required	  minimal	  alteration	  for	  specific	  samples	  (<10%).	  	  	  
Laser	  and	  filter	   Parameter	   Voltage	  
	   FSC	   380	  	  
Blue	  480/10	   SSC	   310	  
Violet	  450/50	   CD3	  Pacblue	   600	  
Violet	  605/40	   CD4	  Qdot605	   575	  
Green	  585/51	   γδ 	  TCR	  PE	   450	  
Red	  730/45	   IFNγ 	  Alexafluor	  700	   625	  
Red	  660/20	   IL17a	  Alexafluor	  647	   661	  
Blue	  685/35	   IL22	  PerCP.eFluor710	   650	  
Green	  780/60	   CD27	  PE.Cy7	   685	  
Violet	  670/30	   CD45RA	  QDot655	   500	  
Blue	  515/20	   Ki67	  FITC	   600	  
Violet	  605/40	   CD8	  QDot605	   575	  
Red	  660/20	   CD25	  APC	   660	  
Blue	  515/20	   CD39	  FITC	   600	  
Green	  585/51	   Foxp3	  PE	   450	  
	   	   	  	  
Table	  2.	  Optimised	  voltages	  for	  multi-­‐parameter	  flow	  cytometry	  assay	  
4.1.3. Gating	  Strategy	  for	  short	  term	  cytokine	  panel	  A	  hierarchical	  gating	  strategy	  was	  used	  to	  select	  proliferating	  single-­‐cell	  γδ,	  CD4+	  and	  CD4-­‐	  T	  cell	  populations,	  Figure	  8.	  	  Gates	  for	  T	  cells	  expressing	  cytokines	  were	  set	  using	  the	  unstimulated	  control	  (Nil	  well).	  	  A	  Boolean	  combination	  was	  used	  to	  determine	  T	  cells	  producing	  multiple	  combinations	  of	  cytokines.	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Figure	  8	  Hierarchical	  Gating	  Strategy	  for	  selection	  of	  T	  cells	  expressing	  cytokines	  in	  
response	  to	  BCG	  antigens	  
Representative	  dot	  plots	  from	  a	  child	  healthy	  control	  are	  shown.	  (A)	  gating	  strategy	  used	  
to	  identify	  γδ,	  CD4	  and	  CD8	  T	  cells	  are	  shown.	  From	  left	  to	  right,	  CD3	  vs	  Time	  is	  shown	  to	  
detect	  differences	  in	  flow.	  	  Two	  aggregate	  exclusion	  gates	  were	  used	  –	  CD4	  QDot605	  vs	  
CD45RA	  QDot655	  and	  IFNγ	  Alexafluor700	  vs	  CD27	  PeCy7.	  Cell	  doublets	  were	  excluded	  with	  
forward	  scatter	  area	  versus	  forward	  scatter	  height	  parameters.	  	  Next,	  dead	  cells	  as	  stained	  
by	  a	  viability	  stain	  are	  gated	  out	  and	  live	  CD3	  T	  cells	  gated	  in.	  Plotting	  FSC-­‐A	  vs	  SSC-­‐A	  
allows	  confirmation	  of	  the	  lymphocyte	  population	  based	  on	  size	  and	  granularity.	  	  Plotting	  
γδ	  T	  cell	  receptor	  vs	  FSC-­‐A	  followed	  by	  CD4	  vs	  FSC-­‐A	  allows	  the	  immunophenotyping	  of	  
these	  two	  different	  cell	  types;	  γδ-­‐	  and	  CD4-­‐	  cells	  are	  denoted	  CD8	  T	  cells.	  	  (B)	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unstimulated	  and	  BCG	  stimulated	  conditions	  in	  a	  child	  healthy	  control.	  	  Gates	  were	  set	  
using	  an	  unstimulated	  control.	  	  A	  Boolean	  combination	  was	  then	  used	  to	  determine	  T	  cells	  
producing	  multiple	  combinations	  of	  cytokines.	  Figure	  9	  shows	  how	  dead	  cells	  stained	  by	  a	  viability	  stain	  can	  be	  seen	  in	  a	  specially	  prepared	  sample.	  	  	  
	  
Figure	  9	  –	  Use	  of	  the	  live	  dead	  stain	  Aqua	  
The	  live	  dead	  stain	  Aqua	  identifies	  dead	  cells	  (seen	  in	  the	  AmCyan	  channel).	  	  A	  sample	  was	  
heated	  at	  90°C	  for	  5	  minutes	  to	  kill	  the	  cells	  and	  mixed	  with	  an	  equal	  volume	  of	  live	  cells	  
before	  staining.	  	  This	  allows	  the	  positive	  identification	  of	  live	  cells	  (Viability	  dye	  negative).	  	  	  For	  the	  gating	  strategy	  however,	  CD3	  vs	  the	  viability	  stain	  allows	  identification	  of	  live	  CD3+	  T	  cells	  and	  exclusion	  of	  dead	  cells	  (Figure	  10).	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Figure	  10	  –	  Hierarchical	  Gating	  strategy	  for	  selection	  of	  proliferating	  T	  cells	  producing	  
cytokines	  of	  interest	  in	  response	  to	  BCG	  stimulation.	  
Representative	  dot	  plots	  from	  a	  child	  with	  tuberculosis	  are	  shown.	  (A)	  gating	  strategy	  used	  
to	  identify	  proliferating	  γδ,	  CD4	  and	  CD8	  T	  cells	  is	  shown.	  From	  left	  to	  right,	  CD3	  vs	  Time	  is	  
shown	  to	  detect	  differences	  in	  flow.	  	  Two	  aggregate	  exclusion	  gates	  were	  used	  –	  CD8	  
QDot605	  vs	  CD45RA	  QDot655	  and	  IFNγ	  Alexafluor700	  vs	  CD27	  PeCy7.	  Cell	  doublets	  were	  
excluded	  with	  forward	  scatter	  area	  versus	  forward	  scatter	  height	  parameters.	  	  Next,	  dead	  
cells	  as	  stained	  by	  a	  viability	  stain	  are	  gated	  out	  and	  live	  CD3	  T	  cells	  gated	  in.	  Plotting	  FSC-­‐
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granularity.	  	  Cells	  stimulated	  for	  6	  days	  attain	  a	  blastic	  quality	  and	  are	  larger	  than	  normal	  
lymphocytes.	  	  Plotting	  IFNγ	  vs	  CD8	  allows	  the	  identification	  of	  CD8+	  and	  –	  T	  cells.	  	  Further	  
gating	  on	  the	  CD8-­‐	  T	  cells	  with	  IFNγ	  vs	  the	  γδ	  T	  cell	  receptor	  allows	  the	  identification	  of	  γδ	  
T	  cells	  and	  CD8-­‐γδ-­‐	  (denoted	  CD4)	  T	  cells.	  	  (B)	  Representative	  dot	  plots	  of	  cytokine	  
expression	  (IFNγ,	  IL17,	  IL22)	  in	  Ki67+	  CD4+	  T	  cells	  from	  unstimulated	  and	  BCG	  stimulated	  
conditions	  in	  a	  child	  with	  tuberculosis.	  	  Gates	  were	  set	  using	  an	  unstimulated	  control.	  	  A	  
Boolean	  combination	  was	  then	  used	  to	  determine	  T	  cells	  producing	  multiple	  combinations	  
of	  cytokines.	  
4.1.4. Gating	  controls	  	  As	  mentioned	  in	  the	  methods	  section	  a	  number	  of	  controls	  have	  been	  incorporated	  into	  the	  panels	  in	  order	  to	  ensure	  accurate	  gating.	  Figures	  11	  and	  12	  demonstrate	  two	  examples	  of	  these	  controls.	  	  Gates	  are	  initially	  set	  on	  the	  unstimulated	  sample	  as	  an	  internal	  negative	  control	  to	  identify	  the	  true	  antigen	  stimulated	  populations.	  	  These	  gates	  are	  then	  applied	  to	  the	  antigen-­‐stimulated	  samples.	  	  
	  
Figure	  11	  –	  An	  example	  of	  an	  internal	  control.	  
An	  example	  of	  an	  internal	  control.	  	  An	  unstimulated	  sample	  is	  used	  to	  set	  the	  gates	  to	  
identify	  IFNγ	  and	  IL17	  production	  by	  CD4+	  T	  cells	  (in	  red).	  	  An	  SEB	  stimulated	  sample	  
(Blue)	  is	  superimposed	  to	  demonstrate	  the	  positive	  populations.	  In	  order	  to	  correctly	  position	  a	  gate	  for	  CD25	  T	  cell	  positivity	  on	  the	  CD3+CD4+Foxp3	  population,	  levels	  of	  background	  fluorescence	  on	  negative	  population	  should	  be	  identified.	  	  Figure	  12	  shows	  how	  this	  can	  be	  performed	  by	  leaving	  out	  the	  antibody	  of	  interest	  (Fluorescence	  minus	  one	  or	  FMO).	  	  FMO	  controls	  are	  samples	  labeled	  with	  all	  antibodies	  of	  the	  multicolor	  test	  sample	  except	  one.	  	  As	  such,	  a	  five-­‐color	  test	  sample	  may	  require	  five	  different	  FMO	  control	  samples.	  	  They	  can	  be	  considered	  the	  counterpart	  of	  singly	  stained	  positive	  controls	  in	  multicolor	  experiments	  and	  include	  an	  
CD4+ population
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internal	  negative	  control.	  	  For	  consistency,	  FMO	  controls	  have	  been	  included	  where	  required	  in	  this	  study.	  	  Single-­‐stained	  mouse	  beads	  were	  used	  to	  calculate	  compensations	  for	  every	  run.	  
	  
Figure	  12	  –	  an	  example	  of	  FMO	  gating.	  
It	  can	  be	  difficult	  to	  distinguish	  the	  CD25+	  population	  from	  the	  remainder	  of	  the	  CD4+	  
population.	  	  In	  this	  example	  using	  an	  FMO,	  a	  gate	  can	  be	  set	  to	  distinguish	  the	  CD25	  
positive	  cells.	  	  The	  top	  image	  demonstrates	  a	  fully	  stained	  sample	  (blue)	  superimposed	  on	  
an	  FMO	  sample	  (red),	  which	  has	  no	  CD25	  APC	  antibody	  included	  in	  the	  staining.	  
4.1.5. Gating	  Strategy	  Regulatory	  T	  cells	  The	  gating	  strategy	  for	  identifying	  regulatory	  T	  cells	  is	  demonstrated	  in	  Figure	  13.	  Plotting	  FSC	  vs	  SSC	  allows	  doublet	  discrimination,	  then	  the	  lymphocyte	  population	  is	  identified	  by	  size	  and	  granularity.	  	  Plotting	  CD3+	  vs	  CD4+	  allows	  the	  identification	  of	  CD3+	  CD4+	  T	  cells.	  	  Using	  FMO	  controls,	  the	  appropriate	  gating	  for	  CD25,	  CD39	  and	  FOXP3	  is	  determined	  as	  demonstrated	  above,	  allowing	  the	  accurate	  identification	  of	  functional	  regulatory	  T	  cells	  (CD3+CD4+CD25+CD39+FOXP3+).	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Figure	  13	  -­‐	  Sequential	  gating	  strategy	  for	  identification	  of	  regulatory	  T	  cell	  subsets	  of	  
interest.	  	  	  
Representative	  plots	  from	  a	  healthy	  control	  child	  are	  shown.	  	  From	  left	  to	  right,	  CD3	  vs	  
Time	  is	  shown	  to	  detect	  differences	  in	  flow.	  	  Cell	  doublets	  were	  excluded	  with	  forward	  
scatter	  area	  versus	  forward	  scatter	  height	  parameters.	  Plotting	  FSC-­‐A	  vs	  SSC-­‐A	  allows	  
identification	  of	  the	  lymphocyte	  population	  based	  on	  size	  and	  granularity.	  	  CD4+	  CD3+	  T	  
cells	  are	  identified,	  followed	  by	  CD4+CD25+	  T	  cells.	  	  Using	  FMO	  gates,	  FOXP3	  and	  CD39	  
gates	  are	  placed	  to	  identify	  the	  CD3+CD4+CD25+CD39+FOXP3+	  population.	  
4.2. Optimisation	  of	  whole	  blood	  intracellular	  cytokine	  measurement	  
assay	  
Aim	  To	  optimize	  the	  concentration	  of	  antigens	  in	  a	  whole	  blood	  assay	  and	  to	  determine	  the	  optimal	  time-­‐point	  to	  harvest	  cells	  in	  order	  to	  detect	  intracellular	  cytokines	  by	  flow	  cytometry	  
4.2.1. Antigens	  for	  use	  in	  Whole	  Blood	  Intracellular	  cytokine	  Assay	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Figure	  14	  –	  Optimisation	  of	  cytokine	  production	  in	  response	  to	  SEB	  
Cytokine	  production	  (IFNγ	  and	  IL17)	  by	  γδ	  and	  CD4+	  T	  cells	  in	  response	  to	  whole	  blood	  
stimulation	  with	  SEB	  at	  different	  concentrations	  (10µg/l,	  5µg/l	  and	  1µg/l)	  and	  for	  
different	  times	  (17	  hours	  vs	  22	  hours).	  	  5µg/l	  was	  chosen	  as	  the	  optimal	  concentration	  and	  
the	  experiments	  were	  repeated	  in	  greater	  numbers	  to	  determine	  the	  optimal	  stimulation	  
time.	  BCG	  vaccinated	  adult	  healthy	  control	  samples	  were	  used	  (n=2).	  
4.2.1.2. BCG	  stimulation	  BCG	  was	  tested	  at	  concentrations	  of	  2.5x106,	  1.25x105,	  6.25x105	  cfu/ml	  in	  healthy	  BCG	  vaccinated	  adult	  donors.	  	  These	  concentrations	  were	  used	  based	  on	  previous	  studies	  carried	  out	  in	  the	  SAATVI	  laboratory	  in	  Cape	  Town	  (personal	  recommendation).	  	  Figure	  15	  below	  demonstrates	  the	  percentage	  IFNγ	  and	  IL17	  producing	  CD4+	  and	  γδ	  T	  cells	  in	  response	  to	  different	  concentrations	  of	  BCG.	  	  
!"#$%&'()(*+
Me
d 10 5 1 Me
























d 10 5 1 Me






















d 10 5 1 Me





























d 10 5 1 Me



























	   70	  
	  
Figure	  15	  Optimisation	  of	  BCG	  concentration	  for	  short	  term	  assay	  
Cytokine	  production	  (IFNγ	  and	  IL17	  by	  γδ	  and	  CD4+	  T	  cells)	  in	  response	  to	  whole	  blood	  
incubation	  with	  BCG	  at	  different	  concentrations	  (2.5x106,	  1.25x105,	  6.25x105	  cfu/ml)	  and	  
at	  different	  time	  points.	  	  The	  lowest	  concentration	  was	  deemed	  sub-­‐optimal	  and	  further	  
optimization	  was	  performed	  to	  confirm	  the	  optimal	  concentration	  and	  incubation	  time.	  
BCG	  vaccinated	  adult	  healthy	  control	  samples	  were	  used	  (n=4).	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Figure	  16	  Optimisation	  of	  BCG	  concentration	  and	  time	  
Cytokine	  production	  (IFNγ	  and	  IL17	  by	  γδ	  and	  CD4+	  T	  cells)	  following	  whole	  blood	  
incubation	  with	  BCG	  at	  different	  concentrations	  (2.5x106,	  1.25x105	  cfu/ml)	  at	  different	  
time	  points.	  	  A	  concentration	  of	  2.5x106	  cfu/ml	  was	  chosen.	  BCG	  vaccinated	  adult	  healthy	  
control	  samples	  are	  shown	  (n=8).	  
4.2.1.3. Positive	  Control	  for	  γδ 	  T	  cells.	  Isopentenyl	  pyrophosphate	  (IPP),	  a	  phosphoantigen,	  has	  been	  described	  as	  a	  γδ	  T	  cell	  activator	  and	  is	  used	  for	  T	  cell	  proliferation	  studies40,146.	  	  The	  Vγ9Vδ2	  subset	  of	  γδ	  T	  cells	  is	  known	  to	  respond	  to	  IPP	  and	  so	  it	  was	  chosen	  as	  a	  second	  positive	  control	  as	  it	  was	  unclear	  whether	  SEB	  would	  suffice.	  	  Final	  concentrations	  of	  25	  and	  50µM	  IPP	  were	  chosen.	  	  IPP	  can	  be	  broken	  down	  by	  phosphatases	  in	  the	  blood,	  limiting	  its	  efficacy;	  this	  can	  be	  bypassed	  by	  diluting	  blood	  1:10	  so	  this	  was	  compared	  also	  (Verbal	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and	  IL17A	  producing	  γδ	  T	  cells	  present	  at	  either	  concentration	  of	  IPP,	  or	  with	  dilution.	  	  As	  SEB	  stimulated	  both	  IFNγ	  and	  IL17A	  production	  by	  γδ	  T	  cells,	  further	  optimization	  of	  IPP	  for	  use	  as	  a	  positive	  control	  in	  a	  short-­‐term	  whole	  blood	  assay	  was	  not	  performed.	  	  	  
4.2.2. Optimum	  time	  course	  for	  whole	  blood	  intracellular	  cytokine	  
production	  The	  optimal	  time	  for	  stimulation	  with	  and	  without	  Brefeldin	  was	  also	  examined.	  	  Hanekom	  et	  al	  describe	  a	  17	  hour	  optimal	  incubation,	  with	  addition	  of	  SEB	  and	  BCG	  antigens	  to	  whole	  blood	  for	  5	  hours,	  followed	  by	  the	  addition	  of	  Brefeldin	  for	  12	  hours	  prior	  to	  harvesting136.	  	  However,	  this	  group	  was	  looking	  at	  IFNγ	  producing	  CD4+	  T	  cells	  and	  the	  optimum	  stimulation	  time	  for	  IL17A	  production	  from	  either	  CD4+	  or	  γδ	  T	  cells	  had	  not	  been	  assessed.	  	  Cells	  were	  stimulated	  in	  3	  different	  ways:	  2hrs	  antigen	  alone,	  followed	  by	  overnight	  with	  the	  addition	  of	  Brefeldin;	  5hrs	  antigen	  alone,	  followed	  by	  overnight	  with	  Brefeldin;	  and	  overnight	  with	  antigens	  alone,	  followed	  by	  5	  hours	  with	  Brefeldin.	  	  Figure	  17	  demonstrates	  the	  percentage	  of	  cytokine	  production	  at	  the	  3	  different	  time	  points	  described.	  	  There	  was	  no	  significant	  difference	  between	  the	  time	  points	  for	  BCG	  stimulated	  cytokine	  production,	  but	  a	  trend	  to	  higher	  levels	  was	  noted	  in	  the	  overnight	  stimulation	  so	  this	  was	  chosen	  for	  the	  ongoing	  experiments.	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Figure	  17	  –	  Optimisation	  of	  time	  for	  short	  term	  whole	  blood	  assay	  
Cytokine	  production	  (IFNγ	  and	  IL17	  by	  γδ	  and	  CD4+	  T	  cells)	  following	  whole	  blood	  
incubation	  with	  SEB	  (5µg/ml)	  and	  BCG	  (2.5x106	  cfu/ml)	  at	  three	  different	  time	  points	  
(T1=	  Brefeldin	  added	  after	  2	  hours,	  T2=	  Brefeldin	  added	  after	  5	  hours,	  T3=	  Brefeldin	  added	  
after	  an	  overnight	  stimulation).	  	  An	  overnight	  stimulation	  followed	  by	  5	  hours	  incubation	  
with	  Brefeldin	  was	  chosen.	  	  BCG	  vaccinated	  adult	  healthy	  control	  samples	  were	  used	  (n=5).	  
4.3. Optimisation	  of	  whole	  blood	  assay	  and	  Enzyme-­‐linked	  
Immunosorbent	  Assay	  (ELISA)	  







































































































































































	   74	  
Cell	  culture	  supernatants	  were	  collected	  on	  Day	  1	  and	  6	  for	  measurement	  by	  IFNγ	  and	  IL17A	  ELISA	  to	  determine	  the	  optimum	  concentration	  of	  antigens	  for	  use	  in	  the	  whole	  blood	  assay.	  Positive	  Control	  -­‐	  SEB	  was	  tested	  at	  a	  final	  concentration	  of	  0.5,	  1	  and	  5µg/ml	  for	  the	  IFNγ	  ELISA.	  	  Equal	  responses	  were	  found	  at	  all	  3	  concentrations	  and	  a	  concentration	  of	  1µg/ml	  was	  chosen	  for	  ongoing	  assays.	  	  	  BCG	  was	  tested	  at	  a	  final	  concentration	  of	  1x105,	  2.5x105	  and	  5x105	  cfu/ml.	  	  Again,	  equal	  IFNγ	  responses	  were	  noted	  at	  all	  3	  concentrations.	  	  A	  concentration	  of	  5x105	  cfu/ml	  was	  chosen	  for	  ongoing	  assays.	  
	  
Figure	  18	  –	  Optimisation	  for	  cytokine	  release	  (IFNγ)	  from	  whole	  blood	  assay	  
Cytokine	  release	  (IFNγ)	  following	  whole	  blood	  incubation	  with	  SEB	  (0.5,	  1	  and	  5µg/ml)(A)	  
and	  BCG	  (1x105,	  2.5x105	  and	  5x105	  cfu/ml)	  (B).	  	  Cytokine	  was	  measured	  using	  ELISA	  in	  
supernatants	  harvested	  on	  Day	  1	  and	  Day	  6.	  SEB	  at	  a	  concentration	  of	  1µg/ml	  and	  BCG	  at	  
a	  concentration	  of	  5x105	  cfu/ml	  were	  chosen	  for	  future	  assays.	  	  Optimal	  secretion	  was	  
noted	  on	  Day	  6.	  	  BCG	  vaccinated	  adult	  healthy	  control	  samples	  were	  used	  (n=5).	  Using	  these	  concentrations	  of	  SEB	  and	  BCG,	  a	  further	  whole	  blood	  assay	  using	  both	  adult	  and	  paediatric	  healthy	  control	  samples	  was	  performed.	  	  Supernatants	  were	  harvested	  on	  Days	  1,3	  and	  6	  and	  results	  for	  IFNγ	  are	  shown	  in	  Figure	  16	  and	  IL17	  in	  Figure	  19.	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Figure	  19	  -­‐	  Optimisation	  for	  cytokine	  release	  (IL17)	  from	  whole	  blood	  assay	  
Cytokine	  release	  (IL17)	  following	  whole	  blood	  incubation	  with	  SEB	  (1µg/ml)	  (A)	  and	  BCG	  
(5x105	  cfu/ml)	  (B).	  	  Cytokine	  was	  measured	  using	  ELISA	  in	  supernatants	  harvested	  on	  Day	  
1,	  Day	  3	  and	  Day	  6.	  	  Optimal	  secretion	  was	  noted	  on	  Day	  6.	  	  BCG	  vaccinated	  adult	  and	  child	  
healthy	  control	  samples	  were	  used	  (n=5).	  	  Not	  all	  samples	  had	  a	  response.	  
4.4. Role	  of	  addition	  of	  IL2	  to	  samples	  in	  the	  6	  day	  
Lymphoproliferation	  Assay	  A	  review	  of	  the	  literature	  on	  methods	  used	  to	  culture	  γδ	  T	  cells	  suggests	  that	  the	  addition	  of	  IL2	  on	  day	  2	  or	  3	  is	  required	  to	  stimulate	  cell	  turnover,	  however	  many	  of	  these	  experiments	  were	  performed	  either	  on	  isolated	  γδ	  T	  cells	  or	  PBMCs.	  	  In	  order	  to	  determine	  whether	  the	  addition	  of	  IL2	  to	  maintain	  the	  γδ	  T	  cell	  population	  was	  required	  over	  a	  6-­‐day	  assay,	  blood	  from	  the	  first	  6	  TB	  paediatric	  patients	  was	  incubated	  in	  duplicate	  as	  described	  previously	  with	  SEB,	  BCG	  and	  IPP	  antigens.	  	  IL2	  was	  added	  on	  day	  3	  to	  half	  of	  the	  samples.	  PMA/Ionomycin	  were	  added	  with	  Brefeldin	  for	  four	  hours	  prior	  to	  harvesting	  to	  stimulate	  cytokine	  production.	  	  Not	  all	  subjects	  demonstrated	  a	  proliferative	  response	  to	  SEB	  and	  BCG.	  	  The	  percentage	  of	  Ki67+	  T	  cells	  expressing	  the	  cytokines	  IFNγ	  and	  IL17	  are	  shown	  in	  Table	  4.	  	  There	  was	  no	  statistical	  difference	  noted	  due	  to	  the	  addition	  of	  IL2.	  	  IPP	  does	  not	  induce	  Ki67+	  lymphoproliferation	  in	  γδ	  T	  cells,	  however	  γδ	  T	  cells	  demonstrate	  proliferative	  capacity	  with	  both	  SEB	  and	  BCG	  in	  some	  subjects	  supporting	  the	  use	  of	  SEB	  as	  a	  positive	  control	  rather	  than	  IPP.	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Table	  3	  -­‐	  Percentage	  cytokine	  expressing	  cells	  from	  CD4	  and	  γδ 	  T	  cells	  in	  response	  to	  various	  
antigen	  stimulation	  in	  the	  presence	  or	  absence	  of	  IL2	  	  	  
Cytokine	  production	  (IFNγ	  and	  IL17	  by	  γδ	  and	  CD4+	  T	  cells)	  following	  whole	  blood	  
incubation	  with	  SEB	  (5µg/ml).	  BCG	  (2.5x106	  cfu/ml)	  and	  IPP	  (25μM)	  with	  and	  without	  the	  
addition	  of	  IL2.	  BCG	  vaccinated	  child	  healthy	  control	  samples	  were	  used	  (n=6).	  Median	  
values	  and	  interquartile	  range	  in	  brackets	  are	  given.	  	  p	  value	  ns	  indicates	  >0.05	  
	  The	  percentage	  of	  IL17	  producing	  T	  cells	  was	  lower,	  but	  there	  was	  a	  trend	  to	  increased	  amounts	  in	  the	  BCG	  stimulated	  samples	  compared	  to	  the	  unstimulated	  samples.	  	  This	  data	  for	  IFNγ	  expressing	  γδ	  T	  cells	  is	  shown	  in	  figure	  20.	  
	  
Figure	  20	  –	  Cytokine	  expression	  on	  γδ 	  T	  cells	  in	  the	  presence	  and	  absence	  of	  IL2	  
No IL2 IL2 added  p value No IL2 IL2 added p value
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Percentage	  of	  IFNγ	  expressing	  γδ	  T	  cells	  following	  incubation	  of	  whole	  blood	  for	  6	  days	  
with	  RPMI,	  SEB	  (1μg/ml),	  BCG	  (5x105cfu/ml)	  and	  IPP	  (25μM)	  +/-­‐	  IL2	  addition	  on	  Day	  3.	  	  
On	  Day	  6,	  PMA/Ionomycin	  and	  Brefeldin	  were	  added	  for	  4	  hours	  prior	  to	  harvesting	  of	  
cells.	  There	  are	  no	  significant	  differences	  due	  to	  IL2.	  	  All	  samples	  are	  from	  children	  with	  
presumed	  TB	  (n=6).	  	  Horizontal	  bars	  represent	  median	  values.	  	  A	  one-­‐way	  ANOVA	  
performed	  showed	  a	  p	  value	  >0.05.	  The	  percentage	  of	  total	  CD3+	  T	  cells	  expressing	  the	  γδ	  T	  cell	  receptor	  in	  all	  stimulation	  conditions	  at	  both	  day	  1	  and	  day	  6,	  with	  and	  without	  IL2	  were	  examined	  to	  identify	  any	  differences.	  	  No	  statistical	  differences	  were	  identified	  (Figure	  21).	  
	  
Figure	  21	  –	  Effect	  of	  IL2	  on	  γδ	  T	  cells	  in	  6	  day	  assay	  
Percentage	  of	  CD3+	  T	  cells	  expressing	  the	  γδ	  T	  cell	  receptor	  following	  incubation	  of	  whole	  
blood	  at	  various	  stimulation	  conditions	  for	  2	  different	  time	  points	  (overnight	  and	  6	  days).	  	  
Half	  of	  the	  samples	  incubated	  for	  6	  days	  had	  IL2	  added	  on	  Day	  3.	  	  There	  are	  no	  significant	  
differences	  between	  any	  of	  the	  groups.	  	  Unstimulated,	  SEB	  stimulated	  and	  BCG	  stimulated	  
samples	  are	  pooled.	  	  All	  samples	  are	  from	  children	  with	  presumed	  TB	  (n=6).	  In	  view	  of	  these	  results	  and	  concern	  regarding	  a	  potentially	  biased	  effect	  of	  adding	  external	  cytokines	  to	  the	  samples,	  it	  was	  decided	  not	  to	  add	  IL2	  on	  day	  3	  of	  this	  assay.	  
4.5. Difference	  in	  cytokine	  expression	  and	  proliferation	  in	  response	  to	  
Mtb	  specific	  antigens	  rather	  than	  BCG	  In	  order	  to	  compare	  our	  healthy	  control	  cohort	  with	  the	  TB	  disease	  cohort,	  we	  chose	  BCG	  as	  a	  surrogate	  for	  mycobacterial	  specific	  responses,	  as	  being	  sensitized	  to	  Mtb	  specific	  antigens	  was	  an	  exclusion	  criteria	  for	  the	  healthy	  control	  group.	  	  However,	  as	  we	  know	  that	  BCG	  vaccination	  does	  not	  lead	  to	  full	  protection	  from	  TB	  disease,	  it	  is	  
Percentage Gammadelta T cells 
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likely	  that	  there	  are	  differences	  in	  the	  immune	  responses	  to	  BCG	  and	  Mtb.	  	  In	  order	  to	  address	  this,	  we	  included	  pooled	  ESAT6	  and	  CFP10	  overlapping	  peptides	  as	  a	  further	  stimulation	  condition	  in	  the	  6	  day	  assay	  –	  this	  would	  allow	  us	  to	  measure	  secreted	  cytokines	  at	  day	  1	  and	  day	  6	  and	  additionally	  phenotypical	  and	  functional	  responses	  of	  T	  cells	  on	  day	  6.	  	  Due	  to	  cost	  and	  available	  blood	  volumes,	  it	  was	  not	  practical	  to	  include	  these	  antigens	  for	  the	  short	  term	  whole	  blood	  assay.	  	  In	  addition,	  we	  compared	  heat	  killed	  Mycobacterium	  tuberculosis	  reference	  strain	  H37Rv	  (hkH37RV)	  T	  cell	  responses	  with	  BCG	  and	  ESAT	  6/CFP10	  responses	  in	  a	  subset	  of	  children	  as	  there	  may	  be	  some	  differences	  in	  responses	  to	  whole	  bacteria	  compared	  to	  specific	  antigens.	  	  
4.5.1. ESAT6/CFP10	  overlapping	  peptide	  pool	  The	  peptides	  were	  sourced	  from	  Peptide	  and	  Protein	  Research	  UK	  and	  a	  combined	  pool	  of	  peptides	  (15-­‐mers	  overlapping	  by	  10)	  spanning	  the	  mycobacterial	  proteins	  early	  secretory	  antigenic	  target-­‐6	  (ESAT-­‐6)	  and	  culture	  filtrate	  protein-­‐10	  (CFP-­‐10)	  were	  used	  (each	  peptide	  at	  a	  final	  concentration	  of	  10µg/ml).	  	  	  
4.5.2. Heat	  Killed	  Mycobacterium	  tuberculosis	  (H37Rv	  strain)	  The	  Mycobacterium	  tuberculosis	  reference	  strain	  (H37Rv)	  was	  obtained	  as	  a	  gift	  from	  the	  medical	  mycobacteriology	  research	  group	  (MMRU)	  at	  the	  University	  of	  Cape	  Town.	  It	  was	  heat	  killed	  as	  previously	  described.	  	  In	  brief	  H37Rv	  was	  heat	  killed	  using	  the	  method	  derived	  from	  Doig	  and	  colleagues	  (Doig	  et	  al.,	  2002).	  McCartney	  bottles	  containing	  mid	  log	  H37Rv	  were	  placed	  into	  a	  waterproof,	  leakproof,	  sealable	  plastic	  container	  filled	  two	  thirds	  full	  with	  water.	  This	  was	  then	  placed	  in	  a	  waterbath	  at	  80°C	  for	  30	  minutes.	  To	  verify	  that	  killing	  had	  occurred,	  50μl	  from	  each	  McCartney	  bottle	  was	  plated	  onto	  7H11	  agar	  and	  incubated	  at	  37°C	  for	  12	  weeks.	  Following	  verification,	  the	  heat	  killed	  H37Rv	  antigen	  stocks	  were	  pooled	  and	  frozen	  in	  10ml	  aliquots	  at	  -­‐20°C	  until	  required.	  H37RV	  was	  used	  at	  a	  final	  concentration	  of	  5	  x	  106	  cfu/ml.	  
4.5.3. Results	  of	  subset	  of	  children	  stimulated	  with	  BCG,	  H37Rv	  and	  ESAT6	  
CFP10	  A	  subset	  of	  12	  children	  from	  the	  TB	  disease	  cohort	  had	  all	  3	  mycobacterial	  conditions	  set	  up	  for	  the	  6	  day	  Ki67	  assay.	  	  Cells	  were	  harvested	  as	  previously	  described	  and	  stained	  for	  flow	  cytometry	  using	  the	  panel	  described	  in	  Chapter	  3.	  	  The	  percentage	  of	  proliferating	  and	  cytokine	  expressing	  cells	  for	  the	  CD4	  and	  γδ	  T	  cell	  phenotypes	  are	  shown	  in	  Table	  5.	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  Table	  4	  Percentage	  of	  cytokine	  expressing	  T	  cells	  following	  stimulation	  for	  6	  days	  under	  
different	  mycobacterial	  conditions	  
The	  median	  percentage	  and	  interquartile	  range	  (IQR)	  of	  each	  cytokine	  and	  Ki67	  is	  shown	  
for	  the	  different	  stimulation	  conditions.	  	  The	  T	  cell	  phenotype	  is	  shown	  along	  the	  left	  side.	  	  
All	  samples	  were	  from	  children	  with	  Tuberculosis	  (n=12).	  	  A	  one-­‐way	  ANOVA	  and	  Mann-­‐
Whitney	  test	  was	  performed	  for	  each	  comparison	  and	  p-­‐values	  are	  shown	  to	  the	  right	  of	  
the	  table.	  Significant	  values	  are	  highlighted	  in	  red.	  	  (ns=	  not	  significant,	  p>0.05).	  
	  Although	  there	  are	  significant	  differences	  in	  magnitude	  of	  response,	  the	  pattern	  of	  response	  was	  similar,	  as	  can	  be	  demonstrated	  by	  looking	  at	  CD4	  T	  cells	  in	  figure	  22.	  
	  
Figure	  22	  Pattern	  of	  proliferation	  and	  cytokine	  expression	  in	  CD4	  T	  cells	  stimulated	  by	  
hkH37Rv,	  BCG	  and	  ESAT6/CFP10	  
This	  figure	  shows	  the	  percentage	  of	  proliferating	  (Ki67+)	  and	  cytokine	  producing	  Ki67+CD8-­‐γδ-­‐	  
[CD4+]	  T	  cells	  following	  whole	  blood	  incubation	  with	  H37RV	  (5x106cfu/ml,)	  BCG	  (2.5x106	  cfu/ml)	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or	  ESAT	  6/CFP	  10	  peptide	  pool	  (10µg/ml)	  for	  6	  days	  followed	  by	  4	  hours	  incubation	  with	  Brefeldin,	  
PMA	  and	  Ionomycin	  (PI).	  	  Whole	  blood	  from	  children	  with	  TB	  disease	  was	  used	  (n=12).	  	  Data	  was	  
compared	  using	  a	  one	  way	  ANOVA	  and	  Mann	  Whitney	  test	  and	  is	  presented.	  	  Horizontal	  bars	  
represent	  median	  values.	  	  As	  the	  pattern	  of	  response	  was	  similar,	  for	  the	  remainder	  of	  the	  thesis	  we	  used	  BCG	  responses	  for	  ease	  of	  comparison	  of	  data.	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5. Clinical	  Results	  
5.1. Introduction	  It	  is	  well	  recognized	  that	  factors	  such	  as	  poverty,	  overcrowding,	  food	  insecurity,	  HIV	  infection	  and	  malnutrition	  are	  risk	  factors	  for	  both	  TB	  infection	  rates	  and	  TB	  disease.	  There	  is	  also	  some	  evidence	  that	  malnutrition	  may	  affect	  immune	  function	  predisposing	  children	  to	  tuberculosis	  progression,	  and	  the	  resulting	  disease	  and	  inflammatory	  response	  further	  worsens	  the	  nutritional	  state147	  .	  	  	  	  Hence	  it	  was	  essential	  that	  information	  on	  these	  risk	  factors	  was	  collected	  as	  part	  of	  the	  study	  so	  that	  these	  factors	  could	  be	  examined	  as	  part	  of	  the	  analysis.	  	  A	  number	  of	  publications	  have	  looked	  at	  the	  spectrum	  of	  TB	  disease	  in	  Cape	  Town	  previously,	  identifying	  high	  levels	  of	  morbidity	  amongst	  children,	  in	  particular	  those	  with	  HIV	  infection	  and	  younger	  age2,148.	  	  While	  the	  main	  purpose	  of	  this	  study	  was	  to	  compare	  immune	  responses	  of	  the	  different	  disease	  phenotypes	  and	  healthy	  children	  of	  different	  ages,	  the	  description	  of	  the	  study	  cohort	  and	  comparison	  with	  other	  recent	  South	  African	  cohorts	  is	  also	  of	  value.	  	  	  	  	  	  	  
Additionally,	  detailed	  characterization	  of	  the	  cohort	  allowing	  accurate	  classification	  of	  the	  patients	  into	  study	  groups	  was	  essential,	  and	  indeed	  one	  of	  the	  strengths	  of	  this	  study.	  	  Two	  recent	  publications	  have	  discussed	  methods	  of	  classifying	  TB	  disease	  in	  children.	  Wiseman	  et	  al	  proposed	  a	  classification	  system	  for	  disease	  severity	  in	  children,	  while	  Graham	  et	  al	  proposed	  clinical	  case	  definitions	  for	  the	  classification	  of	  intra-­‐thoracic	  disease	  of	  tuberculosis	  in	  children149,150.	  	  Both	  of	  these,	  along	  with	  previous	  work	  by	  Marais	  et	  al	  and	  Nicol	  et	  al	  were	  invaluable	  for	  the	  classification	  of	  this	  study	  cohort151-­‐153.	  	  
This	  chapter	  describes	  the	  study	  cohort	  including	  demographics,	  socio-­‐economic	  risk	  factors	  for	  TB	  disease,	  clinical	  findings,	  investigations	  and	  results,	  followed	  by	  the	  classification	  of	  the	  cohort	  into	  disease	  groups.	  	  	  	  	  	  	  
5.2. Study	  Cohort	  Between	  May	  2011	  and	  August	  2012	  233	  children	  were	  recruited	  from	  Red	  Cross	  War	  Memorial	  Children’s	  Hospital	  in	  Cape	  Town,	  South	  Africa.	  	  Ethical	  approval	  was	  granted	  by	  the	  Faculty	  of	  Health	  Sciences	  Human	  Research	  Ethics	  Committee	  at	  the	  University	  of	  Cape	  Town	  (HREC	  062/2011)	  and	  the	  study	  also	  had	  hospital	  approval.	  	  Children	  with	  TB	  were	  identified	  by	  the	  study	  team	  following	  discussion	  with	  the	  clinical	  teams	  on	  the	  ward	  and	  were	  approached	  on	  the	  children’s	  ward	  with	  their	  parents.	  	  The	  study	  was	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described	  to	  them	  in	  an	  appropriate	  language	  (Xhosa,	  Africaans	  or	  English	  by	  the	  study	  nurse,	  Sr.	  Magwebu)	  and	  they	  were	  given	  a	  patient	  information	  leaflet	  in	  the	  appropriate	  language.	  	  Written	  consent	  was	  obtained	  following	  full	  explanation	  of	  the	  study.	  	  The	  children	  in	  the	  age-­‐related	  healthy	  control	  group	  were	  approached	  either	  in	  the	  outpatient	  clinic	  or	  on	  the	  ward	  prior	  to	  elective	  surgery.	  	  A	  second	  patient	  information	  leaflet	  for	  this	  group	  was	  available	  in	  Xhosa,	  Africaans	  and	  English	  and	  following	  full	  explanation	  of	  the	  study,	  written	  consent	  was	  obtained.	  	  	  Examples	  of	  the	  patient	  information	  leaflets	  and	  consent	  forms	  are	  available	  in	  Appendix	  1.	  	  	  Following	  recruitment	  to	  the	  study,	  demographic	  and	  clinical	  data	  was	  collected	  from	  each	  participating	  child	  to	  assess	  general	  health;	  this	  included	  a	  symptom	  and	  contact	  history	  based	  screening	  tool	  to	  assess	  risk	  of	  TB	  infection	  or	  disease.	  	  Two	  case	  report	  forms	  (CRF)	  were	  utilised,	  a	  more	  detailed	  one	  including	  data	  on	  investigations	  and	  treatment	  for	  the	  TB	  cohort	  and	  a	  simpler	  one	  for	  the	  healthy	  controls	  (Appendix	  2).	  	  Data	  on	  presenting	  symptoms,	  clinical	  examination	  and	  investigations	  were	  collected	  to	  classify	  children	  into	  the	  different	  patient	  groups	  as	  described	  below.	  	  Since	  HIV	  infection	  would	  represent	  a	  significant	  confounder	  in	  any	  study	  of	  immunological	  parameters,	  all	  children	  were	  tested	  for	  HIV.	  	  One	  child	  was	  found	  to	  be	  HIV	  infected	  and	  therefore	  excluded	  from	  the	  study;	  30	  children	  had	  a	  history	  of	  maternal	  HIV	  exposure	  but	  had	  remained	  uninfected.	  	  One	  infant	  was	  found	  to	  be	  HIV	  antibody	  positive	  on	  ELISA,	  but	  confirmed	  HIV	  uninfected	  on	  PCR	  testing	  of	  HIV	  DNA;	  his	  mother	  was	  counseled	  and	  tested	  and	  referred	  to	  her	  local	  clinic	  for	  ongoing	  care.	  Another	  child	  was	  excluded	  from	  the	  study	  as	  she	  died	  before	  samples	  could	  be	  obtained.	  	  8	  children	  were	  excluded	  from	  the	  healthy	  control	  group	  as	  blood	  could	  not	  be	  obtained.	  	  	  Of	  the	  233	  children,	  76	  were	  treated	  for	  TB	  disease	  (active	  TB	  group),	  83	  children	  were	  assigned	  as	  healthy	  age-­‐related	  controls	  and	  25	  had	  latent	  TB	  infection	  (LTBI)	  as	  determined	  by	  Mtb	  sensitivity.	  (Table	  8).	  	  The	  majority	  of	  children	  recruited	  were	  male,	  there	  were	  no	  significant	  differences	  in	  any	  demographic	  characteristics	  between	  patient	  groups.	  
5.3. Socioeconomic	  differences	  A	  table	  of	  socioeconomic	  determinants	  is	  shown	  below	  (Table	  6).	  	  Children	  recruited	  as	  controls	  who	  were	  attending	  Red	  Cross	  War	  Memorial	  Children’s	  Hospital	  for	  elective	  surgical	  procedures	  were	  more	  likely	  to	  live	  in	  formal	  housing	  than	  those	  children	  who	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have	  a	  diagnosis	  of	  TB	  (78.3%	  vs	  60.5%,	  p=0.015).	  	  Children	  with	  extra-­‐pulmonary	  TB	  (EPTB)	  came	  from	  a	  less	  privileged	  group,	  being	  less	  likely	  to	  live	  in	  formal	  housing	  than	  children	  with	  pulmonary	  TB	  (50%	  vs	  66%,	  p=ns)	  and	  significantly	  less	  likely	  to	  live	  in	  formal	  housing	  than	  children	  attending	  for	  elective	  surgical	  procedures	  (50%	  vs	  78.3%,	  p=0.0001).	  	  32%	  of	  the	  entire	  cohort	  reported	  contact	  with	  a	  household	  member	  who	  had	  been	  treated	  for	  TB	  within	  the	  previous	  year,	  of	  these,	  39	  (17%)	  were	  <5yrs	  of	  age,	  but	  only	  3	  (7.7%)	  children	  received	  chemoprophylaxis	  appropriately.	  	  South	  African	  guidelines	  support	  contact	  tracing	  of	  household	  TB	  contacts	  and	  treating	  of	  all	  children	  <5yrs	  of	  age	  with	  6	  months	  Isoniazid	  at	  a	  dose	  of	  10mg/kg.	  	  3	  children	  treated	  for	  TB	  had	  received	  chemoprophylaxis	  appropriately	  but	  had	  subsequently	  developed	  TB	  despite	  this	  –	  one	  of	  these	  had	  culture	  confirmed	  TB,	  the	  other	  2	  were	  treated	  as	  probable	  TB	  and	  had	  tuberculin	  skin	  test	  (TST)	  readings	  of	  >15mm	  and	  suggestive	  chest	  X-­‐ray	  findings.	  
	  
Table	  5	  –	  Socio-­‐economic	  characteristics	  of	  the	  different	  patient	  groups.	  
Values	  are	  number	  of	  children	  with	  percentage	  in	  brackets.	  	  Chi-­‐squared	  tests	  were	  used	  to	  
compare	  different	  groups.	  	  Children	  with	  any	  diagnosis	  of	  TB	  and	  children	  with	  EPTB	  were	  
significantly	  less	  likely	  to	  live	  in	  formal	  housing	  than	  healthy	  control	  children	  (p=0.015	  and	  
P<0.0001	  respectively)	  but	  no	  other	  significant	  differences	  were	  identified.	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median	  0.1550,	  p=0.0001).	  	  Additionally,	  children	  with	  active	  TB	  disease	  had	  lower	  weights	  and	  weight	  for	  height	  ratio	  at	  baseline	  than	  following	  treatment	  (Weight	  baseline	  median	  -­‐0.8950;	  range	  -­‐4.510	  to	  4.170,	  weight	  6	  months	  median	  -­‐0.0550;	  range	  -­‐2.36	  to	  1.96;	  p=0.03,	  WH	  baseline	  median	  -­‐0.5200;	  range	  -­‐4.110	  to	  3.440,	  WH	  6	  months	  median	  0.7900,	  range	  -­‐3.090	  to	  2.020,	  p=0.01).	  	  Figure	  23.	  	  There	  were	  no	  significant	  differences	  in	  z	  scores	  for	  weight,	  height	  or	  WH	  between	  pulmonary	  TB	  and	  extra-­‐pulmonary	  TB	  at	  baseline	  (data	  not	  shown).	  
	  
Figure	  23	  Children	  with	  TB	  had	  significantly	  lower	  z	  scores	  for	  weight	  than	  healthy	  children;	  
this	  had	  not	  completely	  corrected	  by	  the	  end	  of	  treatment	  
Z	  scores	  for	  weight,	  height	  and	  weight/height	  are	  shown	  for	  children	  in	  the	  3	  different	  
groups	  TB	  baseline	  (n=38),	  TB	  after	  6	  months	  treatment	  (n=32)	  and	  healthy	  controls	  
(n=58).	  Data	  was	  compared	  using	  a	  one	  way	  ANOVA	  and	  Mann-­‐Whitney	  test	  and	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5.5. Clinical	  symptoms	  of	  the	  TB	  cohort.	  	  	  All	  of	  the	  common	  symptoms	  of	  cough,	  fever,	  night	  sweats,	  malaise,	  appetite	  loss	  and	  weight	  loss	  were	  described	  in	  the	  children	  belonging	  to	  the	  TB	  cohort	  (Table	  7).	  	  Cough	  was	  the	  commonest	  symptom	  with	  72.4%	  of	  children	  presenting	  with	  a	  cough.	  	  Weight	  loss	  was	  also	  commonly	  described	  in	  55.3%	  of	  cases.	  	  Of	  the	  50	  children	  who	  had	  duration	  of	  symptoms	  recorded,	  the	  duration	  varied	  from	  1	  day	  to	  >6	  months,	  with	  a	  median	  of	  21	  days.	  	  	  
	  
Table	  6	  –	  Clinical	  characteristics	  of	  the	  children	  treated	  for	  TB	  
There	  were	  no	  significant	  differences	  in	  symptoms	  between	  children	  with	  confirmed	  and	  
probable	  pulmonary	  TB	  using	  chi-­‐squared	  testing.	  
5.6. Tuberculin	  Skin	  Test	  (TST)	  results	  and	  routine	  haematological	  
investigations.	  Every	  patient	  who	  was	  enrolled	  had	  a	  TST	  performed	  as	  part	  of	  the	  inclusion	  criteria.	  	  The	  TST	  is	  not	  used	  routinely	  as	  part	  of	  the	  diagnostic	  criteria	  for	  tuberculosis	  in	  South	  Africa	  as	  so	  many	  children	  are	  TST	  positive	  due	  to	  a	  combination	  of	  universal	  BCG	  vaccination	  and	  exposure	  to	  high	  levels	  of	  environmental	  mycobacteria,	  as	  well	  as	  high	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levels	  of	  Mtb	  sensitization	  due	  to	  high	  prevalence	  of	  TB	  in	  the	  community.	  	  However,	  as	  the	  data	  in	  Figure	  22	  demonstrate,	  a	  positive	  TST	  (>10mm)	  can	  be	  a	  useful	  discriminator	  of	  pulmonary	  TB	  disease.	  	  Conversely,	  a	  negative	  TST	  should	  not	  be	  reassuring	  as	  7/19	  (37%)	  of	  children	  with	  culture-­‐confirmed	  extra-­‐pulmonary	  TB	  had	  no	  reaction	  to	  tuberculin	  after	  72	  hours.	  	  Both	  pulmonary	  (PTB)	  and	  extrapulmonary	  TB	  (EPTB)	  were	  significantly	  more	  likely	  to	  present	  with	  a	  positive	  TST	  than	  possible	  TB	  (p<0.0001	  and	  p=0.0005	  respectively).	  	  There	  were	  no	  significant	  differences	  in	  TST	  readings	  between	  culture	  confirmed	  TB	  (DPTB/DEPTB)	  and	  probable	  TB	  (PPTB/PEPTB).	  	  TST	  readings	  were	  significantly	  higher	  in	  children	  with	  pulmonary	  TB	  than	  in	  children	  with	  extrapulmonary	  TB	  (p=0.012)	  	  	  
	   	  
Figure	  24	  -­‐	  A	  TST	  of	  10mm	  discriminates	  children	  with	  pulmonary	  TB	  from	  those	  without,	  
but	  is	  less	  useful	  for	  extra-­‐pulmonary	  TB.	  	  	  Skin	  induration	  is	  measured	  by	  experienced	  nurses	  48-­‐72	  hours	  after	  placement	  of	  tuberculin	  intradermally.	  	  The	  table	  shows	  the	  median	  and	  range	  of	  TST	  readings	  in	  different	  patient	  groups.	  The	  graph	  demonstrates	  how	  these	  compare	  with	  a	  cut-­‐off	  of	  10mm.	  	  Data	  was	  compared	  using	  a	  one-­‐way	  ANOVA	  and	  Mann-­‐Whitney	  tests	  and	  significant	  results	  are	  presented	  as	  shown.	  	  Horizontal	  bars	  represent	  median	  values.	  Although	  investigative	  blood	  tests	  such	  as	  full	  blood	  count	  and	  C-­‐reactive	  protein	  were	  not	  done	  as	  part	  of	  the	  study,	  results	  from	  any	  tests	  done	  by	  the	  managing	  clinician	  were	  recorded	  in	  the	  database.	  	  Blood	  tests	  were	  performed	  as	  clinical	  indicated	  and	  results	  were	  not	  available	  for	  all	  children.	  	  There	  were	  no	  significant	  differences	  in	  blood	  test	  results	  between	  different	  patient	  groups	  (data	  not	  shown).	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defined	  according	  to	  three	  categories	  as	  previously	  described	  in	  other	  studies2,151,154.	  	  	  1)	  Definite	  TB:	  M	  tuberculosis	  was	  isolated	  from	  culture	  specimens	  in	  all	  children	  in	  this	  group.	  	  Specimens	  included	  nasopharyngeal	  aspirate,	  gastric	  washing,	  induced	  sputum,	  fine-­‐needle	  aspirate	  of	  lymph	  node,	  pleural	  fluid,	  ascitic	  fluid,	  cerebrospinal	  fluid,	  bone	  biopsy,	  joint	  effusion	  fluid	  or	  skin	  biopsy.	  	  2)	  Probable	  TB:	  in	  the	  absence	  of	  culture	  confirmation	  all	  children	  in	  this	  group	  had	  all	  of	  the	  following:	  symptoms	  and	  signs	  consistent	  with	  active	  TB;	  abnormal	  radiography	  consistent	  with	  TB	  and/or	  abnormal	  cerebro-­‐spinal	  fluid	  (CSF)	  consistent	  with	  tuberculous	  meningitis;	  response	  to	  TB	  therapy;	  and	  a	  history	  of	  TB	  contact.	  	  3)	  Possible	  TB:	  these	  children	  had	  signs	  and	  symptoms	  consistent	  with	  active	  TB	  and	  existing	  risk	  factors	  for	  active	  TB,	  such	  as	  history	  of	  TB	  contact	  or	  previous	  TB	  diagnosis.	  	  Subsequently,	  however,	  the	  treating	  paediatrician	  made	  an	  alternative	  diagnosis	  or	  felt	  that	  TB	  was	  unlikely.	  Therefore,	  none	  of	  the	  children	  in	  this	  group	  ever	  received	  TB	  treatment.	  	  All	  of	  these	  children	  were	  followed	  up	  at	  3	  months	  post	  enrollment	  and	  confirmed	  to	  have	  made	  a	  clinical	  improvement.	  	  If	  there	  was	  no	  clinical	  improvement,	  they	  were	  re-­‐investigated	  for	  TB	  at	  that	  point.	  	  Children	  with	  Possible	  TB	  were	  not	  included	  in	  the	  analysis	  of	  active	  TB	  cases.	  	  Children	  with	  Definite	  and	  Probable	  TB,	  described	  as	  ‘active	  TB’	  for	  this	  study,	  were	  followed	  up	  for	  6	  months.	  	  42/76	  children	  had	  culture	  confirmed	  TB	  (55%)	  which	  is	  higher	  than	  the	  average	  rate	  in	  children	  (normally	  around	  30%)	  and	  this	  can	  be	  attributed	  to	  a	  number	  of	  factors	  including	  patient	  selection	  for	  the	  study	  and	  co-­‐enrollment	  on	  a	  diagnostic	  study	  leading	  to	  very	  vigilant	  sample	  collection	  and	  use	  of	  optimal	  diagnostic	  techniques	  including	  the	  new	  GeneXpert	  test.	  	  It	  does	  demonstrate	  also	  that	  a	  high	  index	  of	  suspicion	  and	  vigorous	  sample	  collection	  can	  result	  in	  improved	  culture	  confirmation	  rates	  and	  health	  care	  professionals	  in	  all	  settings	  should	  endeavor	  to	  confirm	  the	  diagnosis	  of	  TB	  in	  children.	  
























Probable	  TB	   34	  
2yr	  10mth	  
(6mth	  -­‐11yr	  7mth)	  
15	  
(44%)	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LTBI	   25	  
3yr	  9mth	  
(4mth-­‐	  11yr	  1mth)	  
10	  (40%)	  
Table	  7	  Characteristics	  of	  Study	  Group	  
The	  median	  age	  of	  the	  extra-­‐pulmonary	  TB	  group	  (EPTB)	  is	  unexpectedly	  older	  than	  the	  
median	  age	  of	  the	  pulmonary	  TB	  group	  (PTB)	  (5yr	  4mth	  vs	  3yr	  9mth,	  p=0.17)	  DPTB=	  
definite	  pulmonary	  TB,	  PPTB	  =	  probable	  pulmonary	  TB,	  DEPTB	  =	  definite	  extra-­‐pulmonary	  
TB,	  PEPTB=	  probable	  extra-­‐pulmonary	  TB,	  LTBI	  =	  latent	  TB	  infection	  Based	  on	  clinical	  and	  microbiological	  findings,	  these	  children	  were	  further	  classified	  according	  to	  the	  site	  of	  disease	  as	  having	  either	  pulmonary	  disease	  or	  extra-­‐pulmonary	  disease.	  	  Pulmonary	  disease	  refers	  to	  disease	  isolated	  to	  the	  pleural	  cavity	  which	  has	  not	  spread	  either	  directly	  via	  the	  lymph	  nodes	  or	  via	  hematogenous	  bacillary	  spread.	  	  Complicated	  intrathoracic	  lymph	  node	  disease,	  defined	  as	  the	  presence	  of	  nodal	  large	  airway	  compression,	  is	  classified	  as	  pulmonary	  disease,	  regardless	  of	  severity.	  	  Pleural	  effusions	  were	  classified	  as	  extra-­‐pulmonary	  if	  the	  pleural	  fluid	  sampled	  contained	  Mtb,	  whereby	  it	  was	  deemed	  to	  be	  hematogenous	  disease	  spread,	  rather	  than	  being	  due	  to	  the	  more	  commonly	  described	  hypersensitivity	  phenomenon	  in	  older	  children.	  	  Additionally,	  empyema,	  or	  the	  presence	  of	  pus	  with	  or	  without	  acid-­‐fast	  bacilli	  (AFB)	  in	  the	  pleural	  space	  is	  classified	  as	  extra-­‐pulmonary	  disease.	  	  Tuberculous	  pericarditis	  is	  described	  to	  arise	  from	  spread	  from	  adjacent	  nodes	  or	  from	  hematogenous	  bacillary	  spread,	  hence	  is	  extra-­‐pulmonary	  disease.	  	  Culture	  positive	  ulcerating	  extra-­‐thoracic	  lymph	  node	  disease	  or	  lymph	  node	  disease	  in	  the	  presence	  of	  a	  sinus	  or	  fistula	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represents	  evidence	  of	  uncontrolled	  disease	  and	  was	  considered	  extra-­‐pulmonary,	  but	  enlarged	  cervical	  lymph	  nodes	  in	  the	  presence	  of	  typical	  pulmonary	  disease	  were	  not	  classified	  as	  extra-­‐pulmonary	  disease.	  	  All	  forms	  of	  central	  nervous	  system	  (CNS)	  disease,	  including	  tuberculous	  meningitis,	  granulomata	  and	  tuberculoma	  reflect	  hematogenous	  organism	  dissemination	  and	  as	  such	  were	  classified	  as	  extra-­‐pulmonary	  disease.	  	  	  CNS	  disease	  was	  designated	  as	  meningitis	  if	  there	  was	  evidence	  of	  meningeal	  involvement	  on	  radiology	  or	  if	  there	  were	  CSF	  abnormalities	  consistent	  with	  TB	  meningitis	  (increased	  white	  cells	  and	  protein,	  decreased	  glucose	  +/-­‐	  AFB’s	  seen).	  	  All	  abdominal	  TB	  was	  classified	  as	  extra-­‐pulmonary	  disease	  as	  its	  assumed	  pathogenesis	  is	  lymphatic	  or	  hematogenous	  spread	  from	  a	  pulmonary	  focus	  or	  rupture	  of	  abdominal	  nodes	  into	  the	  peritoneal	  cavity.	  	  Tuberculous	  hypersensitivity	  phenomena	  such	  as	  erythema	  nodosum,	  erythema	  induratum	  and	  reactive	  arthritis	  were	  not	  classified	  as	  extra-­‐pulmonary	  disease.	  	  Tuberculous	  arthritis	  in	  isolation	  usually	  represents	  a	  reactive	  immunologic	  phenomenon,	  but	  in	  conjunction	  with	  synovitis	  or	  osteitis	  usually	  represents	  hematogenous	  spread	  to	  the	  vascular	  synovium	  and	  was	  described	  as	  extra-­‐pulmonary	  disease.	  	  Similarly,	  tuberculous	  spondylitis	  which	  implies	  hematogenous	  dissemination	  to	  the	  vertebral	  body	  or	  the	  vascularized	  disk	  is	  described	  as	  extra-­‐pulmonary	  disease.	  	  A	  table	  with	  a	  breakdown	  of	  the	  cases	  of	  extra-­‐pulmonary	  disease	  is	  found	  below	  (Table	  9).	  	  All	  but	  two	  of	  the	  children	  had	  pulmonary	  disease	  in	  addition	  to	  disease	  in	  another	  site.	  	  There	  is	  a	  trend	  towards	  younger	  children	  having	  more	  multi-­‐site	  disease	  than	  older	  children	  but	  it	  is	  not	  significant.	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Table	  8	  -­‐	  Classification	  of	  extra-­‐pulmonary	  TB	  cases	  showing	  sites	  of	  disease.	  	  
Increasing	  age	  in	  months	  is	  represented	  in	  blue	  along	  the	  left	  side	  of	  the	  table,	  the	  different	  
age	  groups	  (<1	  (n=3),	  >1<2	  (n=3),	  >2<5	  (n=7),>5	  (n=15))	  are	  segregated	  by	  bold	  bars.	  	  
Number	  of	  different	  sites	  of	  disease	  is	  represented	  in	  colour	  on	  the	  right	  side	  of	  the	  table.	  	  
Definite	  cases	  are	  in	  dark	  blue,	  probable	  cases	  are	  in	  lighter	  blue.	  (n=28)	  
5.8. TB	  Treatment.	  	  A	  total	  of	  76	  children	  received	  a	  full	  course	  of	  TB	  treatment.	  Of	  these,	  37	  received	  a	  standard	  3-­‐drug	  treatment	  regimen	  containing	  Rifampicin,	  Isoniazid	  and	  Pyrazinamide;	  34	  received	  4	  drugs,	  24	  of	  these	  had	  Ethambutol	  and	  10	  had	  Ethionamide.	  	  Ethionamide	  is	  routinely	  added	  for	  treatment	  of	  TB	  meningitis	  in	  South	  Africa.	  	  5	  children	  received	  a	  standard	  multi-­‐drug	  resistant	  (MDR)	  treatment	  regimen	  and	  were	  transferred	  to	  Brooklyn	  Chest	  hospital	  for	  ongoing	  care	  –	  of	  these,	  2	  had	  culture	  confirmed	  MDR	  TB	  and	  the	  other	  3	  were	  household	  contacts	  of	  cases	  of	  MDR	  TB.	  	  A	  further	  child	  was	  originally	  started	  on	  an	  MDR	  regimen,	  but	  stopped	  once	  drug	  sensitivities	  showed	  a	  sensitive	  strain	  of	  Mtb.	  	  11	  children	  received	  prednisolone	  –	  7	  of	  whom	  had	  meningitis,	  the	  others	  had	  mediastinal	  lymphadenopathy.	  	  Of	  note,	  bloods	  were	  taken	  prior	  to	  treatment	  with	  steroids.	  Pyridoxine	  was	  uncommonly	  added	  in	  only	  7	  cases	  –	  5	  of	  whom	  were	  on	  MDR	  regimens.	  	  





























4 1 1 1 3
9 1 1 2
11 1 1
18 1 1 2
21 1 1 1 1 4
23 1 1 1 3
28 1 1 2
31 1 1 1 3
38 1 1 1 3
38 1 1 2
49 1 1 2
53 1 1 2
58 1 1 2
60 1 1 1 3
65 1 1 2
80 1 1 2
81 1 1 2
88 1 1 2
90 1 1
91 1 1 2
99 1 1 2
100 1 1 2
109 1 1 2
114 1 1 2
134 1 1 2
134 1 1 2
136 1 1 1 3
142 1 1 2
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areas,	  for	  example,	  the	  presenting	  symptoms	  described	  by	  Marais	  et	  al	  were	  similar152.	  	  Mahomed	  et	  al	  recently	  identified	  similar	  socio-­‐economic	  risk	  factors	  including	  male	  sex,	  household	  TB	  contact,	  low	  income	  and	  low	  education	  level	  as	  predictive	  factors	  for	  TB	  infection	  in	  adolescents	  in	  the	  Western	  Cape155.	  	  The	  spectrum	  of	  disease	  in	  a	  cohort	  from	  the	  Western	  Cape	  of	  South	  Africa	  studied	  in	  2003-­‐2004	  was	  similar	  with	  a	  few	  noteworthy	  differences.	  	  They	  also	  had	  a	  high	  rate	  of	  bacterial	  confirmation	  of	  54%,	  70%	  of	  their	  children	  had	  intra-­‐thoracic	  TB	  (described	  as	  PTB	  in	  our	  cohort)	  and	  16.4%	  had	  extra-­‐thoracic	  TB	  (described	  as	  EPTB	  in	  our	  cohort).	  	  Of	  note	  however,	  they	  identified	  that	  79%	  of	  all	  non-­‐HIV	  extra-­‐thoracic	  TB	  occurred	  in	  children	  <3yrs	  of	  age.	  In	  contrast,	  40%	  (8	  of	  20	  children)	  were	  <3yrs	  of	  age	  in	  our	  cohort.	  	  Their	  setting	  was	  5	  primary	  health	  clinics	  compared	  to	  a	  tertiary	  hospital	  which	  may	  account	  for	  some	  of	  this	  difference	  as	  the	  children	  who	  present	  to	  Red	  Cross	  Hospital	  are	  more	  severely	  unwell	  and	  younger	  children	  with	  more	  non-­‐specific	  findings	  may	  have	  been	  identified	  as	  part	  of	  active-­‐case	  finding	  rather	  than	  presenting	  themselves	  to	  a	  hospital.	  	  It	  may	  also	  be	  that	  increased	  community	  awareness	  over	  the	  last	  8-­‐10	  years	  in	  Cape	  Town	  has	  resulted	  in	  parents	  presenting	  with	  both	  their	  symptoms	  and	  their	  unwell	  children	  at	  an	  earlier	  stage.	  	  Or	  perhaps	  there	  has	  been	  a	  change	  in	  BCG	  vaccine	  protectiveness	  against	  a	  changing	  strain	  of	  Mtb	  so	  that	  younger	  children	  are	  afforded	  greater	  protection.	  	  	  One	  risk	  factor	  for	  TB	  disease	  that	  should	  be	  eliminated	  or	  at	  least	  dramatically	  reduced	  is	  that	  of	  being	  a	  household	  contact	  for	  TB.	  	  Despite	  46%	  of	  the	  TB	  cohort	  having	  a	  household	  contact	  for	  TB,	  only	  7.7%	  received	  chemoprophylaxis	  appropriately.	  	  None	  of	  this	  cohort	  were	  diagnosed	  with	  TB	  following	  active-­‐case	  finding	  and	  it	  is	  well	  recognized	  in	  the	  Western	  Cape	  that	  this	  is	  an	  area	  of	  weakness	  in	  the	  health	  system.	  	  In	  a	  recent	  study	  by	  Du	  Preez	  et	  al,	  of	  those	  eligible	  for	  preventive	  therapy,	  the	  majority	  (71%)	  represented	  a	  missed,	  recorded	  opportunity	  with	  the	  source	  case	  commonly	  being	  a	  parent156.	  	  They	  estimated	  that	  timely	  provision	  of	  preventive	  therapy	  would	  have	  prevented	  up	  to	  200	  of	  the	  reported	  TB	  cases	  and	  a	  number	  of	  TB-­‐related	  deaths	  in	  their	  study.	  	  	  
7.9%	  of	  the	  TB	  cohort	  had	  a	  z	  score	  of	  -­‐3	  at	  time	  of	  diagnosis.	  	  As	  there	  is	  evidence	  of	  malnutrition	  impacting	  on	  the	  immune	  response,	  it	  will	  be	  important	  to	  analyse	  the	  TB	  cohort	  data	  with	  this	  in	  mind.	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6. Mycobacterial	  immune	  responses	  in	  healthy	  controls	  
according	  to	  age	  	  
6.1. Introduction	  As	  described	  in	  Chapter	  1,	  infants	  and	  younger	  children	  are	  recognized	  to	  have	  increased	  susceptibility	  to	  TB	  infection	  and	  disease	  and	  to	  the	  development	  of	  the	  more	  severe	  disseminated	  forms	  of	  TB	  compared	  to	  older	  children	  and	  adults.	  	  One	  of	  the	  hypotheses	  of	  this	  study	  is	  that	  there	  are	  age-­‐related	  differences	  in	  the	  immune	  responses	  to	  mycobacteria	  which	  may	  influence	  susceptibility	  to	  disease.	  In	  particular,	  we	  hypothesised	  that	  the	  propensity	  to	  develop	  more	  contained	  forms	  of	  TB	  disease	  with	  age	  is	  regulated	  by	  a	  shift	  from	  a	  primarily	  IL17	  immune	  phenotype	  in	  very	  young	  children	  towards	  a	  predominantly	  IFNγ	  response	  in	  older	  children	  and	  adults	  as	  shown	  in	  Figure	  3.	  To	  address	  this	  question,	  in	  addition	  to	  the	  cohort	  affected	  by	  tuberculosis,	  I	  recruited	  a	  cross-­‐sectional,	  age-­‐matched	  group	  of	  80	  healthy,	  HIV-­‐negative,	  ethnically	  matched	  and	  BCG-­‐vaccinated,	  children	  with	  no	  history	  of	  TB	  contact	  and	  no	  evidence	  of	  Mtb	  sensitisation	  	  (as	  defined	  by	  a	  negative	  IGRA).	  	  Results	  were	  stratified	  to	  the	  following	  age	  groups:	  <1,	  >1<2,	  >2<5,	  >5	  (n=20	  in	  each	  group)	  in	  line	  with	  other	  age-­‐stratification	  intervals	  as	  described	  in	  Chapter	  5.	  This	  group	  serves	  as	  the	  reference	  standard	  to	  describe	  the	  baseline	  characteristics	  of	  IL17-­‐producing	  T-­‐cell	  populations	  and	  cytokine	  milieu	  in	  healthy	  children	  and	  is	  important	  to	  interpret	  the	  relevance	  of	  any	  changes	  that	  might	  be	  induced	  by	  infection	  with	  M.tuberculosis.	  	  Any	  changes	  could	  just	  be	  a	  reflection	  of	  an	  age-­‐related	  development	  of	  immune	  responses	  or	  in	  fact	  an	  Mtb-­‐triggered	  phenomenon.	  To	  recruit	  a	  healthy,	  age-­‐matched	  control	  group	  from	  the	  same	  ethnic	  and	  environmental	  background	  was	  therefore	  important	  to	  generate	  a	  reference	  standard,	  especially	  in	  the	  absence	  of	  published	  age-­‐related	  data	  of	  the	  detailed	  immunophenotyping	  I	  undertook	  for	  this	  thesis.	  There	  is	  some	  evidence	  of	  an	  age-­‐dependent	  maturation	  of	  the	  immune	  response	  after	  birth,	  including	  some	  work	  highlighting	  the	  possibility	  of	  a	  predominant	  IL17	  response	  in	  younger	  infants.	  	  Schatorje	  et	  al	  have	  shown	  that	  the	  number	  of	  naïve	  helper	  and	  cytotoxic	  T	  cells	  (CD3+CD4+CD27+CD45RA+	  and	  CD3+CD8+CD45RA+CD197+	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respectively)	  increase	  after	  birth	  and	  peak	  between	  2	  and	  15	  months	  before	  falling	  to	  adult	  levels	  by	  the	  age	  of	  5yrs157.	  	  Murine	  studies	  demonstrate	  that	  naïve	  T	  cells	  produce	  IL17	  in	  response	  to	  mycobacteria,	  switching	  to	  IFNγ	  as	  the	  T	  cell	  response	  matures.	  	  Black	  et	  al	  demonstrated	  that	  human	  newborn	  naïve	  T	  cells	  produce	  greater	  amounts	  of	  IL17	  and	  IL21	  under	  Th17	  polarising	  conditions	  compared	  to	  adult	  naïve	  T	  cells,	  whereas	  IFNγ	  production	  was	  produced	  in	  significantly	  greater	  amounts	  by	  adult	  naïve	  T	  cells	  than	  neonatal158.	  	  Additionally,	  under	  unstimulated	  conditions,	  Th17	  cell	  genes	  including	  IL-­‐23R,	  STAT3,	  and	  RORγT	  were	  98-­‐,	  2.2-­‐,	  and	  4.2-­‐fold	  higher	  in	  term	  infants	  than	  adult	  cells.	  	  It	  has	  been	  previously	  described	  that	  neonatal	  production	  of	  IFNγ	  in	  response	  to	  mycobacterial	  antigens	  is	  suppressed	  compared	  to	  adults.	  	  This	  defective	  response	  is	  specific	  to	  αβ	  T	  cells	  and	  in	  contrast,	  a	  proportion	  of	  neonatal	  γδ	  T	  cells	  have	  comparable	  IFNγ	  responses	  to	  PMA/Ionomycin	  stimulation	  to	  adult	  cells159.	  	  However,	  as	  the	  proportion	  of	  naïve	  non-­‐	  IFNγ	  producing	  γδ	  T	  cells	  is	  greater	  in	  younger	  infants,	  the	  overall	  production	  of	  IFNγ	  is	  less	  than	  that	  in	  adults.	  	  The	  mycobacterial	  specific	  immune	  responses	  of	  γδ	  T	  cells,	  in	  particular	  production	  of	  IL17	  and	  IL21,	  have	  not	  been	  studied	  in	  children.	  	  In	  this	  chapter	  I	  will	  describe	  the	  T	  cell	  phenotypes	  induced	  by	  mycobacterial	  stimulation	  (BCG)	  in	  children	  of	  different	  ages	  and	  define	  the	  cytokines	  they	  produce,	  with	  particular	  emphasis	  on	  IFNγ,	  IL17	  and	  the	  related	  cytokine	  IL22.	  	  I	  also	  describe	  the	  memory	  phenotype	  of	  these	  cells	  to	  determine	  whether	  a	  predominance	  of	  naïve	  cells	  is	  associated	  with	  different	  cytokine	  production	  and	  if	  the	  balance	  of	  these	  cells	  is	  age-­‐dependent.	  	  
6.2. Methods	  The	  methods	  used	  for	  this	  part	  of	  the	  study	  include	  1)	  the	  whole	  blood	  short	  term	  stimulation	  assay	  to	  assess	  effector	  responses	  to	  BCG	  as	  measured	  by	  IFNγ,	  IL17	  and	  IL22	  expression	  in	  T	  cells	  of	  different	  phenotypes	  and	  2)	  the	  Ki67	  flow-­‐cytometric	  lymphoproliferation	  assay	  to	  assess	  memory	  responses	  to	  BCG	  as	  measured	  by	  intracellular	  IFNγ,	  IL17	  and	  IL22.	  	  All	  of	  these	  methods	  were	  performed	  as	  described	  in	  Chapter	  3.	  	  	  For	  the	  analysis,	  the	  background	  level	  in	  unstimulated	  samples	  from	  subtracted	  from	  stimulated	  samples.	  	  Where	  background	  subtraction	  of	  the	  value	  of	  the	  unstimulated	  samples	  from	  the	  value	  of	  the	  stimulated	  samples	  resulted	  in	  values	  less	  than	  zero,	  negative	  values	  were	  set	  to	  zero.	  	  To	  eliminate	  the	  systematic	  bias	  inherent	  in	  increasing	  only	  negative	  values,	  all	  measurements	  below	  a	  nominal	  value	  of	  0.01	  (for	  frequencies	  of	  cells	  expressing	  intracellular	  cytokines)	  were	  also	  set	  to	  zero.	  	  All	  participants	  responded	  to	  the	  SEB	  positive	  control.	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6.3. 	  T	  cell	  phenotype	  and	  cytokine	  production	  following	  overnight	  
stimulation	  with	  BCG	  The	  T	  cell	  phenotype	  (γδ,	  CD4+	  and	  γδ-­‐CD4-­‐	  [described	  as	  CD8+	  henceforth])	  and	  function	  was	  measured	  as	  an	  assessment	  of	  effector	  T	  cell	  function.	  	  The	  percentage	  of	  cytokine	  producing	  T	  cells	  was	  compared	  in	  4	  different	  age-­‐groups	  -­‐	  <1,	  >1<2,	  >2<5,	  >5	  to	  determine	  differences	  with	  maturation	  of	  the	  immune	  response.	  	  These	  age-­‐ranges	  were	  chosen	  as	  the	  increasing	  susceptibility	  for	  TB	  disease	  dissemination	  has	  been	  noted	  to	  correlate	  with	  these	  decreasing	  ages	  (Marais).	  	  The	  different	  T	  cell	  phenotypes	  were	  examined	  individually	  initially	  and	  correlations	  were	  subsequently	  assessed.	  
6.3.1. Phenotype	  of	  T	  cells	  following	  overnight	  stimulation	  with	  BCG	  in	  
healthy	  children	  of	  different	  ages.	  Following	  harvesting	  of	  the	  cells	  from	  an	  overnight	  whole	  blood	  assay,	  the	  percentages	  of	  CD4+,	  γδ	  and	  CD8+	  T	  cells	  were	  determined	  in	  all	  children	  using	  flow	  cytometry	  as	  described	  previously.	  	  Table	  10	  shows	  these	  results.	  	  	  	  
	  
Table	  9	  The	  T	  cell	  phenotype	  of	  children	  of	  different	  ages	  following	  stimulation	  with	  BCG	  –	  
children	  under	  1	  have	  a	  significant	  predominance	  of	  CD4+	  T	  cells	  
The	  T	  cell	  phenotype	  is	  expressed	  both	  as	  a	  percentage	  of	  CD3+	  T	  cells	  then	  as	  an	  absolute	  
value	  (abs).	  The	  median	  value	  and	  the	  interquartile	  range	  (IQR)	  for	  each	  group	  is	  shown.	  
Absolute	  numbers	  are	  per	  250μl	  whole	  blood.	  	  A	  one-­‐way	  ANOVA	  followed	  by	  a	  Mann	  
Whitney	  t-­‐test	  for	  all	  comparisons	  was	  performed,	  with	  p	  values	  shown	  on	  the	  right	  side	  of	  
the	  table.	  (ns=	  not	  significant,	  p>0.05).	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phenotype	  between	  the	  other	  age	  groups.	  	  When	  the	  absolute	  numbers	  of	  T	  cell	  types	  were	  compared,	  there	  were	  no	  differences	  in	  number	  of	  CD4+	  T	  cells	  between	  the	  age	  groups,	  but	  the	  absolute	  number	  of	  both	  γδ	  and	  CD8+	  T	  cells	  increased	  after	  the	  first	  year	  of	  age.	  	  	  
6.3.2. Cytokine	  function	  of	  different	  T	  cell	  phenotypes	  following	  overnight	  
stimulation	  with	  BCG	  The	  percentages	  of	  IFNγ,	  IL17	  and	  IL22	  producing	  T	  cells	  in	  all	  3	  cell	  types	  were	  measured	  and	  the	  results	  are	  shown	  in	  Table	  11.	  
	  
Table	  10	  Percentage	  cytokine	  production	  by	  different	  T	  cell	  phenotypes	  in	  children	  of	  
different	  ages	  	  
The	  median	  percentage	  and	  interquartile	  range	  (IQR)	  of	  each	  cytokine	  is	  shown	  for	  the	  
different	  age	  groups.	  	  The	  T	  cell	  phenotype	  is	  shown	  along	  the	  left	  side.	  	  A	  one-­‐way	  ANOVA	  
and	  Mann-­‐Whitney	  test	  was	  performed	  for	  each	  comparison	  and	  p-­‐values	  are	  shown	  to	  the	  
right	  of	  the	  table.	  Any	  comparisons	  not	  shown	  were	  not	  significant.	  	  (ns=	  not	  significant,	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cells	  fell	  with	  increasing	  age.	  	  There	  were	  no	  differences	  in	  CD8+	  T	  cell	  cytokine	  production	  with	  age.	  	  	  
	  
Figure	  25	  -­‐	  BCG	  specific	  CD4+	  T	  cells	  produce	  significantly	  lower	  levels	  of	  IL17	  and	  IL22	  in	  
infants	  under	  1yr	  of	  age	  in	  comparison	  to	  older	  children	  
This	  figure	  shows	  the	  percentage	  of	  cytokine	  producing	  CD4+	  T	  cells	  following	  whole	  blood	  
incubation	  with	  BCG	  (2.5x106	  cfu/ml)	  overnight	  followed	  by	  5	  hours	  incubation	  with	  
Brefeldin.	  	  The	  results	  from	  healthy	  child	  controls	  of	  different	  age	  groups	  (<1yr	  (n=19),	  
>1yr<2yr	  (n=17),	  >2yr<5yr	  (n=22),	  >5yr	  (n=19))	  are	  compared.	  	  A	  –	  percentage	  IFNγ	  
producing	  CD4+	  T	  cells;	  B	  -­‐	  percentage	  IL17	  producing	  CD4+	  T	  cells;	  C	  –	  percentage	  IL22	  
producing	  CD4+	  T	  cells.	  Data	  was	  compared	  using	  a	  one	  way	  ANOVA	  and	  Mann	  Whitney	  
test	  and	  is	  shown	  on	  the	  graph	  when	  significant.	  	  Data	  is	  presented	  on	  a	  log	  scale.	  	  All	  
values	  of	  0	  were	  assigned	  a	  value	  of	  0.001	  in	  order	  that	  all	  the	  children	  in	  the	  group	  are	  
represented	  on	  the	  graph.	  	  Note	  the	  different	  y	  axis	  scales	  on	  each	  graph.	  Horizontal	  bars	  
represent	  median	  values.	  	  The	  dotted	  line	  represents	  a	  cut-­‐off	  of	  0.01	  for	  a	  significant	  
response.	  	  There	  are	  more	  non-­‐responders	  in	  the	  children	  <1yr	  of	  age	  than	  in	  the	  older	  age	  groups.	  It	  has	  previously	  been	  reported	  that	  nonspecific	  Th1	  responses	  differ	  with	  age	  and	  given	  that	  there	  was	  no	  significant	  difference	  between	  BCG	  induced	  IFNγ	  CD4+	  T	  cell	  production	  between	  age,	  we	  investigated	  the	  difference	  in	  SEB	  induced	  cytokine	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responses	  with	  age.	  	  Figure	  26	  demonstrates	  that	  SEB	  responses	  increase	  with	  age,	  while	  there	  are	  no	  significant	  differences	  in	  antigen	  specific	  (BCG)	  IFNγ	  responses	  with	  age.	  	  This	  pattern	  was	  also	  seen	  in	  γδ	  T	  cell	  responses	  (data	  not	  shown).	  
	  
Figure	  26	  Differences	  in	  non-­‐specific	  (SEB)	  vs	  antigen-­‐specific	  (BCG)	  CD4+	  T	  cell	  responses	  
with	  age	  
The	  median	  percentage	  of	  IFNγ	  producing	  CD4+	  T	  cells	  following	  whole	  blood	  incubation	  
with	  BCG	  (2.5x106	  cfu/ml)	  or	  SEB	  1μg/ml	  overnight	  followed	  by	  5	  hours	  incubation	  with	  
Brefeldin.	  	  The	  results	  from	  healthy	  child	  controls	  of	  different	  age	  groups	  (<1yr	  (n=19),	  
>1yr<2yr	  (n=17),	  >2yr	  (n=41))	  are	  compared.	  The	  >2yr<5yr	  and	  >5yr	  groups	  were	  
combined	  as	  there	  was	  no	  differences	  between	  them.	  	  Data	  was	  compared	  using	  a	  one	  way	  
ANOVA	  and	  Mann	  Whitney	  test	  and	  is	  shown	  on	  the	  graph	  when	  significant.	  	  Data	  is	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Figure	  27	  Positive	  correlation	  between	  cytokine	  producing	  CD4+	  T	  cells	  
Cytokine	  producing	  CD4+	  T	  cells	  were	  correlated	  with	  each	  other	  using	  a	  Spearman	  
Coefficient	  for	  nonparametric	  data.	  	  Note	  the	  different	  scales	  on	  the	  graph.	  	  Blood	  from	  
healthy	  children	  of	  all	  ages	  combined	  was	  used	  (n=78)	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6.4. BCG	  induced	  Ki67	  T	  cell	  proliferation	  The	  short	  term	  assay	  assesses	  the	  effector	  memory	  response	  of	  T	  cells	  to	  BCG	  stimulation.	  	  In	  order	  to	  assess	  central	  memory	  responses,	  whole	  blood	  was	  also	  stimulated	  with	  BCG	  for	  6	  days	  and	  Ki67+	  T	  cells	  were	  enumerated	  to	  assess	  proliferation	  potential	  in	  response	  to	  BCG.	  	  Subsequently,	  the	  frequency	  of	  BCG-­‐specific	  T	  cells	  expressing	  cytokines	  was	  measured	  to	  assess	  the	  functional	  capacity	  of	  proliferating	  antigen-­‐specific	  T	  cells.	  	  	  
6.5. Phenotype	  and	  function	  of	  T	  cells	  after	  6	  days	  stimulation	  with	  
BCG	  The	  percentage	  and	  absolute	  number	  of	  each	  T	  cell	  phenotype	  (CD4,	  CD8	  and	  γδ)	  was	  measured	  using	  flow	  cytometry	  as	  described	  previously	  (Table	  12).	  	  
	  
Table	  11	  The	  percentage	  and	  absolute	  number	  of	  each	  T	  cell	  phenotype	  following	  BCG	  
stimulation	  of	  whole	  blood	  for	  6	  days	  
The	  T	  cell	  phenotype	  (CD4,	  CD8,	  γδ)	  	  is	  expressed	  both	  as	  a	  percentage	  of	  CD3+	  T	  cells	  and	  
as	  absolute	  values	  (abs)	  in	  healthy	  children	  (n=78).	  The	  median	  value	  and	  the	  interquartile	  
range	  (IQR)	  for	  each	  group	  is	  shown.	  	  Absolute	  numbers	  are	  per	  250μl	  whole	  blood.	  	  A	  one-­‐
way	  ANOVA	  followed	  by	  a	  Mann	  Whitney	  t-­‐test	  for	  all	  comparisons	  was	  performed,	  with	  p	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6.5.1. Ki67	  proliferation	  and	  cytokine	  production	  of	  T	  cells	  following	  
stimulation	  with	  BCG	  for	  6	  days	  The	  percentage	  of	  Ki67	  proliferating	  T	  cells	  of	  each	  phenotype	  and	  the	  percentage	  of	  these	  cells	  that	  were	  producing	  the	  cytokines	  of	  interest	  were	  measured.	  	  This	  data	  is	  shown	  in	  Table	  13.	  	  	  	  
	  
Table	  12	  Expression	  of	  Ki67,	  IFNγ,	  IL17	  and	  IL22	  in	  CD4,	  CD8	  and	  γδ	  T	  cells	  in	  children	  of	  
different	  ages	  
The	  median	  percentage	  and	  interquartile	  range	  (IQR)	  of	  each	  cytokine	  and	  Ki67	  is	  shown	  
for	  the	  different	  age	  groups	  (n=78).	  	  The	  T	  cell	  phenotype	  is	  shown	  along	  the	  left	  side.	  	  A	  
one-­‐way	  ANOVA	  and	  Mann-­‐Whitney	  test	  was	  performed	  for	  each	  comparison	  and	  p-­‐values	  
are	  shown	  to	  the	  right	  of	  the	  table.	  Comparisons	  that	  were	  not	  significant	  are	  not	  shown	  in	  
this	  table.	  (ns=	  not	  significant,	  p>0.05).	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Figure	  28	  Proliferative	  responses	  of	  CD4+	  T	  cells	  in	  response	  to	  BCG	  stimulation	  decreases	  
with	  age.	  	  	  
This	  figure	  shows	  the	  percentage	  of	  Ki67+CD8-­‐γδ-­‐	  [CD4+]	  T	  cells	  following	  whole	  blood	  incubation	  
with	  BCG	  (2.5x106	  cfu/ml)	  for	  6	  days	  followed	  by	  4	  hours	  incubation	  with	  Brefeldin,	  PMA	  and	  
Ionomycin	  (PI).	  	  The	  results	  from	  healthy	  child	  controls	  of	  different	  age	  groups	  (<1yr	  (n=19),	  
>1yr<2yr	  (n=17),	  >2yr<5yr	  (n=22),	  >5yr	  (n=19))	  are	  compared.	  Data	  was	  compared	  using	  a	  one	  
way	  ANOVA	  and	  Mann	  Whitney	  test	  and	  is	  presented.	  	  Horizontal	  bars	  represent	  median	  values.	  The	  percentage	  of	  cytokine	  producing	  Ki67+	  T	  cells	  was	  also	  measured	  from	  these	  samples.	  	  The	  median	  frequencies	  of	  both	  IL17	  and	  IL22	  producing	  Ki67+	  CD4+	  T	  cells	  were	  low,	  between	  0.5-­‐2%	  with	  no	  significant	  differences	  between	  age	  groups	  (Figure	  27,	  B	  and	  C).	  	  In	  contrast,	  robust	  BCG	  specific	  KI67+IFNγ+	  responses	  were	  identified	  in	  all	  age	  groups,	  but	  these	  decreased	  significantly	  with	  age	  (<1yr	  median	  25.8%	  (IQR	  9.5-­‐64.9%);	  >5yr	  median	  8.9%	  (IQR	  2.6-­‐20.8%),	  p=0.0195).	  (Figure	  27,	  A)	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Figure	  29	  -­‐	  Increasing	  age	  is	  associated	  with	  a	  significant	  decrease	  of	  frequency	  of	  IFNγ-­‐,	  but	  
not	  IL17-­‐	  or	  IL22-­‐	  Ki67+	  CD4+	  T	  cells.	  	  	  
This	  figure	  shows	  the	  percentage	  of	  cytokine	  producing	  Ki67+CD8-­‐γδ-­‐	  [CD4+]	  T	  cells	  following	  
whole	  blood	  incubation	  with	  BCG	  (2.5x106	  cfu/ml)	  for	  6	  days	  followed	  by	  4	  hours	  incubation	  with	  
Brefeldin,	  PMA	  and	  Ionomycin	  (PI).	  	  The	  results	  from	  healthy	  child	  controls	  of	  different	  age	  groups	  
(<1yr	  (n=19),	  >1yr<2yr	  (n=17),	  >2yr<5yr	  (n=22),	  >5yr	  (n=19))	  are	  compared.	  A	  –	  percentage	  IFNγ	  
producing	  Ki67+CD8-­‐γδ-­‐	  T	  cells;	  B	  -­‐	  percentage	  IL17	  producing	  Ki67+CD8-­‐γδ-­‐	  T	  cells;	  C	  –	  
percentage	  IL22	  producing	  Ki67+CD8-­‐γδ-­‐	  T	  cells.	  	  Data	  was	  compared	  using	  a	  one	  way	  ANOVA	  and	  
Mann	  Whitney	  test	  and	  is	  presented.	  	  Note	  the	  different	  scales	  on	  each	  graph.	  	  Horizontal	  bars	  
represent	  median	  values.	  	  An	  inverse	  correlation	  between	  CD4+Ki67+	  proliferation	  and	  age	  in	  months	  can	  be	  seen	  in	  Figure	  30,	  although	  there	  is	  heterogeneity	  of	  responses	  at	  a	  younger	  age.	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Figure	  30	  There	  is	  an	  inverse	  correlation	  between	  proliferative	  response	  and	  increasing	  age.	  	  	  
A	  correlation	  between	  the	  percentage	  of	  CD4+Ki67+	  T	  cells	  and	  age	  in	  months	  was	  calculated	  using	  
Spearman’s	  coefficient	  for	  non-­‐parametric	  data.	  	  Each	  point	  represents	  a	  healthy	  control	  child,	  
n=78.	  	  	  The	  frequency	  of	  Ki67+γδ	  T	  cells	  follows	  a	  similar	  pattern	  to	  the	  CD4+	  T	  cells,	  with	  a	  statistically	  significant	  decrease	  in	  the	  median	  frequency	  from	  38%	  (IQR	  22.3-­‐65.3%)	  and	  52%	  (IQR	  19.5-­‐62.9%)	  in	  the	  <1yr	  and	  >1yr<2yr	  age	  groups	  respectively	  to	  13.5%	  (IQR	  2.7-­‐37.5%)	  in	  the	  >5yr	  age	  group	  (p=0.0157).	  	  In	  addition	  to	  proliferative	  capacity,	  cytokine	  production	  by	  Ki67+γδ	  T	  cells	  was	  also	  measured.	  	  The	  pattern	  mirrored	  that	  of	  Ki67	  lymphoproliferation,	  but	  the	  differences	  in	  percentages	  of	  cytokine-­‐producing	  cells	  were	  not	  significant	  between	  the	  age	  groups.	  Similarly	  to	  CD4+	  Ki67+	  T	  cells,	  the	  frequency	  of	  IL17	  and	  IL22	  producing	  Ki67+γδ	  T	  cells	  were	  low	  in	  comparison	  with	  IFNγ	  producing	  Ki67+γδ	  T	  cells.	  In	  particular,	  there	  was	  considerable	  heterogeneity	  in	  IL17	  producing	  Ki67+γδ	  T	  cells	  responses	  amongst	  children	  <1yr	  of	  age.	  It	  is	  of	  note	  that	  10/19	  children	  in	  this	  age	  group	  had	  no	  measurable	  response	  at	  all.	  (Figure	  31).	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Figure	  31	  -­‐	  BCG	  stimulated	  proliferating	  γδ	  T	  cells	  show	  no	  differences	  in	  frequency	  of	  IFNγ,	  
IL17	  or	  IL22	  production	  in	  different	  age	  groups.	  	  	  
This	  figure	  shows	  the	  percentage	  of	  cytokine	  producing	  Ki67+γδ	  T	  cells	  following	  whole	  blood	  
incubation	  with	  BCG	  (2.5x106	  cfu/ml)	  for	  6	  days	  followed	  by	  4	  hours	  incubation	  with	  Brefeldin,	  PMA	  
and	  Ionomycin	  (PI).	  	  The	  results	  from	  healthy	  child	  controls	  of	  different	  age	  groups	  (<1yr	  (n=19),	  
>1yr<2yr	  (n=17),	  >2yr<5yr	  (n=22),	  >5yr	  (n=19))	  are	  compared.	  A	  –	  percentage	  IFNγ	  producing	  
Ki67+γδ	  T	  cells;	  B	  -­‐	  percentage	  IL17	  producing	  Ki67+γδ	  T	  cells;	  C	  –	  percentage	  IL22	  producing	  
Ki67+γδ	  T	  cells.	  	  Data	  was	  compared	  using	  a	  one	  way	  ANOVA	  and	  Mann	  Whitney	  test	  and	  
significant	  p	  values	  are	  shown.	  	  Data	  is	  presented	  on	  a	  log	  scale	  and	  all	  non-­‐responders	  with	  values	  
of	  0	  were	  assigned	  a	  value	  of	  0.01	  so	  that	  all	  the	  children	  in	  the	  group	  are	  represented	  on	  the	  graph.	  	  
Note	  the	  different	  scales	  on	  each	  graph.	  	  Horizontal	  bars	  represent	  median	  values.	  The	  proliferative	  capacity	  of	  CD8+	  T	  cells	  decreased	  with	  age,	  with	  the	  median	  frequency	  decreasing	  from	  17.3%	  (IQR	  10.4-­‐41.2%)	  in	  the	  <1yr	  age	  group	  to	  2.03%	  (IQR	  0.7-­‐10.4%)	  in	  the	  >5yr	  age	  group.	  	  These	  median	  values	  are	  notably	  lower	  than	  those	  of	  the	  CD4	  and	  γδ	  groups	  suggesting	  that	  CD8	  T	  cells	  proliferate	  less	  than	  CD4	  or	  γδ	  T	  cells	  in	  response	  to	  BCG	  stimulation	  for	  6	  days.	  	  Ki67+CD8+	  T	  cells	  demonstrate	  some	  capacity	  for	  cytokine	  production,	  although	  this	  is	  lower	  than	  that	  in	  CD4+	  or	  γδ	  T	  cells.	  	  The	  pattern	  of	  cytokine	  production	  is	  similar	  to	  that	  seen	  in	  the	  other	  cell	  phenotypes	  with	  significantly	  higher	  frequencies	  of	  IFNγ	  and	  IL22	  producing	  cells	  in	  <1yr	  olds	  compared	  to	  those	  >5yrs	  (p=0.0048	  and	  p=0.0034	  respectively).	  The	  trend	  is	  similar	  for	  IL17+Ki67+CD8+	  T	  cells	  but	  does	  not	  reach	  significance.	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To	  address	  whether	  the	  decrease	  in	  lymphoproliferative	  responses	  with	  age	  was	  an	  antigen	  specific	  phenomenon	  or	  not,	  lymphoproliferation	  to	  SEB	  was	  examined.	  	  With	  increasing	  age,	  there	  is	  an	  increase	  in	  Ki67+	  CD4+	  T	  cells.	  This	  trend	  is	  followed	  for	  IFNγ	  production,	  but	  does	  not	  reach	  significance	  (Figure	  32).	  	  
	  
Figure	  32	  Proliferative	  responses	  of	  CD4+	  T	  cells	  in	  response	  to	  SEB	  stimulation	  increase	  
with	  age	  
This	  figure	  shows	  the	  percentage	  of	  Ki67+CD8-­‐γδ-­‐	  [CD4+]	  T	  cells	  following	  whole	  blood	  incubation	  
with	  SEB	  (1μg/ml)	  for	  6	  days	  followed	  by	  4	  hours	  incubation	  with	  Brefeldin,	  PMA	  and	  Ionomycin	  
(PI).	  	  The	  results	  from	  healthy	  child	  controls	  of	  different	  age	  groups	  (<1yr	  (n=19),	  >1yr<2yr	  (n=17),	  
>2yr<5yr	  (n=22),	  >5yr	  (n=19))	  are	  compared.	  Data	  was	  compared	  using	  a	  one	  way	  ANOVA	  and	  
Mann	  Whitney	  test	  and	  is	  presented.	  	  Horizontal	  bars	  represent	  median	  values.	  
6.6. Memory	  phenotype	  of	  T	  cells	  The	  cell	  surface	  markers	  CD27	  and	  CD45RA	  are	  both	  markers	  of	  naïve	  T	  cells.	  Their	  expression	  on	  antigen	  experienced	  T	  cells	  have	  been	  used	  to	  infer	  memory	  phenotype	  and	  their	  expression	  decreases	  with	  increasing	  cell	  differentiation.	  Conventionally,	  dual	  positive	  cells	  (CD27+CD45RA+)	  are	  considered	  naïve	  or	  undifferentiated	  (N).	  	  A	  population	  expressing	  CD27	  alone	  (CD27+CD45RA-­‐)	  is	  described	  as	  a	  central	  memory	  (CM)	  population;	  these	  are	  very	  sensitive	  to	  antigen	  stimulation,	  expanding	  rapidly	  and	  demonstrating	  flexibility	  in	  cytokine	  production	  –	  depending	  on	  the	  cytokine	  milieu	  they	  can	  produce	  either	  IFNγ	  or	  IL17	  for	  example.	  	  By	  contrast,	  the	  absence	  of	  CD27	  (a	  lymph	  node	  homing	  marker)	  allows	  cells	  to	  migrate	  to	  the	  site	  of	  infection	  –	  typically	  a	  characteristic	  of	  short	  lived	  effector	  cells.	  	  Effector	  memory	  T	  cells	  which	  express	  neither	  marker	  (EM;	  CD27-­‐CD45RA-­‐),	  respond	  to	  antigen	  stimulation	  but	  have	  a	  lower	  capacity	  for	  expansion	  following	  stimulation-­‐	  they	  are	  committed	  to	  which	  cytokine	  they	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will	  produce.	  	  Terminally	  differentiated	  memory	  cells	  appear	  late	  in	  the	  immune	  response,	  likely	  due	  to	  cytokine	  rather	  than	  antigenic	  stimulation.	  	  They	  re-­‐express	  CD45RA	  (CD27-­‐CD45RA+,	  TEMRA),	  and	  do	  not	  expand	  rapidly.	  	  As	  described	  previously,	  infants	  and	  younger	  children	  have	  greater	  proportions	  of	  naïve	  T	  cells	  and	  these	  are	  believed	  to	  be	  more	  likely	  to	  produce	  IL17	  than	  IFNγ	  in	  response	  to	  mycobacteria77.	  	  This	  study	  hypothesized	  that	  younger	  children	  were	  more	  likely	  to	  express	  naïve	  IL17	  producing	  T	  cells	  than	  older	  children,	  hence	  describing	  which	  memory	  markers	  are	  expressed	  in	  children	  of	  different	  ages	  and	  whether	  they	  changed	  with	  age	  was	  of	  interest	  to	  our	  hypothesis.	  	  
6.6.1. Memory	  phenotype	  of	  T	  cells	  in	  response	  to	  overnight	  BCG	  
stimulation	  The	  memory	  phenotype	  of	  T	  cells	  as	  described	  by	  expression	  of	  the	  markers	  CD27	  and	  CD45RA	  following	  overnight	  stimulation	  with	  BCG	  is	  shown	  in	  Table	  14.	  	  The	  majority	  of	  CD4+	  T	  cells	  in	  all	  patient	  groups	  were	  naïve	  or	  a	  CD27+CD45RA+	  phenotype.	  	  Although	  they	  remained	  the	  largest	  proportion,	  this	  percentage	  decreased	  significantly	  with	  increasing	  age,	  in	  line	  with	  the	  trend	  observed	  in	  the	  overall	  CD4	  T	  cell	  population	  (Figure	  33).	  	  Of	  note,	  the	  pattern	  was	  the	  same	  in	  unstimulated	  and	  BCG	  stimulated	  cells.	  	  	  
Table	  13	  Expression	  of	  memory	  markers	  CD27	  and	  CD45RA	  on	  CD4,	  CD8	  and	  γδ	  T	  cells	  in	  
children	  of	  different	  ages	  after	  overnight	  stimulation	  with	  BCG	  
The	  median	  percentage	  and	  interquartile	  range	  (IQR)	  of	  four	  different	  memory	  phenotypes	  
(Naïve	  or	  CD27+CD45RA+,	  Central	  Memory	  or	  CD27+CD45RA-­‐,	  Effector	  Memory	  CD27-­‐
CD45RA-­‐	  and	  Terminally	  differentiated	  effector	  memory	  CD27-­‐CD45RA+)	  is	  shown	  for	  the	  
different	  age	  groups	  (<1yr	  (n=19),	  >1yr<2yr	  (n=18),	  >2yr<5yr	  (n=22),	  >5yr	  (n=19).	  	  The	  T	  cell	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Figure	  33	  -­‐	  Infants	  have	  higher	  proportions	  of	  naïve	  CD4+	  T	  cells	  than	  older	  children.	  
Phenotypic	  marker	  expression	  on	  unstimulated	  (A)	  and	  BCG	  stimulated	  (B)	  CD4+	  T	  cells	  in	  healthy	  
children	  <1yr	  of	  age	  (n=19).	  	  (C)	  compares	  the	  percentage	  of	  naïve	  T	  cells	  in	  healthy	  children	  of	  
different	  ages.	  	  Data	  was	  compared	  using	  a	  one	  way	  ANOVA	  and	  Mann	  Whitney	  test	  and	  significant	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Figure	  34	  -­‐	  As	  the	  proportion	  of	  naïve	  cells	  decreases	  with	  age,	  the	  proportion	  of	  central	  
memory	  and	  terminally	  differentiated	  cells	  increases.	  	  	  
Phenotypic	  marker	  expression	  on	  BCG	  stimulated	  CD4+	  T	  cells	  in	  children	  <1yr	  of	  age	  (n=19)	  (A)	  
and	  children	  >5yrs	  of	  age	  (n=19)	  (B).	  	  Horizontal	  bars	  represent	  median	  values.	  	  The	  different	  memory	  phenotypes	  of	  γδ	  T	  cells	  are	  more	  evenly	  distributed	  than	  those	  of	  CD4+	  T	  cells	  and	  there	  are	  significantly	  fewer	  naïve	  cells	  in	  all	  age	  groups,	  Figure	  35.	  	  	  	  
	  
Figure	  35	  –	  The	  expression	  of	  naïve	  memory	  markers	  differs	  between	  γδ	  and	  CD4	  T	  cells	  
The	  percentage	  of	  naïve,	  CD27+CD45RA+	  memory	  marker	  expression	  on	  CD4	  and	  γδ	  T	  cells	  
in	  children	  of	  different	  ages	  (<1yr	  (n=19),	  >1yr<2yr	  (n=18),	  >2yr<5yr	  (n=22),	  >5yr	  (n=19).	  	  
Data	  was	  compared	  using	  a	  one	  way	  ANOVA	  and	  Mann	  Whitney	  test	  and	  significant	  p	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The	  pattern	  of	  memory	  phenotypical	  markers	  on	  CD8+	  T	  cells	  mirrors	  that	  seen	  in	  CD4+	  T	  cells	  rather	  than	  γδ	  T	  cells	  with	  a	  predominance	  of	  a	  naïve	  phenotype	  at	  all	  ages,	  but	  especially	  in	  the	  <1yr	  olds,	  and	  an	  increase	  in	  terminally	  differentiated	  cells	  with	  age.	  
6.6.2. Memory	  phenotype	  of	  cytokine	  producing	  cells	  after	  overnight	  
stimulation	  with	  BCG	  The	  expression	  of	  the	  memory	  markers	  on	  BCG	  stimulated	  IFNγ	  producing	  CD4+	  T	  cells	  was	  measured	  (Table	  15).	  	  
	  
Table	  14	  Expression	  of	  memory	  markers	  on	  CD4+	  T	  cells	  and	  IFNγ	  producing	  CD4+	  T	  cells	  	  
The	  median	  percentage	  and	  interquartile	  range	  (IQR)	  of	  four	  different	  memory	  phenotypes	  
on	  both	  IFNγ	  producing	  and	  all	  CD4+	  T	  cells	  is	  shown	  for	  the	  different	  age	  groups.	  	  The	  T	  
cell	  phenotype	  is	  shown	  along	  the	  left	  side.	  There	  is	  no	  significant	  difference	  in	  the	  expression	  of	  memory	  markers	  in	  different	  age	  groups.	  	  IFNγ	  is	  produced	  by	  CD4+	  T	  cells	  expressing	  all	  4	  combinations	  of	  memory	  markers,	  including	  naïve	  T	  cells.	  The	  production	  of	  IL17	  and	  IL22	  was	  too	  low	  to	  reliably	  determine	  the	  memory	  phenotype	  of	  the	  cells	  producing	  these.	  

























































































Expression on CD4+IFNγ+ T cellsExpression on all CD4+ T cells
	   110	  
	  
	  
Table	  15	  Expression	  of	  memory	  markers	  on	  CD4	  and	  γδ	  T	  cells	  in	  children	  of	  different	  ages	  
following	  6	  days	  stimulation	  with	  BCG	  
The	  median	  percentage	  of	  4	  combinations	  of	  memory	  markers	  and	  interquartile	  range	  
(IQR)	  in	  children	  of	  different	  ages	  is	  shown	  (<1yr	  (n=19),	  >1yr<2yr	  (n=18),	  >2yr<5yr	  (n=22),	  
>5yr	  (n=19).	  	  The	  T	  cell	  phenotype	  is	  shown	  along	  the	  left	  side.	  	  A	  one-­‐way	  ANOVA	  and	  
Mann-­‐Whitney	  test	  was	  performed	  for	  the	  different	  comparisons.	  Significant	  p	  values	  are	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Figure	  36	  –	  Children	  under	  a	  year	  of	  age	  have	  greater	  numbers	  of	  effector	  memory	  and	  
terminally	  differentiated	  effector	  memory	  CD4+	  T	  cells	  in	  response	  to	  BCG	  stimulation	  for	  6	  
days	  than	  older	  children	  
Phenotypic	  marker	  expression	  on	  BCG	  specific	  CD4+	  T	  cells	  in	  healthy	  children	  of	  different	  
ages	  (<1yr	  (n=19)(A),	  >1<2yr	  (n=18)	  (B),	  >2<5yr	  (n=22)	  (C),	  >5yr	  (n=19)	  (D)).	  	  Data	  was	  
compared	  using	  a	  one	  way	  ANOVA	  and	  Mann	  Whitney	  test	  and	  significant	  data	  is	  
presented	  as	  shown.	  	  Horizontal	  bars	  represent	  median	  values.	  The	  frequencies	  of	  expression	  of	  memory	  markers	  on	  IFNγ,	  IL17	  and	  IL22	  producing	  BCG	  specific	  CD4+	  T	  cells	  were	  analysed	  individually	  and	  the	  results	  shown	  in	  table	  17.	  	  
	  
Table	  16	  Expression	  of	  memory	  markers	  on	  cytokine	  producing	  CD4	  and	  γδ	  T	  cells	  in	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The	  median	  percentage	  and	  interquartile	  range	  (IQR)	  of	  4	  combinations	  of	  memory	  
markers	  on	  cytokine	  producing	  T	  cells	  following	  stimulation	  with	  BCG	  for	  6	  days	  in	  
children	  of	  different	  ages	  is	  shown	  (<1yr	  (n=19),	  >1yr<2yr	  (n=18),	  >2yr<5yr	  (n=22),	  >5yr	  
(n=19).	  	  The	  T	  cell	  phenotype	  is	  shown	  along	  the	  left	  side.	  	  The	  cytokine	  produced	  by	  the	  T	  
cells	  and	  the	  different	  age	  groups	  are	  indicated	  along	  the	  top.	  	  	  In	  children	  <1yr	  of	  age,	  nearly	  all	  of	  the	  cytokine	  production	  in	  both	  CD4	  and	  γδ	  T	  cells	  arises	  from	  effector	  memory	  (EM)	  T	  cells	  expressing	  neither	  CD27	  nor	  CD45RA	  (highlighted	  in	  the	  table).	  	  This	  predominance	  of	  cytokine	  production	  by	  EM	  T	  cells	  persists	  until	  2	  yrs	  of	  age	  in	  IFNγ	  producing	  CD4	  T	  cells,	  but	  not	  IFNγ	  producing	  γδ	  T	  cells.	  	  In	  γδ	  T	  cells,	  the	  central	  memory	  population	  contributes	  equally	  to	  IFNγ	  production	  in	  response	  to	  BCG	  stimulation	  in	  children	  >1yr	  of	  age.	  	  IL17	  and	  IL22	  is	  produced	  almost	  entirely	  by	  EM	  CD4	  and	  γδ	  T	  cells	  in	  all	  age	  groups.	  	  
6.7. Summary	  of	  Key	  Findings	  Previous	  studies	  have	  examined	  BCG	  responses	  in	  healthy	  TB	  uninfected	  children,	  concentrating	  mainly	  on	  IFNγ,	  IL2	  and	  TNF	  production	  by	  CD4+	  T	  cells,	  only	  measuring	  IL17	  in	  a	  couple	  of	  studies	  and	  often	  focusing	  on	  infant	  responses	  as	  part	  of	  larger	  vaccine	  studies16,160-­‐163.	  	  To	  date,	  none	  have	  assessed	  the	  impact	  of	  age	  or	  compared	  CD4,	  γδ	  and	  CD8	  phenotypes	  and	  the	  combination	  of	  IFNγ,	  IL17	  and	  IL22	  cytokines	  they	  produce.	  	  The	  two	  main	  findings	  of	  this	  age-­‐related	  analysis	  are	  that	  healthy	  BCG	  vaccinated	  children	  of	  all	  ages,	  including	  infants	  under	  a	  year	  of	  age,	  have	  robust	  CD4+IFNγ	  responses	  to	  short	  term	  BCG	  stimulation	  and	  that	  BCG	  memory	  responses	  wane	  with	  increasing	  age.	  	  I	  will	  now	  discuss	  all	  of	  the	  significant	  findings	  of	  the	  analysis	  in	  the	  context	  of	  the	  current	  literature.	  
6.7.1. Short	  term	  BCG	  stimulation	  of	  whole	  blood	  Our	  cohort	  shows	  that	  children	  under	  one	  year	  of	  age	  have	  a	  higher	  percentage	  of	  CD4+	  T	  cells	  than	  older	  children,	  decreasing	  to	  adult	  levels	  by	  the	  age	  of	  >2yr	  as	  previously	  described164.	  Our	  data	  also	  confirm	  previous	  findings	  that	  healthy	  BCG	  vaccinated	  children	  of	  all	  ages,	  including	  infants	  under	  one	  year	  of	  age,	  have	  robust	  CD4+	  IFNγ	  responses	  to	  short	  term	  BCG	  stimulation16,161,165.	  	  Additionally,	  we	  demonstrate	  that	  there	  is	  no	  difference	  in	  BCG	  responses	  with	  increasing	  age	  using	  this	  assay,	  in	  contrast	  to	  the	  increasing	  responses	  to	  non-­‐specific	  stimulation	  with	  SEB	  with	  age	  that	  have	  been	  described166	  .	  When	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measuring	  longitudinal	  changes	  in	  BCG	  induced	  T	  cell	  responses	  in	  infants,	  Soares	  et	  al	  identified	  that	  the	  CD4+IFNγ	  response	  peaked	  at	  10	  weeks	  and	  then	  waned	  by	  one	  year	  of	  age,	  which	  contrasts	  with	  our	  own	  findings,	  although	  the	  populations	  are	  comparable	  between	  the	  two	  studies162.	  	  However,	  Soares’	  study	  was	  limited	  to	  children	  under	  one	  year	  of	  age	  whereas	  we	  compare	  responses	  in	  children	  up	  to	  5	  yrs	  of	  age.	  It	  is	  possible	  that	  ongoing	  exposure	  to	  environmental	  mycobacteria	  or	  even	  repeated	  exposure	  to	  Mtb	  explain	  why	  we	  did	  not	  observe	  significant	  difference	  in	  IFNγ	  responses	  with	  higher	  age.	  The	  aim	  of	  the	  Soares	  study	  was	  to	  optimize	  the	  timepoints	  for	  measurements	  of	  vaccine	  responses	  in	  trials	  of	  novel	  vaccines,	  while	  we	  set	  out	  to	  analyse	  the	  age-­‐related	  developments	  of	  effector	  memory	  in	  a	  wider	  age	  context	  in	  order	  to	  be	  able	  to	  match	  the	  data	  with	  our	  childhood	  TB	  cases.	  Similarly	  to	  Soares	  et	  al,	  we	  have	  shown	  that	  IL17	  is	  only	  produced	  in	  very	  small	  quantities	  by	  CD4+	  T	  cells	  following	  BCG	  stimulation.	  	  In	  addition,	  we	  show	  for	  the	  first	  time	  that	  very	  little	  IL17	  is	  produced	  by	  γδ	  or	  CD8+	  T	  cells	  in	  children,	  as	  has	  previously	  been	  found	  by	  Scriba	  et	  al	  in	  healthy	  adults84.	  	  Of	  interest,	  we	  also	  describe	  for	  the	  first	  time	  that	  IL17	  and	  IL22	  expression	  by	  both	  CD4	  and	  γδ	  T	  cells	  increases	  with	  age	  and	  that	  IL22	  is	  expressed	  in	  higher	  quantities	  than	  IL17	  by	  both	  CD4	  and	  γδ	  T	  cells	  in	  children	  of	  all	  ages.	  	  Additionally,	  similarly	  to	  a	  number	  of	  adult	  studies,	  we	  did	  not	  identify	  ‘polyfunctional’	  T	  cells	  producing	  combinations	  of	  IFNγ,	  IL17	  and	  IL2284,92,93.	  	  	  The	  increase	  in	  IL17	  and	  IL22	  with	  increasing	  age	  is	  interesting	  and	  may	  either	  reflect	  a	  more	  ‘sophisticated’	  effector	  T	  cell	  response	  with	  age,	  or	  perhaps,	  as	  BCG	  memory	  responses	  wane	  with	  increasing	  age	  	  (described	  below),	  the	  effector	  response	  is	  more	  multifactorial.	  	  Unfortunately,	  the	  memory	  phenotype	  of	  these	  cytokine	  producing	  T	  cells	  could	  not	  be	  measured	  definitively	  in	  this	  study,	  as	  the	  magnitude	  of	  the	  elicited	  response	  was	  too	  small	  to	  give	  meaningful	  results.	  Future	  work	  could	  address	  this	  question	  by	  using	  larger	  blood	  volumes	  or	  cell	  sorting	  techniques,	  but	  this	  remains	  difficult	  to	  do	  in	  children.	  	  In	  contrast	  to	  the	  CD4+	  T	  cell	  response	  described,	  the	  γδ	  T	  cell	  response	  to	  short	  term	  stimulation	  of	  whole	  blood	  with	  BCG	  showed	  that	  children	  <1yr	  of	  age	  produce	  lower	  levels	  of	  IFNγ	  and	  higher	  levels	  of	  IL22	  than	  children	  >1yr	  of	  age.	  	  Our	  original	  hypothesis	  suggested	  that	  younger	  children	  might	  have	  a	  higher	  γδ	  IL17	  T	  cell	  response	  and	  lower	  γδ	  and	  CD4+	  IFNγ	  T	  cell	  response	  than	  older	  children	  resulting	  in	  an	  increase	  in	  susceptibility	  to	  severe	  TB	  disease.	  Our	  work	  has	  not	  confirmed	  this	  hypothesis	  and	  our	  data	  does	  not	  provide	  convincing	  evidence	  of	  the	  importance	  of	  IL17	  in	  the	  immune	  response	  to	  mycobacteria	  in	  healthy	  BCG	  vaccinated	  children.	  	  	  Despite	  murine	  work	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strongly	  suggesting	  a	  role	  for	  IL17	  in	  mycobacterial	  immunity,	  in	  particular	  γδ	  T	  cell	  produced	  IL17,	  there	  is	  now	  an	  increasing	  body	  of	  evidence	  disputing	  this	  in	  humans84,93,117	  and	  we	  add	  the	  first	  paediatric	  data	  in	  this	  context.	  Moreover,	  data	  suggesting	  that	  IL17	  is	  produced	  in	  greater	  quantities	  by	  γδ	  T	  cells	  is	  not	  supported	  by	  our	  study.	  	  In	  contrast,	  despite	  evidence	  that	  IL22	  deficiency	  in	  mice	  has	  no	  effect	  on	  Mtb	  infection,	  it	  appears	  it	  may	  play	  a	  more	  significant	  role	  in	  non-­‐human	  and	  human	  primates92,167,168.	  	  A	  number	  of	  recent	  studies	  looking	  at	  mycobacterial	  antigen	  induced	  IL22	  expression	  in	  adults,	  both	  healthy	  and	  with	  TB	  disease,	  have	  also	  found	  that	  IL22	  is	  expressed	  in	  higher	  quantities	  than	  IL1784,93.	  Although	  IL22	  was	  initially	  described	  as	  being	  produced	  by	  ‘Th17’	  cells	  alongside	  IL17A69,169,	  more	  recent	  work	  has	  supported	  a	  distinct	  role	  for	  IL22	  in	  protection	  from	  pathogens	  including	  mycobacteria	  at	  ‘environmental	  surfaces’	  such	  as	  the	  gut	  mucosa	  and	  airways84,92.	  	  Interestingly	  in	  a	  non-­‐human	  primate	  model,	  IL22	  expression	  is	  suppressed	  by	  γδ	  T	  cell	  activation	  via	  a	  pathway	  including	  IFNγ.	  	  This	  is	  the	  first	  paediatric	  study	  to	  demonstrate	  IL22	  production	  by	  either	  CD4	  or	  γδ	  T	  cells	  in	  response	  to	  mycobacterial	  stimulation.	  	  In	  our	  study,	  IL22	  is	  produced	  in	  conjunction	  with	  IFNγ	  by	  CD4	  and	  γδ	  T	  cells,	  but	  by	  a	  distinct	  subset,	  as	  part	  of	  both	  an	  effector	  and	  central	  memory	  recall	  response	  to	  BCG	  in	  children	  of	  all	  ages.	  	  It	  is	  produced	  in	  greater	  quantities	  as	  part	  of	  the	  effector	  response	  in	  older	  children	  than	  younger	  children,	  and	  is	  produced	  in	  equal	  quantities	  as	  part	  of	  the	  central	  memory	  response	  in	  children	  of	  all	  ages,	  in	  contrast	  to	  IFNγ	  which	  is	  produced	  in	  lower	  quantities	  as	  the	  BCG	  vaccine	  response	  wanes.	  	  This	  suggests	  IL22	  is	  more	  important	  as	  part	  of	  the	  immediate	  effector	  response	  rather	  than	  the	  central	  memory	  response	  to	  BCG.	  	  Our	  current	  understanding	  of	  the	  role	  of	  IL22	  in	  immune	  responses	  to	  pathogens	  is	  that	  when	  produced	  alone	  it	  can	  be	  protective	  and	  regenerative	  of	  the	  mucosal	  barrier	  and	  when	  secreted	  alongside	  inflammatory	  cytokines	  such	  as	  IFNγ,	  TNFα	  and	  IL2	  it	  promotes	  a	  greater	  inflammatory	  response88,90.	  	  In	  the	  context	  of	  BCG	  vaccine	  responses,	  it	  is	  likely	  to	  be	  important	  in	  enhancing	  the	  inflammatory	  response	  and	  inducing	  the	  production	  of	  chemokines	  to	  recruit	  adaptive	  immune	  cells	  to	  the	  site	  of	  infection.	  	  Further	  studies	  examining	  the	  role	  played	  by	  IL22	  in	  the	  paediatric	  immune	  response	  to	  TB	  are	  warranted.	  Similarly	  to	  Murray	  et	  al,	  we	  found	  that	  BCG	  stimulation	  induces	  an	  IFNγ	  expressing	  	  CD8+	  T	  cell	  response,	  although	  of	  lower	  magnitude	  than	  the	  CD4+	  response170.	  	  Furthermore,	  this	  response	  is	  not	  age-­‐dependent	  in	  any	  way	  and	  it	  also	  does	  not	  include	  a	  robust	  IL17	  or	  IL22	  response.	  	  Although	  there	  is	  evidence	  that	  CD8+	  T	  cells	  are	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important	  in	  the	  immune	  response	  to	  mycobacteria,170-­‐172	  neither	  IL17	  nor	  IL22	  production	  by	  CD8+	  T	  cells	  appeared	  to	  play	  a	  role	  in	  our	  cohorts.	  	  We	  found	  a	  positive	  correlation	  between	  IFNγ	  and	  both	  IL17	  and	  IL22	  producing	  T	  cells	  confirming	  that	  those	  individuals	  who	  respond	  to	  short	  term	  stimulation	  of	  whole	  blood	  with	  BCG	  produce	  all	  3	  cytokines	  rather	  than	  IL17	  and/or	  IL22	  being	  down-­‐regulated	  in	  the	  presence	  of	  IFNg.	  	  Individuals	  in	  our	  cohort	  could	  be	  best	  described	  as	  “responders”,	  which	  includes	  a	  more	  general	  cytokine	  response,	  or	  “non-­‐responders”.	  Similarly,	  previous	  studies	  comparing	  T	  cell	  responses	  to	  BCG	  and	  novel	  TB	  vaccine	  candidates	  have	  found	  correlations	  between	  IFNγ,	  TNFα	  and	  IL2	  and	  in	  some	  age	  or	  patient	  groups,	  IL1716,86,161.	  	  The	  prognostic	  significance	  of	  being	  a	  cytokine	  “responder”	  to	  BCG	  however	  remain	  currently	  unclear	  and	  not	  related	  to	  protection:	  Kagina	  et	  al	  found	  no	  differences	  in	  the	  magnitude	  of	  cytokine	  responses	  to	  BCG	  at	  10	  weeks	  of	  age	  in	  children	  who	  became	  TB	  cases,	  household	  controls	  or	  community	  controls.	  In	  a	  recently	  published	  Phase	  IIb	  clinical	  trial	  in	  the	  same	  population,	  none	  of	  a	  variety	  of	  cytokine	  responses	  to	  the	  novel	  vaccine	  MVA85A	  were	  associated	  with	  protection	  from	  TB173.	  	  	  	  These	  findings	  disprove	  part	  of	  our	  null	  hypothesis	  ie.	  that	  there	  are	  no	  age-­‐related	  differences	  in	  the	  T	  cell	  populations	  present	  in	  the	  circulating	  blood.	  Instead	  of	  providing	  evidence	  for	  an	  imbalance	  between	  IFNγ	  and	  IL17	  production	  in	  younger	  children,	  our	  results	  confirm	  a	  positive	  correlation	  between	  these	  two	  cytokines.	  	  We	  initially	  suggested	  that	  this	  hypothetical	  imbalance	  could	  be	  due	  to	  a	  predominance	  of	  naïve	  γδ	  T	  cells	  producing	  IL17,	  and	  our	  data	  show	  indeed	  that	  with	  increasing	  age,	  IL22	  producing	  γδ	  T	  cells	  decrease	  and	  IFNγ	  γδ	  T	  cells	  increase.	  There	  was	  a	  similar	  trend	  for	  IL17	  but	  it	  didn’t	  reach	  significance.	  	  This	  data	  supports	  an	  important	  role	  for	  γδ	  T	  cells	  in	  the	  immune	  response	  to	  BCG	  in	  healthy	  children	  producing	  IFNγ	  –	  and	  show	  that	  there	  is	  a	  significant	  increase	  in	  this	  response	  with	  increasing	  age,	  perhaps	  contributing	  to	  some	  of	  the	  differences	  in	  susceptibility	  to	  disseminated	  disease.	  This	  will	  be	  examined	  further	  in	  chapter	  7.	  
6.7.2. Memory	  phenotype	  of	  T	  cells	  following	  short	  term	  stimulation	  assay	  The	  memory	  phenotype	  of	  the	  CD4+	  T	  cells	  activated	  in	  the	  short-­‐term	  assay	  demonstrated	  a	  predominance	  of	  naïve	  CD45RA+CD27+	  T	  cells	  in	  the	  under	  1yr	  old	  age	  group	  as	  has	  been	  previously	  described.	  This	  decreased	  as	  expected	  with	  age	  to	  make	  room	  for	  larger	  proportions	  of	  central	  memory	  and	  effector	  memory	  CD4+	  T	  cells.	  In	  contrast,	  the	  proportion	  of	  naïve	  γδ	  T	  cells	  in	  younger	  children	  were	  not	  as	  high	  as	  described	  in	  the	  literature,	  but	  still	  decreased	  significantly	  with	  increasing	  age77,174.	  	  This	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might	  suggest	  that	  differentiation	  of	  γδ	  T	  cells	  occurs	  at	  an	  earlier	  age	  than	  that	  of	  antigen-­‐specific	  CD4+	  T	  cells	  which	  corresponds	  with	  the	  hypothesis	  that	  the	  response	  to	  mycobacteria	  is	  initiated	  by	  a	  γδ	  T	  cell	  response	  and	  matures	  to	  a	  combined	  γδ	  and	  CD4	  T	  cell	  response	  with	  time.	  	  When	  the	  surface	  marker	  expression	  of	  cytokine	  producing	  CD4+	  T	  cells	  was	  examined,	  unlike	  Soares	  et	  al	  who	  described	  that	  the	  majority	  of	  IFNγ	  producing	  CD4+	  T	  cells	  were	  of	  an	  effector	  memory	  type,	  we	  describe	  a	  wide	  spread	  of	  phenotypes	  including	  naïve,	  central	  memory	  and	  effector	  memory,	  with	  only	  a	  few	  TEMRA	  cells	  present161.	  	  Unfortunately,	  the	  populations	  of	  IL17	  and	  IL22	  producing	  T	  cells	  were	  too	  small	  to	  reliably	  detect	  the	  surface	  marker	  expression.	  The	  failure	  of	  BCG	  induced	  T	  cells	  to	  evolve	  into	  a	  classical	  central	  memory	  phenotype	  has	  previously	  been	  blamed	  for	  the	  lack	  of	  long-­‐term	  protection	  from	  TB	  infection	  and	  disease	  progression,	  and	  our	  data	  does	  not	  find	  any	  explanations	  to	  contradict	  or	  explain	  this	  phenomenon.	  	  	  
6.7.3. Ki67	  lymphoproliferation	  assay	  results	  Our	  data	  show	  that	  the	  majority	  of	  the	  T	  cells	  present	  after	  6	  days	  stimulation	  of	  whole	  blood	  with	  BCG	  in	  the	  under	  one	  year	  old	  group	  were	  CD4+	  T	  cells.	  	  Both	  the	  percentage	  and	  absolute	  number	  of	  γδ	  T	  cells	  increased	  with	  increasing	  age,	  suggesting	  that	  this	  was	  not	  just	  due	  to	  a	  decrease	  in	  the	  absolute	  number	  of	  antigen-­‐specific	  CD4+	  T	  cells.	  	  	  The	  percentage	  of	  BCG	  stimulated	  Ki67+	  proliferating	  CD4+,	  γδ	  and	  CD8+	  T	  decreased	  significantly	  with	  increasing	  age.	  	  In	  contrast,	  the	  percentage	  of	  SEB	  stimulated	  Ki67+	  proliferating	  CD4+	  T	  cells	  increased	  with	  increasing	  age.	  	  This	  suggests	  that	  we	  are	  describing	  an	  antigen-­‐specific	  phenomenon	  and	  that	  the	  memory	  response	  to	  BCG	  wanes	  with	  age.	  	  The	  cytokine	  expression	  of	  these	  proliferating	  cells	  was	  also	  analysed	  and	  the	  percentage	  of	  IFNγ+Ki67+	  T	  cells	  of	  all	  phenotypes	  decreased	  with	  increasing	  age	  in	  line	  with	  the	  fall	  in	  lymphoproliferation.	  	  However,	  the	  expression	  of	  IL17	  and	  IL22	  did	  not	  follow	  the	  same	  pattern;	  there	  was	  no	  difference	  in	  percentage	  of	  IL17	  and	  IL22	  expressing	  Ki67+	  CD4+	  T	  cells	  with	  age	  and	  the	  percentage	  of	  IL22+Ki67+γδ+	  T	  cells	  fell	  with	  increasing	  age.	  	  Of	  note,	  there	  were	  very	  few	  IL17	  expressing	  Ki67+γδ+	  T	  cells	  in	  any	  age	  group.	  	  There	  are	  no	  differences	  between	  the	  pattern	  of	  CD4+	  and	  γδ	  T	  cell	  responses	  in	  this	  assay.	  	  	  	  Soares	  et	  al	  have	  previously	  shown	  that	  BCG	  specific	  CD4+	  T	  cell	  proliferation	  following	  BCG	  vaccination	  at	  birth	  peaks	  at	  10	  weeks	  of	  age	  and	  waned	  over	  the	  course	  of	  a	  year162.	  	  However,	  no	  longer	  follow	  up	  was	  carried	  out	  in	  these	  studies.	  We	  demonstrate	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that	  children	  <1yr	  of	  age	  have	  very	  high	  levels	  of	  BCG	  induced	  Ki67+CD4+	  T	  cell	  proliferation	  and	  the	  magnitude	  of	  this	  response	  decreases	  significantly	  with	  increasing	  age,	  beyond	  the	  previously	  generated	  data.	  	  Of	  note	  is	  the	  marked	  heterogeneity	  of	  responses	  in	  the	  <1yr	  old	  group,	  most	  likely	  reflecting	  the	  difference	  in	  response	  even	  with	  small	  differences	  in	  age	  as	  seen	  by	  Soares	  et	  al.	  	  It	  is	  unclear	  what	  underlies	  this	  observation,	  which	  many	  investigators	  have	  made	  and	  it	  might	  well	  have	  a	  genetic	  component.	  Although	  the	  frequency	  of	  BCG	  specific	  IFNγ+	  CD4+	  T	  cells	  correlates	  with	  proliferation,	  this	  is	  not	  observed	  of	  IL17-­‐	  and	  IL22+CD4+	  T	  cells.	  	  Children	  <1yr	  of	  age	  have	  a	  marked	  reduction	  in	  expression	  of	  these	  cytokines	  in	  comparison	  with	  older	  children.	  	  Soares	  et	  al	  also	  noted	  very	  low	  levels	  of	  IL17	  in	  proliferating	  CD4	  +	  T	  cells,	  but	  she	  did	  not	  assess	  older	  children	  or	  levels	  of	  IL22	  expression.	  	  This	  is	  the	  first	  time	  that	  results	  with	  this	  assay	  have	  been	  described	  in	  children	  >1yr	  of	  age.	  	  The	  increase	  in	  IL17	  and	  IL22	  with	  increasing	  age	  may	  be	  due	  to	  a	  decrease	  in	  suppression	  by	  IFNγ	  as	  previously	  described	  by	  Cruz	  et	  al,	  or	  may	  reflect	  a	  waning	  of	  BCG	  vaccine	  responsiveness80.	  It	  is	  the	  opposite	  to	  our	  original	  hypothesis,	  based	  on	  the	  published	  literature,	  where	  we	  had	  suggested	  that	  younger	  children	  would	  have	  greater	  IL17	  responses	  than	  older	  children.	  	  Whether	  having	  a	  response	  to	  mycobacterial	  stimulation	  that	  includes	  both	  IL17	  and	  IL22	  as	  well	  as	  IFNγ	  confers	  greater	  protection	  from	  disseminated	  disease	  is	  as	  yet	  unclear	  from	  our	  results,	  but	  it	  is	  of	  interest	  that	  the	  proliferative	  response,	  including	  the	  cytokine	  expression,	  changes	  with	  increasing	  age.	  	  	  Soares	  et	  al	  described	  that	  there	  was	  no	  waning	  of	  the	  proliferative	  response	  to	  tetanus	  toxoid	  with	  age	  in	  her	  cohort	  and	  suggested	  that	  waning	  of	  a	  BCG	  induced	  proliferative	  response	  indicates	  a	  failure	  of	  development	  of	  a	  long-­‐term	  protective	  effect	  of	  the	  BCG	  vaccine.	  	  It	  would	  be	  interesting	  to	  examine	  the	  immunological	  response	  to	  boosters	  of	  the	  BCG	  vaccine	  in	  further	  studies	  to	  see	  if	  it	  is	  possible	  to	  alter	  this	  waning	  of	  the	  proliferative	  response	  with	  time	  –	  and	  to	  determine	  if	  this	  protects	  from	  either	  TB	  disease	  or	  disseminated	  TB	  disease.	  	  However,	  the	  published	  literature	  does	  not	  support	  that	  repeated	  BCG	  vaccination	  induces	  greater	  protection175-­‐177.	  It	  is	  noteworthy	  that	  in	  our	  cohort	  the	  majority	  of	  disseminated	  disease	  was	  described	  in	  older	  children.	  	  	  
6.7.4. Memory	  marker	  expression	  in	  Ki67	  lymphoproliferation	  assay	  The	  expression	  of	  phenotypical	  memory	  markers	  on	  Ki67+	  cytokine	  producing	  BCG	  specific	  CD4+	  T	  cells	  shows	  that	  the	  majority	  of	  cells	  in	  children<1yr	  of	  age	  are	  of	  an	  effector	  memory	  phenotype,	  with	  greater	  proportions	  of	  central	  memory	  and	  other	  phenotypes	  in	  older	  children	  seen.	  	  This	  significant	  shift	  in	  pattern	  of	  memory	  markers	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after	  a	  year	  of	  age	  fits	  with	  the	  previous	  finding	  that	  this	  group	  has	  the	  most	  marked	  proliferation	  and	  cytokine	  production	  in	  response	  to	  BCG	  suggesting	  a	  robust	  antigen	  specific	  effect	  of	  BCG.	  A	  similar	  pattern	  of	  proliferation	  and	  phenotypical	  memory	  marker	  expression	  is	  seen	  on	  γδ	  T	  cells,	  however,	  the	  differences	  between	  younger	  and	  older	  children	  is	  less	  marked	  than	  in	  CD4+	  T	  cells.	  	  Mazzola	  et	  al	  have	  previously	  shown	  marked	  proliferation	  of	  γδT	  cells	  in	  response	  to	  BCG	  vaccination	  in	  young	  infants,	  but	  not	  in	  older	  children178.	  Dieli	  et	  al	  described	  proliferation	  of	  γδ	  T	  cells	  associated	  with	  a	  decrease	  in	  IFNγ	  producing	  capacity	  in	  children	  with	  TB	  infection	  and	  disease	  in	  response	  to	  non-­‐specific	  stimulation,	  but	  the	  phenotype	  and	  function	  of	  BCG	  induced	  proliferating	  γδ	  T	  cells	  in	  healthy	  children	  has	  not	  previously	  been	  described35.	  γδ	  T	  cells	  clearly	  play	  a	  role	  in	  the	  immune	  response	  to	  mycobacteria,	  but	  there	  do	  not	  appear	  to	  be	  significant	  differences	  associated	  with	  age	  in	  children.	  
6.8. Conclusion	  In	  summary,	  all	  healthy	  children	  have	  a	  robust	  effector	  memory	  response	  to	  BCG,	  there	  are	  no	  differences	  in	  CD4+	  IFNγ	  responses	  with	  age,	  but	  CD4	  and	  γδ	  production	  of	  IL22	  increases	  with	  increasing	  age.	  	  There	  is	  a	  decrease	  in	  proliferative	  potential	  in	  response	  to	  longer	  term	  stimulation	  with	  BCG,	  associated	  with	  a	  different	  spectrum	  of	  cytokine	  production	  by	  T	  cells	  with	  increasing	  age	  and	  a	  significant	  shift	  of	  memory	  marker	  expression	  in	  the	  over	  1yr	  old	  age	  group	  which	  may	  reflect	  waning	  BCG	  vaccine	  responsiveness.	  	  It	  is	  interesting	  that	  despite	  the	  <1yr	  old	  group	  showing	  a	  much	  more	  robust	  central	  memory	  response	  and	  increased	  proliferative	  potential	  following	  6	  days	  of	  BCG	  stimulation,	  they	  do	  not	  have	  an	  increased	  effector	  memory	  response	  to	  short	  term	  stimulation	  by	  BCG.	  	  It	  may	  be	  that	  this	  indicates	  an	  age-­‐related	  immune	  deficit	  in	  this	  more	  immediate	  response	  that	  warrants	  further	  investigation	  and	  it	  also	  outlines	  why	  different	  results	  can	  be	  obtained	  when	  using	  different	  time	  courses	  in	  immunological	  studies	  of	  this	  nature,	  which	  sometimes	  limits	  comparisons.	  Although	  there	  are	  significant	  differences	  between	  the	  under	  one	  year	  old	  age	  group	  and	  older	  children,	  there	  are	  very	  few	  differences	  in	  children	  between	  one	  year	  and	  older.	  	  This	  is	  of	  importance	  for	  future	  studies,	  in	  particular	  vaccine	  trials,	  as	  it	  may	  simplify	  study	  design,	  where	  data	  from	  different	  age	  groups	  can	  be	  analysed	  together.	  IL17	  is	  produced	  in	  only	  very	  small	  quantities	  by	  all	  T	  cell	  phenotypes	  in	  both	  assays	  and	  does	  not	  appear	  to	  play	  a	  significant	  role	  in	  the	  immune	  response	  to	  mycobacteria.	  	  In	  contrast,	  IL22	  may	  be	  of	  greater	  importance	  and	  its	  role	  in	  children	  with	  TB	  and	  perhaps	  in	  healthy	  children	  should	  be	  explored	  in	  future	  studies.	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7. Mycobacterial	  immune	  responses	  in	  children	  with	  
different	  manifestations	  of	  TB	  disease	  
7.1. 	  Introduction	  In	  the	  previous	  chapter,	  we	  described	  the	  T	  cell	  phenotypes	  and	  functions	  associated	  with	  stimulation	  by	  mycobacterial	  stimulation	  for	  both	  an	  overnight	  and	  a	  longer	  6	  day	  assay	  in	  children	  of	  different	  ages.	  	  We	  have	  established	  that	  healthy	  BCG	  vaccinated	  children	  of	  all	  ages	  have	  robust	  immune	  responses	  to	  live	  BCG	  and	  shown	  that	  in	  particular	  that	  infants	  under	  a	  year	  of	  age	  are	  able	  to	  mount	  a	  CD4+	  IFNγ	  response	  to	  BCG	  in	  both	  assays	  used	  in	  this	  study.	  	  We	  did	  not	  demonstrate	  a	  shift	  from	  a	  primarily	  IL17	  immune	  phenotype	  in	  very	  young	  children	  towards	  a	  predominantly	  IFNγ	  response	  in	  older	  children	  and	  adults	  as	  hypothesized,	  but	  have	  shown	  other	  significant	  differences	  in	  T	  cell	  phenotype	  and	  cytokine	  expression	  with	  age.	  	  In	  this	  chapter	  we	  wish	  to	  address	  the	  other	  main	  hypothesis	  of	  this	  study,	  that	  containment	  or	  dissemination	  of	  mycobacteria	  in	  children	  with	  TB	  disease	  is	  determined	  by	  the	  balance	  of	  Th1/Th17	  responses.	  	  Th1	  and	  Th17	  responses	  as	  measured	  by	  cytokine	  release	  in	  response	  to	  mycobacterial	  antigens	  have	  recently	  been	  shown	  to	  be	  suppressed	  in	  children	  with	  active	  TB	  disease	  and	  in	  particular,	  extra-­‐pulmonary	  TB	  disease117.	  	  However,	  the	  T	  cell	  phenotypes	  associated	  with	  different	  disease	  phenotypes	  have	  not	  been	  previously	  described	  and	  this	  study	  used	  PPD	  stimulated	  PBMCs	  for	  just	  24	  hours	  to	  describe	  their	  findings.	  	  This	  is	  the	  first	  study	  to	  have	  such	  a	  large	  and	  well	  characterized	  cohort	  of	  children	  with	  TB	  and	  to	  describe	  the	  T	  cell	  phenotype	  and	  function	  in	  both	  short	  and	  long	  term	  assays.	  
7.2. Methods	  The	  methods	  used	  for	  this	  part	  of	  the	  study	  include	  1)	  the	  whole	  blood	  short	  term	  stimulation	  assay	  to	  assess	  effector	  responses	  to	  BCG	  as	  measured	  by	  IFNγ	  and	  IL17	  production;	  2)	  the	  Ki67	  lymphoproliferation	  assay	  to	  assess	  memory	  responses	  to	  BCG	  as	  measured	  by	  IFNγ,	  IL17	  and	  IL22	  and	  3)	  the	  mycobacterial	  growth	  inhibition	  assay.	  	  All	  of	  these	  methods	  were	  performed	  as	  described	  in	  Chapter	  3.	  	  The	  classification	  of	  children	  into	  disease	  groups	  was	  implemented	  as	  described	  in	  Chapter	  5.	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7.3. 	  T	  cell	  phenotype	  and	  cytokine	  production	  following	  overnight	  
stimulation	  with	  BCG	  T	  cell	  phenotype	  (γδ,	  CD4+	  and	  γδ-­‐CD4-­‐	  [CD8+])	  and	  function	  were	  measured.	  The	  percentage	  of	  cytokine	  producing	  T	  cells	  was	  compared	  in	  different	  disease	  phenotypes;	  healthy	  controls,	  latent	  TB	  infection	  (LTBI),	  pulmonary	  TB	  at	  baseline	  (PTB	  T0),	  pulmonary	  TB	  after	  6	  months	  treatment	  (PTB	  T6),	  extra-­‐pulmonary	  TB	  at	  baseline	  (EPTB	  T0)	  and	  extrapulmonary	  TB	  after	  6	  months	  treatment	  (EPTB	  T6).	  	  The	  different	  T	  cell	  phenotypes	  were	  initially	  examined	  individually	  and	  correlations	  were	  subsequently	  assessed.	  
7.3.1. Phenotype	  and	  function	  of	  CD4+	  T	  cells	  following	  overnight	  
stimulation	  with	  BCG	  Following	  harvesting	  of	  the	  cells	  from	  the	  overnight	  whole	  blood	  assay,	  the	  percentages	  of	  CD4+,	  γδ	  and	  CD8+	  T	  cells	  were	  determined	  in	  all	  children	  using	  flow	  cytometry	  as	  described	  previously.	  	  Table	  18	  summarises	  these	  results.	  	  	  
	  
Table	  17	  -­‐	  Percentage	  of	  different	  T	  cell	  phenotypes	  in	  disease	  groups	  
The	  T	  cell	  phenotype	  is	  expressed	  as	  a	  percentage	  of	  CD3+	  T	  cells.	  	  The	  median	  value	  and	  
the	  interquartile	  range	  (IQR)	  for	  each	  group	  is	  shown.	  	  A	  one-­‐way	  ANOVA	  for	  all	  
comparisons	  was	  performed	  which	  showed	  no	  significant	  differences	  between	  disease	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Table	  18	  Cytokine	  production	  by	  T	  cell	  phenotype	  in	  different	  disease	  groups	  
The	  median	  percentage	  and	  interquartile	  range	  (IQR)	  of	  each	  cytokine	  is	  shown	  for	  the	  
different	  disease	  groups	  (HC	  (n=78),	  LTBI	  (n=25),	  PTB	  T0	  (n=38),	  PTB	  T6	  (n=32),	  EPTB	  T0	  
(n=27),	  EPTB	  T6	  (n=20)).	  	  The	  T	  cell	  phenotype	  is	  shown	  along	  the	  left	  side.	  	  A	  one-­‐way	  
ANOVA	  and	  Mann-­‐Whitney	  test	  was	  performed	  for	  each	  comparison	  and	  p-­‐values	  are	  
shown	  to	  the	  right	  of	  the	  table.	  (ns=	  not	  significant,	  p>0.05).	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Children	  with	  pulmonary	  TB,	  LTBI	  and	  healthy	  controls	  expressed	  similar	  amounts	  of	  all	  3	  cytokines	  from	  all	  T	  cell	  phenotypes	  with	  a	  few	  exceptions.	  	  As	  described	  in	  the	  previous	  chapter	  in	  healthy	  children,	  the	  magnitude	  of	  the	  IL17	  responses	  was	  very	  low	  in	  all	  cell	  types	  and	  groups.	  	  CD8	  T	  cells	  produced	  negligible	  quantities	  of	  either	  IL17	  or	  IL22,	  but	  of	  note,	  there	  was	  significantly	  lower	  expression	  of	  IFNγ	  in	  the	  PTB	  group	  than	  the	  healthy	  controls.	  	  Expression	  of	  IFNγ	  by	  γδT	  cells	  was	  significantly	  lower	  in	  active	  TB	  than	  in	  LTBI	  and	  healthy	  controls,	  and	  the	  expression	  in	  LTBI	  was	  significantly	  higher	  than	  healthy	  controls.	  	  The	  most	  consistent	  finding	  amongst	  all	  T	  cell	  types	  was	  an	  increase	  in	  cytokine	  production	  at	  6	  months	  post	  treatment	  of	  TB	  (both	  PTB	  and	  EPTB)	  –	  this	  was	  seen	  for	  IFNγ	  expression	  by	  all	  3	  cell	  types	  and	  IL22	  expression	  by	  CD4	  T	  cells.	  	  Figure	  37	  illustrates	  some	  of	  these	  findings	  for	  IFNγ	  expressing	  γδ	  T	  cells.	  
	  
Figure	  37	  IFNγ 	  producing	  BCG	  specific	  γδ 	  T	  cells	  are	  highest	  6	  months	  after	  TB	  treatment	  
This	  figure	  shows	  the	  percentage	  of	  IFNγ	  producing	  γδ	  T	  cells	  following	  whole	  blood	  
incubation	  with	  BCG	  (2.5x106cfu/ml)	  overnight	  followed	  by	  5	  hours	  incubation	  with	  
Brefeldin.	  	  The	  results	  from	  children	  in	  the	  different	  disease	  categories	  are	  compared	  (HC	  
(n=78),	  LTBI	  (n=25),	  PTB	  T0	  (n=38),	  PTB	  T6	  (n=32),	  EPTB	  T0	  (n=27),	  EPTB	  T6	  (n=20)).	  	  
Data	  was	  compared	  using	  a	  one	  way	  ANOVA	  and	  Mann	  Whitney	  tests	  and	  is	  shown	  on	  the	  
graph	  where	  significant.	  	  Data	  is	  presented	  on	  a	  log	  scale.	  	  All	  values	  of	  0	  were	  assigned	  a	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Horizontal	  bars	  represent	  median	  values.	  	  The	  dotted	  line	  represents	  a	  cut-­‐off	  of	  0.01	  for	  a	  
significant	  response.	  
7.4. BCG	  induced	  T	  cell	  proliferation	  The	  short	  term	  assay	  assesses	  the	  effector	  memory	  response	  of	  T	  cells	  to	  BCG	  stimulation.	  	  In	  order	  to	  assess	  central	  memory	  responses,	  whole	  blood	  was	  stimulated	  with	  BCG	  for	  6	  days	  and	  Ki67+	  T	  cells	  were	  enumerated	  to	  assess	  proliferation	  potential	  in	  response	  to	  BCG.	  	  Following	  this,	  the	  frequency	  of	  BCG-­‐specific	  T	  cells	  expressing	  cytokines	  was	  measured	  to	  assess	  the	  functional	  capacity	  of	  antigen-­‐specific	  T	  cells.	  	  
7.4.1. Phenotype	  of	  T	  cells	  after	  6	  days	  stimulation	  with	  BCG	  The	  percentage	  of	  each	  T	  cell	  phenotype	  (CD4,	  CD8	  and	  γδ)	  was	  measured	  using	  flow	  cytometry	  as	  described	  previously	  (Table	  20).	  
	  
Table	  19	  The	  percentage	  of	  each	  T	  cell	  phenotype	  following	  stimulation	  of	  whole	  blood	  with	  
BCG	  or	  ESAT6/CFP10	  for	  6	  days	  –	  the	  proportion	  of	  CD4	  T	  cells	  is	  significantly	  increased	  in	  
PTB	  
Whole	  blood	  was	  diluted	  1:10	  and	  incubated	  with	  BCG	  (5x105	  cfu/ml)	  for	  6	  days,	  then	  
PMA,	  Ionomycin	  and	  Brefeldin	  were	  added	  for	  4	  hours	  before	  cells	  were	  harvested	  for	  flow	  
cytometry.	  	  The	  T	  cell	  phenotype	  (CD4,	  CD8,	  γδ)	  is	  expressed	  as	  a	  percentage	  of	  CD3+	  T	  
cells.	  The	  median	  value	  and	  the	  interquartile	  range	  (IQR)	  for	  each	  group	  is	  shown.	  	  A	  one-­‐
way	  ANOVA	  followed	  by	  a	  Mann	  Whitney	  t-­‐test	  for	  all	  comparisons	  was	  performed,	  with	  p	  
values	  shown	  on	  the	  right	  side	  of	  the	  table.	  	  Any	  comparisons	  not	  shown	  were	  not	  






























































(14.9-25) p=0.0023 p<0.0001 p<0.0001 p=0.0007
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7.4.2. Ki67	  proliferation	  and	  cytokine	  production	  of	  T	  cells	  following	  
stimulation	  with	  BCG	  for	  6	  days	  The	  percentage	  of	  Ki67	  proliferating	  T	  cells	  of	  each	  phenotype	  and	  the	  percentage	  of	  these	  cells	  that	  were	  producing	  the	  cytokines	  of	  interest	  were	  measured	  following	  stimulation	  with	  both	  BCG	  and	  Esat6/CFP10	  for	  6	  days.	  	  The	  patterns	  for	  BCG	  and	  Esat6/CFP	  10	  were	  similar,	  as	  described	  in	  Chapter	  4.	  	  Therefore,	  data	  from	  BCG	  stimulation	  only	  is	  shown	  in	  Table	  21.	  	  	  
	  
Table	  20	  Expression	  of	  Ki67,	  IFNγ,	  IL17	  and	  IL22	  in	  CD4,	  CD8	  and	  γδ	  T	  cells	  in	  children	  with	  
different	  manifestations	  of	  TB	  disease	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The	  median	  percentage	  and	  interquartile	  range	  (IQR)	  of	  each	  cytokine	  and	  Ki67	  is	  shown	  
for	  the	  different	  disease	  groups	  (HC	  (n=78),	  LTBI	  (n=25),	  PTB	  T0	  (n=38),	  PTB	  T6	  (n=32),	  
EPTB	  T0	  (n=27),	  EPTB	  T6	  (n=20)).	  	  The	  T	  cell	  phenotype	  is	  shown	  along	  the	  left	  side.	  	  	  	  
	  
Table	  21	  Results	  of	  one-­‐way	  ANOVA	  and	  Mann-­‐Whitney	  tests	  comparing	  Ki67	  proliferation	  
and	  cytokine	  expression	  in	  children	  with	  different	  phenotypes	  of	  disease	  
A	  one-­‐way	  ANOVA	  and	  Mann-­‐Whitney	  test	  was	  performed	  for	  each	  comparison	  and	  p-­‐
values	  are	  shown	  to	  the	  right	  of	  the	  table.	  Comparisons	  that	  are	  not	  shown	  on	  the	  table	  are	  

























0.0005 0.0047 0.03 ns <0.0001 ns ns ns ns ns
IFNγ 
(IQR)
<0.0001 0.0045 ns ns <0.0001 ns ns ns ns ns
IL17 
(IQR)
<0.0001 0.0009 0.03 ns <0.0001 0.04 0.04 0.0005 ns ns
IL22 
(IQR)
<0.0001 ns ns ns <0.0001 ns ns 0.048 ns 0.03
Ki67 
(IQR)
0.04 ns ns ns ns ns ns ns ns ns
IFNγ 
(IQR)
0.006 ns ns 0.04 0.001 ns ns ns 0.04 ns
IL17 
(IQR)
0.34 ns ns ns ns ns ns ns ns ns
IL22 
(IQR)
0.11 ns ns ns ns ns ns ns ns ns
Ki67 
(IQR)
0.22 ns ns ns ns ns ns ns ns ns
IFNγ 
(IQR)
0.15 ns ns ns ns ns ns ns ns ns
IL17 
(IQR)
0.25 ns ns ns ns ns ns ns ns ns
IL22 
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significant	  increase	  in	  CD4+	  IL17	  expression	  and	  to	  a	  slightly	  lower	  magnitude,	  IL22.	  	  Figure	  38	  illustrates	  these	  findings.	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The	  percentage	  of	  cytokine	  producing	  Ki67+CD8-­‐γδ-­‐	  [CD4+]	  T	  cells	  following	  whole	  blood	  
incubation	  with	  BCG	  (2.5x106	  cfu/ml)	  for	  6	  days	  followed	  by	  4	  hours	  incubation	  with	  Brefeldin,	  PMA	  
and	  Ionomycin	  (PI)	  is	  shown.	  	  The	  results	  from	  different	  disease	  groups	  are	  compared	  (HC	  (n=78),	  
LTBI	  (n=25),	  PTB	  T0	  (n=38),	  PTB	  T6	  (n=32),	  EPTB	  T0	  (n=27),	  EPTB	  T6	  (n=20)).	  	  A	  –	  percentage	  
Ki67	  expressing	  CD4+	  T	  cells;	  B	  -­‐	  percentage	  IFNγ	  producing	  Ki67+CD4+	  T	  cells;	  C	  –	  percentage	  IL17	  
producing	  Ki67+CD4+	  T	  cells;	  D	  –	  percentage	  IL22	  producing	  Ki67+CD4+	  T	  cells.	  	  Data	  was	  
compared	  using	  a	  one	  way	  ANOVA	  and	  Mann	  Whitney	  test	  and	  significant	  results	  are	  presented	  as	  
shown.	  	  Note	  the	  different	  scales	  on	  each	  graph.	  	  Horizontal	  bars	  represent	  median	  values.	  	  A	  correlation	  between	  IFNγ	  and	  either	  IL17	  or	  IL22	  illustrates	  that	  the	  magnitude	  of	  response	  for	  all	  3	  cytokines	  increases	  in	  a	  linear	  fashion,	  figure	  39.	  
	  
Figure	  39	  -­‐	  There	  is	  a	  linear	  relationship	  between	  IFNγ ,	  IL17	  and	  IL22	  produced	  by	  CD4+	  T	  
cells	  
The	  association	  between	  IFNγ	  expression	  by	  Ki67+	  CD4+	  T	  cells	  and	  IL17	  or	  IL22	  is	  
examined	  using	  a	  Spearman	  non-­‐parametric	  correlation.	  	  The	  results	  from	  all	  TB	  cases	  are	  
included	  in	  this	  figure	  (n=67).	  	  	  When	  γδ	  T	  cell	  cytokine	  expression	  is	  examined,	  it	  is	  noted	  that	  there	  is	  a	  significantly	  higher	  expression	  of	  IFNγ	  in	  pulmonary	  TB	  at	  both	  time	  points	  compared	  to	  healthy	  controls	  –	  this	  is	  not	  seen	  in	  extrapulmonary	  TB,	  perhaps	  suggesting	  a	  relative	  suppression	  of	  the	  γδ	  T	  cell	  response	  in	  more	  severe	  disease.	  	  There	  are	  no	  significant	  differences	  in	  IL17	  or	  IL22	  production	  by	  γδ	  T	  cells	  between	  disease	  groups.	  	  	  The	  proliferative	  and	  cytokine	  responses	  of	  CD8+	  T	  cells	  are	  much	  lower	  than	  those	  of	  CD4	  or	  γδ	  T	  cells	  and	  there	  are	  no	  significant	  differences	  between	  disease	  groups,	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suggesting	  less	  of	  a	  role	  for	  CD8+	  T	  cells	  in	  the	  memory	  response	  to	  BCG	  in	  children	  with	  TB.	  	  	  To	  ensure	  that	  there	  were	  no	  immunological	  differences	  between	  culture	  confirmed	  and	  probable	  TB,	  these	  two	  groups	  were	  compared.	  	  	  There	  were	  no	  differences	  in	  cytokine	  expression	  by	  any	  of	  the	  T	  cell	  phenotypes	  between	  the	  2	  groups,	  the	  data	  for	  CD4+	  T	  cells	  is	  shown	  in	  Table	  23.	  	  
	  
Table	  22	  Cytokine	  expression	  by	  CD4+	  T	  cells	  in	  children	  with	  either	  culture	  confirmed	  TB	  or	  
probable	  TB	  shows	  no	  significant	  differences.	  
The	  median	  percentage	  and	  interquartile	  range	  (IQR)	  of	  each	  cytokine	  and	  Ki67	  is	  shown	  
for	  the	  children	  with	  either	  culture	  confirmed	  (n=30)	  or	  probable	  TB	  (n=24)	  at	  baseline	  
and	  following	  treatment.	  	  The	  T	  cell	  phenotype	  and	  assay	  type	  is	  shown	  along	  the	  left	  side.	  	  
A	  one-­‐way	  ANOVA	  was	  performed	  for	  each	  comparison;	  none	  were	  found	  to	  be	  of	  
significance.	  	  (ns=	  not	  significant,	  p>0.05).	  In	  summary,	  this	  analysis	  shows	  no	  difference	  between	  healthy	  children,	  those	  with	  latent	  TB	  infection	  and	  children	  with	  active	  TB	  disease	  at	  time	  of	  TB	  diagnosis	  –	  whether	  that	  is	  pulmonary	  or	  extrapulmonary.	  	  There	  is	  a	  significant	  increase	  in	  both	  effector	  and	  memory	  responses	  to	  mycobacteria	  6	  months	  post	  diagnosis	  of	  TB	  as	  measured	  by	  IFNγ	  expression	  by	  CD4,	  γδ	  and	  CD8	  T	  cells	  after	  short	  term	  stimulation	  with	  BCG,	  and	  an	  increase	  in	  KI67	  lymphoproliferation	  by	  CD4	  and	  γδ	  T	  cells	  with	  an	  associated	  increase	  in	  all	  3	  cytokines	  measured	  after	  6	  day	  stimulation	  with	  BCG.	  	  This	  is	  less	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marked	  in	  extrapulmonary	  TB	  and	  may	  suggest	  an	  underlying	  defect	  in	  these	  children	  in	  their	  ability	  to	  respond	  to	  what	  is	  effectively	  a	  ‘boost’	  of	  their	  BCG	  vaccine.	  	  	  
7.5. 	  Expression	  of	  memory	  markers	  
7.5.1. Memory	  phenotype	  of	  T	  cells	  in	  response	  to	  overnight	  BCG	  
stimulation	  The	  memory	  phenotype	  of	  T	  cells	  as	  described	  by	  expression	  of	  the	  markers	  CD27	  and	  CD45RA	  following	  overnight	  stimulation	  with	  BCG	  is	  shown	  in	  Table	  24.	  	  	  
	  
Table	  23	  Expression	  of	  memory	  markers	  CD27	  and	  CD45RA	  on	  T	  cells	  of	  different	  phenotypes	  
in	  children	  in	  all	  disease	  groups	  
The	  median	  percentage	  and	  interquartile	  range	  (IQR)	  of	  four	  different	  memory	  phenotypes	  
(Naïve	  or	  CD27+CD45RA+,	  Central	  Memory	  or	  CD27+CD45RA-­‐,	  Effector	  Memory	  CD27-­‐
CD45RA-­‐	  and	  Terminally	  differentiated	  effector	  memory	  CD27-­‐CD45RA+)	  is	  shown	  for	  the	  
different	  disease	  groups	  (HC	  (n=78),	  LTBI	  (n=25),	  PTB	  T0	  (n=38),	  PTB	  T6	  (n=32),	  EPTB	  T0	  
(n=27),	  EPTB	  T6	  (n=20)).	  	  The	  T	  cell	  phenotype	  is	  shown	  along	  the	  left	  side.	  	  A	  one-­‐way	  
ANOVA	  was	  performed	  for	  each	  comparison.	  (ns=non	  significant,	  p>0.05)	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There	  were	  no	  significant	  differences	  in	  surface	  memory	  phenotype	  expression	  between	  the	  different	  groups.	  	  The	  predominant	  memory	  phenotype	  of	  CD4	  T	  cells	  was	  CD27+CD45RA+,	  usually	  described	  as	  naïve,	  whereas	  the	  gammadelta	  T	  cells	  showed	  a	  greater	  variety	  of	  surface	  memory	  marker	  expression.	  
	  
7.5.2. Memory	  phenotype	  of	  T	  cells	  following	  6	  days	  stimulation	  with	  BCG	  Following	  incubation	  of	  whole	  blood	  with	  BCG	  for	  6	  days,	  it	  would	  be	  expected	  that	  the	  majority	  of	  cells	  would	  have	  responded	  to	  the	  antigens	  to	  become	  either	  central	  memory,	  effector	  memory	  or	  terminally	  differentiated	  T	  cells.	  	  Table	  25	  demonstrates	  the	  expression	  of	  memory	  markers	  on	  CD4	  and	  γδ	  T	  cells	  following	  BCG	  stimulation	  in	  the	  6	  day	  lymphoproliferation	  assay.	  
	  
Table	  24	  Expression	  of	  memory	  markers	  on	  CD4	  and	  γδ	  T	  cells	  in	  children	  from	  all	  disease	  
groups	  following	  6	  days	  stimulation	  with	  BCG	  
The	  median	  percentage	  of	  4	  combinations	  of	  memory	  markers	  and	  interquartile	  range	  
(IQR)	  in	  children	  in	  the	  different	  disease	  classifications	  is	  shown	  (HC	  (n=78),	  LTBI	  (n=25),	  
PTB	  T0	  (n=38),	  PTB	  T6	  (n=32),	  EPTB	  T0	  (n=27),	  EPTB	  T6	  (n=20)).	  	  The	  T	  cell	  phenotype	  is	  
shown	  along	  the	  left	  side	  and	  the	  disease	  classification	  groups	  along	  the	  top.	  	  A	  one-­‐way	  
ANOVA	  and	  Mann-­‐Whitney	  test	  was	  performed	  for	  the	  different	  comparisons.	  Significant	  p	  
values	  are	  shown.	  (ns=	  not	  significant,	  p>0.05).	  	  Comparisons	  not	  shown	  on	  the	  table	  were	  
not	  significant.	  Children	  in	  the	  healthy	  control	  group	  had	  lower	  proportions	  of	  antigen-­‐specific	  central	  memory	  CD4+	  and	  γδ	  T	  cells	  than	  children	  in	  the	  other	  groups	  –	  and	  this	  was	  significant	  for	  pulmonary	  TB	  at	  baseline	  and	  6	  months	  post	  treatment.	  	  In	  CD4+	  T	  cells,	  there	  was	  a	  shift	  from	  central	  memory	  (CD27+CD45RA-­‐)	  to	  TEMRA	  (CD27-­‐CD45RA+)	  T	  cells,	  but	  in	  
PTB T0 PTB T6 EPTB T0 EPTB T6 HC LTBI One-way ANOVA
PTB vs 
HC
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the	  γδ	  T	  cell	  population,	  there	  were	  more	  of	  both	  effector	  memory	  (CD27-­‐CD45RA-­‐)	  and	  TEMRA	  (CD27-­‐CD45RA+)	  T	  cells.	  	  This	  pattern	  was	  similar	  when	  the	  expression	  of	  memory	  markers	  of	  Ki67+cytokine	  producing	  T	  cells	  was	  analysed,	  Table	  26.	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Table	  25	  -­‐	  Expression	  of	  memory	  markers	  on	  Ki67+	  cytokine	  producing	  T	  cells	  
The	  median	  percentage	  of	  4	  combinations	  of	  memory	  markers	  and	  interquartile	  range	  
(IQR)	  in	  children	  in	  the	  different	  disease	  classifications	  is	  shown	  (HC	  (n=78),	  LTBI	  (n=25),	  
PTB	  T0	  (n=38),	  PTB	  T6	  (n=32),	  EPTB	  T0	  (n=27),	  EPTB	  T6	  (n=20)).	  	  The	  T	  cell	  phenotype	  is	  
shown	  along	  the	  top	  and	  cytokine	  expression	  and	  disease	  classification	  along	  the	  left	  hand	  
side.	  	  The	  values	  in	  blue	  are	  those	  that	  are	  significantly	  different	  to	  the	  others.	  
	  
7.6. Mycobacterial	  growth	  inhibition	  assay	  in	  children	  with	  different	  
severity	  of	  TB	  We	  have	  described	  the	  T	  cell	  phenotype	  and	  cytokine	  expression	  in	  children	  with	  different	  manifestations	  of	  TB	  disease.	  	  To	  determine	  whether	  these	  phenotypic	  profiles	  are	  associated	  with	  a	  functional	  correlate,	  a	  mycobacterial	  growth	  inhibition	  assay	  was	  performed	  as	  described	  in	  Chapter	  3	  at	  the	  6	  month	  time	  point.	  Unfortunately,	  it	  was	  not	  possible	  to	  perform	  the	  assay	  at	  the	  time	  of	  diagnosis	  as	  the	  majority	  of	  children	  had	  already	  been	  started	  on	  either	  antibiotic	  or	  anti-­‐TB	  therapy	  when	  consented	  for	  the	  study.	  	  A	  growth	  ratio	  for	  each	  child	  was	  calculated	  as	  previously	  described	  and	  the	  pulmonary	  TB	  group	  compared	  with	  the	  extrapulmonary	  TB	  group	  as	  seen	  in	  Figure	  40.	  
	  
Figure	  40	  There	  is	  no	  difference	  in	  mycobacterial	  growth	  inhibition	  in	  children	  with	  
pulmonary	  and	  extrapulmonary	  TB	  
Whole	  blood	  was	  incubated	  with	  H37RV	  lux	  for	  96	  hours	  and	  then	  the	  luminescence	  
measured	  as	  previously	  described.	  	  Samples	  were	  analysed	  in	  triplicate.	  	  The	  luminescence	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blood	  from	  children	  with	  PTB	  T6	  (n=18)	  and	  EPTB	  T6	  (n=8)	  are	  shown.	  	  The	  growth	  ratio	  
of	  children	  in	  the	  two	  TB	  groups	  were	  compared	  by	  a	  one-­‐way	  ANOVA.	  	  	  The	  growth	  ratio	  in	  probable	  and	  confirmed	  TB	  for	  each	  group	  was	  also	  compared	  and	  no	  significant	  difference	  found.	  	  	  
7.7. Summary	  of	  Key	  Findings	  There	  have	  been	  a	  paucity	  of	  studies	  examining	  the	  immune	  response	  to	  TB	  in	  children	  to	  date	  and	  those	  that	  have	  been	  performed	  have	  either	  had	  small	  numbers	  of	  participants,	  concentrated	  on	  one	  T	  cell	  phenotype	  or	  have	  just	  looked	  at	  secreted	  cytokines.	  	  This	  is	  the	  first	  study	  of	  its	  kind	  to	  have	  such	  a	  well	  characterized	  group	  of	  patients,	  to	  compare	  baseline	  and	  ‘cured’	  immune	  responses	  and	  to	  compare	  such	  a	  broad	  range	  of	  T	  cell	  phenotypes	  in	  two	  different	  immunological	  assays	  with	  complex	  multicolour	  flow	  cytometry.	  	  Additionally	  we	  have	  sought	  to	  include	  a	  functional	  assay	  to	  determine	  if	  our	  findings	  correlate	  with	  a	  functional	  effect	  on	  mycobacterial	  growth.	  	  The	  main	  findings	  of	  this	  study	  are:	  1.)	  there	  is	  a	  suppression	  of	  Th1	  responses	  in	  both	  the	  short	  term	  and	  longer	  term	  assays	  in	  children	  with	  TB	  at	  the	  time	  of	  diagnosis	  which	  is	  boosted	  and	  significantly	  higher	  at	  6	  months	  post	  treatment	  than	  in	  healthy	  controls	  or	  children	  with	  latent	  TB	  infection	  and	  2.)	  this	  ‘boosting’	  effect	  is	  not	  as	  marked	  in	  children	  with	  extra-­‐pulmonary	  TB	  which	  may	  be	  due	  to	  a	  subtle	  immune	  defect	  in	  this	  group	  of	  children.	  	  I	  will	  now	  discuss	  all	  of	  the	  significant	  findings	  of	  the	  analysis	  in	  the	  context	  of	  the	  current	  literature.	  
7.7.1. Short	  Term	  BCG	  stimulation	  of	  whole	  blood	  There	  was	  no	  difference	  in	  levels	  of	  IFNγ	  CD4+T	  cells	  between	  the	  different	  groups	  at	  the	  time	  of	  diagnosis,	  but	  at	  6	  months	  post	  treatment,	  the	  levels	  in	  the	  PTB	  group	  were	  significantly	  higher	  than	  at	  baseline	  or	  than	  healthy	  controls.	  	  This	  trend	  was	  also	  seen	  for	  EPTB	  but	  did	  not	  reach	  significance.	  	  IL22+	  CD4+	  T	  cells	  followed	  the	  same	  pattern.	  	  IFNγ+	  γδ+	  T	  cells	  were	  significantly	  lower	  in	  patients	  with	  TB	  than	  healthy	  controls	  or	  children	  with	  LTBI	  and	  demonstrated	  a	  similar	  boosting	  effect	  at	  the	  end	  of	  treatment.	  This	  is	  the	  first	  study	  in	  children	  using	  flow	  cytometry	  to	  compare	  these	  well-­‐characterized	  patient	  groups,	  demonstrating	  an	  antigen	  specific	  boosting	  of	  effector	  memory	  responses	  following	  TB	  disease	  and	  describing	  which	  T	  cell	  phenotype	  is	  responsible.	  	  	  Although	  we	  have	  not	  demonstrated	  a	  difference	  between	  pulmonary	  and	  extra-­‐pulmonary	  TB	  at	  baseline,	  there	  is	  no	  significant	  boosting	  effect	  of	  the	  effector	  memory	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response	  in	  this	  group	  for	  either	  CD4	  or	  γδ	  T	  cells.	  	  This	  may	  be	  because	  in	  these	  patients	  there	  is	  a	  delay	  in	  the	  recovery	  from	  disease	  and	  if	  the	  responses	  were	  repeated	  at	  a	  later	  time	  point	  the	  results	  would	  be	  the	  same	  as	  for	  the	  PTB	  group	  –	  or	  it	  may	  represent	  a	  subtle	  immune	  defect	  in	  this	  patient	  group	  leading	  to	  their	  susceptibility	  to	  develop	  EPTB	  in	  the	  first	  place.	  	  Two	  papers	  have	  previously	  examined	  this	  question	  in	  adults.	  	  Fiske	  et	  al	  looked	  at	  in	  vitro	  responses	  in	  patients	  at	  the	  end	  of	  treatment	  for	  EPTB	  by	  extracting	  and	  then	  infecting	  macrophages	  with	  H37RV	  Mtb	  and	  then	  incubating	  these	  with	  PBMCs	  for	  48	  hours101.	  	  Supernatants	  were	  collected	  and	  the	  secreted	  cytokines	  analysed	  to	  show	  that	  IFNγ,	  IL6,	  IL10	  and	  TNFα	  were	  suppressed	  and	  IL17	  increased	  in	  EPTB	  vs	  PTB.	  	  However,	  they	  did	  not	  compare	  the	  patient	  groups	  at	  the	  time	  of	  diagnosis.	  	  Goletti	  et	  al	  also	  looked	  at	  adult	  patients	  who	  had	  been	  previously	  treated	  for	  EPTB	  and	  PTB	  using	  both	  ELISPOT	  and	  flow	  cytometry	  and	  described	  that	  those	  patients	  with	  EPTB	  and	  particularly	  those	  with	  severe	  disease	  were	  less	  likely	  to	  have	  either	  IFNγ+CD4+	  effector	  memory	  or	  central	  memory	  responses	  to	  ESAT	  6	  and	  CFP	  10	  TB	  peptides	  than	  patients	  with	  less	  severe	  pulmonary	  TB179.	  	  An	  inadequate	  production	  of	  memory	  T	  cells	  could	  potentially	  lead	  to	  the	  development	  of	  TB	  at	  sites	  distant	  from	  the	  site	  of	  primary	  infection	  after	  the	  initial	  control	  of	  TB.	  	  Given	  the	  differences	  Fiske	  et	  al	  found	  following	  incubation	  of	  Mtb	  infected	  macrophages	  with	  PBMCs,	  perhaps	  there	  is	  an	  inadequate	  activation	  of	  memory	  cells	  by	  these	  antigen	  presenting	  cells	  in	  patients	  who	  subsequently	  develop	  extra-­‐pulmonary	  TB.	  	  We	  did	  not	  show	  a	  significant	  difference	  in	  the	  memory	  phenotype	  between	  the	  patient	  groups	  and	  in	  particular	  there	  were	  no	  differences	  in	  effector	  memory	  T	  cells.	  	  Previously,	  other	  groups	  have	  described	  a	  predominance	  of	  effector	  memory	  cells	  in	  active	  TB	  disease	  compared	  to	  healthy	  controls180,181	  Additionally,	  Petruccioli	  et	  al	  described	  that	  at	  6	  months	  post	  treatment,	  the	  pool	  of	  central	  memory	  T	  cells	  had	  increased	  to	  make	  this	  group	  more	  similar	  to	  the	  healthy	  controls.	  	  	  	  	  There	  were	  no	  significant	  differences	  in	  IL17	  production	  by	  any	  of	  the	  patient	  groups.	  	  Although	  no	  previous	  groups	  have	  looked	  at	  differences	  in	  IL17	  production	  by	  T	  cells	  using	  flow	  cytometry,	  a	  recent	  study	  looking	  at	  secreted	  cytokines	  from	  unstimulated	  and	  PPD	  or	  CFP	  stimulated	  PBMCs	  in	  children	  with	  TB	  disease	  in	  India	  did	  not	  find	  any	  differences	  in	  IL17	  production	  either117,121.	  	  Matthews	  et	  al,	  using	  flow	  cytometry	  to	  enumerate	  cytokine	  producing	  CD4+	  T	  cells	  in	  adults	  with	  TB	  pericardial	  disease	  also	  found	  very	  little	  IL1793.	  	  She	  however	  identified	  high	  levels	  of	  IL22	  producing	  CD4+	  T	  cells.	  	  IL22+CD4+	  T	  cells	  in	  our	  study	  showed	  the	  same	  pattern	  of	  response	  as	  IFNγ+	  CD4+	  T	  cells	  –	  with	  a	  boosting	  of	  response	  at	  6	  months	  post	  treatment.	  	  There	  is	  no	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evidence	  in	  this	  data	  to	  support	  our	  hypothesis	  that	  susceptibility	  for	  severe	  TB	  disease	  is	  due	  to	  an	  imbalance	  between	  IL17	  and	  IFNγ	  production	  by	  γδ	  or	  CD4	  T	  cells.	  	  
7.7.2. The	  Ki67	  lymphoproliferation	  assay	  This	  is	  the	  first	  study	  to	  look	  at	  Ki67	  lymphoproliferation	  in	  children	  with	  TB,	  previous	  work	  has	  all	  been	  to	  look	  at	  BCG	  vaccine	  responses	  in	  healthy	  children.	  	  	  Our	  data	  show	  that	  there	  are	  significantly	  more	  CD4+	  T	  cells	  in	  children	  with	  PTB	  than	  in	  the	  other	  patient	  groups	  –	  underlining	  the	  importance	  of	  this	  cell	  type	  in	  the	  immune	  response	  to	  mycobacteria.	  	  	  Similarly	  to	  the	  findings	  of	  the	  short	  term	  assay,	  we	  saw	  no	  differences	  in	  Ki67+CD4+	  T	  cell	  lymphoproliferation	  at	  baseline	  although	  there	  was	  a	  trend	  to	  suppression	  of	  both	  proliferation	  and	  cytokine	  production	  especially	  in	  children	  with	  EPTB.	  	  Again	  at	  the	  end	  of	  treatment	  there	  was	  a	  significant	  increase	  in	  Ki67+CD4+	  lymphoproliferation	  and	  this	  was	  associated	  with	  a	  significant	  increase	  in	  all	  3	  cytokines	  (IFNγ,	  IL17	  and	  IL22).	  	  This	  boosting	  response	  following	  disease	  has	  implications	  for	  vaccine	  studies,	  but	  it	  is	  interesting	  that	  recurrent	  doses	  of	  BCG	  vaccine	  do	  not	  increase	  protection	  from	  TB	  disease	  in	  previous	  studies175,176.	  	  Additionally,	  evidence	  of	  boosting	  of	  BCG	  induced	  immune	  responses	  with	  novel	  vaccine	  candidates	  (MVA85A)	  have	  recently	  failed	  to	  correlate	  with	  protection	  from	  TB	  disease173,182.	  	  Furthermore,	  having	  had	  TB	  disease	  is	  recognized	  as	  a	  risk	  factor	  for	  further	  episodes	  of	  TB	  disease,	  however	  this	  my	  be	  due	  to	  epidemiological	  factors,	  failure	  for	  complete	  clearance	  of	  Mtb	  from	  the	  body	  or	  permanent	  lung	  damage	  predisposing	  to	  repeat	  infection.	  	  It	  may	  alternatively	  be	  that	  this	  is	  a	  specific	  Mtb	  effect	  and	  understanding	  the	  difference	  between	  the	  response	  to	  Mtb	  and	  BCG	  may	  hold	  the	  answer	  to	  a	  protective	  immune	  response.	  	  For	  future	  work,	  it	  would	  be	  interesting	  to	  follow	  this	  cohort	  of	  children	  for	  a	  longer	  period	  to	  monitor	  the	  changes	  in	  their	  immune	  responses	  and	  whether	  they	  have	  further	  episodes	  of	  TB	  disease	  –	  this	  is	  difficult	  in	  the	  South	  African	  setting	  however	  as	  the	  risk	  of	  re-­‐exposure	  to	  TB	  is	  so	  high.	  Similarly	  to	  the	  finding	  in	  the	  healthy	  control	  group	  in	  the	  previous	  chapter,	  this	  data	  shows	  that	  patients	  who	  have	  a	  strong	  proliferative	  response	  also	  produce	  large	  amounts	  of	  cytokine	  –	  and	  that	  there	  is	  a	  significant	  positive	  correlation	  between	  all	  3	  cytokines.	  	  This	  suggests	  that	  there	  may	  be	  a	  genetic	  predisposition	  to	  being	  either	  a	  ‘strong	  cytokine	  responder’	  to	  mycobacteria	  or	  not.	  	  The	  implications	  of	  being	  a	  strong	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responder	  are	  not	  understood,	  but	  it	  does	  not	  appear	  to	  correlate	  with	  protection	  from	  disease.	  The	  pattern	  of	  lymphoproliferation	  and	  cytokine	  production	  is	  the	  same	  for	  both	  γδ	  and	  CD4	  T	  cells.	  γδ	  T	  cells	  have	  not	  been	  examined	  using	  this	  Ki67	  lymphoproliferative	  assay	  previously,	  but	  Dieli	  et	  al	  isolated	  and	  cultured	  γδ	  T	  cells	  in	  children	  with	  pulmonary	  TB	  and	  described	  an	  increased	  proliferative	  capacity	  associated	  with	  decreased	  IFNγ	  production	  when	  compared	  to	  healthy	  controls35.	  Rojas	  et	  al	  described	  that	  IFNγ	  production	  by	  γδ	  T	  cells	  after	  7	  days	  stimulation	  with	  mycobacterial	  antigens	  in	  Ugandan	  patients	  with	  TB	  were	  suppressed	  compared	  to	  healthy	  controls	  at	  the	  time	  of	  diagnosis183.	  Neither	  of	  these	  groups	  have	  looked	  at	  proliferative	  capacity	  or	  cytokine	  responses	  of	  γδ	  T	  cells	  following	  treatment	  for	  TB	  disease.	  	  	  Following	  6	  days	  stimulation	  with	  BCG,	  the	  pattern	  of	  memory	  marker	  expression	  was	  similar	  on	  all	  CD4	  and	  γδ	  T	  cells	  in	  all	  groups	  with	  TB	  (PTB,	  EPTB	  and	  LTBI)	  –	  however,	  the	  pattern	  on	  cells	  from	  healthy	  controls	  was	  significantly	  different	  showing	  lower	  levels	  of	  central	  memory	  and	  higher	  levels	  of	  TEMRA	  terminally	  differentiated	  T	  cells	  than	  the	  TB	  group.	  	  This	  is	  likely	  to	  be	  due	  to	  there	  already	  being	  an	  expansion	  of	  effector	  memory	  T	  cells	  due	  to	  the	  presence	  of	  mycobacterial	  antigens	  in	  the	  patient	  group	  at	  baseline,	  and	  a	  greater	  pool	  of	  central	  memory	  cells	  present	  due	  to	  recent	  exposure/infection.	  	  In	  the	  above	  comparisons,	  both	  short	  term	  and	  longer	  term,	  there	  are	  only	  slight	  differences	  between	  healthy	  controls	  and	  latent	  TB	  infection	  which	  was	  unexpected.	  	  This	  may	  be	  due	  to	  the	  fact	  that	  the	  LTBI	  cohort	  were	  identified	  from	  healthy	  children	  who	  did	  not	  have	  known	  household	  contacts	  but	  were	  subsequently	  found	  to	  be	  ESAT	  6/CFP	  10	  sensitised	  rather	  than	  a	  ‘typical’	  case	  of	  latent	  TB,	  identified	  from	  screening	  current	  household	  contacts	  of	  pulmonary	  TB	  and	  perhaps	  more	  likely	  to	  have	  primed	  effector	  memory	  cells	  in	  the	  periphery.	  	  
7.7.3. Mycobacterial	  growth	  assay	  There	  were	  no	  differences	  in	  mycobacterial	  growth	  inhibition	  between	  the	  pulmonary	  and	  extra-­‐pulmonary	  TB	  disease	  groups.	  	  This	  assay	  was	  performed	  at	  the	  end	  of	  treatment	  and	  at	  this	  time,	  although	  we	  identified	  some	  subtle	  immunological	  differences	  between	  these	  disease	  groups,	  it	  did	  not	  translate	  into	  a	  functional	  difference.	  	  In	  future	  work,	  it	  would	  be	  of	  interest	  to	  do	  this	  assay	  at	  the	  time	  of	  
	   138	  
diagnosis	  before	  treatment	  had	  started	  to	  determine	  if	  there	  are	  functional	  differences	  at	  that	  point.	  
7.8. Conclusions	  There	  is	  a	  trend	  to	  suppression	  of	  antigen	  specific	  Th1	  responses	  in	  children	  with	  active	  TB	  disease	  in	  line	  with	  previous	  publications,	  although	  this	  does	  not	  reach	  significance.	  	  There	  is	  however	  a	  significant	  ‘boosting’	  of	  both	  the	  effector	  memory	  and	  central	  memory	  response	  to	  BCG	  stimulation	  of	  whole	  blood	  as	  measured	  by	  both	  of	  our	  assays	  following	  treatment	  of	  pulmonary	  TB	  disease.	  	  This	  boosting	  effect	  is	  not	  as	  significant	  for	  extra-­‐pulmonary	  TB	  and	  may	  indicate	  a	  subtle	  immune	  dysregulation	  or	  immune	  defect	  that	  predisposes	  them	  to	  develop	  more	  severe	  TB	  disease	  initially.	  	  Future	  work	  should	  concentrate	  on	  following	  these	  children	  for	  longer	  to	  see	  if	  the	  boosting	  occurs	  at	  a	  later	  stage	  and	  to	  see	  if	  there	  is	  any	  implication	  for	  future	  protection	  from	  TB	  disease.	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8. 	  	  Role	  of	  regulatory	  T	  cells	  children	  with	  TB	  
8.1. Introduction	  As	  described	  in	  chapter	  1,	  regulatory	  T	  cells	  (Tregs)	  have	  previously	  been	  shown	  to	  be	  increased	  in	  human	  tuberculosis	  infection	  and	  disease97,99,184	  	  and	  present	  in	  higher	  numbers	  in	  patients	  with	  extra-­‐pulmonary	  TB	  disease	  compared	  to	  pulmonary	  disease100,185.	  These	  studies	  were	  performed	  in	  adults	  with	  TB	  and	  to	  date,	  the	  role	  of	  regulatory	  T	  cells	  in	  paediatric	  TB	  has	  not	  been	  explored,	  although	  a	  number	  of	  groups	  have	  investigated	  regulatory	  T	  cells	  in	  both	  healthy	  children	  and	  those	  with	  allergic	  and	  autoimmune	  conditions	  186-­‐188.	  	  The	  current	  literature	  has	  few	  and	  conflicting	  data	  regarding	  the	  relationship	  between	  Tregs	  and	  age,	  and	  none	  relate	  to	  TB	  in	  children.	  We	  chose	  to	  measure	  CD4+	  CD39+	  FOXP3+	  T	  cells	  based	  on	  the	  most	  recent	  literature	  suggesting	  that	  these	  markers	  most	  accurately	  identify	  functionally	  suppressive	  regulatory	  T	  cells	  in	  humans107,189,190,	  influence	  mycobacterial	  specific	  responses	  in	  patients	  with	  TB	  disease108	  and	  play	  a	  role	  in	  influencing	  the	  immune	  response	  to	  novel	  TB	  vaccines87,191.	  IL10	  is	  made	  by	  T	  cells,	  B	  cells,	  neutrophils,	  macrophages	  and	  dendritic	  cells	  and	  inhibits	  the	  ability	  of	  macrophages	  and	  dendritic	  cells	  from	  activating	  Th1	  T	  cells	  via	  blockage	  of	  pro-­‐inflammatory	  cytokines	  such	  as	  TNFα	  and	  IL12.	  	  It	  can	  also	  directly	  inhibit	  phagocytosis	  and	  the	  production	  of	  reactive	  oxygen	  products.	  	  IL10	  is	  increased	  in	  the	  lungs	  and	  blood	  of	  patients	  with	  TB	  disease	  and	  neutralization	  of	  IL10	  enhances	  and	  sustains	  Th1	  and	  IL17	  responses	  to	  Mtb192.	  	  Regulatory	  T	  cells	  serve	  as	  a	  major	  source	  of	  immunoregulatory	  IL10125.	  We	  were	  therefore	  interested	  in	  examining	  IL10	  production	  in	  children	  with	  different	  manifestations	  of	  TB	  disease.	  In	  this	  chapter	  we	  will	  describe	  how	  regulatory	  T	  cells	  change	  in	  children	  of	  different	  ages	  and	  different	  disease	  phenotypes	  of	  tuberculosis,	  measure	  correlations	  between	  regulatory	  T	  cells	  and	  the	  other	  T	  cell	  phenotypes	  described	  as	  part	  of	  our	  extensive	  immunological	  analysis	  of	  children	  with	  TB	  disease.	  We	  also	  measured	  secreted	  levels	  of	  IL10	  following	  stimulation	  with	  BCG	  in	  the	  different	  patient	  groups.	  
8.2. Methods	  The	  whole	  blood	  intracellular	  cytokine	  release	  assay	  described	  in	  chapter	  3	  was	  used	  and	  both	  unstimulated	  and	  BCG	  stimulated	  samples	  were	  stained	  with	  the	  regulatory	  T	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cell	  markers	  CD3,	  CD4,	  CD25,	  CD39	  and	  FOXP3.	  	  In	  addition,	  secreted	  IL10	  was	  measured	  using	  the	  Bio-­‐Rad	  luminex	  method	  as	  described.	  	  Analysis	  was	  performed	  as	  previously	  described.	  
8.3. Results	  
8.3.1. Differences	  between	  unstimulated	  and	  BCG	  stimulated	  T	  regs	  Unstimulated	  and	  BCG	  stimulated	  whole	  blood	  samples	  were	  compared	  for	  the	  entire	  cohort	  of	  children.	  	  The	  median	  percentage	  of	  regulatory	  T	  cells	  was	  0.9%	  (IQR	  0.34-­‐1.58)	  and	  1.19%	  (IQR	  0.57-­‐2.3)	  for	  unstimulated	  and	  BCG	  stimulated	  respectively	  (Table	  26).	  	  However,	  when	  the	  results	  in	  the	  healthy	  control	  cohort	  and	  TB	  disease	  cohort	  were	  analysed	  separately,	  this	  difference	  was	  shown	  to	  be	  due	  to	  the	  TB	  disease	  cohort	  alone	  (Figure	  41).	  	  As	  we	  have	  identified	  differences	  between	  unstimulated	  and	  BCG	  stimulated	  regulatory	  T	  cells,	  for	  all	  comparisons	  we	  present	  both	  sets	  of	  data.	  	  	  	  
	  
Table	  26	  The	  percentage	  of	  CD4+CD39+FOXP3+	  T	  cells	  in	  children	  
The	  percentage	  of	  CD4+CD39+FOXP3+	  T	  cells	  in	  whole	  blood	  stimulated	  with	  RPMI	  (NIL)	  
or	  BCG	  (2.5x106cfu/ml)	  overnight	  before	  Brefeldin	  (10μg/ml)	  was	  added	  for	  5	  hours.	  	  
Whole	  blood	  from	  all	  children	  (n=232),	  healthy	  controls	  (n=75)	  and	  children	  with	  TB	  
disease	  (n=76)	  are	  shown.	  	  The	  table	  shows	  the	  percentage	  and	  inter-­‐quartile	  range	  in	  
each	  group.	  	  A	  one-­‐way	  ANOVA	  and	  Mann-­‐Whitney	  Tests	  were	  performed	  and	  p	  values	  
shown.	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Figure	  41	  Difference	  in	  percentage	  of	  CD4+CD39+FOXP3+	  T	  cells	  following	  BCG	  stimulation	  
This	  figure	  shows	  the	  percentage	  of	  CD4+CD39+FOXP3+	  T	  cells	  in	  whole	  blood	  stimulated	  
with	  RPMI	  or	  BCG	  (2.5x106cfu/ml)	  overnight	  before	  Brefeldin	  (10μg/ml)	  was	  added	  for	  5	  
hours.	  	  Whole	  blood	  from	  all	  children	  in	  the	  cohort	  are	  pooled	  for	  this	  figure	  (n=	  232).	  	  The	  
table	  shows	  the	  percentage	  and	  inter-­‐quartile	  range	  in	  each	  group.	  	  A	  one-­‐way	  ANOVA	  and	  
Mann-­‐Whitney	  Tests	  were	  performed	  and	  p	  values	  shown.	  	  Data	  is	  presented	  on	  a	  log	  scale.	  	  
Horizontal	  lines	  represent	  median	  values.	  
8.3.2. Regulatory	  T	  cells	  in	  children	  of	  different	  ages	  The	  percentages	  of	  CD4+CD39+FOXP3+	  T	  cells	  were	  measured	  and	  compared	  in	  healthy	  children	  of	  different	  ages	  (Table	  27).	  	  The	  percentage	  was	  significantly	  increased	  in	  children	  >2yrs	  of	  age	  compared	  to	  children	  <1yr	  of	  age	  for	  both	  unstimulated	  and	  BCG	  stimulated	  whole	  blood.	  	  There	  were	  no	  significant	  differences	  between	  children	  <1yr	  of	  age	  and	  children	  >1yr<2yrs	  (comparison	  not	  shown	  in	  this	  table).	  	  
	  
Table	  27	  Percentage	  of	  CD4+CD39+FOXP3+	  T	  cells	  in	  children	  of	  different	  ages	  
The	  median	  percentage	  and	  interquartile	  range	  (IQR)	  is	  shown	  for	  the	  different	  age	  groups	  
(<1yr	  (n=18),	  >1yr<2yr	  (n=16),	  >2yr<5yr	  (n=22),	  >5yr	  (n=19)).	  	  The	  stimulation	  condition	  
is	  shown	  along	  the	  left	  side.	  	  A	  one-­‐way	  ANOVA	  and	  Mann-­‐Whitney	  test	  was	  performed	  for	  









































(0.5-1.9) ***0.0001 **p=0.0012 ***p=0.004 **p=0.0022
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There	  is	  a	  positive	  correlation	  between	  percentage	  of	  regulatory	  T	  cells	  and	  increasing	  age	  (Figure	  42).	  	  
	  
Figure	  42	  Positive	  correlation	  between	  increasing	  age	  in	  months	  and	  percentage	  of	  
regulatory	  T	  cells	  
The	  correlation	  between	  CD4+CD3+FOXP3+	  T	  cells	  and	  age	  in	  months	  is	  examined	  using	  
the	  Spearman	  non-­‐parametric	  correlation.	  	  The	  results	  from	  all	  healthy	  children	  are	  
included	  in	  this	  figure	  (n=75).	  	  	  Associations	  between	  the	  percentages	  of	  BCG	  induced	  regulatory	  T	  cells	  and	  cytokine	  producing	  T	  cells	  of	  different	  phenotypes	  in	  healthy	  children	  of	  different	  ages	  were	  examined	  and	  the	  results	  shown	  in	  Table	  28.	  
























	   143	  
	  
Table	  28	  The	  relationship	  between	  percentage	  of	  BCG	  induced	  regulatory	  T	  cells	  and	  
cytokine	  expressing	  T	  cells	  is	  examined	  using	  a	  Spearman	  Correlation	  
The	  association	  between	  BCG	  induced	  CD4+CD39+FOXP3+	  T	  cells	  and	  cytokine	  expressing	  
T	  cells	  of	  different	  phenotypes	  is	  examined	  using	  non-­‐parametric	  Spearman	  correlation.	  	  
Samples	  from	  healthy	  children	  were	  used	  (n=75).	  	  T	  cell	  phenotype	  and	  cytokine	  expression	  
is	  on	  the	  left	  side	  of	  the	  graph.	  Significant	  p	  values	  are	  highlighted	  in	  blue.	  There	  were	  no	  significant	  correlations	  between	  Tregs	  and	  cytokine	  producing	  CD4+	  or	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Figure	  43	  -­‐	  Secreted	  IL10	  levels	  in	  healthy	  children	  of	  different	  ages	  
Whole	  blood	  diluted	  1:10	  with	  RPMI	  was	  incubated	  with	  BCG	  (2.5x106cfu/ml)	  for	  6	  days	  
and	  supernatants	  collected	  on	  day	  6	  and	  levels	  of	  IL10	  measured	  by	  luminex.	  	  Levels	  from	  4	  
groups	  of	  children	  of	  different	  ages	  are	  represented	  here	  (<1yr	  (n=18),	  >1yr<2yr	  (n=15),	  
>2yr<5yr	  (n=19),	  >5yr	  (n=14)).	  	  .	  	  A	  one-­‐way	  ANOVA	  was	  done	  and	  p	  value	  is	  displayed.	  	  
Horizontal	  bars	  represent	  median	  values.	  
8.3.3. Regulatory	  T	  cells	  in	  children	  with	  TB	  disease	  CD4+CD39+FOXP3+	  Regulatory	  T	  cells	  were	  measured	  in	  healthy	  children,	  children	  with	  LTBI,	  pulmonary	  TB	  and	  extra-­‐pulmonary	  TB	  and	  are	  displayed	  in	  table	  29.	  
	  	  
	  
Table	  29	  Percentage	  of	  regulatory	  T	  cells	  in	  children	  with	  TB	  disease	  
The	  percentage	  and	  inter-­‐quartile	  range	  of	  CD4+CD39+FOXP3+	  regulatory	  T	  cells	  in	  
children	  with	  different	  disease	  phenotypes	  were	  measured	  in	  both	  unstimulated	  and	  BCG	  
stimulated	  whole	  blood	  ((HC	  (n=75),	  LTBI	  (n=22),	  PTB	  T0	  (n=38),	  PTB	  T6	  (n=35),	  EPTB	  T0	  
(n=26),	  EPTB	  T6	  (n=18)).	  	  A	  one-­‐way	  ANOVA	  and	  Mann	  Whitney	  test	  was	  performed	  for	  
each	  comparison	  and	  is	  shown	  in	  the	  bottom	  half	  of	  the	  table.	  Significant	  values	  are	  
highlighted	  in	  blue.	  	  	  	  











































ANOVA PTB T0 vs HC
PTB T6 vs 
HC
PTB T0 vs 
LTBI
PTB T6 vs 
LTBI
EPTB T0 vs 
HC
EPTB T6 Vs 
HC
EPTB T0 vs 
LTBI
EPTB T6 vs 
LTBI
NIL <0.0001 ***0.0008 ***<0.0001 ***0.0003 ***0.0002
BCG <0.0001 ***<0.0001 ***<0.0001 ***0.003 ***<0.0001 ***0.0001 ***0.0008
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There	  were	  significantly	  higher	  levels	  of	  regulatory	  T	  cells	  in	  children	  with	  TB	  compared	  to	  healthy	  controls,	  both	  pulmonary	  and	  extra-­‐pulmonary,	  both	  at	  baseline	  and	  following	  6	  months	  treatment	  in	  unstimulated	  and	  BCG	  stimulated	  whole	  blood.	  There	  were	  no	  significant	  differences	  between	  pulmonary	  and	  extra-­‐pulmonary	  TB	  in	  either	  stimulation	  condition,	  and	  no	  significant	  differences	  between	  healthy	  controls	  and	  LTBI	  were	  noted.	  	  The	  findings	  from	  unstimulated	  blood	  are	  represented	  graphically	  in	  figure	  44.	  	  When	  whole	  blood	  is	  stimulated	  with	  BCG,	  there	  are	  also	  significantly	  higher	  levels	  of	  regulatory	  T	  cells	  in	  both	  phenotypes	  of	  TB	  disease	  at	  the	  end	  of	  treatment	  compared	  to	  LTBI;	  this	  is	  not	  the	  case	  at	  the	  time	  of	  diagnosis.	  	  
	  
Figure	  44	  Regulatory	  T	  cells	  are	  significantly	  increased	  in	  TB	  compared	  to	  healthy	  children	  
The	  percentages	  of	  CD4+CD39+FOXP3+	  T	  cells	  in	  unstimulated	  whole	  blood	  in	  different	  
phenotypes	  of	  TB	  disease	  are	  represented	  here	  on	  a	  log	  scale.	  	  A	  one-­‐way	  ANOVA	  and	  
Mann-­‐Whitney	  test	  was	  performed	  for	  each	  comparison	  and	  significant	  results	  displayed	  
here.	  Horizontal	  bars	  represent	  median	  values.	  Associations	  between	  CD4+CD39+FOXP3+	  regulatory	  T	  cells	  and	  cytokine	  expressing	  T	  cells	  were	  sought	  in	  children	  with	  TB	  disease.	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Table	  30	  Spearman	  correlations	  between	  CD4+CD39+FOXP3+	  T	  cells	  and	  cytokine	  
expressing	  CD4+,	  γδ+	  and	  CD8+	  T	  cells	  show	  no	  significant	  associations.	  
The	  association	  between	  BCG	  induced	  CD4+CD39+FOXP3+	  T	  cells	  and	  cytokine	  expressing	  
T	  cells	  of	  different	  phenotypes	  is	  examined	  using	  a	  non-­‐parametric	  Spearman	  correlation.	  	  
T	  cell	  phenotype	  and	  cytokine	  expression	  is	  on	  the	  left	  side	  of	  the	  graph.	  	  Samples	  from	  
children	  with	  TB	  disease	  (PTB	  and	  EPTB)	  at	  baseline	  (T0,	  n=64)	  and	  following	  treatment	  
(T6,	  n=53)	  Significant	  p	  values	  are	  highlighted	  in	  blue.	  There	  were	  no	  significant	  correlations	  between	  regulatory	  T	  cells	  and	  cytokine	  producing	  CD4+	  T	  cells	  in	  patients	  with	  TB	  disease	  at	  either	  time	  point.	  	  There	  was	  a	  trend	  towards	  an	  inverse	  correlation	  between	  regulatory	  T	  cells	  and	  IL17	  expressing	  γδ	  T	  cells,	  but	  this	  did	  not	  reach	  significance.	  The	  only	  significant	  finding	  was	  a	  positive	  correlation	  between	  Tregs	  and	  IFNγ+CD8+	  T	  cells	  at	  baseline.	  	  	  Secreted	  levels	  of	  IL10	  were	  measured	  in	  supernatants	  collected	  from	  whole	  blood	  stimulated	  with	  BCG	  for	  6	  days	  as	  described	  in	  Chapter	  3	  (Table	  31).	  	  	  
	  
Table	  31	  Levels	  of	  secreted	  IL10	  following	  BCG	  stimulation	  in	  children	  with	  different	  
manifestations	  of	  TB	  disease	  
Secreted	  IL10	  (pg/ml)	  was	  measured	  in	  supernatants	  following	  stimulation	  of	  whole	  blood	  
with	  BCG	  for	  6	  days	  in	  children	  with	  different	  manifestations	  of	  TB	  disease	  (PTB	  T0	  (n=30),	  





IFNγ 0.13 0.27 0.22 0.11
IL17 0.02 0.87 0.1 0.47
IL22 0.03 0.83 0.19 0.18
IFNγ 0.07 0.62 0.15 0.29
IL17 -0.23 0.07 0.02 0.84
IL22 -0.18 0.16 -0.21 0.13
IFNγ 0.28 0.03 0.21 0.12
IL17 -0.14 0.27 0.05 0.74
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Figure	  45	  IL10	  is	  secreted	  by	  children	  with	  all	  disease	  phenotypes,	  but	  is	  significantly	  higher	  
in	  children	  with	  extrapulmonary	  TB	  following	  treatment	  compared	  to	  LTBI	  and	  healthy	  
controls	  
Whole	  blood	  diluted	  1:10	  with	  RPMI	  was	  incubated	  with	  BCG	  (2.5x106cfu/ml)	  for	  6	  days	  
and	  supernatants	  collected	  on	  day	  6	  and	  levels	  of	  IL10	  measured	  by	  luminex.	  	  Levels	  from	  
children	  with	  different	  phenotypes	  of	  TB	  disease	  are	  represented	  on	  the	  figure	  and	  median	  
values	  and	  interquartile	  ranges	  shown	  in	  the	  table	  (PTB	  T0	  (n=30),	  PTB	  T6	  (n=19),	  EPTB	  
T0	  (n=23),	  EPTB	  T6	  (n=17),	  LTBI	  (n=12),	  HC	  (n=66)).	  	  A	  one-­‐way	  ANOVA	  and	  Mann	  
Whitney	  test	  for	  each	  comparison	  was	  done	  and	  significant	  p	  values	  are	  displayed.	  	  
Horizontal	  bars	  represent	  median	  values.	  	  There	  is	  a	  trend	  to	  increased	  levels	  in	  children	  with	  TB,	  both	  pulmonary	  and	  extra-­‐pulmonary	  at	  both	  time	  points,	  however	  this	  only	  reaches	  significance	  for	  children	  with	  extra-­‐pulmonary	  TB	  at	  the	  end	  of	  treatment	  (Figure	  45).	  	  	  
8.4. Summary	  of	  Key	  Findings	  The	  role	  of	  regulatory	  T	  cells	  in	  TB	  in	  children	  has	  not	  previously	  been	  explored	  and	  paediatric	  studies	  on	  regulatory	  T	  cells	  in	  healthy	  children	  have	  not	  studied	  other	  T	  cell	  phenotypes	  and	  functions	  simultaneously.	  	  Our	  data	  show	  that	  there	  are	  increased	  numbers	  of	  regulatory	  T	  cells	  in	  the	  peripheral	  blood	  with	  increasing	  age	  and	  we	  propose	  that	  this	  might	  impact	  on	  the	  described	  changes	  in	  the	  cytokine	  expression	  of	  T	  cell	  phenotypes	  reported	  in	  our	  work	  on	  children	  of	  different	  ages.	  	  Additionally	  we	  report	  for	  the	  first	  time	  that	  children	  with	  TB	  disease	  demonstrate	  a	  boosting	  of	  regulatory	  T	  cell	  numbers	  with	  in	  vitro	  mycobacterial	  stimulation	  that	  is	  not	  seen	  in	  healthy	  controls;	  children	  with	  TB	  disease	  have	  significantly	  greater	  numbers	  of	  regulatory	  T	  cells	  than	  healthy	  controls	  and	  this	  is	  even	  higher	  in	  children	  at	  the	  end	  of	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treatment.	  	  Although	  it	  does	  not	  reach	  significance,	  children	  with	  extra-­‐pulmonary	  TB	  have	  higher	  numbers	  of	  regulatory	  T	  cells	  at	  baseline	  and	  following	  treatment	  and	  significantly	  higher	  levels	  of	  secreted	  IL10	  than	  children	  with	  pulmonary	  TB,	  LTBI	  or	  healthy	  controls	  following	  treatment.	  	  We	  propose	  that	  there	  is	  an	  excessive	  induction	  of	  FOXP3+	  regulatory	  T	  cells	  in	  the	  periphery	  in	  children	  with	  extra-­‐pulmonary	  TB	  that	  persists	  following	  treatment,	  but	  whether	  this	  is	  due	  to	  an	  underlying	  defect	  leading	  to	  increased	  susceptibility	  or	  is	  as	  a	  result	  of	  increased	  bacterial	  load	  or	  prolonged	  duration	  of	  mycobacterial	  antigen	  exposure	  is	  unclear.	  	  	  I	  will	  now	  discuss	  all	  of	  the	  significant	  findings	  of	  the	  analysis	  in	  the	  context	  of	  the	  current	  literature.	  	  	  
8.4.1. Regulatory	  T	  cells	  increase	  with	  increasing	  age	  	  Our	  data	  show	  that	  the	  percentage	  of	  regulatory	  T	  cells	  present	  in	  both	  unstimulated	  and	  BCG	  stimulated	  peripheral	  blood	  increases	  with	  increasing	  age.	  	  As	  part	  of	  a	  study	  describing	  thymopoeisis,	  Arismendi	  et	  al	  showed	  an	  inverse	  correlation	  between	  CD4+CD25+Foxp3+	  T	  cells	  and	  patient	  age	  (r	  =	  -­‐0.467;	  p	  =	  0.04)	  in	  children	  from	  1yr	  to	  19yrs	  of	  age,	  similar	  to	  Teran	  et	  al,	  who	  restricted	  their	  analysis	  to	  children	  under	  5	  yrs	  of	  age193,194.	  	  However	  Fuchizawa	  et	  al	  found	  that	  numbers	  stabilized	  and	  did	  not	  change	  after	  the	  first	  few	  days	  of	  life195.	  	  Despite	  the	  finding	  that	  numbers	  of	  regulatory	  T	  cells	  increase	  with	  age,	  no	  significant	  difference	  in	  secreted	  IL10	  levels	  was	  identified	  in	  the	  children	  of	  different	  ages.	  	  IL10	  is	  produced	  by	  a	  number	  of	  different	  cell	  types	  and	  monocyte	  production	  is	  likely	  to	  account	  for	  the	  majority	  of	  the	  secreted	  cytokine	  measured	  in	  this	  assay.	  	  It	  would	  be	  of	  interest	  to	  measure	  intracellular	  IL10,	  IL35	  and	  TGFβ	  levels	  in	  regulatory	  T	  cells	  using	  flow	  cytometry	  in	  children	  of	  different	  ages,	  as	  well	  as	  to	  measure	  the	  functional	  capacity	  of	  the	  regulatory	  T	  cells	  through	  such	  mechanisms	  as	  ATP	  consumption	  in	  a	  future	  study,	  as	  previously	  done	  by	  some	  groups191.	  	  In	  the	  optimization	  for	  this	  study,	  I	  attempted	  unsuccessfully	  to	  measure	  IL10	  as	  part	  of	  the	  regulatory	  T	  cell	  panel.	  	  I	  have	  subsequently	  discovered	  a	  method	  to	  do	  this,	  but	  it	  was	  unfortunately	  too	  late	  for	  this	  study.	  	  	  	  
8.4.2. Regulatory	  T	  cells	  are	  increased	  following	  BCG	  stimulation	  in	  
children	  with	  TB	  disease	  In	  vitro	  mycobacterial	  stimulation	  of	  whole	  blood	  with	  BCG	  leads	  to	  a	  significant	  increase	  of	  regulatory	  T	  cells	  in	  patients	  with	  TB	  disease.	  	  Children	  with	  TB	  disease	  are	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likely	  to	  have	  pre-­‐primed	  antigen	  specific	  regulatory	  T	  cells	  in	  their	  blood	  which	  expand	  rapidly	  on	  re-­‐stimulation	  with	  a	  mycobacterial	  antigen	  accounting	  for	  this	  finding.	  Human	  FOXP3+	  regulatory	  T	  cells	  exist	  in	  two	  forms	  –	  either	  thymically	  derived	  or	  peripherally	  induced.	  	  No	  cell	  surface	  markers	  have	  been	  identified	  to	  distinguish	  between	  the	  two	  types	  and	  it	  is	  unclear	  if	  there	  are	  any	  functional	  differences.	  	  Antigen-­‐specific	  peripherally	  induced	  regulatory	  T	  cells	  have	  been	  demonstrated	  to	  be	  actively	  suppressive	  using	  the	  same	  mechanisms	  as	  thymically	  derived	  regulatory	  T	  cells,	  i.e.	  via	  direct	  cell	  to	  cell	  contact,	  IL10	  production	  and	  ATP	  consumption95.	  	  The	  main	  difference	  is	  that	  peripherally	  induced	  regulatory	  T	  cells	  have	  a	  shorter	  life	  span	  than	  those	  derived	  from	  the	  thymus96.	  	  This	  readiness	  for	  rapid	  expansion	  may	  be	  of	  importance	  in	  children	  with	  higher	  bacterial	  loads	  of	  mycobacteria,	  or	  those	  who	  take	  longer	  to	  clear	  mycobacteria	  from	  the	  site	  of	  disease.	  	  We	  chose	  to	  study	  BCG	  stimulated	  samples	  in	  line	  with	  previous	  publications	  102,103in	  order	  to	  allow	  direct	  comparison	  with	  the	  cytokine	  expressing	  T	  cell	  phenotypes	  already	  examined	  in	  the	  previous	  chapters,	  but	  also	  included	  the	  levels	  of	  regulatory	  T	  cells	  found	  in	  unstimulated	  samples	  in	  our	  work.	  	  Both	  unstimulated	  and	  BCG	  stimulated	  regulatory	  T	  cells	  followed	  similar	  trends	  in	  each	  comparison,	  but	  the	  percentage	  of	  regulatory	  T	  cells	  was	  higher	  in	  the	  BCG	  stimulated	  samples	  as	  might	  be	  expected.	  	  	  	  	  
8.4.3. Children	  with	  TB	  have	  higher	  levels	  of	  regulatory	  T	  cells	  Our	  data	  demonstrate	  higher	  levels	  of	  regulatory	  T	  cells	  in	  unstimulated	  blood	  in	  children	  with	  either	  pulmonary	  or	  extrapulmonary	  TB	  than	  healthy	  controls.	  	  This	  has	  been	  shown	  for	  adults	  with	  TB	  previously97,99,184.	  	  Following	  treatment,	  this	  higher	  level	  of	  regulatory	  T	  cells	  persists	  and,	  although	  it	  does	  not	  reach	  significance,	  appears	  to	  be	  of	  greater	  magnitude	  in	  children	  with	  extra-­‐pulmonary	  TB.	  	  DeAlmeida	  previously	  reported	  higher	  levels	  of	  regulatory	  T	  cells	  in	  adult	  patients	  who	  had	  been	  treated	  for	  EPTB	  compared	  to	  those	  treated	  for	  PTB100.	  	  The	  expansion	  of	  regulatory	  T	  cells	  in	  response	  to	  BCG	  stimulation	  was	  significantly	  greater	  in	  patients	  with	  pulmonary	  and	  extra-­‐pulmonary	  TB	  than	  healthy	  controls	  at	  baseline	  and	  both	  healthy	  controls	  and	  those	  children	  with	  LTBI	  at	  6	  months	  post	  treatment.	  	  Although	  it	  does	  not	  reach	  significance,	  there	  is	  a	  trend	  to	  higher	  levels	  in	  those	  children	  with	  extrapulmonary	  TB.	  	  It	  is	  interesting	  that	  it	  is	  higher	  after	  treatment	  as	  presumably	  the	  mycobacterial	  antigen	  load	  at	  this	  time	  is	  lower	  than	  at	  diagnosis	  and	  it	  suggests	  a	  memory	  response	  of	  regulatory	  T	  cells	  –	  this	  has	  been	  described	  previously	  in	  murine	  models96,196	  .	  	  The	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longevity	  of	  peripherally	  induced	  regulatory	  T	  cells	  is	  not	  described	  in	  the	  literature.	  	  An	  alternative	  explanation	  may	  be	  that	  the	  presence	  of	  these	  regulatory	  T	  cells	  reflects	  an	  increased	  susceptibility	  of	  these	  children	  to	  develop	  TB	  disease,	  perhaps	  due	  to	  an	  underlying	  genetic	  predisposition,	  unfortunately,	  the	  answer	  to	  this	  question	  is	  beyond	  the	  scope	  of	  this	  study.	  	  Longitudinally	  following	  children	  with	  different	  levels	  of	  regulatory	  T	  cells	  to	  measure	  their	  susceptibility	  to	  disease	  or	  monitoring	  the	  expansion	  of	  regulatory	  T	  cells	  to	  mycobacterial	  antigens	  in	  this	  cohort	  with	  time	  might	  provide	  an	  explanation.	  	  We	  looked	  for	  correlations	  between	  regulatory	  T	  cells	  and	  mycobacterial	  growth	  inhibition	  in	  children	  at	  the	  end	  of	  treatment,	  but	  did	  not	  find	  a	  significant	  difference,	  but	  the	  numbers	  were	  small	  and	  it	  would	  be	  of	  interest	  to	  repeat	  this	  on	  a	  larger	  scale.	  	  Previous	  work	  has	  reported	  that	  human	  regulatory	  T	  cells	  lead	  to	  the	  suppression	  of	  IFNγ	  production	  by	  T	  cells,	  both	  γδ	  and	  CD4	  in	  TB98,197,198,	  but	  not	  IL17107,184	  	  and	  their	  effect	  on	  IL22	  production	  has	  not	  been	  examined.	  	  We	  did	  not	  identify	  any	  direct	  correlations	  between	  the	  number	  of	  regulatory	  T	  cells	  and	  cytokine	  expression	  in	  other	  T	  cell	  phenotypes	  in	  this	  cohort.	  Although	  there	  was	  a	  trend	  to	  higher	  levels	  of	  secreted	  IL10	  following	  BCG	  stimulation	  in	  children	  with	  pulmonary	  and	  extrapulmonary	  TB	  at	  baseline	  and	  6	  months	  post	  treatment	  compared	  to	  healthy	  controls,	  this	  only	  reached	  significance	  in	  children	  with	  extrapulmonary	  TB	  at	  the	  end	  of	  treatment.	  	  Kumar	  et	  al	  showed	  no	  significant	  differences	  in	  IL10	  production	  after	  24	  hour	  stimulation	  of	  PBMC’s	  in	  children	  with	  TB	  compared	  to	  healthy	  controls	  or	  in	  ex	  vivo	  plasma	  samples	  from	  the	  same	  groups	  of	  children	  and	  in	  addition,	  adult	  studies	  have	  also	  failed	  to	  identify	  differences	  in	  IL10	  or	  TGFβ	  in	  active	  TB	  compared	  to	  healthy	  controls199.	  	  	  	  	  
8.5. Conclusion	  The	  number	  of	  regulatory	  T	  cells	  in	  the	  peripheral	  circulation	  of	  healthy	  children	  increase	  as	  they	  get	  older.	  	  This	  is	  not	  associated	  with	  an	  increase	  in	  secreted	  IL10	  levels,	  but	  may	  be	  responsible	  for	  the	  increase	  in	  IL17	  and	  IL22	  producing	  T	  cells	  described	  in	  Chapter	  6.	  	  	  Regulatory	  T	  cells	  are	  increased	  in	  children	  with	  TB,	  both	  at	  baseline	  and	  following	  treatment,	  and	  they	  readily	  expand	  in	  response	  to	  BCG	  stimulation	  at	  both	  time	  points,	  but	  this	  is	  more	  marked	  in	  those	  children	  with	  extrapulmonary	  disease	  and	  in	  particular,	  following	  treatment.	  	  This	  cannot	  be	  explained	  by	  an	  age	  difference,	  as	  the	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median	  age	  of	  the	  pulmonary	  and	  extrapulmonary	  groups	  was	  not	  significantly	  different.	  	  We	  do	  not	  have	  data	  on	  bacterial	  load	  at	  diagnosis	  or	  time	  to	  clearance	  of	  mycobacteria	  to	  determine	  if	  this	  plays	  a	  role	  –	  this	  would	  be	  of	  interest	  for	  future	  studies.	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9. 	  	  Secreted	  cytokines	  from	  whole	  blood	  stimulation	  
with	  mycobacterial	  antigens	  in	  children	  with	  TB	  
9.1. Introduction	  In	  this	  chapter	  I	  explore	  the	  function	  of	  the	  previously	  described	  T	  cells	  involved	  in	  the	  Th1/Th17	  pathways	  by	  examining	  cytokines	  secreted	  following	  BCG	  stimulation	  of	  whole	  blood.	  	  A	  commercial	  blend	  of	  soluble	  biomarkers	  involved	  in	  the	  IL17	  immune	  response	  pathway	  was	  chosen.	  	  These	  included	  IL1β,	  IL4,	  IL6,	  IL10,	  IL17A,	  IL17F,	  IL21,	  IL22,	  IL23,	  IL31,	  IL33,	  IFNγ,	  sCD40L	  and	  TNFα.	  	  A	  brief	  description	  of	  each	  cytokine	  and	  its	  reported	  role	  in	  mycobacterial	  immune	  responses	  or	  in	  the	  IL17	  pathway	  supporting	  its	  inclusion	  in	  this	  panel	  is	  given	  in	  Chapter	  1.	  
9.2. Methods	  Supernatants	  from	  whole	  blood	  stimulated	  for	  6	  days	  with	  RPMI,	  SEB	  and	  BCG	  were	  analysed	  by	  multiplex	  ELISA	  to	  determine	  levels	  of	  secreted	  chemokines	  and	  cytokines	  as	  described	  in	  Chapter	  3.	  	  Results	  shown	  are	  for	  BCG	  stimulated	  samples.	  	  The	  unstimulated	  sample	  value	  was	  subtracted	  from	  the	  stimulated	  sample	  value	  to	  determine	  the	  response	  attributable	  to	  the	  antigenic	  stimulation.	  	  All	  negative	  values	  were	  assigned	  a	  value	  of	  zero.	  	  Statistical	  analysis	  was	  performed	  as	  described	  in	  Chapter	  3.	  
9.3. Results	  
9.3.1. Differences	  in	  children	  of	  different	  ages	  The	  levels	  of	  cytokines	  were	  measured	  and	  compared	  in	  healthy	  children	  of	  different	  ages.	  	  Table	  32	  and	  Figure	  46	  show	  the	  results	  of	  this	  analysis.	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Table	  32	  Secreted	  Cytokine	  production	  following	  BCG	  stimulation	  in	  healthy	  children	  of	  
different	  ages.	  
Median	  secreted	  cytokine	  levels	  (pg/ml)	  with	  interquartile	  range	  for	  each	  group	  is	  shown.	  	  
Samples	  from	  healthy	  children	  in	  different	  age	  groups	  were	  used	  (<1yr	  (n=20),	  >1yr<2yr	  
(n=15),	  >2yr<5yr	  (n=19),	  >5yr	  (n=14)).	  	  A	  one-­‐way	  ANOVA	  followed	  by	  a	  Mann-­‐Whitney	  
test	  for	  all	  comparisons	  was	  performed,	  p	  values	  are	  shown	  and	  significant	  results	  are	  
highlighted	  in	  blue.	  (ns=	  not	  significant,	  p>0.05)	  The	  levels	  of	  IL17A	  were	  very	  low	  in	  all	  ages	  and	  the	  majority	  of	  IL17	  measured	  was	  the	  IL17F	  homodimer.	  	  Additionally,	  the	  levels	  of	  IL33	  and	  IL4	  were	  very	  low	  and	  unlikely	  to	  be	  of	  biological	  significance.	  	  	  
<1yr >1yr<2yr >2yr<5yr >5yr ANOVA <1yr vs >1yr<2yr
<1yr vs 
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Figure	  46	  –	  Secretion	  of	  IL1β ,	  IL6,	  IL23	  and	  TNFα 	  in	  response	  to	  BCG	  stimulation	  for	  6	  days	  
peak	  in	  healthy	  infants	  between	  1-­‐2yrs	  of	  age	  –	  this	  correlates	  with	  lower	  levels	  of	  IL4	  and	  
IL33	  
This	  figure	  shows	  cytokine	  levels	  (pg/ml)	  measured	  in	  supernatants	  collected	  from	  whole	  
blood	  stimulated	  for	  6	  days	  with	  RPMI	  or	  BCG	  (1x105cfu/ml)	  using	  multiplex	  ELISA	  in	  
healthy	  children	  of	  different	  ages.	  A	  =	  <1yr	  of	  age	  (n=20),	  B	  =	  >1yr<2yr	  of	  age	  (n=15),	  C=	  
>2yr<5yr	  of	  age	  (n=19)	  and	  D=	  >5yrs	  of	  age	  (n=14).	  	  a)	  Levels	  of	  the	  Type	  I	  cytokines	  IFNγ	  
and	  TNFα,	  b)	  Levels	  of	  Type	  II	  cytokines	  IL4	  and	  IL33,	  c)	  Levels	  of	  cytokines	  associated	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with	  the	  IL17	  pathway,	  IL1β,	  IL6,	  IL17F,	  IL21,	  IL22	  and	  IL23	  and	  d)	  Levels	  of	  IL10.	  	  Results	  
are	  shown	  as	  net	  cytokine	  production	  (with	  medium	  control	  values	  subtracted)	  using	  box-­‐
and-­‐whisker	  plots	  with	  whiskers	  showing	  minimum	  and	  maximum	  values,	  horizontal	  bars	  
represent	  median	  values.	  	  Data	  is	  shown	  on	  a	  log	  scale.	  One-­‐way	  ANOVAs	  were	  used	  for	  
comparisons	  and	  p	  values	  were	  calculated	  using	  a	  Mann-­‐Whitney	  test.	  *	  denotes	  p<0.05,	  **	  
denotes	  <0.005	  and	  ***	  denotes	  <0.0001.	  In	  contrast	  to	  the	  flow	  data	  presented	  in	  Chapter	  6	  which	  showed	  higher	  levels	  of	  IFNγ	  expressing	  CD4	  T	  cells,	  there	  were	  no	  significant	  differences	  in	  levels	  of	  secreted	  IFNγ	  in	  younger	  children.	  	  
9.3.2. Secreted	  cytokine	  data	  in	  children	  with	  different	  manifestations	  of	  
TB	  disease	  The	  levels	  of	  cytokines	  were	  measured	  and	  compared	  in	  children	  with	  different	  manifestations	  of	  TB	  disease.	  	  Table	  33	  and	  Figure	  47	  show	  the	  results	  of	  this	  analysis.	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Table	  33	  –	  Secreted	  cytokine	  levels	  following	  BCG	  stimulation	  in	  children	  with	  different	  
disease	  manifestations	  of	  TB	  disease	  and	  infection	  
Median	  secreted	  cytokine	  levels	  (pg/ml)	  and	  interquartile	  range	  are	  displayed	  in	  this	  table.	  	  
Cytokines	  are	  as	  shown	  along	  the	  left	  margin	  and	  TB	  disease	  group	  along	  the	  top	  (HC	  
(n=68),	  LTBI	  (n=14),	  PTB	  T0	  (n=34),	  PTB	  T6	  (n=25),	  EPTB	  T0	  (n=24),	  EPTB	  T6	  (n=17).	  	  A	  
one-­‐way	  ANOVA	  followed	  by	  a	  Mann-­‐Whitney	  test	  for	  all	  comparisons	  was	  performed,	  p	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values	  are	  shown	  and	  significant	  results	  are	  highlighted	  in	  blue.	  (ns=	  not	  significant,	  
p>0.05)	  
	  
Figure	  47	  –	  Healthy	  children	  secrete	  higher	  levels	  of	  IL1β 	  and	  IL6	  in	  response	  to	  BCG	  
stimulation	  than	  children	  with	  TB	  
This	  figure	  shows	  cytokine	  levels	  (pg/ml)	  measured	  in	  supernatants	  collected	  from	  whole	  
blood	  stimulated	  for	  6	  days	  with	  RPMI	  or	  BCG	  (1x105cfu/ml)	  using	  multiplex	  ELISA	  in	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children	  with	  different	  manifestations	  of	  TB	  disease.	  H=	  Healthy	  Controls	  (n=68),	  L=	  LTBI	  
(n=14),	  P0	  =	  pulmonary	  TB	  Baseline	  (n=34),	  P6	  =	  pulmonary	  TB	  6	  months	  post	  treatment	  
(n=25),	  E0=	  EPTB	  Baseline	  (n=24),	  E6	  =	  EPTB	  6	  months	  post	  treatment	  (n=17).	  	  a)	  Levels	  
of	  the	  Type	  I	  cytokines	  IFNγ	  and	  TNFα,	  b)	  Levels	  of	  Type	  II	  cytokines	  IL4	  and	  IL33,	  c)	  Levels	  
of	  cytokines	  associated	  with	  the	  IL17	  pathway,	  IL1β,	  IL6,	  IL17F,	  IL21,	  IL22	  and	  IL23.	  	  
Results	  are	  shown	  as	  net	  cytokine	  production	  (with	  medium	  control	  values	  subtracted)	  
using	  box-­‐and-­‐whisker	  plots	  with	  whiskers	  showing	  minimum	  and	  maximum	  values,	  
horizontal	  bars	  represent	  median	  values.	  	  Data	  is	  shown	  on	  a	  log	  scale.	  One-­‐way	  ANOVAs	  
were	  used	  for	  comparisons	  and	  p	  values	  were	  calculated	  using	  a	  Mann-­‐Whitney	  test.	  *	  
denotes	  p<0.05,	  **	  denotes	  <0.005	  and	  ***	  denotes	  <0.001.	  Again	  levels	  of	  IL17A,	  IL4	  and	  IL33	  are	  unlikely	  to	  reach	  biological	  significance.	  	  Levels	  of	  IFNγ	  and	  TNFα,	  the	  type	  I	  cytokines,	  were	  suppressed	  in	  both	  pulmonary	  and	  extrapulmonary	  TB	  disease	  at	  baseline	  compared	  to	  healthy	  controls.	  	  When	  the	  cytokines	  associated	  with	  the	  IL17	  pathway	  are	  examined,	  there	  are	  no	  clear	  patterns.	  	  There	  are	  lower	  levels	  of	  IL1β	  in	  children	  with	  LTBI	  compared	  to	  healthy	  controls	  and	  children	  with	  pulmonary	  TB	  at	  baseline.	  	  This	  is	  similarly	  seen	  for	  IL6	  when	  children	  with	  LTBI	  were	  compared	  to	  healthy	  controls.	  	  There	  is	  a	  trend	  to	  higher	  levels	  of	  IL6	  in	  children	  with	  extrapulmonary	  TB	  following	  treatment	  than	  other	  children	  –	  this	  reaches	  significance	  when	  compared	  to	  those	  children	  with	  LTBI.	  	  Children	  with	  extrapulmonary	  TB	  have	  significantly	  lower	  levels	  of	  IL17F	  compared	  to	  healthy	  controls,	  there	  is	  a	  trend	  for	  this	  to	  be	  the	  case	  for	  children	  with	  pulmonary	  TB	  also,	  however	  this	  does	  not	  reach	  significance	  due	  to	  a	  heterogeneity	  of	  responses.	  	  Children	  with	  extrapulmonary	  TB	  display	  a	  trend	  to	  higher	  levels	  of	  IL21	  and	  IL23	  than	  the	  other	  groups	  at	  6	  months	  post	  treatment	  –	  this	  only	  reaches	  significance	  when	  compared	  to	  healthy	  controls	  and	  children	  with	  pulmonary	  TB	  following	  treatment	  for	  IL21	  and	  IL23	  respectively.	  	  
9.3.3. Correlation	  between	  cytokine	  profile	  at	  baseline	  and	  following	  6	  
months	  TB	  treatment	  To	  examine	  whether	  children	  respond	  similarly	  to	  BCG	  when	  unwell	  with	  TB	  diagnosis	  and	  following	  treatment,	  I	  looked	  at	  correlations	  between	  their	  secreted	  cytokines	  at	  these	  two	  time	  points	  (Table	  34).	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Table	  34	  Correlation	  between	  cytokines	  at	  baseline	  and	  following	  6	  months	  TB	  treatment	  in	  
children	  with	  TB	  
Cytokines	  at	  the	  two	  different	  time	  points	  in	  children	  with	  TB	  disease,	  both	  pulmonary	  and	  
extra-­‐pulmonary,	  were	  correlated	  with	  each	  other	  (n=42).	  Significant	  results	  are	  shown	  
here	  in	  blue.	  	  	  
9.4. Correlations	  between	  secreted	  cytokines	  and	  data	  collected	  from	  
flow	  cytometry	  
9.4.1. Correlations	  between	  cytokine	  expressing	  T	  cells	  and	  secreted	  
cytokines	  In	  order	  to	  identify	  whether	  different	  T	  cell	  phenotypes	  are	  associated	  with	  different	  patterns	  of	  cytokine	  secretion,	  I	  looked	  for	  correlations	  between	  cytokine	  expressing	  T	  cells	  of	  different	  phenotypes	  and	  the	  secreted	  cytokines	  as	  described	  above	  (Table	  35).	  	  There	  are	  positive	  correlations	  between	  IFNγ,	  IL17	  and	  IL22	  expressing	  T	  cells	  and	  IL17A/F,	  Il22,	  IL31	  +/-­‐	  IFNγ	  secreted	  cytokines	  and	  the	  pattern	  is	  similar	  for	  all	  cytokine	  expressing	  T	  cells.	  	  There	  is	  no	  evidence	  of	  suppression	  of	  either	  IL17	  or	  IL22	  secretion	  when	  IFNγ	  is	  expressed	  by	  T	  cells	  in	  this	  data	  set.	  	  IL31	  is	  positively	  correlated	  with	  cytokine	  expression	  by	  both	  CD4	  and	  γδ	  T	  cells	  and	  most	  likely	  reflects	  upregulation	  of	  an	  inflammatory	  immune	  response.	  	  There	  was	  no	  significant	  correlation	  with	  IL10	  responses	  although	  with	  all	  T	  cell	  phenotypes	  there	  was	  a	  trend	  towards	  an	  inverse	  
Cytokine Median at T0 (pg/ml)




IL1β 1479 1484 0.4864 0.0011
IL4 14.9 7.9 0.5488 0.0002
IL6 25290 24140 0.379 0.01
IL10 598 532 0.46 0.002
IL22 115 158 0.54 0.0003
IL23 103 61 0.789 <0.0001
IL33 3.8 2.3 0.432 0.004
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correlation	  (data	  not	  shown).	  	  IFNγ+Ki67+CD8+	  T	  cells	  were	  the	  only	  phenotype	  to	  display	  an	  inverse	  correlation	  with	  secreted	  Type	  II	  cytokines.	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Percentages	  of	  cytokine	  expressing	  T	  cells	  following	  stimulation	  with	  BCG	  for	  6	  days	  were	  
correlated	  with	  secreted	  cytokines	  (pg/ml)	  following	  stimulation	  with	  BCG	  for	  6	  days	  for	  
all	  children	  in	  the	  study	  (n=161).	  	  Only	  statistically	  significant	  results	  are	  shown.	  	  As	  the	  
data	  was	  non-­‐parametric,	  a	  Spearman	  comparison	  was	  done.	  	  Positive	  correlations	  are	  
highlighted	  in	  blue	  and	  negative	  correlations	  are	  highlighted	  in	  red.	  
9.4.2. Correlation	  between	  regulatory	  T	  cells	  and	  secreted	  cytokines	  Regulatory	  T	  cells	  are	  responsible	  for	  modulating	  the	  immune	  response	  by	  suppressing	  the	  production	  of	  pro-­‐inflammatory	  cytokines.	  As	  I	  have	  described	  earlier,	  the	  percentage	  of	  regulatory	  T	  cells	  is	  increased	  in	  children	  with	  TB	  and	  persists	  by	  6	  months	  post	  treatment	  therefore	  I	  have	  examined	  these	  groups	  separately	  to	  look	  for	  correlations	  (Table	  36).	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There	  is	  an	  inverse	  correlation	  between	  regulatory	  T	  cells	  and	  pro-­‐inflammatory	  cytokine	  secretion,	  this	  is	  most	  significant	  for	  IL1β	  in	  the	  total	  cohort	  or	  in	  healthy	  controls	  alone.	  	  The	  levels	  of	  regulatory	  T	  cells	  were	  highest	  in	  the	  extrapulmonary	  TB	  group	  at	  6	  months	  post	  treatment	  and	  it	  is	  of	  interest	  that	  this	  is	  the	  only	  group	  to	  show	  a	  significant	  inverse	  correlation	  with	  IFNγ	  secretion.	  
9.4.3. Mtb	  lux	  growth	  inhibition	  and	  cytokine	  expression	  I	  have	  shown	  that	  there	  are	  some	  differences	  in	  T	  cell	  phenotypes	  and	  secreted	  cytokines	  following	  BCG	  stimulation	  in	  children	  with	  different	  disease	  manifestations	  of	  TB.	  To	  explore	  whether	  this	  translates	  into	  a	  functional	  effect,	  I	  looked	  at	  correlations	  between	  mycobacterial	  growth	  inhibition	  as	  measured	  in	  the	  TB	  lux	  assay	  and	  cytokine	  expression	  in	  those	  patients.	  	  As	  shown	  in	  Chapter	  6,	  there	  was	  no	  difference	  in	  ability	  to	  restrict	  mycobacterial	  growth	  between	  children	  with	  pulmonary	  TB	  and	  extrapulmonary	  TB	  after	  treatment,	  so	  for	  this	  analysis	  I	  compared	  the	  entire	  cohort	  together.	  I	  looked	  at	  correlations	  between	  mycobacterial	  growth	  restriction	  and	  cytokine	  expressing	  CD4+,	  γδ	  +	  and	  CD8+	  T	  cells	  following	  short	  term	  and	  6	  day	  stimulation	  with	  BCG	  and	  there	  were	  no	  significant	  correlations.	  	  There	  were	  no	  correlations	  between	  regulatory	  T	  cells	  and	  growth	  restriction	  (Figure	  46).	  Finally,	  there	  were	  no	  correlations	  between	  any	  of	  the	  cytokines	  measured	  and	  mycobacterial	  growth	  inhibition	  in	  this	  cohort.	  	  
	  
Figure	  48	  There	  is	  a	  trend,	  but	  no	  significant	  inverse	  correlation	  between	  regulatory	  T	  cells	  
and	  mycobacterial	  growth	  inhibition	  in	  children	  with	  TB	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The	  percentage	  of	  CD4+CD39+FOXP3+	  T	  cells	  in	  children	  with	  TB	  was	  correlated	  with	  the	  
mycobacterial	  growth	  inhibition	  ratio	  as	  described	  previously	  (n=17).	  	  A	  non-­‐parametric	  
Spearman	  coefficient	  was	  calculated	  and	  results	  are	  shown	  on	  the	  graph.	  
9.5. SUMMARY	  OF	  FINDINGS	  Although	  the	  release	  of	  secreted	  cytokines	  in	  response	  to	  mycobacterial	  antigens	  in	  healthy	  children	  has	  been	  investigated	  by	  a	  number	  of	  groups,	  these	  have	  largely	  been	  in	  the	  context	  of	  examining	  BCG	  vaccination	  responses	  in	  either	  children	  under	  one	  year	  of	  age	  or	  adolescents	  and	  to	  attempt	  to	  address	  questions	  such	  as	  the	  optimal	  timing	  of	  BCG	  vaccination17,18,200,	  geographical	  differences	  or	  the	  role	  of	  revaccination201.	  	  This	  is	  the	  first	  study	  to	  look	  at	  age-­‐related	  differences	  in	  BCG	  responses	  in	  children	  of	  all	  ages	  and	  to	  compare	  them	  with	  those	  of	  children	  with	  TB	  disease.	  	  We	  demonstrate	  that	  younger	  children	  have	  higher	  levels	  of	  pro-­‐inflammatory	  cytokines	  than	  older	  children	  and	  that	  healthy	  children	  have	  higher	  levels	  of	  pro-­‐inflammatory	  cytokines	  than	  children	  with	  TB	  infection	  or	  disease.	  	  Of	  note,	  at	  6	  months	  post	  treatment,	  this	  ‘suppression’	  of	  pro-­‐inflammatory	  cytokine	  release	  recovers	  in	  both	  pulmonary	  and	  extra-­‐pulmonary	  TB	  and	  in	  addition	  children	  with	  EPTB	  demonstrate	  a	  ‘boost’	  in	  Th17	  cytokines	  that	  is	  not	  seen	  in	  those	  children	  with	  PTB	  or	  LTBI.	  	  In	  general	  secreted	  cytokine	  data	  correlates	  with	  intra-­‐cellular	  cytokine	  expression	  in	  the	  flow	  cytometry	  assays	  and	  this	  has	  potential	  implications	  for	  future	  study	  design,	  as	  it	  may	  be	  unnecessary	  to	  do	  both	  assays.	  I	  will	  now	  discuss	  all	  of	  the	  significant	  findings	  of	  the	  analysis	  in	  the	  context	  of	  the	  current	  literature.	  	  	  
9.5.1. 	  	  1-­‐2yr	  old	  healthy	  children	  have	  higher	  levels	  of	  pro-­‐inflammatory	  
cytokines	  than	  older	  children	  Following	  stimulation	  of	  whole	  blood	  with	  live	  BCG,	  the	  secreted	  levels	  of	  IL1β,	  IL23,	  IL6	  and	  TNFα	  peak	  in	  the	  1-­‐2yr	  age	  group,	  this	  is	  associated	  with	  lower	  levels	  of	  Type	  II	  or	  anti-­‐inflammatory	  cytokines	  (IL4,	  IL33)	  but	  not	  IL10.	  	  The	  levels	  of	  IFNγ,	  IL21	  and	  IL22	  followed	  a	  similar	  trend	  but	  did	  not	  reach	  significance.	  	  The	  levels	  of	  secreted	  IFNγ,	  TNFα,	  IL2	  and	  IL6	  following	  PPD	  stimulation	  in	  whole	  blood	  have	  previously	  been	  described	  to	  be	  increased	  in	  healthy	  BCG	  vaccinated	  infants	  in	  the	  UK	  at	  3	  months	  of	  age202.	  A	  further	  similar	  study	  by	  the	  same	  group	  comparing	  responses	  at	  3	  months	  and	  12	  months	  of	  age	  in	  Malawian	  infants	  found	  no	  significant	  difference	  in	  the	  levels	  of	  these	  pro-­‐inflammatory	  cytokines	  at	  these	  two	  different	  time	  points111.	  	  In	  the	  second	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study,	  they	  also	  noted	  that	  there	  was	  a	  strong	  correlation	  between	  IFNγ	  production	  and	  the	  other	  cytokines	  including	  IL17,	  IL4,	  IL13	  and	  IL10	  and	  surmised	  that	  those	  who	  responded	  strongly	  to	  immunization,	  produced	  a	  heterogenous	  cytokine	  response	  increasing	  both	  pro-­‐	  and	  anti-­‐inflammatory	  cytokines.	  However,	  neither	  of	  these	  studies	  examined	  children	  after	  12	  months	  of	  age.	  	  It	  may	  be	  that	  BCG	  responses	  rise	  beyond	  12	  months	  of	  age,	  peaking	  by	  2	  yrs	  of	  age	  and	  then	  waning	  as	  children	  get	  older.	  	  One	  study	  of	  longitudinal	  PPD	  responses	  up	  to	  2	  yrs	  in	  Indonesian	  infants	  reported	  that	  levels	  of	  IFNγ	  in	  a	  6	  day	  whole	  blood	  assay	  (WBA)	  remained	  the	  same	  up	  to	  24	  months,	  but	  that	  levels	  of	  IL5	  and	  IL13	  gradually	  waned	  with	  time;	  in	  a	  24	  hour	  WBA,	  levels	  of	  IL10	  showed	  no	  change,	  while	  levels	  of	  TNFα	  waned	  with	  time203.	  	  Weir	  et	  al	  studying	  PPD	  induced	  IFNγ	  responses	  in	  adolescents	  showed	  a	  peak	  at	  3	  months	  followed	  by	  a	  gradual	  waning	  over	  3	  yrs	  post	  re-­‐vaccination;	  in	  addition	  14yrs	  post	  infant	  BCG	  vaccination,	  measurable	  IFNγ	  responses	  were	  present	  in	  80%	  of	  those	  tested,	  however	  they	  looked	  at	  IFNγ	  alone201.	  	  Although	  it	  is	  reassuring	  that	  the	  levels	  of	  secreted	  levels	  of	  IFNγ	  following	  BCG	  stimulation	  do	  not	  change	  with	  age,	  the	  significantly	  lower	  levels	  of	  the	  other	  pro-­‐inflammatory	  cytokines	  IL1β,	  IL6	  and	  TNFα	  in	  children	  <1yr	  of	  age	  compared	  to	  those	  between	  1-­‐2yrs	  of	  age	  despite	  more	  recent	  BCG	  vaccination	  may	  represent	  an	  important	  age-­‐related	  difference	  in	  the	  innate	  responses	  to	  BCG	  vaccination	  that	  should	  be	  further	  explored.	  	  Burl	  et	  al	  examined	  cytokine	  responses	  to	  toll-­‐like	  receptor	  (TLR)	  agonists	  and	  showed	  robust	  and	  stable	  production	  of	  IL1β,	  IL6	  and	  TNFα	  at	  all	  ages	  from	  birth	  to	  twelve	  months,	  but	  she	  did	  not	  explore	  responses	  in	  older	  children204.	  	  Describing	  the	  ontogeny	  of	  TLR	  responses	  in	  neonates	  and	  children	  up	  to	  2yrs	  of	  age	  in	  comparison	  with	  adult	  levels,	  Kollmann	  et	  al	  report	  that	  TNFα	  and	  IL23	  were	  higher	  in	  infants	  than	  adults,	  that	  IL6	  and	  IL23	  fell	  from	  birth	  to	  2yrs	  when	  they	  reach	  adult	  levels	  and	  that	  IFNγ	  and	  IL12p70	  levels	  remain	  lower	  than	  adult	  levels	  even	  by	  2yrs	  of	  age28.	  	  Recent	  advances	  in	  optimization	  of	  the	  measurement	  of	  innate	  cell	  responses	  to	  mycobacteria	  mean	  that	  a	  similar	  study	  looking	  at	  children	  of	  different	  ages	  is	  now	  feasible	  and	  warranted205.	  The	  levels	  of	  IL1β,	  IL6	  and	  IL23	  were	  higher	  in	  the	  younger	  age-­‐groups;	  previous	  work	  has	  shown	  that	  in	  the	  presence	  of	  these	  3	  cytokines,	  naïve	  T	  cells	  differentiate	  into	  IL17	  and	  IL22	  expressing	  T	  cells77.	  Some	  of	  the	  secreted	  IL17	  or	  IL22	  may	  be	  coming	  from	  other	  cell	  types,	  such	  as	  natural	  killer	  (NK)	  cells	  88,	  accounting	  for	  this	  difference,	  this	  is	  one	  of	  the	  limiting	  factors	  of	  secreted	  cytokine	  assays	  and	  including	  alternative	  cell	  types	  including	  NK	  cells	  in	  any	  future	  work	  examining	  the	  innate	  responses	  could	  be	  worthwhile.	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In	  this	  study	  we	  report	  that	  the	  levels	  of	  regulatory	  T	  cells	  are	  higher	  in	  healthy	  children	  over	  2	  years	  of	  age	  compared	  with	  children	  under	  2	  years	  of	  age	  which	  would	  correspond	  with	  the	  finding	  that	  pro-­‐inflammatory	  markers	  are	  lower	  in	  the	  older	  children.	  	  	  9.5.2. Healthy	  children	  produce	  higher	  levels	  of	  pro-­‐inflammatory	  
cytokines	  (IL1β ,	  TNFα)	  than	  children	  with	  tuberculosis	  infection	  or	  
disease.	  In	  our	  cohort,	  the	  levels	  of	  Th1	  (IFNγ,	  TNFα)	  and	  Th17	  (IL17,	  IL1β,	  IL6)	  were	  suppressed	  in	  children	  with	  TB	  disease	  at	  the	  time	  of	  diagnosis	  compared	  to	  healthy	  controls.	  	  Of	  note,	  IL17F	  was	  only	  significantly	  suppressed	  in	  EPTB	  and	  not	  PTB	  when	  compared	  to	  healthy	  controls.	  	  In	  our	  study,	  the	  assay	  was	  repeated	  after	  6	  months	  of	  TB	  treatment,	  and	  at	  this	  time	  point	  the	  cytokine	  responses	  were	  found	  to	  have	  returned	  to	  be	  the	  same	  as	  those	  seen	  in	  healthy	  controls.	  	  In	  children	  with	  ETPB	  however,	  there	  were	  some	  differences	  at	  the	  end	  of	  treatment;	  levels	  of	  IL4,	  IL10,	  IL21	  and	  IL23	  were	  higher	  than	  those	  seen	  in	  the	  other	  groups.	  	  Previous	  groups	  have	  described	  a	  suppression	  of	  IFNγ	  production	  in	  patients	  with	  active	  TB	  disease	  at	  the	  time	  of	  diagnosis	  compared	  to	  healthy	  controls32,33,117,206	  and	  that	  this	  suppression	  was	  prolonged	  for	  up	  to	  12	  months32.	  	  A	  couple	  of	  studies	  have	  compared	  the	  cytokines	  secreted	  in	  patients	  with	  different	  manifestations	  of	  disease	  and	  found	  that	  IFNγ	  was	  more	  suppressed	  in	  EPTB	  than	  PTB	  at	  the	  time	  of	  diagnosis207,208	  and	  following	  treatment101,209	  .	  	  However,	  the	  majority	  of	  these	  studies	  were	  in	  adults	  and	  mainly	  compared	  secreted	  cytokines	  following	  stimulation	  of	  whole	  blood	  or	  PBMCs	  under	  a	  variety	  of	  different	  antigen	  stimulation	  conditions,	  including	  unstimulated,	  PHA,	  LPS,	  PPD	  and	  RD1	  antigens,	  making	  comparison	  quite	  difficult.	  	  Kumar	  et	  al	  reporting	  the	  only	  paediatric	  study,	  found	  no	  differences	  between	  EPTB	  and	  PTB,	  but	  described	  lower	  levels	  of	  IFNγ,	  TNFα,	  IL4,	  IL13,	  IL17A,	  IL21	  and	  IL23	  in	  children	  with	  active	  TB	  compared	  to	  healthy	  controls117.	  	  They	  also	  described	  that	  among	  children	  with	  EPTB,	  those	  with	  neurologic	  involvement	  exhibited	  more	  significantly	  diminished	  PPD	  induced	  IFNγ	  and	  IL17	  production	  (n=9)121.	  	  	  
In	  this	  study,	  the	  flow	  cytometry	  data	  demonstrated	  an	  increase	  in	  IFNγ	  production	  by	  CD4	  and	  γδ	  T	  cells	  after	  treatment	  that	  is	  not	  supported	  by	  the	  secreted	  cytokine	  data.	  	  As	  mentioned	  above,	  this	  may	  be	  because	  IFNγ	  is	  made	  by	  different	  cell	  types	  not	  measured	  in	  our	  flow	  cytometry	  panel.	  	  Additionally,	  the	  flow	  cytometry	  enumerates	  the	  number	  of	  cells	  producing	  cytokine	  but	  not	  the	  quantity	  of	  cytokine	  produced	  by	  each	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cell.	  When	  the	  cytokine	  expressing	  cells	  from	  flow	  were	  correlated	  with	  secreted	  cytokine	  levels,	  there	  were	  however	  appropriate	  positive	  correlations.	  	  	  	  
We	  also	  examined	  correlations	  between	  regulatory	  T	  cells	  and	  secreted	  cytokine	  expression.	  	  The	  most	  significant	  inverse	  correlation	  overall	  was	  with	  IL1β,	  TNFα	  and	  IFNγ,	  which	  corresponds	  with	  our	  understanding	  of	  the	  suppressive	  capacity	  of	  regulatory	  T	  cells.	  	  	  
9.5.3. No	  correlations	  identified	  between	  the	  mycobacterial	  growth	  
restriction	  assay	  and	  secreted	  cytokines,	  percentage	  of	  cytokine	  
expressing	  T	  cells	  or	  regulatory	  T	  cells	  In	  this	  study,	  we	  hoped	  to	  demonstrate	  that	  any	  identified	  differences	  in	  T	  cell	  phenotype	  or	  cytokine	  expression	  might	  be	  associated	  with	  a	  functional	  difference	  as	  measured	  by	  the	  mycobacterial	  growth	  restriction	  assay,	  however	  no	  differences	  were	  identified.	  	  There	  were	  only	  25	  children	  who	  had	  comparable	  data	  and	  this	  may	  have	  been	  a	  limiting	  factor.	  	  Additionally	  we	  only	  performed	  this	  assay	  on	  children	  who	  had	  TB	  disease	  at	  the	  6	  month	  time	  point,	  it	  would	  have	  been	  preferable	  to	  do	  at	  the	  time	  of	  diagnosis	  and	  in	  the	  healthy	  control	  group,	  however	  this	  was	  not	  feasible	  in	  this	  study.	  	  
9.6. 	  Conclusions	  Healthy	  children	  between	  the	  ages	  of	  1	  and	  2	  years	  have	  a	  robust	  pro-­‐inflammatory	  cytokine	  response	  to	  BCG	  stimulation	  of	  whole	  blood	  which	  subsequently	  wanes	  with	  increasing	  age	  in	  line	  with	  the	  published	  literature.	  	  However,	  the	  response	  in	  children	  under	  one	  year	  was	  more	  heterogenous	  and	  lower	  and	  may	  reflect	  an	  innate	  immune	  defect	  which	  could	  be	  further	  explored	  in	  a	  future	  study.	  Children	  with	  TB	  disease	  demonstrate	  a	  suppression	  of	  BCG	  cytokine	  responses	  at	  the	  time	  of	  diagnosis	  compared	  to	  healthy	  controls,	  this	  is	  similar	  in	  both	  PTB	  and	  EPTB	  and	  largely	  recovers	  by	  6	  months	  post	  treatment.	  	  However,	  there	  are	  distinct	  differences	  in	  the	  cytokine	  responses	  in	  those	  children	  with	  EPTB	  after	  treatment,	  as	  also	  described	  in	  the	  flow	  data	  from	  this	  study.	  	  I	  will	  explore	  this	  further	  in	  the	  discussion.	  	  	  	  Disappointingly,	  we	  did	  not	  find	  a	  functional	  correlate	  between	  the	  mycobacterial	  growth	  restriction	  assay	  and	  T	  cell	  phenotype	  or	  cytokine	  expression	  in	  this	  study.	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10. Discussion	  At	  the	  time	  of	  development	  and	  design	  of	  this	  study	  and	  based	  on	  the	  published	  literature,	  we	  formulated	  the	  hypothesis	  that	  younger	  children	  would	  have	  a	  distinct	  and	  different	  antigen	  specific	  immune	  response	  to	  mycobacteria	  than	  older	  children.	  This	  in	  turn	  could	  potentially	  provide	  an	  explanation	  for	  the	  higher	  susceptibility	  to	  TB	  disease,	  in	  particular	  severe	  disease.	  In	  a	  first	  step,	  we	  aimed	  to	  investigate	  whether	  age	  needed	  to	  be	  taken	  into	  account	  when	  analyzing	  and	  interpreting	  any	  antigen-­‐specific	  immune	  responses	  in	  the	  disease-­‐specific	  part	  of	  our	  study.	  We	  therefore	  set	  out	  to	  compare	  antigen	  specific	  responses	  to	  mycobacteria	  in	  healthy,	  BCG	  vaccinated	  children	  of	  different	  ages,	  focusing	  on	  CD4,	  γδ	  and	  regulatory	  T	  cells	  and	  the	  cytokines	  IFNγ,	  IL17	  and	  IL22,	  in	  line	  with	  the	  model	  underlying	  our	  hypothesis.	  	  Depending	  on	  our	  findings,	  we	  planned	  to	  subsequently	  determine	  whether	  any	  phenotypical	  or	  functional	  difference	  in	  the	  mycobacterial	  specific	  T	  cell	  response	  identified	  in	  younger	  children	  was	  also	  detectable	  in	  those	  children	  with	  more	  severe	  disseminated	  extra-­‐pulmonary	  TB.	  	  Based	  on	  the	  published	  age-­‐related	  susceptibility	  data,	  we	  anticipated	  that	  the	  majority	  of	  the	  children	  with	  extrapulmonary	  TB	  in	  our	  cohort	  would	  be	  in	  the	  younger	  age	  groups	  i.e.	  under	  2	  yrs	  of	  age.	  	  	  Interestingly,	  we	  discovered	  instead	  that	  younger	  children	  have	  comparable	  effector	  responses	  and	  indeed	  stronger	  antigen	  specific	  memory	  responses	  to	  BCG	  than	  older	  children.	  We	  also	  discovered	  that	  children	  younger	  than	  1	  year	  of	  age	  are	  distinct	  in	  their	  responses	  relating	  to	  innate	  immunity	  but	  that	  the	  results	  obtained	  in	  children	  above	  the	  age	  of	  1	  did	  not	  show	  any	  significant	  differences	  compared	  to	  the	  older	  groups.	  In	  addition,	  the	  median	  age	  of	  the	  cohort	  of	  children	  with	  extra-­‐pulmonary	  TB	  was	  older	  than	  expected.	  Based	  on	  these	  findings,	  there	  was	  no	  need	  to	  analyse	  the	  antigen	  specific	  responses	  to	  mycobacteria	  in	  children	  with	  different	  disease	  manifestations	  of	  TB	  disease	  according	  to	  their	  age.	  We	  made	  a	  number	  of	  interesting	  observations	  with	  regards	  to	  age-­‐related	  immune	  responses	  to	  BCG	  in	  healthy	  children.	  	  In	  this	  concluding	  chapter,	  I	  will	  therefore	  reflect	  on	  the	  sentinel	  findings	  from	  my	  analysis	  of	  age-­‐related	  effector	  and	  memory	  responses	  to	  BCG	  in	  healthy	  children	  and	  within	  the	  TB	  cohort	  separately.	  	  	  
10.1. Immune	  responses	  in	  healthy	  children	  of	  different	  ages	  Most	  of	  the	  previous	  work	  looking	  at	  mycobacterial	  immune	  responses	  in	  children	  has	  focused	  on	  BCG	  vaccine	  responses	  in	  infants	  under	  a	  year	  of	  age111,161,200.	  	  Additionally,	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most	  studies	  comparing	  differences	  in	  both	  BCG	  and	  other	  age-­‐related	  immune	  responses	  have	  analysed	  neonatal	  or	  infant	  immune	  responses,	  often	  using	  cord	  blood,	  as	  venipuncture	  in	  very	  small	  babies	  is	  challenging.	  	  Distinct	  differences	  in	  neonatal	  immune	  responses	  compared	  to	  adults	  have	  been	  described,	  particularly	  in	  TLR	  responses,	  and	  these	  have	  been	  summarized	  in	  a	  number	  of	  excellent	  reviews	  210,211.	  	  These	  accepted	  differences	  in	  neonatal	  immune	  responses	  compared	  to	  those	  seen	  in	  adults	  has	  resulted	  in	  problems	  for	  investigators	  and	  reviewers	  when	  trying	  to	  define	  appropriate	  control	  groups	  or	  creating	  complicated	  controls	  groups	  of	  different	  ages	  for	  studies,	  including	  BCG	  and	  novel	  TB	  candidate	  vaccine	  trials.	  	  My	  study	  uniquely	  compared	  mycobacterial	  immune	  responses	  in	  children	  from	  birth	  to	  16	  years	  of	  age	  stratified	  into	  four	  different	  age	  groups.	  In	  particular,	  I	  included	  children	  over	  the	  age	  of	  two	  years,	  and	  separated	  a	  large	  range	  of	  ages	  in	  line	  with	  age	  groups	  that	  have	  been	  defined	  for	  routine	  immunological	  markers	  often	  used	  in	  the	  context	  of	  clinical	  diagnostics.	  	  Our	  data	  demonstrates	  that	  children	  of	  all	  ages	  have	  robust	  and	  comparable	  antigen	  specific	  effector	  and	  central	  memory	  recall	  immune	  responses	  to	  BCG	  as	  measured	  by	  IFNγ	  production	  by	  CD4+,	  γδ	  and	  CD8+	  T	  cells.	  	  This	  important	  finding	  may	  simplify	  the	  design	  of	  control	  groups	  for	  vaccine	  candidate	  studies	  in	  the	  future	  as	  children	  of	  all	  ages	  can	  be	  compared	  together	  when	  considering	  antigen-­‐specific	  responses.	  We	  have	  shown	  in	  children	  of	  all	  ages	  that	  it	  seems	  unlikely	  that	  IL17	  plays	  a	  significant	  role	  in	  the	  immune	  response	  to	  BCG	  in	  humans:	  although	  IL17	  is	  produced	  by	  both	  CD4+	  and	  γδ	  T	  cells	  in	  response	  to	  BCG	  stimulation	  of	  whole	  blood,	  both	  in	  a	  short	  term	  effector	  assay	  and	  a	  longer	  term	  central	  memory	  assay,	  the	  magnitude	  of	  response	  is	  very	  low.	  In	  addition,	  we	  have	  not	  demonstrated	  a	  counter	  regulatory	  role	  between	  IL17	  and	  IFNγ	  in	  contrast	  with	  the	  findings	  in	  the	  murine	  model.	  	  Rather	  then	  interacting	  with	  IFNγ	  in	  an	  antagonistic	  fashion,	  as	  we	  initially	  proposed	  in	  our	  model,	  those	  patients	  who	  produce	  IL17	  in	  response	  to	  mycobacterial	  stimulation,	  also	  produce	  IFNγ	  and	  IL22	  and	  could	  be	  described	  as	  ‘strong	  responders’.	  	  This	  may	  be	  due	  to	  genetic	  differences,	  but	  the	  clinical	  significance	  is	  unclear	  and	  it	  does	  not	  appear	  to	  be	  associated	  with	  increased	  protection	  from	  disease	  as	  previously	  shown173,182,200.	  	  IL22	  was	  included	  in	  our	  flow	  cytometry	  panel	  as	  recent	  studies	  had	  identified	  distinct	  subsets	  of	  T	  cells	  producing	  IL22	  in	  adults	  with	  pulmonary	  and	  pericardial	  TB84,93.	  	  Its	  role	  in	  paediatric	  BCG	  responses	  had	  not	  yet	  been	  explored.	  	  This	  is	  the	  first	  paediatric	  study	  to	  demonstrate	  IL22	  production	  by	  either	  CD4	  or	  γδ	  T	  cells	  in	  response	  to	  mycobacterial	  stimulation.	  	  We	  report	  that	  IL22	  is	  produced	  in	  greater	  magnitude	  than	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IL17	  by	  both	  CD4	  and	  γδ	  T	  cells	  in	  both	  the	  effector	  and	  central	  memory	  assays	  in	  response	  to	  BCG	  stimulation	  of	  whole	  blood	  and	  further,	  was	  not	  co-­‐produced	  with	  IL17	  as	  has	  been	  suggested	  in	  the	  murine	  literature.	  	  Additionally,	  in	  our	  study,	  IL22	  is	  produced	  in	  conjunction	  with	  IFNγ	  by	  CD4	  and	  γδ	  T	  cells,	  but	  by	  a	  distinct	  subset	  of	  cells,	  as	  part	  of	  both	  the	  effector	  and	  central	  memory	  recall	  response	  to	  BCG	  in	  children	  of	  all	  ages.	  	  It	  is	  produced	  in	  greater	  quantities	  as	  part	  of	  the	  effector	  response	  in	  older	  children	  than	  younger	  children,	  and	  in	  equal	  quantities	  as	  part	  of	  the	  central	  memory	  response	  in	  children	  of	  all	  ages.	  This	  is	  in	  contrast	  to	  IFNγ	  which	  is	  produced	  in	  lower	  quantities	  as	  the	  BCG	  vaccine	  response	  wanes	  with	  age.	  	  These	  results	  suggest	  that	  IL22	  might	  be	  more	  important	  as	  part	  of	  the	  immediate	  effector	  response	  rather	  than	  the	  central	  memory	  response	  to	  BCG.	  	  According	  to	  our	  current	  understanding	  of	  the	  role	  of	  IL22	  in	  immune	  responses	  to	  pathogens;	  this	  cytokine	  can	  be	  protective	  and	  regenerative	  of	  the	  mucosal	  barrier	  when	  produced	  alone,	  and	  it	  promotes	  a	  greater	  inflammatory	  response	  when	  secreted	  alongside	  inflammatory	  cytokines	  such	  as	  IFNγ,	  TNFα	  and	  IL2	  88,90.	  	  In	  the	  context	  of	  BCG	  vaccine	  responses,	  our	  data	  suggests	  IL22	  is	  made	  by	  effector	  T	  cells	  and	  appears	  to	  be	  important	  in	  enhancing	  the	  inflammatory	  response,	  most	  likely	  through	  the	  induction	  of	  chemokines	  leading	  to	  the	  recruitment	  of	  adaptive	  immune	  cells	  to	  the	  site	  of	  infection.	  	  Our	  analysis	  of	  the	  T	  cell	  phenotypes	  and	  cytokine	  expression	  data	  from	  the	  flow	  cytometry	  assays	  identified	  only	  a	  few	  age-­‐related	  differences,	  and	  of	  particular	  note	  for	  our	  hypothesis	  we	  report	  that	  CD4+IFNγ	  and	  γδ+IFNγ	  responses	  to	  BCG	  are	  comparable	  in	  all	  ages.	  	  In	  contrast,	  SEB	  stimulation	  of	  whole	  blood	  resulted	  in	  an	  age-­‐related	  increase	  in	  IFNγ	  expression	  by	  both	  CD4	  and	  γδ	  T	  cells	  as	  previously	  published	  for	  CD4+T	  cells	  alone–	  this	  has	  been	  described	  up	  to	  the	  age	  of	  11	  and	  even	  at	  this	  age,	  adult	  SEB	  responses	  were	  found	  to	  be	  of	  greater	  magnitude166.	  	  This	  has	  also	  been	  described	  for	  PMA/Ionomycin	  stimulation	  –	  and	  the	  data	  from	  the	  Ki67	  assay	  in	  our	  study	  supports	  this	  also212.	  	  However,	  there	  are	  distinct	  differences	  identified	  between	  children	  under	  one	  year	  of	  age	  and	  older	  children	  on	  exploration	  of	  the	  secreted	  cytokine	  data,	  when	  a	  broader	  spectrum	  of	  cytokines	  was	  available	  for	  examination.	  	  The	  disadvantage	  of	  this	  laboratory	  method	  is	  that	  the	  cell	  type	  producing	  the	  cytokine	  is	  not	  known,	  however,	  we	  can	  draw	  deductions	  as	  to	  which	  arm	  of	  the	  immune	  system	  is	  involved	  based	  on	  the	  patterns	  seen.	  	  We	  identified	  that	  infants	  have	  lower	  secreted	  levels	  of	  the	  cytokines	  IL1β,	  IL23,	  IL6	  and	  TNFα	  in	  response	  to	  BCG	  stimulation	  of	  whole	  blood	  than	  older	  children.	  These	  age	  related	  differences	  in	  IFNγ	  responses	  to	  SEB	  and	  secreted	  cytokine	  expression	  following	  BCG	  stimulation	  together	  suggest	  that	  children	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under	  a	  year	  of	  age	  have	  an	  immaturity	  of	  their	  non-­‐specific	  T	  cell	  response	  or	  the	  innate	  immune	  response.	  	  Defining	  the	  mechanism	  of	  this	  age	  related	  difference	  is	  beyond	  the	  scope	  of	  this	  study,	  but	  it	  suggests	  a	  possible	  age-­‐dependent	  deficiency	  in	  the	  activity	  of	  the	  antigen	  presenting	  cells	  (APCs).	  	  APCs	  represent	  the	  key	  link	  between	  the	  innate	  and	  adaptive	  immune	  system.	  	  The	  major	  human	  APCs	  are	  monocytes,	  classical	  and	  plasmacytoid	  dendritic	  cells	  (DCs)	  as	  well	  as	  B	  cells.	  	  Stimulation	  of	  APCs	  induces	  antigen	  presentation,	  expression	  of	  co-­‐stimulatory	  molecules	  and	  secretion	  of	  cytokines	  that	  direct	  the	  ensuing	  adaptive	  immune	  response	  –	  for	  example,	  IL12	  production	  by	  DCs,	  which	  results	  in	  the	  production	  of	  IFNγ	  and	  promotes	  the	  development	  of	  effector	  T	  cells.	  	  As	  previous	  work	  demonstrates	  the	  initial	  activation	  of	  infant	  CD4	  T	  cells	  is	  intact213	  it	  suggests	  that	  there	  may	  a	  subsequent	  deficit	  in	  the	  communication	  between	  APCs	  and	  the	  adaptive	  cells	  of	  the	  immune	  response,	  perhaps	  in	  the	  form	  of	  lower	  production	  of	  key	  cytokines	  by	  dendritic	  cells	  or	  monocytes	  resulting	  in	  a	  suppressed	  adaptive	  immune	  response	  in	  infants.	  	  Upham	  et	  al	  have	  previously	  described	  a	  deficit	  in	  IL12	  levels	  due	  to	  low	  number	  and/or	  function	  of	  dendritic	  cells	  in	  infants	  that	  persists	  up	  to	  the	  age	  of	  1224.	  	  Our	  data	  describing	  lower	  levels	  of	  the	  pro-­‐inflammatory	  cytokines	  IL1β,	  IL6,	  IL23	  and	  TNFα	  demonstrates	  a	  potential	  immaturity	  in	  the	  immune	  response	  to	  mycobacteria,	  as	  has	  been	  described	  for	  other	  pathogens	  or	  mitogens	  previously.	  	  Levy	  et	  al	  has	  previously	  suggested	  that	  differences	  in	  the	  activation	  of	  cells	  of	  the	  innate	  immune	  pathway	  resulting	  in	  different	  cytokine	  profiles	  would	  influence	  T	  cell	  maturation	  in	  infants.	  	  Activation	  of	  APCs	  occurs	  through	  pathogen	  receptor	  receptors	  (PRRs),	  of	  which	  Toll-­‐like	  receptors	  (TLRs)	  are	  the	  best	  described.	  	  Reikie	  and	  others	  have	  looked	  at	  the	  activation	  of	  different	  TLRs	  with	  age	  and	  demonstrated	  various	  cytokine	  profiles	  expressed	  by	  innate	  immune	  cells	  that	  determine	  T	  cell	  response28,204,214.	  	  However,	  these	  studies	  have	  thus	  far	  been	  limited	  to	  infants	  and	  it	  would	  be	  interesting	  to	  extend	  them	  to	  include	  older	  children,	  in	  particular	  examining	  TLR	  stimulation	  by	  mycobacteria	  and	  how	  the	  responses	  differ	  with	  increasing	  age.	  	  Our	  data	  contributes	  to	  this	  literature	  and	  supports	  the	  need	  to	  conduct	  further	  studies	  of	  the	  innate	  immune	  response	  to	  mycobacteria	  in	  children	  of	  all	  ages.	  	  Understanding	  these	  differences	  may	  extend	  our	  understanding	  of	  the	  immune	  response	  to	  BCG	  vaccine	  and	  how	  and	  why	  it	  protects	  some	  children	  from	  TB	  and	  not	  others.	  	  The	  other	  interesting	  finding	  from	  the	  age-­‐related	  cohort	  is	  that	  the	  memory	  response	  as	  measured	  by	  proliferative	  capacity	  and	  IFNγ	  production	  decreases	  with	  increasing	  age	  –	  suggesting	  a	  waning	  of	  BCG	  memory.	  	  This	  has	  been	  described	  previously	  but	  is	  of	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particular	  interest	  when	  examined	  in	  the	  context	  of	  our	  finding	  that	  the	  median	  age	  of	  children	  with	  extra-­‐pulmonary	  TB	  in	  our	  cohort	  was	  5yr	  2mths162,201.	  	  As	  described	  in	  Chapter	  1,	  BCG	  vaccine	  protection	  varies	  from	  0-­‐80%,	  but	  the	  strongest	  evidence	  for	  protection	  is	  against	  disseminated	  TB	  disease	  such	  as	  miliary	  TB	  and	  TB	  meningitis	  in	  children.	  	  This	  raises	  the	  question	  of	  benefit	  of	  re-­‐vaccination	  with	  BCG	  in	  high	  endemic	  areas.	  	  A	  couple	  of	  trials	  have	  looked	  at	  revaccination	  in	  different	  settings	  without	  supporting	  a	  role	  for	  this175,176,	  however	  these	  measured	  TB	  disease	  as	  a	  clinical	  endpoint,	  rather	  than	  ongoing	  protection	  from	  disseminated	  TB.	  	  A	  prime-­‐boost	  strategy,	  with	  the	  boost	  being	  provided	  by	  a	  different	  vaccine	  candidate	  containing	  Mtb	  antigens	  is	  also	  the	  basis	  of	  current	  TB	  vaccine	  proposals.	  	  One	  of	  the	  current	  proposed	  strategies	  would	  involve	  an	  Mtb	  specific	  vaccine	  to	  boost	  BCG	  to	  be	  given	  at	  the	  age	  of	  12	  to	  protect	  adolescents	  as	  they	  represent	  a	  peak	  in	  pulmonary	  TB	  disease	  in	  high	  endemic	  settings,	  however	  our	  data	  may	  support	  the	  role	  of	  one	  of	  these	  boosting	  candidates	  at	  a	  younger	  age	  to	  protect	  against	  disseminated	  disease215.	  	  	  We	  describe	  a	  positive	  relationship	  between	  increasing	  age	  and	  percentage	  of	  regulatory	  T	  cells	  in	  healthy	  children	  in	  our	  study	  in	  both	  unstimulated	  and	  BCG	  stimulated	  whole	  blood,	  but	  we	  cannot	  comment	  on	  the	  clinical	  significance	  of	  this	  observation	  other	  than	  that	  it	  is	  a	  good	  baseline	  to	  interpret	  studies	  of	  regulatory	  T	  cells	  in	  the	  context	  of	  disease	  or	  inflammatory/allergic	  conditions.	  	  	  	  	  	  	  	  
10.2. Immune	  responses	  to	  mycobacteria	  in	  children	  with	  different	  
manifestations	  of	  TB	  disease	  The	  primary	  findings	  of	  the	  analysis	  of	  this	  cohort	  were	  that	  all	  children	  with	  TB	  disease	  had	  suppressed	  antigen	  specific	  effector	  and	  central	  memory	  immune	  responses	  to	  mycobacteria	  at	  the	  time	  of	  diagnosis.	  However	  these	  immune	  responses	  recovered	  and	  indeed	  were	  of	  greater	  magnitude	  at	  6	  months	  post	  treatment	  suggesting	  a	  boosting	  effect	  of	  mycobacterial	  antigen	  exposure	  on	  the	  central	  memory	  compartment	  of	  the	  immune	  response,	  previously	  primed	  by	  BCG	  or	  natural	  exposure.	  	  In	  addition	  we	  describe	  for	  the	  first	  time	  in	  a	  paediatric	  cohort	  that	  numbers	  of	  regulatory	  T	  cells	  are	  increased	  in	  children	  with	  both	  TB	  infection	  and	  disease	  compared	  to	  healthy	  controls.	  	  Finally,	  although	  at	  the	  time	  of	  diagnosis,	  our	  assays	  could	  not	  distinguish	  children	  with	  pulmonary	  TB	  from	  those	  with	  extra-­‐pulmonary	  TB,	  the	  children	  with	  extra-­‐pulmonary	  TB	  demonstrated	  diminished	  boosting	  of	  both	  antigen	  specific	  effector	  and	  central	  memory	  responses	  following	  6	  months	  of	  treatment,	  in	  association	  with	  distinct	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differences	  in	  their	  secreted	  cytokine	  response	  to	  BCG	  stimulation	  of	  whole	  blood	  in	  comparison	  with	  children	  with	  pulmonary	  TB.	  	  One	  of	  the	  unique	  strengths	  of	  our	  cohort	  was	  the	  number	  of	  children	  recruited	  and	  their	  thorough	  clinical	  characterization	  into	  distinct	  patient	  groups.	  	  It	  is	  noteworthy	  that	  there	  were	  no	  significant	  differences	  between	  the	  immune	  responses	  to	  mycobacteria	  in	  the	  probable	  and	  confirmed	  TB	  groups	  allowing	  them	  to	  be	  analysed	  together.	  	  It	  was	  surprising	  that	  the	  median	  age	  of	  children	  with	  extra-­‐pulmonary	  TB	  was	  5yrs	  in	  our	  cohort,	  but	  this	  is	  likely	  to	  reflect	  protection	  conferred	  by	  BCG	  vaccination	  at	  birth	  in	  our	  population.	  	  It	  also	  suggests	  that	  the	  waning	  BCG	  central	  memory	  response	  described	  in	  our	  age-­‐related	  cohort	  correlates	  with	  protection	  from	  disseminated	  TB,	  although	  this	  is	  difficult	  to	  prove	  without	  designing	  a	  long	  term	  follow	  up	  study	  of	  infants	  from	  time	  of	  BCG	  vaccination	  with	  regular	  testing	  of	  their	  immune	  responses	  to	  BCG	  and	  clinical	  outcome.	  	  	  	  	  Demonstrating	  that	  the	  patterns	  of	  immune	  responses	  to	  BCG,	  Mtb	  specific	  antigens	  ESAT	  6	  and	  CFP	  10	  and	  heat	  killed	  H37RV	  stimulation	  of	  whole	  blood	  were	  equivalent	  is	  of	  great	  value	  for	  future	  studies	  of	  mycobacterial	  immune	  responses	  and	  eliminates	  the	  need	  for	  complex	  assays	  involving	  multiple	  antigens	  requiring	  large	  blood	  volumes	  in	  future	  paediatric	  studies.	  	  	  We	  report	  that	  children	  with	  active	  TB	  disease	  have	  suppressed	  levels	  of	  antigen	  specific	  immune	  responses	  to	  mycobacteria	  as	  has	  been	  described	  in	  adult	  studies	  previously32,120,179,206.	  	  A	  number	  of	  hypotheses	  regarding	  this	  phenomenon	  have	  been	  discussed	  in	  the	  literature,	  including	  compartmentalization	  of	  these	  cells	  at	  the	  site	  of	  disease	  or	  an	  active	  and	  selective	  depletion	  of	  Mtb	  specific	  T	  cells	  during	  TB32.	  	  A	  number	  of	  groups	  have	  measured	  immune	  responses	  at	  the	  site	  of	  disease	  in	  adults	  and	  identified	  greater	  numbers	  of	  Mtb	  specific	  T	  cells	  in	  comparison	  to	  blood	  93,199,	  not	  only	  of	  the	  CD4+IFNγ	  phenotype,	  but	  also	  IL22+CD4+	  T	  cells93	  and	  polyfunctional	  T	  cells216.	  	  Performing	  invasive	  procedures	  such	  as	  bronchoscopy	  to	  obtain	  fluid	  from	  the	  site	  of	  disease	  is	  ethically	  and	  practically	  challenging	  in	  children	  so	  studies	  of	  this	  kind	  are	  unlikely	  to	  be	  performed	  in	  the	  future.	  	  	  Our	  data	  comparing	  antigen	  specific	  effector	  and	  central	  memory	  responses	  could	  not	  distinguish	  between	  the	  pulmonary	  and	  extra-­‐pulmonary	  TB	  groups	  at	  the	  time	  of	  diagnosis,	  however	  6	  months	  later,	  those	  children	  with	  extra-­‐pulmonary	  TB	  were	  distinctly	  different.	  	  Both	  groups	  of	  children	  recovered	  from	  a	  marked	  suppression	  of	  both	  their	  antigen	  specific	  effector	  and	  central	  memory	  responses	  to	  levels	  that	  were	  of	  
	   173	  
greater	  magnitude	  than	  those	  reported	  in	  either	  the	  healthy	  children	  or	  those	  with	  LTBI.	  	  This	  is	  of	  relevance	  in	  the	  context	  of	  vaccine	  studies	  as	  it	  implies	  that	  using	  a	  prime	  boost	  strategy	  with	  Mtb	  specific	  antigens	  is	  likely	  to	  result	  in	  a	  boosting	  of	  IFNγ,	  IL17	  and	  IL22	  CD4	  and	  γδ	  T	  cell	  responses	  –	  however,	  it	  is	  unclear	  whether	  this	  will	  correlate	  with	  protection	  from	  TB	  disease	  and	  a	  recent	  efficacy	  study	  of	  the	  novel	  vaccine	  candidate	  MVA85A	  does	  not	  support	  this173.	  	  Of	  greater	  interest	  is	  the	  discovery	  that	  although	  those	  children	  with	  EPTB	  were	  capable	  of	  boosting	  their	  antigen	  specific	  immune	  responses	  at	  the	  end	  of	  therapy,	  this	  was	  of	  a	  lesser	  magnitude	  than	  those	  children	  with	  PTB.	  	  We	  cannot	  say	  whether	  this	  is	  purely	  attributable	  to	  a	  higher	  bacterial	  burden	  of	  disease	  or	  slower	  clearance	  rates	  of	  mycobacteria	  as	  we	  did	  not	  collect	  this	  data	  in	  our	  study,	  but	  it	  is	  recognized	  that	  patients	  with	  EPTB	  have	  higher	  rates	  of	  culture-­‐confirmation	  and	  also	  relapse	  than	  those	  with	  PTB,	  justifying	  a	  longer	  treatment	  course	  with	  anti-­‐tuberculous	  therapy,	  possibly	  associated	  with	  higher	  burden	  of	  organisms.	  Also	  difficult	  to	  determine	  is	  whether	  this	  cohort	  of	  children	  represent	  a	  group	  for	  whom	  their	  original	  BCG	  vaccine	  was	  less	  effective	  –	  perhaps	  through	  inadequate	  administration,	  an	  intercurrent	  infection,	  perinatal	  influences	  such	  as	  maternal	  infection/nutrition	  or	  concurrent	  exposure	  to	  non-­‐tuberculous	  mycobacteria	  or	  helminths.	  	  Given	  that	  there	  were	  no	  significant	  differences	  in	  the	  adaptive	  immune	  responses	  at	  the	  time	  of	  diagnosis,	  this	  seems	  an	  unlikely	  explanation.	  	  Measured	  responses	  at	  10	  weeks	  post	  BCG	  vaccination	  in	  a	  Cape	  Town	  cohort	  could	  not	  distinguish	  between	  infants	  at	  risk	  of	  TB	  disease	  over	  time,	  further	  refuting	  this	  possibility.	  	  Alternatively,	  our	  results	  may	  represent	  preliminary	  evidence	  that	  some	  children	  developed	  EPTB	  due	  to	  an	  underlying	  problem	  with	  either	  their	  ability	  to	  develop	  a	  protective	  central	  memory	  immune	  response	  or	  diminished	  expansion	  of	  effector	  memory	  cells	  following	  re-­‐exposure	  to	  mycobacterial	  antigens.	  They	  additionally	  displayed	  higher	  levels	  of	  the	  secreted	  cytokines	  IL21,	  IL23	  and	  IL10	  in	  comparison	  with	  those	  children	  with	  pulmonary	  TB,	  the	  significance	  of	  this	  unusual	  combination	  is	  unclear.	  	  The	  levels	  of	  regulatory	  T	  cells	  were	  not	  significantly	  different	  in	  this	  cohort,	  but	  IL10	  may	  also	  be	  produced	  by	  monocytes	  in	  whole	  blood.	  	  IL21	  is	  recognized	  to	  be	  of	  importance	  in	  B	  cell	  activation	  via	  follicular	  T	  helper	  cells,	  which	  may	  be	  of	  importance	  in	  long	  term	  memory	  responses217,218	  and	  IL23	  promotes	  an	  inflammatory	  response	  via	  activation	  STAT4	  in	  memory	  CD4	  T	  cells	  resulting	  in	  production	  of	  IFNγ.	  	  Further	  work	  to	  confirm	  these	  findings	  and	  determine	  whether	  they	  are	  the	  result	  of	  differences	  in	  mycobacterial	  burden	  or	  clearance	  rates	  is	  warranted.	  	  Repeating	  the	  assays	  at	  a	  later	  time	  point	  may	  also	  reveal	  similar	  responses	  in	  both	  the	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pulmonary	  and	  extra-­‐pulmonary	  groups,	  although	  in	  adult	  studies,	  Fiske	  et	  al	  found	  differences	  up	  to	  12	  months	  later.	  	  	  	  	  The	  innate	  immune	  responses	  to	  mycobacteria	  have	  not	  been	  investigated	  widely	  in	  children	  or	  adults	  with	  TB	  disease.	  	  As	  described	  above,	  it	  appears	  likely	  that	  healthy	  infants	  under	  a	  year	  of	  age	  have	  a	  different	  spectrum	  of	  innate	  immune	  responses.	  These	  children	  represent	  the	  group	  who	  in	  a	  pre-­‐BCG	  vaccine	  era	  had	  the	  highest	  risk	  of	  EPTB	  and	  it	  would	  be	  of	  interest	  to	  explore	  this	  field	  further.	  	  Since	  our	  experimental	  set-­‐up	  focused	  on	  acquired	  responses	  and	  distinct	  T	  cell	  subsets,	  we	  were	  not	  in	  a	  position	  to	  examine	  the	  innate	  responses	  specifically.	  Our	  secreted	  cytokine	  data	  has	  not	  shown	  any	  significant	  differences	  in	  those	  cytokines	  specifically	  associated	  with	  innate	  immune	  responses	  in	  children	  with	  ETPB	  compared	  to	  PTB,	  however	  this	  is	  a	  relatively	  crude	  technique	  and	  more	  specific	  assays	  in	  a	  similar	  cohort	  may	  reveal	  different	  results.	  One	  of	  our	  key	  findings	  is	  the	  significant	  increase	  in	  regulatory	  T	  cells	  in	  children	  with	  TB,	  both	  pulmonary	  and	  extra-­‐pulmonary.	  However	  it	  is	  unclear	  whether	  this	  is	  a	  cause	  or	  an	  effect,	  i.e.	  due	  to	  an	  underlying	  susceptibility	  for	  TB	  disease,	  or	  an	  appropriate	  response	  to	  the	  presence	  of	  mycobacteria	  and	  Mtb	  induced	  T	  cell	  activation	  in	  disease.	  	  Although	  an	  increase	  in	  regulatory	  T	  cells	  in	  TB	  disease	  has	  been	  described	  in	  adults	  and	  animal	  models,	  it	  is	  unclear	  whether	  this	  confers	  protection	  by	  preventing	  excessive	  inflammation	  or	  is	  pathogenic	  as	  it	  suppresses	  a	  protective	  immune	  reaction98,219.	  	  The	  role	  of	  regulatory	  T	  cells	  as	  part	  of	  an	  effective	  vaccine	  response	  has	  been	  investigated	  in	  a	  couple	  of	  animal	  and	  human	  models.	  	  In	  a	  murine	  model,	  Quinn	  et	  al	  found	  that	  despite	  the	  inactivation	  of	  regulatory	  T	  cells	  leading	  to	  increased	  numbers	  of	  antigen	  specific	  IFNγ+	  CD4	  T	  cells,	  this	  was	  not	  associated	  with	  increased	  protection	  from	  virulent	  Mtb	  infection109.	  	  DeCassan	  et	  al	  described	  both	  the	  induction	  of	  regulatory	  T	  cells	  in	  response	  to	  the	  vaccine	  candidate	  MVA85A,	  and	  an	  association	  with	  higher	  levels	  of	  CD4+CD39+FOXP3+	  T	  cells	  in	  those	  with	  pre-­‐existing	  immune	  responses	  to	  mycobacterial	  antigens87.	  	  This	  is	  of	  relevance	  in	  our	  cohort	  as	  we	  report	  a	  more	  pronounced	  increase	  in	  the	  percentage	  of	  regulatory	  T	  cells	  after	  6	  months	  treatment,	  in	  particular	  in	  those	  children	  with	  EPTB.	  In	  addition,	  the	  levels	  of	  IL10	  were	  significantly	  raised	  only	  in	  children	  with	  EPTB	  at	  the	  end	  of	  treatment.	  	  Although	  this	  may	  be	  explained	  at	  the	  time	  of	  diagnosis	  by	  the	  presence	  of	  mycobacteria	  in	  the	  blood,	  this	  is	  unlikely	  to	  be	  the	  case	  after	  6	  months	  of	  effective	  treatment	  for	  TB.	  	  Alternatively,	  the	  recall	  response	  to	  BCG	  resulting	  in	  expansion	  of	  effector	  T	  cells	  at	  the	  end	  of	  treatment	  may	  also	  result	  in	  the	  expansion	  of	  regulatory	  T	  cells	  in	  parallel.	  	  However,	  the	  number	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of	  regulatory	  T	  cells	  was	  increased	  in	  both	  unstimulated	  and	  BCG	  stimulated	  blood	  of	  children	  previously	  treated	  for	  TB	  compared	  to	  healthy	  controls	  as	  previously	  described	  in	  adult	  cohorts101.	  These	  findings	  may	  alternatively	  indicate	  the	  potential	  for	  underlying	  dysregulation	  of	  the	  immune	  response	  in	  those	  children	  who	  develop	  TB.	  	  Our	  study	  was	  not	  designed	  to	  determine	  whether	  differences	  in	  regulatory	  T	  cells	  increases	  susceptibility	  to	  TB	  disease	  or	  to	  examine	  the	  functionality	  of	  these	  identified	  regulatory	  T	  cells	  in	  patients	  in	  the	  different	  disease	  groups,	  but	  further	  work	  to	  explore	  these	  questions	  is	  warranted.	  	  In	  both	  the	  age-­‐related	  and	  TB	  disease	  cohorts	  we	  have	  described	  study	  participants	  who	  are	  ‘strong	  responders’	  to	  mycobacterial	  antigen	  stimulation,	  having	  both	  a	  strong	  proliferative	  response	  and	  also	  producing	  large	  amounts	  of	  cytokine	  –	  and	  there	  is	  a	  significant	  positive	  correlation	  between	  all	  3	  cytokines	  measured.	  	  This	  suggests	  that	  there	  may	  be	  a	  genetic	  predisposition	  to	  being	  either	  a	  ‘strong	  cytokine	  responder’	  to	  mycobacteria	  or	  not.	  	  The	  implications	  of	  being	  a	  strong	  responder	  are	  not	  understood,	  but	  it	  does	  not	  appear	  to	  correlate	  with	  protection	  from	  disease	  in	  other	  studies173,200.	  	  	  Interestingly	  recent	  reports	  suggest	  that	  high	  or	  low	  reactivity	  in	  tuberculin	  skin	  test	  responses	  may	  be	  genetically	  determined,	  although	  again,	  the	  implications	  of	  this	  for	  protection	  are	  not	  known220.	  	  	  We	  did	  not	  find	  any	  correlation	  between	  either	  T	  cell	  phenotype	  or	  cytokine	  production	  and	  mycobacterial	  growth	  inhibition	  in	  this	  study	  –	  this	  may	  be	  due	  to	  small	  numbers	  as	  not	  all	  children	  had	  enough	  blood	  taken	  at	  venepuncture	  to	  have	  this	  additional	  assay	  at	  6	  months	  post	  treatment.	  	  	  The	  role	  of	  γδ	  T	  cells	  in	  the	  immune	  response	  to	  mycobacteria	  in	  children	  has	  been	  uniquely	  characterized	  using	  multiparameter	  flow	  cytometry	  techniques	  in	  this	  study.	  	  We	  report	  that	  although	  they	  expand,	  proliferate	  and	  express	  all	  3	  cytokines	  of	  interest	  in	  response	  to	  BCG	  stimulation	  equally	  in	  children	  of	  all	  ages	  and	  with	  all	  manifestations	  of	  TB	  disease,	  they	  do	  not	  appear	  to	  behave	  in	  a	  counter	  regulatory	  fashion	  to	  CD4	  T	  cells,	  rather	  functioning	  in	  a	  similar	  manner,	  and	  do	  not	  contribute	  large	  quantities	  of	  either	  IL17	  or	  IL22	  to	  the	  cytokine	  milieu.	  	  Previous	  groups	  have	  demonstrated	  some	  of	  these	  findings	  before,	  but	  the	  work	  presented	  in	  this	  thesis	  is	  the	  first	  study	  to	  look	  at	  all	  of	  this	  data	  together35,178.	  	  The	  memory	  marker	  expression	  of	  γδ	  T	  cells	  was	  the	  only	  difference	  between	  CD4	  T	  cells	  and	  γδ	  T	  cells	  in	  our	  study–	  there	  were	  fewer	  naïve	  γδ	  T	  cells	  and	  a	  broader	  spread	  of	  the	  other	  3	  memory	  phenotypes	  in	  healthy	  younger	  children	  in	  response	  to	  BCG	  stimulation	  of	  whole	  blood.	  	  Our	  data	  fails	  to	  prove	  our	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hypothesis	  that	  the	  primary	  response	  to	  mycobacteria	  is	  production	  of	  IL17	  by	  naïve	  γδ	  T	  cells,	  however,	  this	  is	  most	  likely	  to	  be	  a	  result	  of	  looking	  at	  BCG	  recall	  responses	  in	  a	  BCG	  vaccinated	  cohort	  and	  a	  limitation	  of	  our	  study	  as	  discussed	  below.	  	  	  Although	  we	  did	  not	  design	  this	  study	  to	  look	  at	  CD8	  T	  cells,	  we	  report	  valuable	  data	  regarding	  both	  their	  role	  in	  BCG	  vaccine	  responses	  in	  healthy	  children	  and	  their	  role	  in	  the	  immune	  response	  in	  children	  with	  TB	  disease.	  	  Previous	  work	  has	  shown	  that	  CD8	  T	  cells	  in	  10	  week	  old	  infants	  produce	  granulysin	  and	  perforin	  following	  BCG	  vaccination221.	  	  Additionally	  Tena-­‐Coki	  et	  al	  have	  shown	  that	  mycobacteria	  specific	  CD8	  T	  cells	  produce	  IFNγ	  in	  both	  healthy	  children	  and	  those	  with	  active	  TB	  disease160,	  in	  our	  cohort,	  CD8	  T	  cells	  in	  whole	  blood	  of	  both	  healthy	  children	  of	  all	  ages	  and	  children	  with	  TB	  disease	  responded	  to	  BCG	  stimulation	  by	  producing	  IFNγ,	  but	  only	  negligible	  quantities	  of	  either	  IL17	  or	  IL22.	  	  Additionally	  they	  were	  capable	  of	  proliferating	  in	  response	  to	  6	  day	  stimulation	  with	  BCG,	  but	  this	  was	  at	  a	  much	  lower	  magnitude	  than	  the	  response	  seen	  in	  CD4	  or	  γδ	  T	  cells.	  	  	  
10.3. Limiting	  Factors	  In	  the	  age-­‐related	  cohort,	  we	  did	  not	  include	  an	  adult	  group	  for	  comparison,	  but	  rather	  described	  all	  children	  over	  the	  age	  of	  5	  years	  to	  have	  an	  equivalent	  immune	  response	  to	  adults.	  	  This	  was	  based	  on	  the	  incidence	  of	  primary	  progressive	  TB	  disease	  and	  disseminated	  TB	  disease,	  and	  age	  groups	  that	  have	  been	  defined	  for	  routine	  immunological	  markers	  often	  used	  in	  the	  context	  of	  clinical	  diagnostics,	  but	  it	  would	  have	  been	  preferable	  for	  a	  study	  looking	  at	  age-­‐relate	  differences	  to	  possibly	  also	  include	  an	  adult	  group	  for	  completeness.	  	  	  An	  additional	  control	  group	  of	  interest	  would	  have	  been	  children	  who	  were	  not	  BCG	  vaccinated.	  	  This	  group	  was	  impossible	  to	  recruit	  in	  South	  Africa	  as	  all	  children	  are	  vaccinated	  at	  birth	  and	  it	  would	  be	  unethical	  in	  an	  area	  of	  such	  high-­‐endemicity	  for	  TB	  to	  not	  vaccinate	  with	  BCG.	  	  Comparison	  with	  an	  unvaccinated	  group	  from	  the	  UK	  was	  considered,	  but	  the	  environmental	  and	  genetic	  differences	  were	  thought	  to	  be	  too	  great	  to	  allow	  any	  significant	  comparison.	  Ideally,	  all	  of	  the	  children	  in	  the	  TB	  disease	  cohort	  would	  have	  been	  followed	  for	  a	  further	  period	  of	  possibly	  two	  years	  to	  determine	  whether	  the	  boosting	  effect	  seen	  in	  pulmonary	  TB	  and	  in	  particular	  the	  diminished	  boosting	  effect	  in	  extra-­‐pulmonary	  TB	  returned	  to	  healthy	  control	  levels	  with	  time.	  	  However,	  this	  was	  beyond	  the	  scope	  of	  this	  study	  in	  terms	  of	  time	  and	  finances	  –	  in	  addition,	  the	  mobile	  population	  of	  Khayelitsha	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where	  many	  of	  the	  study	  participants	  lived	  means	  that	  the	  lost	  to	  follow	  up	  rate	  over	  a	  2	  year	  period	  would	  be	  very	  substantial.	  	  It	  was	  only	  through	  the	  extreme	  dedication	  of	  the	  study	  team	  that	  we	  managed	  to	  persuade	  so	  many	  of	  our	  participants	  to	  return	  for	  the	  6	  month	  follow	  up	  point.	  	  A	  further	  limiting	  factor	  that	  all	  investigators	  performing	  paediatric	  studies	  face	  is	  that	  of	  small	  blood	  volumes.	  	  Although	  we	  were	  resourceful	  and	  managed	  to	  perform	  a	  number	  of	  assays	  on	  a	  relatively	  small	  volume	  of	  blood,	  with	  a	  larger	  volume	  of	  blood	  we	  could	  have	  identified	  the	  memory	  marker	  expression	  on	  the	  cytokine	  producing	  T	  cells	  in	  the	  short	  term	  effector	  assay	  which	  could	  have	  been	  of	  potential	  interest.	  	  	  	  
10.4. Future	  Work	  Work	  carried	  out	  in	  this	  thesis	  has	  led	  to	  a	  detailed	  characterization	  of	  the	  antigen	  specific	  adaptive	  immune	  response	  to	  BCG	  in	  healthy	  children	  of	  different	  ages	  and	  children	  with	  TB	  disease.	  	  We	  demonstrated	  that	  there	  are	  remarkably	  few	  differences	  in	  these	  responses	  with	  age	  or	  indeed	  between	  different	  disease	  manifestations,	  which	  was	  a	  bit	  disappointing,	  as	  our	  main	  question	  regarding	  the	  mechanisms	  determining	  extra-­‐pulmonary	  TB	  remains	  unresolved.	  	  The	  next	  steps	  to	  explore	  age-­‐related	  differences	  in	  the	  immune	  responses	  to	  mycobacteria	  would	  include	  examination	  of	  the	  innate	  immune	  responses.	  	  Shey	  et	  al	  have	  developed	  a	  whole	  blood	  intracellular	  cytokine	  assay	  for	  measuring	  innate	  responses	  to	  mycobacteria	  using	  flow	  cytometry	  and	  a	  number	  of	  groups	  have	  examined	  the	  ontogeny	  of	  TLR	  responses	  in	  healthy	  children	  up	  to	  2	  yrs	  of	  age	  that	  could	  be	  adapted	  to	  investigate	  mycobacterial	  induction	  of	  TLR’s	  and	  their	  responses205.	  	  A	  study	  combining	  these	  two	  techniques,	  but	  comparing	  innate	  immune	  responses	  in	  healthy	  children	  up	  to	  the	  age	  of	  12	  in	  both	  low	  and	  high	  endemic	  settings	  for	  TB	  in	  the	  presence	  and	  absence	  of	  priming	  with	  BCG	  vaccination	  could	  greatly	  expand	  our	  understanding	  of	  the	  immune	  response	  to	  mycobacteria.	  Although	  we	  have	  measured	  the	  levels	  of	  regulatory	  T	  cells	  in	  this	  study,	  demonstrating	  that	  they	  increase	  with	  increasing	  age	  in	  healthy	  children	  and	  are	  increased	  in	  patients	  with	  TB	  disease,	  we	  have	  not	  explored	  the	  function	  of	  this	  population	  of	  T	  cells	  in	  children,	  either	  healthy	  or	  with	  TB	  disease.	  	  As	  our	  data	  indicate	  that	  an	  underlying	  immune	  dysregulation	  may	  play	  a	  role	  in	  susceptibility	  to	  extra-­‐pulmonary	  TB	  disease,	  it	  would	  be	  of	  interest	  to	  define	  the	  function	  of	  regulatory	  T	  cells	  in	  children	  and	  determine	  whether	  the	  presence	  of	  phenotypical	  regulatory	  T	  cells	  correlates	  with	  a	  functional	  suppression.	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Although	  we	  did	  not	  find	  any	  correlations	  between	  the	  antigen	  specific	  immune	  response	  and	  the	  mycobacterial	  growth	  inhibition	  assay	  in	  our	  study,	  future	  work	  could	  include	  manipulations	  of	  cell	  populations,	  such	  as	  Tregs,	  within	  this	  assay	  to	  determine	  whether	  there	  is	  a	  functional	  effect.	  	  Given	  unlimited	  resources,	  it	  would	  have	  been	  ideal	  to	  also	  measure	  innate	  immune	  responses	  in	  our	  study	  groups	  –	  unfortunately	  this	  was	  not	  possible,	  however	  future	  studies	  concentrating	  on	  the	  innate	  immune	  response	  are	  warranted.	  	  
10.5. Concluding	  remarks	  In	  summary,	  we	  have	  shown	  that	  antigen	  specific	  immune	  responses	  to	  BCG	  stimulation	  of	  whole	  blood	  in	  healthy	  children	  of	  different	  ages	  and	  with	  different	  manifestations	  of	  TB	  disease	  are	  robust	  and	  comparable.	  We	  have	  identified	  that	  immaturity	  of	  the	  innate	  immune	  response	  to	  BCG	  in	  children	  under	  a	  year	  of	  age	  warrants	  further	  study	  and	  may	  hold	  the	  key	  to	  the	  increased	  susceptibility	  to	  TB	  infection	  and	  disease	  in	  this	  age	  group.	  	  We	  report	  a	  waning	  of	  BCG	  vaccine	  responses	  as	  measured	  by	  Ki67	  proliferation	  in	  children	  up	  to	  12	  years	  of	  age	  for	  the	  first	  time	  and	  suggest	  that	  re-­‐vaccination	  with	  BCG,	  or	  a	  novel	  TB	  vaccine	  candidate	  may	  provide	  additional	  protection	  from	  extra-­‐pulmonary	  TB	  disease	  in	  children	  between	  2yrs	  and	  older.	  	  Using	  a	  BCG-­‐primed	  population	  of	  children,	  we	  demonstrate	  that	  studies	  of	  healthy	  children	  of	  different	  ages	  provide	  crucial	  information	  about	  maturation	  of	  antigen-­‐specific	  and	  innate	  immune	  responses.	  This	  knowledge	  is	  of	  particular	  relevance	  for	  diagnostic	  tests,	  such	  as	  IGRA,	  since	  their	  reliability	  in	  young	  children	  has	  been	  questioned.	  We	  have	  no	  reason	  to	  believe	  that	  the	  antigen-­‐specific	  responses	  should	  be	  in	  any	  way	  deficient,	  however,	  due	  to	  the	  less	  vigorous	  responses	  to	  controls	  such	  as	  SEB	  or	  PHA,	  performance	  might	  be	  impaired	  in	  very	  young	  age,	  as	  the	  antigen-­‐specific	  results	  would	  be	  invalidated	  if	  the	  control	  responses	  are	  insufficient.	  We	  do	  not	  show	  any	  differences	  in	  the	  antigen	  specific	  immune	  responses	  to	  mycobacteria	  between	  children	  with	  different	  manifestations	  of	  TB	  disease	  at	  the	  time	  of	  diagnosis,	  but	  support	  further	  studies	  of	  the	  innate	  response	  in	  these	  cohorts.	  	  We	  report	  for	  the	  first	  time	  that	  children	  with	  TB	  disease	  have	  increased	  numbers	  of	  regulatory	  T	  cells.	  	  Additionally	  we	  have	  demonstrated	  that	  children	  with	  extra-­‐pulmonary	  TB	  have	  a	  diminished	  boosting	  response	  of	  their	  mycobacterial	  antigen	  specific	  immune	  responses	  at	  the	  end	  of	  treatment	  compared	  to	  children	  with	  pulmonary	  TB.	  	  This	  warrants	  further	  exploration	  to	  determine	  whether	  it	  is	  a	  function	  of	  timing,	  bacterial	  load	  or	  mycobacterial	  clearance,	  but	  may	  be	  primary	  evidence	  of	  an	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underlying	  susceptibility	  to	  extrapulmonary	  TB	  –	  either	  through	  an	  ineffective	  expansion	  of	  effector	  cells	  from	  central	  memory	  cells	  in	  response	  to	  re-­‐exposure	  or	  a	  failure	  of	  APC’s	  to	  communicate	  appropriately	  with	  the	  adaptive	  immune	  response.	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12. Appendix	  1	  
12.1. Patient	  information	  leaflet	  and	  consent	  form	  for	  healthy	  
controls	  
PATIENT	  INFORMATION	  AND	  CONSENT	  FORM	  	  
Principal	   Investigators:	   Dr.	   Elizabeth	  Whittaker,	   Associate	   Professor	   Beate	   Kampmann,	  
Professor	  Heather	  Zar,	  Professor	  Mark	  Nicol	  
You	  and	  your	  child	  are	  requested	  to	  participate	  in	  a	  medical	  research	  study	  that	  is	  being	  done	  at	  Red	  Cross	  Memorial	  Children’s	  Hospital.	   	  The	  study	  is	  sponsored	  by	  the	  Wellcome	  Trust.	   	  It	  has	  been	   approved	   by	   the	   University	   of	   Cape	   Town	   Faculty	   of	   Health	   Sciences	   Research	   Ethics	  Committee	  and	  will	  be	  done	  according	  to	  strict	  ethical	  guidelines	  and	  principles.	   	  The	  following	  information	  describes	  the	  study	  and	  your	  child’s	  role	  as	  a	  participant.	  	  Please	  read	  this	  carefully	  and	  feel	  free	  to	  ask	  any	  questions.	  	  	  
Background	  
Tuberculosis	   is	   a	   very	   common	   infection	   in	  South	  Africa	  and	   can	   cause	  bad	   chest	   infections	  or	  serious	   illness	  elsewhere	   in	   the	  body.	   	  Young	  children	  are	  more	   likely	   to	  get	  TB	  disease	  and	  to	  develop	   serious	   illness	   than	   adults.	   	   We	   want	   to	   find	   out	   what’s	   different	   about	   the	   immune	  system	  (way	  of	  fighting	  infection	  in	  our	  bodies)	  of	  young	  children	  with	  tuberculosis	  compared	  to	  older	  children.	  	  	  
Why	  is	  this	  study	  being	  done?	  
We	  want	   to	   see	   if	   there	  are	  any	  differences	   in	   the	  way	   children,	  particularly	  younger	   children,	  fight	  TB	  disease.	  	  This	  could	  help	  us	  to	  develop	  better	  ways	  of	  identifying	  TB	  disease,	  treating	  TB	  or	  even	  help	  us	  to	  develop	  a	  better	  vaccine	  to	  protect	  against	  TB.	  
Why	  has	  your	  child	  been	  chosen?	  
In	  order	  to	  know	  whether	  any	  differences	  in	  the	  immune	  responses	  we	  identify	  in	  children	  with	  TB	  are	   important,	  we	  need	  to	  compare	  them	  to	  how	  the	   immune	  system	  behaves	   in	  uninfected	  children.	  We	  are	   looking	   for	  80	  non-­‐Tuberculosis	   infected	   children.	   	  We	  don’t	   think	  your	   child	  has	  Tuberculosis	  or	  any	  other	  kind	  of	  immune	  problem,	  but	  they	  are	  under	  the	  care	  of	  Red	  Cross	  Memorial	  Children’s	  Hospital	  and	  having	  blood	  tests	  or	  an	  IV	  drip/cannula	  for	  other	  reasons.	  	  
What	  will	  your	  child/you	  have	  to	  do?	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While	  blood	  is	  being	  taken	  we	  would	  like	  to	  take	  a	  small	  amount	  of	  extra	  blood	  (less	  than	  5ml	  or	  1	   teaspoon).	   We	   can	   then	   compare	   this	   blood	   to	   blood	   from	   TB	   infected	   children	   to	   help	  understand	  what	  is	  happening	  in	  the	  fight	  against	  infection.	  	  If	   your	   child’s	   HIV	   status	   is	   not	   known	   then	   he	   or	   she	  will	   be	   tested	   for	   HIV.	   	   This	   is	   part	   of	  routine	  care.	  	  If	  your	  child	  is	  found	  to	  have	  HIV,	  then	  he	  or	  she	  will	  be	  referred	  for	  treatment	  of	  HIV	  and	  antiretroviral	  therapy	  if	  needed.	  A	  swab	  of	  your	  child’s	  nose	  will	  be	  taken	  to	  look	  for	  germs.	  	  
What	  are	  the	  advantages	  of	  my	  child	  being	  in	  the	  study?	  
There	  will	  be	  no	  direct	   advantage	   to	  your	   child	  being	   in	   the	   study,	  but	   the	   information	  we	  get	  might	  help	  protect	  young	  people	  with	  tuberculosis	  in	  the	  future.	  	  	  
Will	  the	  study	  hurt	  or	  make	  your	  child	  feel	  bad?	  
The	  time	  taken	  to	  take	  the	  blood	  sample	  may	  be	  slightly	  longer,	  but	  there	  shouldn’t	  be	  any	  more	  discomfort.	  The	  nasal	  swab	  is	  slightly	  uncomfortable.	  
How	  long	  will	  my	  child	  be	  in	  the	  study?	  
Your	  child	  will	  only	  be	   in	  the	  study	  while	  they	  are	  having	  the	  blood	  taken.	   	  After	  this,	   they	  will	  receive	  routine	  health	  care.	  
Will	  I	  be	  charged	  for	  the	  study?	  
No,	  there	  is	  no	  cost	  to	  you	  
Will	  I	  receive	  any	  payment?	  There	  is	  no	  payment	  involved	  with	  the	  study.	  
Does	  your	  child	  have	  to	  be	  in	  the	  study?	  
You	  may	  choose	  for	  your	  child	  to	  be	  in	  this	  study	  or	  not.	  	  If	  you	  choose	  not	  to	  be	  in	  the	  study,	  then	  your	  child	  will	  get	  routine	  care	  by	  the	  medical	  team.	  
What	  do	  I	  do	  if	  I	  have	  any	  questions?	  




All	  information	  that	  you	  provide	  will	  be	  considered	  confidential,	  and	  no	  mention	  of	  your	  child’s	  name	   or	   any	   other	   identifying	   information	   will	   appear	   on	   the	   stored	   samples	   or	   in	   any	  publication	   in	   connection	   with	   this	   study.	   No	   persons	   other	   than	   the	   health	   care	   workers	  overseeing	   your	   child’s	   care	   and	   the	   study	   nurse	   will	   have	   access	   to	   any	   information	   that	  identifies	  your	  child	  personally.	  	  
You	  may	   also	   choose	   not	   to	   participate	   in	   this	   study	   and	   you	  may	   refuse	   to	   participate	   at	   any	  time.	   This	  will	   not	   in	   any	  way	   affect	   the	   care	   that	   your	   child	  will	   receive.	   You	   do	   not	   have	   to	  explain	  why	  you	  do	  not	  wish	  to	  participate.	  
Storage	  of	  samples	  
If	  any	  of	  the	  blood	  samples	  my	  child	  have	  provided	  for	  this	  research	  project	  is	  unused	  or	  leftover	  when	  the	  project	  is	  completed	  	  
	  I	  give	  my	  permission	  for	  my	  child’s	  samples	  to	  be	  stored	  and	  used	  in	  future	  research	  of	  any	  type	  which	  has	  been	  properly	  approved	  	  
	  I	  give	  permission	  for	  my	  child’s	  samples	  to	  be	  stored	  and	  used	  in	  future	  research	  but	  only	  for	  research	  on	  TUBERCULOSIS	  	  
	   I	   give	   permission	   for	   my	   child’s	   samples	   to	   be	   stored	   and	   used	   in	   future	   research	  except	  for	  research	  about	  _______________________________________.	  	  
	  
OR	  	  	  	  	  	  	   	  I	  wish	  my	  child’s	  samples	  to	  be	  destroyed	  immediately.	  	  
	  
I	  have	  read	  and	  understood	  this	  form.	  My	  questions	  have	  been	  answered.	  	  I	  agree	  to	  allow	  
my	  child	  to	  participate	  in	  this	  study.	  	  
I,	  ___________________________,	   the	  parent/	  legal	  guardian	  of	  _____________________________	  agree	  to	  allow	  her/him	  to	  participate	  in	  this	  study.	  
Signed:	  	  __________________	   Witness:	  	  __________________	  
	  
Date:	   	  	  ___________________	   Date:	   	  	  ___________________	  
	  
Person	  obtaining	  consent:	  Name:	  __________________________________________________	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If	  the	  parent/guardian	  is	  unable	  to	  read	  or	  write	  the	  entire	  counselling	  process	  must	  be	  observed	  by	  an	   independent	  witness	  who	  can	   then	  confirm	  the	  procedure	  once	   the	  parent/guardian	  has	  given	  consent.	  
	  
Fingerprint	  of	  parent/guardian	  
Witness	  




12.2. Patient	  Information	  Leaflet	  and	  Consent	  Form	  for	  TB	  cohort	  
PATIENT	  INFORMATION	  AND	  CONSENT	  FORM	  
Principal	  Investigators:	  Dr.	  Elizabeth	  Whittaker,	  Associate	  Professor	  Beate	  
Kampmann,	  Professor	  Heather	  Zar,	  Professor	  Mark	  Nicol	  You	  and	  your	  child	  are	  requested	  to	  participate	  in	  a	  medical	  research	  study	  that	  is	  being	  done	  at	  Red	  Cross	  Memorial	  Children’s	  Hospital.	  	  The	  study	  is	  sponsored	  by	  the	  Wellcome	  Trust.	  	  It	  has	  been	  approved	  by	  the	  University	  of	  Cape	  Town	  Faculty	  of	  Health	  Sciences	  Research	  Ethics	  Committee	  and	  will	  be	  done	  according	  to	  strict	  ethical	  guidelines	  and	  principles.	  	  The	  following	  information	  describes	  the	  study	  and	  your	  child’s	  role	  as	  a	  participant.	  	  Please	  read	  this	  carefully	  and	  feel	  free	  to	  ask	  any	  questions.	  	  	  
Background	  The	  nurses/doctors	  looking	  after	  your	  child	  suspect	  that	  he/she	  may	  have	  tuberculosis	  (TB).	  	  Tuberculosis	  is	  a	  very	  common	  infection	  in	  South	  Africa	  and	  can	  cause	  bad	  chest	  infections	  or	  serious	  illness	  elsewhere	  in	  the	  body.	  	  Young	  children	  are	  more	  likely	  to	  get	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TB	  disease	  and	  to	  develop	  serious	  illness	  than	  adults.	  	  We	  want	  to	  find	  out	  what’s	  different	  about	  the	  immune	  system	  (way	  of	  fighting	  infection	  in	  our	  bodies)	  of	  children	  with	  tuberculosis	  compared	  to	  adults.	  	  	  
Why	  is	  this	  study	  being	  done?	  We	  want	  to	  see	  if	  there	  are	  any	  differences	  in	  the	  way	  children,	  particularly	  younger	  children,	  fight	  TB	  disease.	  	  This	  could	  help	  us	  to	  develop	  better	  ways	  of	  identifying	  TB	  disease,	  treating	  TB	  or	  even	  help	  us	  to	  develop	  a	  better	  vaccine	  to	  protect	  against	  TB.	  
What	  will	  your	  child/you	  have	  to	  do?	  	  There	  are	  2	  stages	  to	  the	  study.	  
Stage	  1	  When	  we	  suspect	  you	  have	  TB,	  the	  team	  do	  some	  routine	  tests	  –	  these	  include	  a	  TB	  skin	  test	  (Mantoux)	  and	  collecting	  ‘induced	  sputum’	  –	  where	  we	  collect	  mucous	  from	  the	  lung.	  	  If	  your	  child/you	  takes	  part	  in	  the	  study,	  then	  a	  small	  amount	  of	  blood	  (about	  1-­‐2	  teaspoons)	  will	  be	  taken.	  	  We	  will	  test	  how	  good	  your	  child’s	  blood	  is	  at	  fighting	  the	  TB	  disease.	  If	  your	  child’s	  HIV	  status	  is	  not	  known	  then	  he	  or	  she	  will	  be	  tested	  for	  HIV,	  as	  TB	  can	  be	  very	  serious	  in	  children	  with	  HIV	  and	  may	  need	  to	  be	  treated	  for	  longer	  and	  with	  different	  medicines.	  This	  is	  routine	  practice	  at	  the	  clinic.	  If	  your	  child	  is	  found	  to	  have	  HIV,	  then	  he	  or	  she	  will	  be	  referred	  for	  treatment	  of	  HIV	  and	  antiretroviral	  therapy	  if	  needed.	  
Stage	  2	  The	  normal	  treatment	  for	  tuberculosis	  is	  6	  to	  9	  months	  of	  antibiotics,	  then	  your	  child	  will	  be	  seen	  again	  in	  the	  clinic	  to	  check	  you	  are	  fully	  better.	  	  We	  will	  take	  a	  further	  teaspoon	  blood	  sample	  at	  this	  time.	  What	  are	  the	  advantages	  of	  my	  child	  being	  in	  the	  study?	  There	  will	  be	  no	  direct	  advantage	  to	  your	  child	  being	  in	  the	  study,	  but	  the	  information	  we	  get	  might	  help	  protect	  young	  people	  with	  tuberculosis	  in	  the	  future.	  	  	  
Will	  the	  study	  hurt	  or	  make	  your	  child	  feel	  bad?	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  Your	  child	  may	  experience	  discomfort	  from	  the	  needle	  when	  blood	  is	  taken.	  Where	  possible	  this	  blood	  test	  will	  be	  done	  at	  the	  same	  time	  as	  other	  blood	  tests	  and	  using	  an	  anaesthetic	  cream	  to	  dull	  the	  pain	  from	  the	  needle.	  Only	  a	  small	  amount	  of	  blood	  will	  be	  taken.	  
How	  long	  will	  my	  child	  be	  in	  the	  study?	  Your	  child	  will	  be	  followed	  up	  once	  he/she	  have	  completed	  the	  initial	  procedures	  at	  clinic.	  This	  visit	  will	  take	  place	  6	  months	  after	  your	  child	  has	  left	  the	  clinic.	  The	  purpose	  of	  these	  visits	  is	  to	  monitor	  your	  child’s	  progress.	  A	  blood	  sample	  (about	  1	  teaspoon	  of	  blood)	  will	  be	  taken	  at	  6	  months	  for	  repeat	  TB	  tests.	  	  
Will	  I	  be	  charged	  for	  the	  study?	  No,	  there	  is	  no	  cost	  to	  you	  
Will	  I	  receive	  any	  payment?	  We	  will	  reimburse	  you	  for	  travel	  costs	  when	  you	  come	  for	  your	  child’s	  check	  ups.	  
Does	  your	  child	  have	  to	  be	  in	  the	  study?	  You	  may	  choose	  for	  your	  child	  to	  be	  in	  this	  study	  or	  not.	  	  If	  you	  choose	  not	  to	  be	  in	  the	  study,	  then	  your	  child	  will	  get	  routine	  care	  by	  the	  medical	  team.	  
What	  do	  I	  do	  if	  I	  have	  any	  questions?	  For	  questions	  about	  this	  study,	  you	  can	  ask	  the	  study	  staff	  or	  contact	  Dr.	  Elizabeth	  Whittaker	  or	  Prof	  Heather	  Zar	  at	  021	  658	  5318	  or	  021	  658	  5519.	  	  For	  questions	  about	  your	  rights	  as	  a	  study	  participant	  call	  the	  Faculty	  of	  Health	  Sciences	  Human	  Research	  Ethics	  Committee,	  University	  of	  Cape	  Town,	  Tel:	  021	  406	  6338	  
Confidentiality	  All	  information	  that	  you	  provide	  will	  be	  considered	  confidential,	  and	  no	  mention	  of	  your	  child’s	  name	  or	  any	  other	  identifying	  information	  will	  appear	  on	  the	  stored	  samples	  or	  in	  any	  publication	  in	  connection	  with	  this	  study.	  No	  persons	  other	  than	  the	  health	  care	  workers	  overseeing	  your	  child’s	  care	  and	  the	  study	  nurse	  will	  have	  access	  to	  any	  information	  that	  identifies	  your	  child	  personally.	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You	  may	  also	  choose	  not	  to	  participate	  in	  this	  study	  and	  you	  may	  refuse	  to	  participate	  at	  any	  time.	  This	  will	  not	  in	  any	  way	  affect	  the	  care	  that	  your	  child	  will	  receive.	  You	  do	  not	  have	  to	  explain	  why	  you	  do	  not	  wish	  to	  participate.	  
Storage	  of	  samples	  If	  any	  of	  the	  blood	  samples	  my	  child	  have	  provided	  for	  this	  research	  project	  is	  unused	  or	  leftover	  when	  the	  project	  is	  completed	  	  	  I	  give	  my	  permission	  for	  my	  child’s	  samples	  to	  be	  stored	  and	  used	  in	  future	  research	  of	  any	  type	  which	  has	  been	  properly	  approved	  	  	  I	  give	  permission	  for	  my	  child’s	  samples	  to	  be	  stored	  and	  used	  in	  future	  research	  but	  only	  for	  research	  on	  TUBERCULOSIS	  	  	  I	  give	  permission	  for	  my	  child’s	  samples	  to	  be	  stored	  and	  used	  in	  future	  research	  except	  for	  research	  about	  _______________________________________.	  	  	  OR	  	  	  	  	  	  	   	  I	  wish	  my	  child’s	  samples	  to	  be	  destroyed	  immediately.	  	  	  I	  have	  read	  and	  understood	  this	  form.	  My	  questions	  have	  been	  answered.	  	  I	  agree	  to	  allow	  my	  child	  to	  participate	  in	  this	  study.	  	  I,	  ___________________________,	  the	  parent/	  legal	  guardian	  of	  _____________________________	  agree	  to	  allow	  her/him	  to	  participate	  in	  this	  study.	  Signed:	  	  __________________	   Witness:	  	  __________________	  	  Date:	   	  	  ___________________	   Date:	   	  	  ___________________	  	  
Person	  obtaining	  consent:	  Name:	  __________________________________________________	  Role	  in	  Study:	  ____________________________________________	  Signature:	  _______________________________________________	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Date:	  ___________________________________________________	  	  If	  the	  parent/guardian	  is	  unable	  to	  read	  or	  write	  the	  entire	  counselling	  process	  must	  be	  observed	  by	  an	  independent	  witness	  who	  can	  then	  confirm	  the	  procedure	  once	  the	  parent/guardian	  has	  given	  consent.	  	  Fingerprint	  of	  parent/guardian	  	  	  Witness	  I	  confirm	  that	  I	  am	  independent	  of	  the	  study	  and	  that	  I	  witnessed	  the	  entire	  enrolment	  counselling	  process	  in	  the	  home	  language	  of	  the	  parent/guardian.	  Name:	  ______________________________________________________	  Signature:	  ___________________________________________________	  Date:	  _______________________________________________________	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13. Appendix	  2	  
13.1. Case	  Report	  Form	  Healthy	  Controls	  
The	  Role	  of	  IL17	  in	  Childhood	  Tuberculosis	  
	  
Inclusion	  Criteria	   	   	   	   	   	  	  	  	  	  Yes	  	  	  	  	  	  	  	  	  	  No*	  
	  
1.	  Is	  the	  subject	  suspected	  to	  have	  Tuberculosis	  
	  
*	  If	  the	  answer	  is	  yes,	  then	  the	  subject	  is	  not	  eligible	  for	  the	  study	  
	  
	  
Exclusion	  Criteria	   	   	   	   	  	  	  	  	  	  	  	  	  	  	  Yes**	  	  	  	  	  	  	  	  No	  
	  
	  
1.	  Is	  the	  subject	  known	  to	  have	  immunodeficiency	  	  
or	  immune	  suppression	  (including	  HIV)?	  
	  
	  
2.	  Is	  the	  subject	  aged	  older	  than	  18	  years?	  
	  
	  




**	  If	  any	  of	  the	  exclusion	  criteria	  are	  ticked	  yes,	  the	  subject	  is	  not	  eligible	  for	  the	  





Please	  note:	  written	  informed	  consent	  must	  be	  given	  before	  any	  study	  specific	  
procedures	  take	  place.	  
	  
	   	   	   	   	   	   	   	   	   	  	  	  	  Yes	  	  	  No	  
	  
If	  competent,	  has	  the	  subject	  freely	  given	  written	  informed	  consent	  	  	  
	  
	  
If	  not	  competent,	  has	  the	  subject’s	  parent/guardian	  freely	  given	  
written	  informed	  consent?	   	   	  
	  
	  




*not	  essential	  for	  study	  participation	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The	  Role	  of	  IL17	  in	  Childhood	  Tuberculosis	  
	  
STUDY	  DETAILS	  














(Place	  sticker	  below,	  if	  available)	  
	  







	  	  Male	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  	  Female	  
	  
	  
Date	  of	  Birth	  	  
	  
___/_	  	  _/______	  










Name&	   Surname	  
of	   the	   Primary	  
Caregiver	  
	  



























The	  Role	  of	  IL17	  in	  Childhood	  Tuberculosis	  
	  
	  
Have	  you	  ever	  
been	  to	  School?	  
	  
	  
	  Yes	  	  	  	  	  	  	  	  	  	  	  	  	   	  No	  
	  










Grade	  (1-­‐12)	  :_________________	  
Smoking	  in	  Household	  
	  
Does	  the	  Caregiver	  Smoke?	  
	  
	  
	  Yes	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  No	  
	  
	  
Does	  the	  child/Adolescent	  smoke?	  
	  
	  
	  Yes	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  No	  
	  
Number	  of	  Household	  Smokers?	  	  	  	  	  	  	  	  	  	  __________	  
Employment	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Employment	  Status	   	  Employed	  	  	  	   	  Unemployed	  
	  
Housing	  
Housing	   	  Formal	  	  	  	  	  	  	  	   	  Informal	  
Access	  to	  running	  water?	   	  	  Yes	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  No	  
What	  is	  the	  main	  source	  of	  water	  in	  the	  
household?	  
	  In-­‐door	  tap	  water	  	   	  Borehole	  
	  River	  Water	  	  	  	  	  	  	  
	  Outdoor/Communal	  Tap	  
	  Other……………………………..	  
	  	  	  	  ……………………………………	  
	  Unknown	  	  	  	  	  	  	  	  	  	  
	  
What	  type	  of	  toilet	  do	  you	  have	  in	  the	  
house?	  
	  Flush	  toilet	  	  	  	  	  	  	  	  	   	  Pit	  Latrine	  
	  Bucket	  system	  	  	  	   	  None/outdoors	  
	  Other	  ……………………………..	  
	  	  	  	  ……………………………………	  
	  Unknown	  
	  
How	  many	  people	  sleep	  in	  the	  same	  
room	  as	  the	  child	  (not	  counting	  the	  
child)?	  
	  
…….	  People	  	  	  	  	  	   	  Unknown	  
Electricity	  in	  Dwelling?	   	  Yes	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  No	  
Do	  you	  use	  any	  of	  the	  following	  for	  
heating	  and/or	  cooking	  in	  the	  	  
	  Electricity	  	  	  	  	  	   	  Gas	  
	  Coal	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  Paraffin	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household?	  (tick	  all	  that	  apply)	   	  Wood	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TB	  History	  of	  the	  Caregiver	  
	  
Have	  you	  ever	  been	  treated	  for	  TB?	  
	  
	  
	  Yes	  	  	  	   	  No	  	   	  DK	  
	  




	  1x	  	  	  	   	  2x	  	  	   	  >2x	  
	  
	  
When	  did	  you	  start	  TB	  treatment?	  




How	  many	  months	  were	  you	  on	  TB	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If	  Yes,	  date	  of	  Test?	  
	  
_______/________/__________	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INDEX	  CASE:	  Clinical	  Examination	  
IMMUNISATION	  STATUS	  
	  
BCG	  vaccination	  date	  
	  
______/______/________	  







	  Yes	  	  	  	   	  Uncertain	  	  	   	  No	  
	  
EPI	  Schedule	  up	  to	  date?	  
	  
	  
	  Yes	  	  	   	  No	  	  	   	  Card	  not	  available	  
	  





Has	  the	  child	  received	  HiB	  	  
	  
	  
	  Dose	  1	  	   	  Dose	  2	   	  Dose	  3	  	  
Has	  the	  child	  received	  PPV	   	  Dose	  1	  	   	  Dose	  2	   	  Dose	  3	  
	  
Has	  the	  child	  received	  influenza	  vaccine	  
in	  the	  last	  year?	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Past	  Medical	  History	  
	  
Has	  the	  child/adolescent	  ever	  been	  
treated	  for	  TB?	  
	  
	  












How	  many	  times:	  ……………………..	  
	  
	  
Did	  the	  child	  require	  hospital	  admission	  
during	  the	  last	  3	  months?	  
	  
	  
	  	  Yes	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  No	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  DK	  






















.........................................	   ......................................	  
	  
TB	  Contact	  History	  
	  
Has	  anyone	  in	  your	  household	  or	  close	  family,	  
including	  those	  who	  have	  died,	  EVER	  been	  treated	  









If	  YES,	  was	  he/she	  a:	  	  	  	  	  	  	   	  	  	  Parent	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  	  	  Neighbour	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  	  	  Other………………….	  
	  
Did	  the	  child/adolescent	  have	  contact	  
with	  this	  person?	  
	  Yes	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  	  No	  
	  
When	  was	  the	  contact	  treated	  for	  TB?	  
	  
	  Current	  	  	  	   	  <12mths	  	  	   >1yr	  
	  
Has	  the	  child/adolescent	  ever	  received	  
TB	  prevention	  treatment?	  
	  
	  Yes	  	  	  	  	  	  	  	  	  	  	   	  No	  	  	  	  	  	  	  	  	  	  	  	  	   	  DK	  	  	  	  	  
Please	  tick	  all	  that	  apply	  to	  the	  status	  of	  
the	  TB	  Contact:	  
	  AFB	  Pos/Neg	  	  	  	  	  	  	   	  Drug	  sensitive	  
	  Drug	  Resistant	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HIV	  exposure-­‐Exposure	  to	  PMTCT	  intervention	  
	  
















Early	  Infant	  feeding	  (1st	  6	  
mths)	  
	  
(if	  the	  child	  has	  ever	  had	  a	  
bottle	  feed	  or	  any	  other	  feed-­‐
other	  than	  breast	  milk-­‐in	  1st	  6	  
















Are	  you	  currently	  Breastfeeding?	  
	  
(If	  NO,	  when	  did	  you	  stop	  breastfeeding?	  
	  Never	  Breast	  Fed	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Child/Adolescent	  tested	  for	  HIV?	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Clinical	  Examination	  –	  ON	  ADMISSION	  
Nutritional	  Status	  
	  











Oxygen	  saturation:	  …………..%	  
	  
	  RA	  	  	  	  	  	  	  	  	  	  	  	  	   	  Supplemental	  Oxygen	  
	  
	  
Temperature:	  	  ……….. C	  
	  
Pulse:	  	  …………	  beats/min	  
	  
Resp	  rate:	  ……………..breaths/min	  
	  












































	  Eczema	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  Impetigo	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
	  
	  Papular-­‐pruritic	  eruption	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Lymphadenopathy	  




Subcostal	  Recession?	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  Yes	  	  	  	  	  	  	  	  	  	   	  No	  
Dullness	  to	  Percussion	   N	   L	   R	   B	  
Crackles	   N	   L	   R	   B	  
Wheeze	   N	   L	   R	   B	  
Reduced	  breath	  Sounds	   N	   L	   R	   B	  
Abnormal	  breath	  Sounds	   N	   L	   R	   B	  
	  
Cardiovascular	  
Examination	   Normal	   Abnormal	  





Distended	   	  Y	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  N	  
Ascites	   	  Y	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  N	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Splenomegaly	   	  Y	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  N	  




Has	  an	  HIV	  PCR	  been	  sent	  if	  the	  child	  is	  
<18	  months	  old?	  
Y	   ____/____/______	  
	  DD	  	  MM	  	  YYYY	  
N	  
	  
HIV	  TEST	  RESULTS	  
	   Date	   Result	  
HIV	  Determine	   ____/____/______	  
	  DD	  	  	  MM	  	  	  YYYY	  
Negative	   Positive	  
HIV	  ELISA	   _____/___/_____	  
	  DD	  	  	  MM	  	  	  YYYY	  
Negative	   Positive	  
HIV	  DNA	  PCR	   ____/____/______	  
	  DD	  	  	  MM	  	  	  YYYY	  
Negative	   Positive	  
Final	  HIV	  diagnosis:	   Exposed	   Infected	   Uninfected	   Unknown	  
If	  HIV	  positive,	  subject	  is	  not	  eligible	  for	  IL17	  Study	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13.2. Case	  Report	  Form	  Tuberculosis	  cohort	  
The	  Role	  of	  IL17	  in	  Childhood	  Tuberculosis	  
	  
Inclusion	  Criteria	   	   	   	   	   	  	  	  	  	  Yes	  	  	  	  	  	  	  	  	  	  No*	  
	  
1.	  Is	  the	  subject	  suspected	  to	  have	  Tuberculosis	  
	  
*	  If	  the	  answer	  is	  no,	  then	  the	  subject	  is	  not	  eligible	  for	  the	  study	  
	  
	  
Exclusion	  Criteria	   	   	   	   	  	  	  	  	  	  	  	  	  	  	  Yes**	  	  	  	  	  	  	  	  No	  
	  
	  
1.	  Is	  the	  subject	  known	  to	  have	  immunodeficiency	  	  
or	  immune	  suppression	  (including	  HIV)?	  
	  
	  
2.	  Is	  the	  subject	  aged	  older	  than	  18	  years?	  
	  
	  
4.	  Has	  the	  subject	  NOT	  had	  BCG	  vaccine?	   	   	   	  
	  
**	  If	  any	  of	  the	  exclusion	  criteria	  are	  ticked	  yes,	  the	  subject	  is	  not	  eligible	  for	  the	  







Please	  note:	  written	  informed	  consent	  must	  be	  given	  before	  any	  study	  specific	  
procedures	  take	  place.	  
	  
	   	   	   	   	   	   	   	   	   	  	  	  	  Yes	  	  	  No	  
	  
If	  competent,	  has	  the	  subject	  freely	  given	  written	  informed	  consent	  	  	  
	  
	  
If	  not	  competent,	  has	  the	  subject’s	  parent/guardian	  freely	  given	  
written	  informed	  consent?	   	   	  
	  
	  




*not	  essential	  for	  study	  participation	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STUDY	  DETAILS	  














(Place	  sticker	  below,	  if	  available)	  
	  







	  	  Male	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  	  Female	  
	  
	  
Date	  of	  Birth	  	  
	  
___/_	  	  _/______	  










Name&	   Surname	  
of	   the	   Primary	  
Caregiver	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Have	  you	  ever	  
been	  to	  School?	  
	  
	  
	  Yes	  	  	  	  	  	  	  	  	  	  	  	  	   	  No	  
	  










Grade	  (1-­‐12)	  :_________________	  
Smoking	  in	  Household	  
	  
Does	  the	  Caregiver	  Smoke?	  
	  
	  
	  Yes	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  No	  
	  
	  
Does	  the	  child/Adolescent	  smoke?	  
	  
	  
	  Yes	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  No	  
	  
Number	  of	  Household	  Smokers?	  	  	  	  	  	  	  	  	  	  __________	  
Employment	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Employment	  Status	   	  Employed	  	  	  	   	  Unemployed	  
	  
Housing	  
Housing	   	  Formal	  	  	  	  	  	  	  	   	  Informal	  
Access	  to	  running	  water?	   	  	  Yes	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  No	  
What	  is	  the	  main	  source	  of	  water	  in	  the	  
household?	  
	  In-­‐door	  tap	  water	  	   	  Borehole	  
	  River	  Water	  	  	  	  	  	  	  
	  Outdoor/Communal	  Tap	  
	  Other……………………………..	  
	  	  	  	  ……………………………………	  
	  Unknown	  	  	  	  	  	  	  	  	  	  
	  
What	  type	  of	  toilet	  do	  you	  have	  in	  the	  
house?	  
	  Flush	  toilet	  	  	  	  	  	  	  	  	   	  Pit	  Latrine	  
	  Bucket	  system	  	  	  	   	  None/outdoors	  
	  Other	  ……………………………..	  
	  	  	  	  ……………………………………	  
	  Unknown	  
	  
How	  many	  people	  sleep	  in	  the	  same	  
room	  as	  the	  child	  (not	  counting	  the	  
child)?	  
	  
…….	  People	  	  	  	  	  	   	  Unknown	  
Electricity	  in	  Dwelling?	   	  Yes	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  No	  
Do	  you	  use	  any	  of	  the	  following	  for	  
heating	  and/or	  cooking	  in	  the	  	  
	  Electricity	  	  	  	  	  	   	  Gas	  
	  Coal	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  Paraffin	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household?	  (tick	  all	  that	  apply)	   	  Wood	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TB	  History	  of	  the	  Caregiver	  
	  
Have	  you	  ever	  been	  treated	  for	  TB?	  
	  
	  
	  Yes	  	  	  	   	  No	  	   	  DK	  
	  




	  1x	  	  	  	   	  2x	  	  	   	  >2x	  
	  
	  
When	  did	  you	  start	  TB	  treatment?	  




How	  many	  months	  were	  you	  on	  TB	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If	  Yes,	  date	  of	  Test?	  
	  
_______/________/__________	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INDEX	  CASE:	  Clinical	  Examination	  
Visit	  1	  –	  recruitment	  
IMMUNISATION	  STATUS	  
	  
BCG	  vaccination	  date	  
	  
______/______/________	  







	  Yes	  	  	  	   	  Uncertain	  	  	   	  No	  
	  
EPI	  Schedule	  up	  to	  date?	  
	  
	  
	  Yes	  	  	   	  No	  	  	   	  Card	  not	  available	  
	  





Has	  the	  child	  received	  HiB	  	  
	  
	  
	  Dose	  1	  	   	  Dose	  2	   	  Dose	  3	  	  
Has	  the	  child	  received	  PPV	   	  Dose	  1	  	   	  Dose	  2	   	  Dose	  3	  
	  
Has	  the	  child	  received	  influenza	  vaccine	  
	  
	  Dose	  1	  	   	  Dose	  2	   	  Dose	  3	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Past	  Medical	  History	  
	  
Has	  the	  child/adolescent	  ever	  been	  
treated	  for	  TB?	  
	  
	  












How	  many	  times:	  ……………………..	  
	  
	  
Did	  the	  child	  require	  hospital	  admission	  
during	  the	  last	  3	  months?	  
	  
	  
	  	  Yes	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  No	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  DK	  






















.........................................	   ......................................	  
	  
TB	  Contact	  History	  
	  
Has	  anyone	  in	  your	  household	  or	  close	  family,	  
including	  those	  who	  have	  died,	  EVER	  been	  treated	  









If	  YES,	  was	  he/she	  a:	  	  	  	  	  	  	   	  	  	  Parent	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  	  	  Neighbour	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  	  	  Other………………….	  
	  
Did	  the	  child/adolescent	  have	  contact	  
with	  this	  person?	  
	  Yes	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  	  No	  
	  
When	  was	  the	  contact	  treated	  for	  TB?	  
	  
	  Current	  	  	  	   	  <12mths	  	  	   >1yr	  
	  
Has	  the	  child/adolescent	  ever	  received	  
TB	  prevention	  treatment?	  
	  
	  Yes	  	  	  	  	  	  	  	  	  	  	   	  No	  	  	  	  	  	  	  	  	  	  	  	  	   	  DK	  	  	  	  	  
Please	  tick	  all	  that	  apply	  to	  the	  status	  of	  
the	  TB	  Contact:	  
	  AFB	  Pos/Neg	  	  	  	  	  	  	   	  Drug	  sensitive	  
	  Drug	  Resistant	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HIV	  exposure-­‐Exposure	  to	  PMTCT	  intervention	  
	  
















Early	  Infant	  feeding	  (1st	  6	  
mths)	  
	  
(if	  the	  child	  has	  ever	  had	  a	  
bottle	  feed	  or	  any	  other	  feed-­‐
other	  than	  breast	  milk-­‐in	  1st	  6	  
















Are	  you	  currently	  Breastfeeding?	  
	  
(If	  NO,	  when	  did	  you	  stop	  breastfeeding?	  
	  Never	  Breast	  Fed	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Child/Adolescent	  tested	  for	  HIV?	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Clinical	  Examination	  –	  ON	  ADMISSION	  
Nutritional	  Status	  
	  











Oxygen	  saturation:	  …………..%	  
	  
	  RA	  	  	  	  	  	  	  	  	  	  	  	  	   	  Supplemental	  Oxygen	  
	  
	  
Temperature:	  	  ……….. C	  
	  
Pulse:	  	  …………	  beats/min	  
	  
Resp	  rate:	  ……………..breaths/min	  
	  












































	  Eczema	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  Impetigo	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
	  
	  Papular-­‐pruritic	  eruption	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Lymphadenopathy	  




Subcostal	  Recession?	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  Yes	  	  	  	  	  	  	  	  	  	   	  No	  
Dullness	  to	  Percussion	   N	   L	   R	   B	  
Crackles	   N	   L	   R	   B	  
Wheeze	   N	   L	   R	   B	  
Reduced	  breath	  Sounds	   N	   L	   R	   B	  
Abnormal	  breath	  Sounds	   N	   L	   R	   B	  
	  
Cardiovascular	  
Examination	   Normal	   Abnormal	  





Distended	   	  Y	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  N	  
Ascites	   	  Y	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  N	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Splenomegaly	   	  Y	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  N	  





























Did	  the	  patient	  cough	  
during	  the	  NPA?	  
	  Yes	  	  	  	  	  	  	   	  No	  
	  
	  	  Induced	  Sputum	  
	  
Date:	  ____/_____/______	  
	  	  	  	  	  	  	  	  	  	  	  	  DD	  	  MM	  	  YYYY	  
Specimen	  2	  
	  NPA	  
Did	  the	  patient	  cough	  
during	  the	  NPA?	  
	  Yes	  	  	  	  	  	  	   	  No	  
	  
	  	  Induced	  Sputum	  
	  
Date:	  ____/_____/______	  




Did	  the	  patient	  cough	  
during	  the	  NPA?	  
	  Yes	  	  	  	  	  	  	   	  No	  
	  
	  	  Induced	  Sputum	  
	  
Date:	  ____/_____/______	  
	  	  	  	  	  	  	  	  	  	  	  	  DD	  	  MM	  	  YYYY	  
Specimen	  4	  
	  NPA	  
Did	  the	  patient	  cough	  
during	  the	  NPA?	  
	  Yes	  	  	  	  	  	  	   	  No	  
	  
	  	  Induced	  Sputum	  
	  
Date:	  ____/_____/______	  
	  	  	  	  	  	  	  	  	  	  	  	  DD	  	  MM	  	  YYYY	  
Specimen	  5	  
	  NPA	  
Did	  the	  patient	  cough	  
during	  the	  NPA?	  
	  Yes	  	  	  	  	  	  	   	  No	  
	  
	  	  Induced	  Sputum	  
	  
Date:	  ____/_____/______	  
	  	  	  	  	  	  	  	  	  	  	  	  DD	  	  MM	  	  YYYY	  
Specimen	  6	  
	  NPA	  
Did	  the	  patient	  cough	  
during	  the	  NPA?	  
	  Yes	  	  	  	  	  	  	   	  No	  
	  
	  	  Induced	  Sputum	  
	  
Date:	  ____/_____/______	  










Date	   SRE	  no	   Smear	   Culture	   Sensitivit
y	  







	   	   	   	   	   	   	   	   	   	  
	   	   	   	   	   	   	   	   	   	  
	   	   	   	   	   	   	   	   	   	  
	   	   	   	   	   	   	   	   	   	  
	   	   	   	   	   	   	   	   	   	  
	   	   	   	   	   	   	   	   	   	  
	  
SPECIFIC	  STUDY	  INVESTIGATIONS	  
	  
Blood	  Specimen	  for	  Storage?	  
	  
	  Yes	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  No	  
	  
T-­‐Spot	  Result:	   Date:	  ___/___/_____	  
	  	  	  	  	  	  	  	  	  	  DD	  	  	  	  MM	  	  	  	  	  YYYY	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SPUTUM	  	  INDUCTION	  PROCEDURE	  –	  SPECIMEN	  1	  
	  




Sputum	  Induction	  Successful	  
	  
	  Yes	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  No	  
	  
Amount	  of	  Sputum	  Obtained	  
	  




	  	  Coughed	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  Suctioned	  
	  
Side	  Effects	  Noted	  
	  
	  Nose	  Bleed	  	  	  	  	  	  	  	  	  	  	  	  	   	  Vomiting	  
	  Increased	  Cough	  	  	   	  Wheeze	  
	  Other………………………..	  
	  
Was	  BDR	  required	  after	  procedure	  
	  
	  Yes	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  No	  
	  
	  
Oxygen	  Saturation	  After	  Procedure	  
	  
	  
Procedure	  done	  easily	  
	  
	  Very	  Easy	  	  	  	   	  Easy	  	  	   	  Difficult	  





SPUTUM	  	  INDUCTION	  PROCEDURE	  –	  SPECIMEN	  2	  
	  




Sputum	  Induction	  Successful	  
	  
	  Yes	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  No	  
	  
Amount	  of	  Sputum	  Obtained	  
	  




	  	  Coughed	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  Suctioned	  
	  
Side	  Effects	  Noted	  
	  
	  Nose	  Bleed	  	  	  	  	  	  	  	  	  	  	  	  	   	  Vomiting	  




Was	  BDR	  required	  after	  procedure	  
	  
	  Yes	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  No	  
	  
	  
Oxygen	  Saturation	  After	  Procedure	  
	  
	  
Procedure	  done	  easily	  
	  
	  Very	  Easy	  	  	  	   	  Easy	  	  	   	  Difficult	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TEST	  AND	  RESULTS	  	  
	  
Blood	  Culture	  1	   Blood	  Culture	  2	  
Date	  Result	  1:	  ____/____/________	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  DD	  	  MM	  YYYY	  
Date	  Result	  2:	  _____/___/________	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  DD	  	  MM	  YYYY	  
Culture	  1	  pos:	  	   	  Yes	  	  	  	  	  	   	  No	   Culture	  2	  pos:	  	  	   	  Yes	  	  	   	  No	  
If	  YES	  details	  organism	  
	  Strep.	  pneumoniae	  




If	  YES	  details	  organism	  
	  Strep.	  pneumoniae	  






Urine	  Microscopy	  positive?	  (gram	  stain)	   Y	   N	  
>10	  Organisms	   Y	   N	  
Urine	  Culture	  positive	   Y	   N	  
If	  YES	  detail	  organism:	  ……………………………………………	  




Urine	  LAM	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  Y	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  N	  
	  
FBC	   Result	  
	  
Date:	  ___/___/______	  
	  	  	  	  	  	  	  	  	  	  	  DD	  	  	  MM	  	  	  YYYY	  
	  
Specimen	  Number:	  ………………..	  
Hb	  g/dl	   	  
MCV	   	  
WBC	  x	  10^g/L	   	  
Polymorphs	  x	  10^g/L	   No:_______	  %:	  ________	  
Lymphocytes	  x	  10^	  g/L	   No:	  _______	  %:	  ________	  
Platelets	  x	  10^	  g/L	   	  
Smear	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LFT	   Result	  
	  
Date:	  ___/___/________	  
	  	  	  	  	  	  	  	  	  	  	  DD	  	  MM	  	  	  	  	  YYYY	  
	  
Specimen	  No:	  ……………………..	  
Total	  Protein	   	  
Albumin	   	  





Has	  CXR	  been	  completed?	   Y	   ___/___/______	  
DD	  MM	  YYYY	  
N	   DK	  
High	  KV	  View:	  
Result:	  ……………………………………	  
	  	  	  	  	  	  	  	  	  	  	  	  	  ……………………………………	  
	  	  	  	  	  	  	  	  	  	  	  	  	  ……………………………………	  
	  
Y	   ___/___/_____	  
DD	  MM	  YYYY	  
N	   DK	  
Other	  specify………………………………	  
Result:	  	  	  ……………………………………	  
Y	   ___/__/_____	  
DD	  MM	  YYYY	  
N	   DK	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  ……………………………………	  




Date	  of	  reading	   ___/____/_____	  
DD	  	  	  MM	  	  YYYY	  
	  







Other	  Test	  Type:	  ………………………	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  ………………………	  
Specimen	  Number:	  ……………………	  
	  
Date:	  ____/____/_____	  
	  	  	  	  	  	  	  	  	  	  	  DD	  	  	  MM	  	  YYYY	  
Results:	  ……………………………….	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  ………………………………	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  ………………………………	  
	  
Other	  Test	  Type:	  ………………………	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  ………………………	  
Specimen	  Number:	  ……………………	  
	  
Date:	  ____/____/_____	  
	  	  	  	  	  	  	  	  	  	  	  DD	  	  	  MM	  	  YYYY	  
Results:	  ……………………………….	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  ………………………………	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Has	  an	  HIV	  PCR	  been	  sent	  if	  the	  child	  is	  
<18	  months	  old?	  
Y	   ____/____/______	  
	  DD	  	  MM	  	  YYYY	  
N	  
	  
HIV	  TEST	  RESULTS	  
	   Date	   Result	  
HIV	  Determine	   ____/____/______	  
	  DD	  	  	  MM	  	  	  YYYY	  
Negative	   Positive	  
HIV	  ELISA	   _____/___/_____	  
	  DD	  	  	  MM	  	  	  YYYY	  
Negative	   Positive	  
HIV	  DNA	  PCR	   ____/____/______	  
	  DD	  	  	  MM	  	  	  YYYY	  
Negative	   Positive	  
Final	  HIV	  diagnosis:	   Exposed	   Infected	   Uninfected	   Unknown	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CXR	  results	  form	  




11.	   Is	  the	  chest	  x-­‐ray	  	   	   Normal	  	   (go	  to	  end)	   Abnormal	  	  (go	  to	  x)	   N	   A	  
12.	  
Indicate	  the	  distribution	  of	  abnormalities	  
	  




Lung	  area	  involved	  (tick	  applicable	  boxes)	  
Alveolar	  (consolidation)	   Y	   N	   	   RUL	   RML	   RLL	   LUL	   LING	   LLL	   	   Segm	   Lobar	  
Ghon	  focus	   Y	   N	   RUL	   RML	   RLL	   LUL	   LING	   LLL	   Segm	   Lobar	  
Expansile	   Y	   N	   RUL	   RML	   RLL	   LUL	   LING	   LLL	   Segm	   Lobar	  
Cavity	  (number,	  size,	  
thickness)	  
Y	   N	   RUL	   RML	   RLL	   LUL	   LING	   LLL	   	   	   	  
Nodular	  infiltr	  (>2mm)	   Y	   N	   Peri-­‐hilar	   Peripheral	   Right	   Left	  
Miliary	  infiltr	  (	  up	  to	  
2mm)	  
Y	   N	   Peri-­‐hilar	   Peripheral	   Right	   Left	  
Volume	  loss	   Y	   N	   RUL	   RML	   RLL	   LUL	   LING	   LLL	   Segm	   Lobar	  
Hyperinflation	   Y	   N	   RUL	   RML	   RLL	   LUL	   LING	   LLL	   Segm	   Lobar	  
	  	  
251	  
Calcification	  (lung)	   Y	   N	   RUL	   RML	   RLL	   LUL	   LING	   LLL	   Segm	   Lobar	  
Peri-­‐hilar	  streakiness	   Y	   N	   Right	   Left	   	   	   	   	   	   	   	  
AIRWAY	  COMPRESSION	  AND	  OR	  
TRACHEAL	  DISPLACEMENT	  
	  
Right	  paratracheal	   y	   n	   maybe	   Not	  visible	  
Right	  main	  bronchus	   y	   n	   maybe	   Not	  visible	  
Right	  bronchus	  intermedius	   y	   n	   maybe	   Not	  visible	  
Left	  main	  bronchus	   y	   n	   maybe	   Not	  visible	  
NODES	   	  
Peri	  –hilar	  (P-­‐H)	   Y	   N	   R	   L	   SC	   U	  
Paratracheal	  (PT)	   Y	   N	   R	   L	   U	   	  
Calcification	  (nodes)	   Y	   N	   P-­‐H	   PT	   	   	  
PLEURA	   	  
Effusion	   Y	   N	   R	   L	   B-­‐L	   Sm	   Lge	   	   Loculated	   Y	   N	  
	  
HEART	   	   	   	   	   	   	   	   	   	   	   	   	   	   	  
Enlargement	   Y	   N	   U	   	   	   	   	   	   	   	   Pericardial	  
Effusion	  











	   	   	   	  
AP	  view	   Acceptable	   Poor	  but	  readable	   Not	  acceptable	   Not	  readable	  
Lateral	  view	   Acceptable	   Poor	  but	  readable	   Not	  acceptable	   Not	  readable	  
	  
REPORTER	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FINAL	  DIAGNOSIS	  1	  
Diagnosis	  TB	   Y	   N	  
	  
If	  YES	  detail	  the	  site	  of	  disease	  
	  








	  	  PULMONARY	  
	  	  PLEURAL	  EFFUSION	  
	  	  LYMPH	  NODE	  
	  	  MILIARY	  
	  	  LIVER	  
	  	  GASTROINTESTINAL	  
	  	  OTHER:	  ______________	  
	  














Date	  Commenced:	  ___/____/______	  




Date	  completed:	  ___/____/______	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  DD	  	  MM	  	  	  	  YYYY	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FINAL	  DIAGNOSIS	  2	  
Other	  Infections	  
Pneumonia	  






Urinary	  tract	  infection	  







Other	  1:	  ……………………………………………………	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  ……………………………………………………	  
	  




Antibiotics	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  	  Y	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  N	  
	  
Specify:	  	  	  	  	  	  	  ………………………………………….	  
	  	  










Bronchodilators	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  Y	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  N	  
	  
	  
Pyridoxine	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  Y	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  N	  
	  
	  
Other:	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  Y	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  N	  
Specify:	  ………………………………………………………………………	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  ……………………………………………………………………….	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  ………………………………………………………………………..	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Outcome	  of	  case	  
1.	   Death	  
	  
Date	  of	  Death:	  _____/____/_______	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  DD	  	  	  	  MM	  	  	  YYYY	  
	  
Cause	  of	  Death:	  ………………………………………….	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  ………………………………………….	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  ………………………………………….	  
	  
Y	   N	  
2.	   Transferred	  out	  
	  
Date	  of	  Transfer:	  _____/____/______	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  DD	  	  	  	  MM	  	  YYYY	  
	  
New	  Location:	  ………………………………………….	  
	  
Y	   N	  
3.	   Lost	  to	  Follow	  Up	  
	  
Date:	  	  ____/____/_______	  
	  	  	  	  	  	  	  	  	  	  	  	  DD	  	  	  	  MM	  	  YYYY	  




4.	   Relocated	  
	  
Date:	  ____/____/______	  
	  	  	  	  	  	  	  	  	  	  	  DD	  	  	  MM	  	  	  YYYY	  
	  
Y	   N	  
5.	   Excluded	  from	  the	  Study	  
	  
Date:	  ____/____/_______	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Follow-­‐up	  Visit	  (1	  month	  post	  initial	  assessment)	  
	  
Date:	  ____/_____/_____	  
	  	  	  	  	  	  	  	  	  	  	  DD	  MM	  YYYY	  
	  
	  
Staff	  Code/Interviewer:	  …………..	  
	  
Place	  of	  interview:	  ……………………	  
	  











Oedema?	   	  Yes	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  No	  
	  































































Side	  effects	  from	  Drugs?	   	  Yes	  	  	  	  	  	  	  	  	  	  	   	  No	  
Please	  tick	  relevant	  box	  to	  describe	  the	  side	  effect:	  
	  Nausea/Vomiting	  	  
	  Periph	  Neuropathy	  
	  Skin	  Rash	  
	  Hepatitis	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1	  month	  visit	  continued…	  
Changes	  in	  Treatment	  
Has	  there	  been	  a	  change	  in	  Tb	  Treatment?	   Y	   N	   DK	   N/A	  
Has	  there	  been	  a	  change	  in	  steroids?	   Y	   N	   DK	   N/A	  
Have	  antibiotics	  been	  added?	   Y	   N	   DK	   N/A	  
	  
HIV	  exposure-­‐Exposure	  to	  PMTCT	  intervention	  
Was	  Mother	  HIV	  infected	  during	  pregnancy?	   Y	   N	   DK	  






Early	  Infant	  feeding	  (1st	  6	  
mths)	  
	  
(if	  the	  child	  has	  ever	  had	  a	  
bottle	  feed	  or	  any	  other	  feed-­‐
other	  than	  breast	  milk-­‐in	  1st	  6	  












Are	  you	  currently	  Breastfeeding?	  
	  









	  Never	  Breast	  Fed	  
	  Stopped	  ______Months	  ago	  
	  
Child/Adolescent	  tested	  for	  HIV?	  
	  
Y	   N	   DK	  
HIV	  Status?	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Follow-­‐up	  Visit	  (3	  month	  post	  initial	  assessment)	  
	  
Date:	  ____/_____/_____	  
	  	  	  	  	  	  	  	  	  	  	  DD	  MM	  YYYY	  
	  
Staff	  Code/Interviewer:	  …………..	  
	  
Place	  of	  interview:	  ……………………	  
	  
Clinical	  Examination	  -­‐	  3	  
Nutritional	  Status	  
	  








	  Yes	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  No	  
	  






























































Side	  effects	  from	  Drugs?	   	  Yes	  	  	  	  	  	  	  	  	  	  	   	  No	  
Please	  tick	  relevant	  box	  to	  describe	  the	  side	  effect:	  
	  Nausea/Vomiting	  	  
	  Periph	  Neuropathy	  
	  Skin	  Rash	  
	  Hepatitis	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3	  month	  visit	  continued…..	  
	  
Changes	  in	  Treatment	  
	  




































	  	  	  	  	  	   	  Yes	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  No	  
	  




















































HIV	  exposure-­‐Exposure	  to	  PMTCT	  intervention	  
Was	  Mother	  HIV	  infected	  during	  pregnancy?	   Y	   N	   DK	  






Early	  Infant	  feeding	  (1st	  6	  mths)	  
	  
(if	  the	  child	  has	  ever	  had	  a	  
bottle	  feed	  or	  any	  other	  feed-­‐
other	  than	  breast	  milk-­‐in	  1st	  6	  























Are	  you	  currently	  Breastfeeding?	  
	  
(If	  NO,	  when	  did	  you	  stop	  breastfeeding?	  
	  Never	  Breast	  Fed	  








Child/Adolescent	  tested	  for	  HIV?	  
	  
Y	   N	   DK	  
HIV	  Status?	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Follow-­‐up	  Visit	  (6	  month	  post	  initial	  assessment)	  
	  
Date:	  ____/_____/_____	  
	  	  	  	  	  	  	  	  	  	  	  DD	  MM	  YYYY	  
	  
	  
Staff	  Code/Interviewer:	  …………..	  
	  
	  
Place	  of	  interview:	  ……………………	  
	  
Clinical	  Examination	  -­‐	  4	  
Nutritional	  Status	  
	  










	  Yes	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  No	  
	  






























































Side	  effects	  from	  Drugs?	   	  Yes	  	  	  	  	  	  	  	  	  	  	   	  No	  
Please	  tick	  relevant	  box	  to	  describe	  the	  side	  effect:	  
	  Nausea/Vomiting	  	  
	  Periph	  Neuropathy	  
	  Skin	  Rash	  
	  Hepatitis	  









6	  month	  visit	  continued…..	  
Changes	  in	  Treatment	  
	  





























TB	  Treatment	  completed?	  
	  
(If	  No,	  what	  duration	  of	  extension	  for	  
treatment	  is	  given?)	  
	  











	  	  	  	  	  	   	  Yes	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  No	  
	   	   	   	   	  
	  	  
274	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HIV	  exposure-­‐Exposure	  to	  PMTCT	  intervention	  
Was	  Mother	  HIV	  infected	  during	  pregnancy?	   Y	   N	   DK	  






Early	  Infant	  feeding	  (1st	  6	  
mths)	  
	  
(if	  the	  child	  has	  ever	  had	  a	  
bottle	  feed	  or	  any	  other	  feed-­‐
other	  than	  breast	  milk-­‐in	  1st	  6	  












Are	  you	  currently	  Breastfeeding?	  
	  
(If	  NO,	  when	  did	  you	  stop	  breastfeeding?	  
	  Never	  Breast	  Fed	  








Child/Adolescent	  tested	  for	  HIV?	  
	  
Y	   N	   DK	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CXR	  results	  form	  




11.	   Is	  the	  chest	  x-­‐ray	  	   	   Normal	  	   (go	  to	  end)	   Abnormal	  	  (go	  to	  x)	   N	   A	  
12.	  
Indicate	  the	  distribution	  of	  abnormalities	  
	  




Lung	  area	  involved	  (tick	  applicable	  boxes)	  
Alveolar	  (consolidaton)	   Y	   N	   	   RUL	   RML	   RLL	   LUL	   LING	   LLL	   	   Segm	   Lobar	  
Ghon	  focus	   Y	   N	   RUL	   RML	   RLL	   LUL	   LING	   LLL	   Segm	   Lobar	  
Expansile	   Y	   N	   RUL	   RML	   RLL	   LUL	   LING	   LLL	   Segm	   Lobar	  
Cavity	  (number,	  size,	  
thickness)	  
Y	   N	   RUL	   RML	   RLL	   LUL	   LING	   LLL	   	   	   	  
Nodular	  infiltr	  (>2mm)	   Y	   N	   Peri-­‐hilar	   Peripheral	   Right	   Left	  
Miliary	  infiltr	  (	  up	  to	  
2mm)	  
Y	   N	   Peri-­‐hilar	   Peripheral	   Right	   Left	  
Volume	  loss	   Y	   N	   RUL	   RML	   RLL	   LUL	   LING	   LLL	   Segm	   Lobar	  
	  	  
278	  
Hyperinflation	   Y	   N	   RUL	   RML	   RLL	   LUL	   LING	   LLL	   Segm	   Lobar	  
Calcification	  (lung)	   Y	   N	   RUL	   RML	   RLL	   LUL	   LING	   LLL	   Segm	   Lobar	  
Peri-­‐hilar	  streakiness	   Y	   N	   Right	   Left	   	   	   	   	   	   	   	  
AIRWAY	  COMPRESSION	  AND	  OR	  
TRACHEAL	  DISPLACEMENT	  
	  
Right	  paratraceal	   y	   n	   maybe	   Not	  visible	  
Right	  main	  bronchus	   y	   n	   maybe	   Not	  visible	  
Right	  bronchus	  intermedius	   y	   n	   maybe	   Not	  visible	  
Left	  main	  bronchus	   y	   n	   maybe	   Not	  visible	  
NODES	   	  
Peri	  –hilar	  (P-­‐H)	   Y	   N	   R	   L	   SC	   U	  
Paratracheal	  (PT)	   Y	   N	   R	   L	   U	   	  
Calcification	  (nodes)	   Y	   N	   P-­‐H	   PT	   	   	  
PLEURA	   	  
Effusion	   Y	   N	   R	   L	   B-­‐L	   Sm	   Lge	   	   Loculated	   Y	   N	  
	  
HEART	   	   	   	   	   	   	   	   	   	   	   	   	   	   	  
Enlargement	   Y	   N	   U	   	   	   	   	   	   	   	   Pericardial	  
Effusion	  









	   	   	   	  
AP	  view	   Acceptable	   Poor	  but	  readable	   Not	  acceptable	   Not	  readable	  
Lateral	  view	   Acceptable	   Poor	  but	  readable	   Not	  acceptable	   Not	  readable	  
	  
REPORTER	   	   	   	  
	   	  















	   Is	  the	  CXR	  consistent	  with	  TB?	   Y	   N	   Inconclusive	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